{"PMC7274729": [["Specifically, consider the unification problem", [["the unification problem", "PROBLEM", 23, 46]]]], "PMC7341541": [["Nearly everyone is interested, having been taken unawares, by severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102), the coronavirus currently causing a pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 69, 107], ["coronavirus", "DISEASE", 128, 139], ["SARS\u2010CoV\u20102", "ORGANISM", 111, 121], ["coronavirus", "ORGANISM", 128, 139], ["severe acute respiratory syndrome coronavirus", "SPECIES", 62, 107], ["SARS\u2010CoV", "SPECIES", 111, 119], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 62, 107], ["SARS\u2010CoV\u2010", "TEST", 111, 120], ["the coronavirus", "PROBLEM", 124, 139], ["a pandemic", "PROBLEM", 158, 168], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory syndrome", "OBSERVATION", 75, 95], ["coronavirus", "OBSERVATION", 128, 139], ["pandemic", "OBSERVATION", 160, 168]]], ["The imminent emergence of an infective pandemic had been foreseen by viral ecologists such as Nathan Wolfe, who had actually proposed a coronavirus as the most likely candidate.1COVID\u201019 (coronavirus disease 2019) has become a household name in the last few weeks, each day seeing a frenzy of media coverage dominated by politicians; but scientists of all persuasions including immunologists, virologists, epidemiologists and clinicians have become engrossed by this disease.", [["coronavirus", "DISEASE", 136, 147], ["coronavirus disease", "DISEASE", 188, 207], ["coronavirus", "ORGANISM", 136, 147], ["an infective pandemic", "PROBLEM", 26, 47], ["a coronavirus", "PROBLEM", 134, 147], ["coronavirus disease", "PROBLEM", 188, 207], ["a frenzy of media coverage", "TREATMENT", 281, 307], ["this disease", "PROBLEM", 462, 474], ["infective", "OBSERVATION", 29, 38]]], ["Although the disease only emerged last December, in the Chinese province of Wuhan, there have been hundreds of on\u2010line reports and papers, the latter often deposited as pre\u2010prints.", [["the disease", "PROBLEM", 9, 20], ["disease", "OBSERVATION", 13, 20]]], ["There is a need now for consolidation of our knowledge\u2010base on this virus, looking for themes and commonality from different studies around the world reported in peer\u2010reviewed journals.", [["consolidation", "PROBLEM", 24, 37], ["this virus", "PROBLEM", 63, 73], ["different studies", "TEST", 115, 132], ["consolidation", "OBSERVATION", 24, 37]]]], "f514567a1812f7c9c647c12a149880a951f71d62": [["Result:Carbohydrate consumption and frequency of snacking increased in 21% and 23% patients, respectively.", [["Carbohydrate", "CHEMICAL", 7, 19], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Carbohydrate consumption", "TREATMENT", 7, 31]]], ["Interestingly, 27% patients reported an increase in consumption of fruits.", [["fruits", "ANATOMY", 67, 73], ["patients", "ORGANISM", 19, 27], ["fruits", "ORGANISM_SUBDIVISION", 67, 73], ["patients", "SPECIES", 19, 27], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["fruits", "OBSERVATION", 67, 73]]], ["Exercise duration was reduced in 42% and weight gain occurred in 19% patients.", [["weight gain", "DISEASE", 41, 52], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Exercise duration", "TEST", 0, 17]]], ["Frequency of doing self-monitoring of blood glucose (SMBG) was decreased in 23% patients.", [["blood", "ANATOMY", 38, 43], ["glucose", "CHEMICAL", 44, 51], ["glucose", "CHEMICAL", 44, 51], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["glucose", "SIMPLE_CHEMICAL", 44, 51], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["blood glucose", "TEST", 38, 51], ["SMBG", "TEST", 53, 57]]], ["'Mental stress' of any kind was reported in 87% patients.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Mental stress'", "PROBLEM", 1, 15]]], ["Availability of medicine and insulin was uninterrupted in 91% patients.", [["insulin", "GENE_OR_GENE_PRODUCT", 29, 36], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["medicine", "TREATMENT", 16, 24], ["insulin", "TREATMENT", 29, 36]]], ["Knowledge about telemedicine was present in 69% and majority (92%) of these patients preferred video consultation.Conclusion:During 45 days of lockdown increase in carbohydrate intake, decrease in exercise, decreased SMBG and widespread mental stress in patients with T2DM was seen, factors which may destabilize or exacerbate hyperglycemia and hypertension.", [["T2DM", "DISEASE", 268, 272], ["hyperglycemia", "DISEASE", 327, 340], ["hypertension", "DISEASE", 345, 357], ["carbohydrate", "CHEMICAL", 164, 176], ["patients", "ORGANISM", 76, 84], ["carbohydrate", "SIMPLE_CHEMICAL", 164, 176], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 254, 262], ["video consultation", "TEST", 95, 113], ["lockdown increase in carbohydrate intake", "TREATMENT", 143, 183], ["decreased SMBG", "PROBLEM", 207, 221], ["widespread mental stress", "PROBLEM", 226, 250], ["T2DM", "PROBLEM", 268, 272], ["hyperglycemia", "PROBLEM", 327, 340], ["hypertension", "PROBLEM", 345, 357], ["carbohydrate intake", "OBSERVATION", 164, 183], ["widespread", "OBSERVATION_MODIFIER", 226, 236], ["mental stress", "OBSERVATION", 237, 250], ["hypertension", "OBSERVATION", 345, 357]]], ["Some positive changes (e.g. increased intake of fruits) were also observed.Highlights:1.", [["fruits", "ANATOMY", 48, 54], ["fruits", "ORGANISM_SUBDIVISION", 48, 54], ["Some positive changes", "PROBLEM", 0, 21], ["positive", "OBSERVATION", 5, 13]]], ["In patients with type 2 diabetes, lockdown resulted in reduction in duration of exercise, increased consumption of carbohydrates and excess mental stress; all factors which may destabilize glycemia.2.Encouraging traits during this period included increased consumption of fruits, knowledge and willingness for teleconsultation and easy availability of medicines and insulin.Introduction:After COVID-19 epidemic, Indian Government initiated nationwide lockdown from 25 th March 2020 and is currently under a 4 th phase of lockdown.", [["fruits", "ANATOMY", 272, 278], ["type 2 diabetes", "DISEASE", 17, 32], ["carbohydrates", "CHEMICAL", 115, 128], ["patients", "ORGANISM", 3, 11], ["fruits", "ORGANISM_SUBDIVISION", 272, 278], ["insulin", "GENE_OR_GENE_PRODUCT", 366, 373], ["insulin", "PROTEIN", 366, 373], ["patients", "SPECIES", 3, 11], ["type 2 diabetes", "PROBLEM", 17, 32], ["lockdown", "TREATMENT", 34, 42], ["excess mental stress", "PROBLEM", 133, 153], ["teleconsultation", "TEST", 310, 326], ["medicines", "TREATMENT", 352, 361], ["insulin", "TREATMENT", 366, 373], ["COVID", "TEST", 393, 398], ["diabetes", "OBSERVATION", 24, 32], ["reduction", "OBSERVATION_MODIFIER", 55, 64]]], ["This lockdown as a method of counteracting an epidemic mandates people to stay inside their homes, except for carrying out essential activities.Introduction:Uncontrolled diabetes has emerged as one of the major risk factors for mortality in patients with COVID-19 (1).", [["diabetes", "DISEASE", 170, 178], ["COVID-19", "CHEMICAL", 255, 263], ["people", "ORGANISM", 64, 70], ["patients", "ORGANISM", 241, 249], ["people", "SPECIES", 64, 70], ["patients", "SPECIES", 241, 249], ["Uncontrolled diabetes", "PROBLEM", 157, 178], ["COVID", "TEST", 255, 260], ["Uncontrolled", "OBSERVATION_MODIFIER", 157, 169], ["diabetes", "OBSERVATION", 170, 178]]], ["Our recently published mathematical simulation model shows that the nationwide lockdown is estimated to increase the number of patients having uncontrolled diabetes and its complications (2) .This may be due to physical inactivity, alterations in dietary habits, difficulty in procuring medications, insulin, glucose test strips or/and inability to seek guidance from physician.", [["diabetes", "DISEASE", 156, 164], ["glucose", "CHEMICAL", 309, 316], ["glucose", "CHEMICAL", 309, 316], ["patients", "ORGANISM", 127, 135], ["insulin", "GENE_OR_GENE_PRODUCT", 300, 307], ["glucose", "SIMPLE_CHEMICAL", 309, 316], ["patients", "SPECIES", 127, 135], ["uncontrolled diabetes", "PROBLEM", 143, 164], ["its complications", "PROBLEM", 169, 186], ["physical inactivity", "PROBLEM", 211, 230], ["alterations in dietary habits", "PROBLEM", 232, 261], ["medications", "TREATMENT", 287, 298], ["insulin", "TREATMENT", 300, 307], ["glucose test strips", "TREATMENT", 309, 328], ["uncontrolled", "OBSERVATION_MODIFIER", 143, 155], ["diabetes", "OBSERVATION", 156, 164], ["may be due to", "UNCERTAINTY", 197, 210]]], ["Although it is reasonable to assume that these lifestyle changes might occur during lockdown, there are no such data from India.Aim:We hypothesize that prolonged staying at home with limited mobility during lockdown can lead to disruption in diet and lifestyle in patients with type 2 diabetes (T2DM).Methodology:We reviewed records of our previously seen patients with T2DM and selected files of those who had been following up with us regularly.", [["type 2 diabetes", "DISEASE", 278, 293], ["T2DM", "DISEASE", 295, 299], ["T2DM", "DISEASE", 370, 374], ["patients", "ORGANISM", 264, 272], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 356, 364], ["these lifestyle changes", "PROBLEM", 41, 64], ["limited mobility", "PROBLEM", 183, 199], ["type 2 diabetes (T2DM)", "PROBLEM", 278, 300], ["T2DM", "PROBLEM", 370, 374]]], ["Institutional ethics committee approved the study protocol.Statistical Analysis:Data were entered on Google spreadsheet.", [["the study protocol", "TEST", 40, 58]]], ["Frequency analysis was done on STATA version 14.1 (STATA Corp, TX, USA).Results:Our study population (n, 150) 36% were elderly (>60 years) majorly (46.6%) belonged to middle age group (40-60 years), and 16% were less than 40 years of age.", [["Frequency analysis", "TEST", 0, 18], ["STATA version", "TEST", 31, 44], ["Our study population", "TEST", 80, 100]]], ["Gender distribution was as follows; 62% (93) males and 38% (57) females.Results:Detailed results are given in tables 1-3.Diet, Exercise and Weights Changes:More than half (56%) of patients reported that they were taking same quantity of diet as before lockdown whereas one fourth (25%) of patients were eating less than before.", [["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 289, 297], ["Gender distribution", "TEST", 0, 19]]], ["Half of the patients reported that their meal timings were affected during lockdown period.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Quality of diet also changed; carbohydrate consumption increased in 21% whereas 13% patients reported increase in consumption of fat.", [["fat", "ANATOMY", 129, 132], ["carbohydrate", "CHEMICAL", 30, 42], ["carbohydrate", "SIMPLE_CHEMICAL", 30, 42], ["patients", "ORGANISM", 84, 92], ["fat", "TISSUE", 129, 132], ["patients", "SPECIES", 84, 92], ["carbohydrate consumption", "TREATMENT", 30, 54], ["increase", "OBSERVATION_MODIFIER", 102, 110]]], ["Increase in consumption of fruits was recorded in 20%, and interestingly, 7% of patients started eating fruits during lockdown.", [["fruits", "ANATOMY", 27, 33], ["fruits", "ANATOMY", 104, 110], ["fruits", "ORGANISM_SUBDIVISION", 27, 33], ["patients", "ORGANISM", 80, 88], ["fruits", "ORGANISM_SUBDIVISION", 104, 110], ["patients", "SPECIES", 80, 88], ["consumption", "OBSERVATION_MODIFIER", 12, 23]]], ["In 23% of patients there was an increase in frequency of snacking (more than 4 times/day).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["Majority (97%) of patients stated that they did not order food from outside (Table1).Diet, Exercise and Weights Changes:Some form of exercise was followed by 62% of patients; among them, 44% were doing aerobic exercise, 17% yoga, and 3% resistance exercises.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 165, 173]]], ["In 25% of patients there was increase in the duration of exercise and, interestingly, more that 50% increase in the duration of exercise was reported in 10% patients.", [["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 157, 165], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["increase", "OBSERVATION_MODIFIER", 100, 108]]], ["Further, 42% reported there was reduction in their duration of exercise.", [["reduction", "OBSERVATION_MODIFIER", 32, 41]]], ["Changes in weight were reported in 50% patients; of whom 19% stated that they had gained 5-10% weight during lockdown (Table1).Other Lifestyle Habits, Psychological and Other Issues Related to Treatment:Majority of the patients were not in the habit of taking alcohol or tobacco in any form.", [["alcohol", "CHEMICAL", 260, 267], ["alcohol", "CHEMICAL", 260, 267], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 219, 227], ["alcohol", "SIMPLE_CHEMICAL", 260, 267], ["tobacco", "ORGANISM", 271, 278], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 219, 227], ["tobacco", "SPECIES", 271, 278], ["Changes in weight", "PROBLEM", 0, 17]]], ["In those who were in habit of consuming alcohol (11%), there were some positive changes; 8% confirmed that there was decrease in their consumption by 50%.", [["alcohol", "CHEMICAL", 40, 47], ["alcohol", "CHEMICAL", 40, 47], ["alcohol", "SIMPLE_CHEMICAL", 40, 47], ["some positive changes", "PROBLEM", 66, 87], ["positive", "OBSERVATION", 71, 79], ["decrease", "OBSERVATION_MODIFIER", 117, 125]]], ["Significantly, 87% patients stated that they were 'psychologically affected' because of staying at home.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Among them, 10% and 27% of patient said that they had 'low feeling' and decrease in sleep, respectively.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["'low feeling'", "PROBLEM", 54, 67]]], ["For coping stress, 53% patients resorted to watching television, and 16% were engaged in office work ( Table 2) .Other Lifestyle Habits, Psychological and Other Issues Related to Treatment:Frequency of self-monitoring of blood glucose (SMBG) was reduced in 23% patients as compared to before lockdown.", [["blood", "ANATOMY", 221, 226], ["glucose", "CHEMICAL", 227, 234], ["glucose", "CHEMICAL", 227, 234], ["patients", "ORGANISM", 23, 31], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["glucose", "SIMPLE_CHEMICAL", 227, 234], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 261, 269], ["coping stress", "PROBLEM", 4, 17], ["blood glucose", "TEST", 221, 234], ["SMBG", "TEST", 236, 240]]], ["Easy availability of medicines another positive point, reported by 91% patients.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["medicines", "TREATMENT", 21, 30]]], ["When asked about teleconsultation; 69% patients were aware about it and majority (92%) opted for video consultation (Table 3) .Discussion:In our study we noticed mixed responses from patients, both in positive and negative modes, in relation to optimal advice conducive to best health practices.Positive Responses:Majority of the patients tried to maintain their diet as before and few of them tried to decrease their carbohydrate (7%) and fat (4%) consumption.", [["carbohydrate", "CHEMICAL", 418, 430], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 330, 338], ["fat", "TISSUE", 440, 443], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 330, 338], ["video consultation", "TEST", 97, 115], ["our study", "TEST", 141, 150]]], ["Increase in consumption of fruits is an encouraging dietary change.", [["fruits", "ANATOMY", 27, 33], ["fruits", "ORGANISM_SUBDIVISION", 27, 33], ["fruits", "OBSERVATION", 27, 33]]], ["This observation has been reported in a recently published study done in 41 obese Italian children and adolescents, who were monitored for 3 weeks during lockdown (3).", [["children", "ORGANISM", 90, 98], ["adolescents", "ORGANISM", 103, 114], ["children", "SPECIES", 90, 98], ["adolescents", "SPECIES", 103, 114], ["a recently published study", "TEST", 38, 64]]], ["It is interesting that during lockdown home cooked food was consumed by majority of our patients despite availability of processed and home delivered foods in most localities of Delhi.Positive Responses:It is also encouraging that 62% patients continued with physical activity and some even increased it, likely due to the availability of free time.", [["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 235, 243]]], ["This observation was also noticed in a recently published pilot study from south India where 80% of study population followed physical activity during lockdown (4).", [["study population", "TEST", 100, 116]]], ["Our participants also reported having some weight loss during lockdown; 33% reported they lost less than or equal to 5% of their body weight, however, this significance of such small amount of weight loss is difficult to ascertain, as the reporting may be erroneous or biased.Positive Responses:An important point which emerged from the interview was regular supply of medications available to the patients; hence this may not be a major reason for uncontrolled glycemia.", [["body", "ANATOMY", 129, 133], ["weight loss", "DISEASE", 43, 54], ["weight loss", "DISEASE", 193, 204], ["glycemia", "DISEASE", 462, 470], ["participants", "ORGANISM", 4, 16], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["patients", "ORGANISM", 398, 406], ["participants", "SPECIES", 4, 16], ["patients", "SPECIES", 398, 406], ["some weight loss", "PROBLEM", 38, 54], ["weight loss", "PROBLEM", 193, 204], ["medications", "TREATMENT", 369, 380], ["uncontrolled glycemia", "PROBLEM", 449, 470], ["small", "OBSERVATION_MODIFIER", 177, 182], ["amount", "OBSERVATION_MODIFIER", 183, 189], ["weight loss", "OBSERVATION", 193, 204]]], ["However, the situation may be different in smaller towns or other suburban areas where supply chain of medicines is likely to be interrupted.", [["medicines", "TREATMENT", 103, 112], ["smaller", "OBSERVATION_MODIFIER", 43, 50], ["likely to be", "UNCERTAINTY", 116, 128]]], ["Finally, awareness and willingness for teleconsultation is encouraging, particularly when this modality may be an important method of management in future (5), although some roadblocks in its application have been recently noted by us (6).Negative Responses:Disruption of meal timings, increased consumption of carbohydrates and increasing snacking as recorded are roadblocks to good glycemic control and may cause weight gain in these patients.", [["weight gain", "DISEASE", 415, 426], ["carbohydrates", "CHEMICAL", 311, 324], ["patients", "ORGANISM", 436, 444], ["patients", "SPECIES", 436, 444], ["teleconsultation", "TEST", 39, 55], ["carbohydrates", "TREATMENT", 311, 324], ["increasing snacking", "TREATMENT", 329, 348], ["weight gain", "PROBLEM", 415, 426], ["increased", "OBSERVATION_MODIFIER", 286, 295]]], ["These data are similar to those recorded in Italian children and adolescents where intake of potato chips, red meat, and sugar sweetened beverages increased significantly during the lockdown (3).", [["red meat", "ANATOMY", 107, 115], ["sugar", "CHEMICAL", 121, 126], ["children", "ORGANISM", 52, 60], ["meat", "ORGANISM_SUBDIVISION", 111, 115], ["sugar", "SIMPLE_CHEMICAL", 121, 126], ["children", "SPECIES", 52, 60], ["adolescents", "SPECIES", 65, 76], ["potato", "SPECIES", 93, 99], ["potato", "SPECIES", 93, 99], ["potato chips", "TREATMENT", 93, 105]]], ["In addition, decrease in physical activity due to lockdown and closure of parks and gyms, would further exacerbate this situation.", [["closure", "TREATMENT", 63, 70], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["To this end, weight gain (5-10%) reported in only 19% patients is surprising but may be confounded by incorrect reporting or underreporting.", [["weight gain", "DISEASE", 13, 24], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["weight gain", "TEST", 13, 24]]], ["Importantly, in 23% of patients there was reduced self-monitoring of blood glucose (SMBG), which may pose hurdle to corrective measures for glycemic fluctuations.Negative Responses:Most important issue appears to be heightened 'mental stress' and decrease in sleep duration.", [["blood", "ANATOMY", 69, 74], ["glucose", "CHEMICAL", 75, 82], ["glucose", "CHEMICAL", 75, 82], ["patients", "ORGANISM", 23, 31], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["glucose", "SIMPLE_CHEMICAL", 75, 82], ["patients", "SPECIES", 23, 31], ["blood glucose", "TEST", 69, 82], ["SMBG", "TEST", 84, 88], ["corrective measures", "TREATMENT", 116, 135], ["glycemic fluctuations", "PROBLEM", 140, 161], ["heightened 'mental stress'", "PROBLEM", 216, 242], ["decrease in sleep duration", "PROBLEM", 247, 273], ["Most important", "OBSERVATION_MODIFIER", 181, 195], ["decrease", "OBSERVATION_MODIFIER", 247, 255]]], ["Increase in anxiety level is identified as a major factor in a recently conducted online survey done in general population during lockdown in India.", [["anxiety", "DISEASE", 12, 19], ["Increase in anxiety level", "PROBLEM", 0, 25]]], ["In this study, more than 80% reported that they were preoccupied with the thoughts of COVID-19 and 12.5% reported sleep disturbances (7) .", [["sleep disturbances", "DISEASE", 114, 132], ["this study", "TEST", 3, 13], ["COVID", "TEST", 86, 91], ["sleep disturbances", "PROBLEM", 114, 132]]], ["In another study done in China (n, 1210) during initial stages of COVID-19 pandemic; 53.8% rated the psychological impact of the outbreak as moderate or severe (8) .", [["another study", "TEST", 3, 16], ["COVID", "TEST", 66, 71], ["moderate", "OBSERVATION_MODIFIER", 141, 149], ["severe", "OBSERVATION_MODIFIER", 153, 159]]], ["Mental stress and sleep disturbance in our participant's need indepth investigations since these could affect compliance to diet, exercise and drugs.", [["sleep disturbance", "DISEASE", 18, 35], ["participant", "SPECIES", 43, 54], ["Mental stress", "PROBLEM", 0, 13], ["sleep disturbance", "PROBLEM", 18, 35], ["indepth investigations", "TEST", 62, 84], ["drugs", "TREATMENT", 143, 148]]], ["These issues become more daunting to patients in absence of advice from physician or psychologist.Study Limitations:These data, collected from a large metropolitan city cannot be extrapolated to smaller towns.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["These data", "TEST", 116, 126], ["large", "OBSERVATION_MODIFIER", 145, 150]]], ["The responses were subjective and many factors like weight changes could not be ascertained.Conclusion:During the current pandemic there have been many lifestyle changes noted in our participants.", [["participants", "SPECIES", 183, 195], ["weight changes", "PROBLEM", 52, 66], ["many lifestyle changes", "PROBLEM", 147, 169], ["many", "OBSERVATION_MODIFIER", 147, 151], ["lifestyle", "OBSERVATION", 152, 161]]], ["Few of these like taking care of diet and exercise, adding more fruits, having home cooked meals, regular supply of anti-hyperglycemic agents and willingness for teleconsultation could help patients with diabetes maintain good glycemic control.", [["fruits", "ANATOMY", 64, 70], ["diabetes", "DISEASE", 204, 212], ["fruits", "ORGANISM_SUBDIVISION", 64, 70], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["home cooked meals", "TREATMENT", 79, 96], ["anti-hyperglycemic agents", "TREATMENT", 116, 141], ["teleconsultation", "TREATMENT", 162, 178], ["diabetes", "PROBLEM", 204, 212]]], ["However increased carbohydrate consumption, snacking, and physical inactivity, decreased duration of physical activity, reduced SMBG and increase in mental stress will be challenging issues and may exacerbate glycemia.Conflict of Interest:The authors do not mention any conflict of interest regarding this article.Funding:No funding was received for this article.Funding:Table1: Diet, exercise, weight and self-monitoring of blood glucose.", [["blood", "ANATOMY", 425, 430], ["physical inactivity", "DISEASE", 58, 77], ["glycemia", "DISEASE", 209, 217], ["glucose", "CHEMICAL", 431, 438], ["carbohydrate", "CHEMICAL", 18, 30], ["glucose", "CHEMICAL", 431, 438], ["carbohydrate", "SIMPLE_CHEMICAL", 18, 30], ["blood", "ORGANISM_SUBSTANCE", 425, 430], ["glucose", "SIMPLE_CHEMICAL", 431, 438], ["increased carbohydrate consumption", "PROBLEM", 8, 42], ["reduced SMBG", "PROBLEM", 120, 132], ["increase in mental stress", "PROBLEM", 137, 162], ["challenging issues", "PROBLEM", 171, 189], ["glycemia", "PROBLEM", 209, 217], ["weight", "TEST", 395, 401], ["blood glucose", "TEST", 425, 438], ["increased", "OBSERVATION_MODIFIER", 8, 17], ["carbohydrate consumption", "OBSERVATION", 18, 42], ["increase", "OBSERVATION_MODIFIER", 137, 145], ["No", "UNCERTAINTY", 322, 324], ["funding", "OBSERVATION", 325, 332]]], ["More fat intake (ghee, butter, fried foods)Consumption of sugarNo consumption of sugar 88 (132) Increased by 25-50%* 7(10) Same as before 5(8) Lost 5% weight* 3(5)Self-Monitoring of blood glucose frequencySame as before 77 (115 ) Decreased* 23(35)Self-Monitoring of blood glucose frequencyas compared to before lockdown period, ** mental stress of any kind perceived by patient", [["fat", "ANATOMY", 5, 8], ["blood", "ANATOMY", 182, 187], ["blood", "ANATOMY", 266, 271], ["sugarNo", "CHEMICAL", 58, 65], ["glucose", "CHEMICAL", 188, 195], ["glucose", "CHEMICAL", 272, 279], ["sugar", "CHEMICAL", 81, 86], ["glucose", "CHEMICAL", 188, 195], ["glucose", "CHEMICAL", 272, 279], ["fat", "TISSUE", 5, 8], ["butter", "ORGANISM_SUBDIVISION", 23, 29], ["sugar", "SIMPLE_CHEMICAL", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["glucose", "SIMPLE_CHEMICAL", 188, 195], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["glucose", "SIMPLE_CHEMICAL", 272, 279], ["patient", "ORGANISM", 370, 377], ["patient", "SPECIES", 370, 377], ["sugar", "TEST", 81, 86], ["blood glucose frequency", "TEST", 182, 205], ["blood glucose frequencyas", "TEST", 266, 291]]]], "376ac65674202c307c902a12a7cda5ab64162153": [["Identification of SARS-CoV-2 in a Proficiency Testing ProgramConclusions: Overall performance in this SARS-CoV-2 RNA detection challenge was excellent, providing confidence in the results of these new molecular tests and assurance for the clinical and public health decisions based on these test results.Identification of SARS-CoV-2 in a Proficiency Testing ProgramIn December 2019 a cluster of respiratory disease cases were recognized in Wuhan, China.", [["respiratory", "ANATOMY", 395, 406], ["SARS", "DISEASE", 102, 106], ["SARS", "DISEASE", 322, 326], ["respiratory disease", "DISEASE", 395, 414], ["SARS-CoV-2", "ORGANISM", 322, 332], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 322, 330], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["this SARS", "TEST", 97, 106], ["CoV", "TEST", 107, 110], ["these new molecular tests", "TEST", 191, 216], ["these test results", "TEST", 285, 303], ["SARS", "PROBLEM", 322, 326], ["respiratory disease cases", "PROBLEM", 395, 420], ["SARS", "OBSERVATION", 18, 22], ["SARS", "OBSERVATION", 322, 326], ["respiratory disease", "OBSERVATION", 395, 414]]], ["1 By January 2020, the cause of the infections was identified as a novel coronavirus that was later designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["infections", "DISEASE", 36, 46], ["coronavirus", "DISEASE", 73, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 118, 156], ["coronavirus", "ORGANISM", 73, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 111, 156], ["SARS-CoV-2", "SPECIES", 160, 170], ["the infections", "PROBLEM", 32, 46], ["a novel coronavirus", "PROBLEM", 65, 84], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 111, 156], ["SARS", "TEST", 160, 164], ["CoV", "TEST", 165, 168], ["infections", "OBSERVATION", 36, 46], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144]]], ["2 The first confirmed case of SARS-CoV-2 infection in the United States was identified in Washington in a traveler returning from Wuhan.", [["SARS-CoV-2 infection", "DISEASE", 30, 50], ["SARS-CoV-2", "ORGANISM", 30, 40], ["CoV-2", "SPECIES", 35, 40], ["SARS-CoV-2", "SPECIES", 30, 40], ["SARS", "PROBLEM", 30, 34], ["CoV-2 infection", "PROBLEM", 35, 50], ["SARS", "OBSERVATION", 30, 34], ["infection", "OBSERVATION", 41, 50]]], ["3 As of June 1, 2020, over 1.7 million cases and over 102,000 deaths have been reported in the United States.", [["deaths", "DISEASE", 62, 68]]], ["4 The rapid and widespread transmission of the virus led to unprecedented social and economic disruptions as governments ordered schools and businesses closed.Identification of SARS-CoV-2 in a Proficiency Testing ProgramAt the onset of the US SARS-CoV-2 epidemic, testing was limited to the Centers for Disease Control and Prevention (CDC) and state public health laboratories using the CDC-developed reverse transcription (RT) polymerase chain reaction (PCR) assay.", [["SARS", "DISEASE", 177, 181], ["SARS", "DISEASE", 243, 247], ["SARS-CoV-2", "ORGANISM", 177, 187], ["SARS-CoV", "SPECIES", 177, 185], ["the virus", "PROBLEM", 43, 52], ["SARS", "PROBLEM", 177, 181], ["the US SARS", "TEST", 236, 247], ["CoV", "TEST", 248, 251], ["testing", "TEST", 264, 271], ["Disease Control", "TREATMENT", 303, 318], ["the CDC", "TEST", 383, 390], ["reverse transcription (RT) polymerase chain reaction", "PROBLEM", 401, 453], ["PCR", "TEST", 455, 458], ["rapid", "OBSERVATION_MODIFIER", 6, 11], ["widespread", "OBSERVATION_MODIFIER", 16, 26], ["virus", "OBSERVATION", 47, 52], ["SARS", "OBSERVATION", 177, 181]]], ["In early 2020, the urgent and massive demand for testing led to rapid development and validation of commercial and laboratorydeveloped assays to detect SARS-CoV-2.Identification of SARS-CoV-2 in a Proficiency Testing ProgramIn the United States, each clinical laboratory is required to verify performance of Food and DrugKey Points\u2022 Overall performance in this SARS-CoV-2 RNA detection challenge was excellent, providing confidence in the results of these new molecular tests. \u2022 Demand for quality SARS-CoV-2 tests is universal.", [["SARS", "DISEASE", 181, 185], ["SARS", "DISEASE", 361, 365], ["SARS-CoV-2", "ORGANISM", 152, 162], ["SARS-CoV", "SPECIES", 152, 160], ["SARS-CoV", "SPECIES", 181, 189], ["SARS-CoV", "SPECIES", 361, 369], ["testing", "TEST", 49, 56], ["commercial and laboratorydeveloped assays", "TEST", 100, 141], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160], ["SARS", "PROBLEM", 181, 185], ["this SARS", "TEST", 356, 365], ["CoV", "TEST", 366, 369], ["these new molecular tests", "TEST", 450, 475], ["quality SARS", "TEST", 490, 502], ["CoV-2 tests", "TEST", 503, 514]]], ["Laboratories from 46 states and 4 countries participated in the first US assessment of test accuracy. \u2022 Over 30 tests methods were reported by the more than 300 respondents in this challenge.Key PointsAdministration (FDA)-approved and/or validated laboratory diagnostic tests.", [["Laboratories", "TEST", 0, 12], ["the first US assessment", "TEST", 60, 83], ["test accuracy", "TEST", 87, 100], ["Over 30 tests methods", "TEST", 104, 125], ["laboratory diagnostic tests", "TEST", 248, 275]]], ["However, there is no standard for the number of samples to be included in a verification or the acceptable performance level.", [["a verification", "TEST", 74, 88], ["no", "UNCERTAINTY", 18, 20]]], ["5 This means there is considerable variation among laboratory verification studies, leading to concerns about reliability of test results.", [["laboratory verification studies", "TEST", 51, 82], ["test results", "TEST", 125, 137], ["considerable", "OBSERVATION_MODIFIER", 22, 34], ["variation", "OBSERVATION_MODIFIER", 35, 44]]], ["Globally, SARS-CoV-2 molecular tests are being performed in laboratories with a range of experience and technical capacity for nucleic acid amplification testing.", [["nucleic acid", "CHEMICAL", 127, 139], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["2 molecular tests", "TEST", 19, 36], ["technical capacity", "TEST", 104, 122], ["nucleic acid amplification testing", "TEST", 127, 161]]], ["The commercial and laboratory-developed tests, even if validated and approved for use by a regulatory body, have little performance history in wide deployment.", [["body", "ANATOMY", 102, 106], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["tests", "TEST", 40, 45]]], ["Therefore, an objective measure of system-wide product and laboratory quality is needed.Key PointsResults of SARS-CoV-2 testing are used not just for patient management but also for infection control in health care settings and for surveillance data that drive decisions on community-wide sheltering orders.", [["infection", "DISEASE", 182, 191], ["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157], ["SARS-CoV", "SPECIES", 109, 117], ["SARS", "TEST", 109, 113], ["CoV-2 testing", "TEST", 114, 127], ["patient management", "TREATMENT", 150, 168], ["infection", "PROBLEM", 182, 191], ["surveillance data", "TEST", 232, 249]]], ["SARS-CoV-2 test results are the cornerstone of contact tracing activities to control ongoing disease transmission.", [["SARS-CoV-2 test", "TEST", 0, 15], ["ongoing disease transmission", "PROBLEM", 85, 113]]], ["This study was undertaken to evaluate the performance of laboratories enrolled in a SARS-CoV-2 RT-PCR proficiency testing (PT) program and to assess reliability of test kits and methods.Key PointsThe American Proficiency Institute (API) is a PT provider approved by the federal Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).", [["SARS-CoV", "SPECIES", 84, 92], ["This study", "TEST", 0, 10], ["a SARS", "TEST", 82, 88], ["CoV", "TEST", 89, 92], ["PCR proficiency testing", "TEST", 98, 121], ["test kits", "TEST", 164, 173]]], ["5 API provides PT samples and performance analysis to over 20,000 laboratories with over 350 programs.", [["PT samples", "TEST", 15, 25], ["performance analysis", "TEST", 30, 50]]], ["Subscribing laboratories are shipped samples and instructed to test them in the same manner as patient specimens.", [["samples", "ANATOMY", 37, 44], ["specimens", "ANATOMY", 103, 112], ["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["patient specimens", "TEST", 95, 112]]], ["Each laboratory reports its results to API.", [["API", "TEST", 39, 42]]], ["Analysis of PT results has been useful in the past to reveal deficiencies in testing quality and has led to recommendations that improved testing accuracy.", [["Analysis of PT results", "TEST", 0, 22], ["deficiencies in testing quality", "PROBLEM", 61, 92], ["testing accuracy", "TEST", 138, 154], ["deficiencies", "OBSERVATION", 61, 73]]], ["6, 7 The ability of laboratories to correctly detect the presence or absence of SARS-CoV-2 has not previously been studied by CLIA-approved PT organizations.", [["SARS", "DISEASE", 80, 84], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["CLIA", "TEST", 126, 130]]], ["Data from these studies are important because they provide a snapshot of current laboratory practices and accuracy.Key PointsIn this report we present the results of the first US study of SARS-CoV-2 accuracy by API participant laboratories from the 2020 First Test Event.Materials and MethodsData were acquired from a single PT event, 2020 First Test Event, by API.", [["SARS", "DISEASE", 188, 192], ["SARS-CoV", "SPECIES", 188, 196], ["these studies", "TEST", 10, 23], ["the first US study", "TEST", 166, 184], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["MethodsData", "TEST", 285, 296]]], ["As part of this PT event, 2 samples (both noninfectious and manufactured by SeraCare) were shipped overnight in May 2020 to 346 laboratories enrolled in the API program.", [["samples", "ANATOMY", 28, 35]]], ["These subscribers represented domestic and international commercial laboratories, public health laboratories, clinics, hospitals, and diagnostic kit manufacturers.Materials and MethodsThe positive sample (COV-01), containing 5,175 viral copies/mL, was fully extractable with SARS-CoV-2 RNA encoding viral capsid protein and RNase P. It was prepared to be compatible with assays targeting the following regions: ORF1a, RdRp, S (spike), E (envelope), and N (nucleocapsid).", [["sample", "ANATOMY", 197, 203], ["RNase P.", "GENE_OR_GENE_PRODUCT", 324, 332], ["ORF1a", "GENE_OR_GENE_PRODUCT", 411, 416], ["RdRp", "GENE_OR_GENE_PRODUCT", 418, 422], ["S (spike)", "GENE_OR_GENE_PRODUCT", 424, 433], ["E (envelope)", "GENE_OR_GENE_PRODUCT", 435, 447], ["SARS-CoV-2 RNA", "RNA", 275, 289], ["viral capsid protein", "PROTEIN", 299, 319], ["RNase", "PROTEIN", 324, 329], ["ORF1a", "PROTEIN", 411, 416], ["RdRp", "PROTEIN", 418, 422], ["S", "PROTEIN", 424, 425], ["spike", "PROTEIN", 427, 432], ["E", "PROTEIN", 435, 436], ["N", "PROTEIN", 453, 454], ["nucleocapsid", "PROTEIN", 456, 468], ["COV", "TEST", 205, 208], ["SARS", "PROBLEM", 275, 279], ["CoV", "TEST", 280, 283], ["viral capsid protein and RNase P.", "PROBLEM", 299, 332], ["assays", "TEST", 371, 377], ["ORF1a", "TEST", 411, 416], ["RdRp", "TEST", 418, 422], ["viral capsid protein", "OBSERVATION", 299, 319]]], ["The negative sample (COV-02), with 3,951 viral copies/mL, contained recombinant virus particles with sequences for targeting sequences from human RNase P gene.", [["sample", "ANATOMY", 13, 19], ["human", "ORGANISM", 140, 145], ["RNase P", "GENE_OR_GENE_PRODUCT", 146, 153], ["human RNase P gene", "DNA", 140, 158], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["COV", "TEST", 21, 24], ["3,951 viral copies/mL", "PROBLEM", 35, 56], ["recombinant virus particles", "PROBLEM", 68, 95], ["targeting sequences", "TEST", 115, 134]]], ["The proficiency samples were formulated in viral transport media consisting of Tris-buffered saline, with added antimicrobial agents, glycerol, and human proteins.Materials and MethodsParticipating testing sites were located in 50 clinical point-of-care testing sites, 182 hospital-based laboratories, 37 independent laboratories, 3 diagnostic kit manufacturers, and 5 government care facilities; 17 testing sites did not indicate laboratory type.", [["samples", "ANATOMY", 16, 23], ["glycerol", "CHEMICAL", 134, 142], ["Tris", "CHEMICAL", 79, 83], ["glycerol", "CHEMICAL", 134, 142], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 79, 99], ["glycerol", "SIMPLE_CHEMICAL", 134, 142], ["human", "ORGANISM", 148, 153], ["human proteins", "PROTEIN", 148, 162], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["The proficiency samples", "TEST", 0, 23], ["viral transport media", "TREATMENT", 43, 64], ["Tris-buffered saline", "TREATMENT", 79, 99], ["antimicrobial agents", "TREATMENT", 112, 132], ["glycerol", "TREATMENT", 134, 142], ["human proteins", "TREATMENT", 148, 162], ["MethodsParticipating testing sites", "TEST", 177, 211], ["17 testing sites", "TEST", 397, 413]]], ["Participating laboratories were located in 46 US states and 4 international sites (Malaysia, Pakistan, Taiwan, and Vietnam.)Materials and MethodsLaboratories were instructed to submit the interpreted results (detected or not detected) for COV-01 and COV-02, and to provide the instrument and test kit used for testing the samples.", [["samples", "ANATOMY", 322, 329], ["COV-01", "CELL", 239, 245], ["COV-02", "CELL", 250, 256], ["COV", "TEST", 239, 242], ["COV-02", "TREATMENT", 250, 256], ["the instrument and test kit", "TEST", 273, 300], ["testing the samples", "TEST", 310, 329]]], ["Since laboratories using traditional PCR methods could participate, cycle threshold (Ct) values were not requested on the report.", [["traditional PCR methods", "TEST", 25, 48], ["cycle threshold", "TEST", 68, 83], ["Ct) values", "TEST", 85, 95]]], ["Of the 346 laboratories that received proficiency materials, 310 submitted results by the reporting deadline.", [["proficiency materials", "TREATMENT", 38, 59]]], ["The results from these samples were processed with proprietary software developed at API.ResultsCorrect positive results were reported by 302 laboratories (97.4%), with 8 laboratories incorrectly reporting negative results for COV-01 (2.6%).", [["COV-01", "SPECIES", 227, 233], ["these samples", "TEST", 17, 30], ["proprietary software", "TEST", 51, 71], ["COV", "TEST", 227, 230]]], ["Negative results were reported by laboratories using Applied Biosystems/ Quidel Lyra SARS-CoV-2 and Luminex ARIES SARS-CoV-2 and had correct negative results for COV-02.", [["CoV-2", "ORGANISM", 90, 95], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 114, 122], ["COV-02", "SPECIES", 162, 168], ["Biosystems", "TEST", 61, 71], ["Quidel Lyra SARS", "TEST", 73, 89], ["CoV", "TEST", 90, 93], ["Luminex ARIES SARS", "TEST", 100, 118], ["CoV", "TEST", 119, 122], ["COV", "TEST", 162, 165], ["02", "TREATMENT", 166, 168]]], ["For COV-02, 306 laboratories correctly reported negative results (98.3%) \u275aTable 1\u275a.", [["COV-02", "CELL", 4, 10], ["COV", "TEST", 4, 7]]], ["The 9 laboratories who reported a testing problem with sample COV-02 all used the BioGx SARS-CoV-2 reagent on the BD Max System.", [["a testing problem", "TEST", 32, 49], ["sample COV", "TEST", 55, 65], ["02", "TREATMENT", 66, 68], ["the BioGx SARS", "TEST", 78, 92], ["CoV", "TEST", 93, 96]]], ["BioGx users indicated that their results for sample COV-02 were \"unresolved\" due to an internal control failure and were thus nonreportable.", [["BioGx", "CHEMICAL", 0, 5], ["sample COV", "TEST", 45, 55], ["02", "TREATMENT", 56, 58], ["an internal control failure", "PROBLEM", 84, 111], ["failure", "OBSERVATION", 104, 111]]], ["The BioGx SARS-CoV-2 reagent (along with several other testing methods) requires human RNase P to be present in a sample to serve as an endogenous nucleic acid extraction control, which is present in all properly collected patient samples.", [["sample", "ANATOMY", 114, 120], ["samples", "ANATOMY", 231, 238], ["nucleic acid", "CHEMICAL", 147, 159], ["human", "ORGANISM", 81, 86], ["RNase P", "GENE_OR_GENE_PRODUCT", 87, 94], ["patient", "ORGANISM", 223, 230], ["human RNase P", "PROTEIN", 81, 94], ["human", "SPECIES", 81, 86], ["patient", "SPECIES", 223, 230], ["human", "SPECIES", 81, 86], ["The BioGx SARS", "TEST", 0, 14], ["CoV", "TEST", 15, 18], ["human RNase P", "TREATMENT", 81, 94], ["an endogenous nucleic acid extraction control", "TREATMENT", 133, 178]]], ["Sample COV-02 did contain 3,951 copies/mL of RNase P; however, this was very near the limit of detection for the BioGx reagent, resulting in 9 of 25 laboratories using the reagent recovering levels of RNase P below the required threshold of detection.Results\u275aTable 2\u275a shows that all types of laboratories performed well, with consensuses higher than 90%.", [["RNase", "GENE_OR_GENE_PRODUCT", 45, 50], ["RNase", "GENE_OR_GENE_PRODUCT", 201, 206], ["RNase P", "PROTEIN", 45, 52], ["RNase P", "PROTEIN", 201, 208], ["Sample COV", "TEST", 0, 10], ["RNase P", "TEST", 45, 52], ["the BioGx reagent", "TEST", 109, 126], ["laboratories", "TEST", 292, 304], ["consensuses", "TEST", 326, 337]]], ["The manufacturer's category was excluded due to a low number of participants.", [["participants", "SPECIES", 64, 76], ["The manufacturer's category", "TEST", 0, 27]]], ["False-negative results were reported by 4 independent laboratories, 4 hospital-based laboratories, and 1 diagnostic kit manufacturer.", [["negative", "OBSERVATION", 6, 14]]], ["All 5 laboratories that reported false-negative results for COV-01 also reported a falsepositive result for COV-02, indicating probable clerical errors during testing or reporting.ResultsAmong incorrect results reported in this proficiency challenge, 76.9% (10/13) were likely related to clerical error.", [["COV", "TEST", 60, 63], ["COV", "TEST", 108, 111], ["02", "TREATMENT", 112, 114], ["clerical errors", "PROBLEM", 136, 151], ["probable", "UNCERTAINTY", 127, 135], ["clerical errors", "OBSERVATION", 136, 151], ["likely related to", "UNCERTAINTY", 270, 287], ["clerical error", "OBSERVATION", 288, 302]]], ["With the implementation of the CLIA '88 rules, PT evolved from an educational self-assessment tool to a measure that is fundamental for trend analysis, risk management, and laboratory accreditation.", [["trend analysis", "TEST", 136, 150], ["risk management", "TREATMENT", 152, 167]]], ["Performance on PT is a vital, objective indicator of the quality of clinical testing.DiscussionMonitoring and analyzing PT results from a large group of participating clinical laboratories helps to assess the accuracy of test methods applied in a variety of settings and individual laboratory performance.", [["clinical testing", "TEST", 68, 84], ["DiscussionMonitoring", "TEST", 85, 105], ["analyzing PT results", "TEST", 110, 130], ["test methods", "TEST", 221, 233], ["individual laboratory performance", "TEST", 271, 304]]], ["The significance of this With an overall consensus greater than 97%, this SARS-CoV-2 RNA detection challenge indicates excellent accuracy by test participants when evaluated by testing method and type of laboratory.", [["participants", "SPECIES", 146, 158], ["this SARS", "TEST", 69, 78], ["CoV", "TEST", 79, 82], ["RNA detection challenge", "TEST", 85, 108]]], ["The results of this study should provide confidence in clinical laboratory test results for patient management and public health decisions.DiscussionThere are several limitations to this study.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["this study", "TEST", 15, 25], ["clinical laboratory test", "TEST", 55, 79], ["patient management", "TREATMENT", 92, 110], ["this study", "TEST", 182, 192]]], ["While PT materials are designed to mimic patient specimens and be stable, they are not exactly the same matrix and do not have the entire viral genome for safety considerations.", [["specimens", "ANATOMY", 49, 58], ["patient", "ORGANISM", 41, 48], ["matrix", "CELLULAR_COMPONENT", 104, 110], ["viral genome", "DNA", 138, 150], ["patient", "SPECIES", 41, 48], ["patient specimens", "TEST", 41, 58], ["stable", "OBSERVATION_MODIFIER", 66, 72], ["viral genome", "OBSERVATION", 138, 150]]], ["This limitation is demonstrated by the challenges that laboratories using Applied BioSystems/Quidel Lyra reported.", [["Applied BioSystems/Quidel Lyra", "TREATMENT", 74, 104]]], ["SARS-CoV-2 is not an analyte that CLIA requires PT for at this time.", [["SARS", "DISEASE", 0, 4], ["PT", "TREATMENT", 48, 50]]], ["Therefore, the results of this voluntary program do not reflect performance across all laboratories performing SARS-CoV-2 amplification assays.", [["this voluntary program", "TREATMENT", 26, 48], ["SARS", "TEST", 111, 115], ["CoV", "TEST", 116, 119], ["amplification assays", "TEST", 122, 142]]], ["Laboratories may have deployed multiple testing methods, but results are reported for only 1 method per laboratory.", [["multiple testing methods", "TEST", 31, 55]]], ["This study may not accurately represent the true scope of method deployment.", [["This study", "TEST", 0, 10], ["method deployment", "TREATMENT", 58, 75], ["may not accurately represent", "UNCERTAINTY", 11, 39], ["method deployment", "OBSERVATION", 58, 75]]], ["Finally, Ct values were not collected.", [["Ct values", "TEST", 9, 18]]], ["Ct value comparison for sites using the same quantitative PCR method may be valuable to assess interlaboratory variability.DiscussionNegative results for the COV-01 sample were reported by laboratories using Applied Biosystems/Quidel Lyra SARS-CoV-2 and Luminex ARIES SARS-CoV-2; these laboratories had correct negative results for the COV-02 sample.", [["SARS-CoV", "SPECIES", 239, 247], ["SARS-CoV", "SPECIES", 268, 276], ["Ct value comparison", "TEST", 0, 19], ["the same quantitative PCR method", "TEST", 36, 68], ["the COV", "TEST", 154, 161], ["Biosystems", "TEST", 216, 226], ["Quidel Lyra SARS", "TEST", 227, 243], ["CoV", "TEST", 244, 247], ["Luminex ARIES SARS", "TEST", 254, 272], ["CoV", "TEST", 273, 276], ["these laboratories", "TEST", 280, 298], ["the COV", "TEST", 332, 339], ["02 sample", "TEST", 340, 349]]], ["Upon further review, sample COV-01 lacked the target region (pp1ab) of the SARS-CoV-2 genome that is detected by the Quidel Lyra test system.", [["COV-01", "DNA", 28, 34], ["target region", "DNA", 46, 59], ["pp1ab", "DNA", 61, 66], ["SARS-CoV-2 genome", "DNA", 75, 92], ["SARS-CoV", "SPECIES", 75, 83], ["sample COV", "TEST", 21, 31], ["the SARS", "PROBLEM", 71, 79]]], ["Future PT challenge samples should include target gene sequences detected by all FDA-approved SARS-CoV-2 RNA assays.", [["samples", "ANATOMY", 20, 27], ["CoV-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["target gene sequences", "DNA", 43, 64], ["Future PT challenge samples", "TEST", 0, 27], ["target gene sequences", "TEST", 43, 64], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["RNA assays", "TEST", 105, 115]]], ["One of 6 laboratories using Luminex ARIES SARS-CoV-2 reported a negative result for COV-01 but reported expected results for COV-02.", [["COV-02", "CHEMICAL", 125, 131], ["COV-02", "CELL", 125, 131], ["COV-01", "SPECIES", 84, 90], ["COV-02", "SPECIES", 125, 131], ["Luminex ARIES SARS", "TEST", 28, 46], ["CoV", "TEST", 47, 50], ["COV", "TEST", 84, 87], ["COV", "TEST", 125, 128], ["02", "TREATMENT", 129, 131]]], ["This result pattern is not typical of clerical errors, and laboratories using this method should closely monitor test performance through heightened ongoing verification activities.DiscussionFive testing sites reported both a false negative for COV-01 and a false positive for COV-02, suggesting clerical errors.", [["clerical errors", "PROBLEM", 38, 53], ["this method", "TEST", 78, 89], ["test performance", "TEST", 113, 129], ["DiscussionFive testing sites", "TEST", 181, 209], ["COV", "TEST", 245, 248], ["COV", "TEST", 277, 280], ["clerical errors", "PROBLEM", 296, 311], ["not typical", "UNCERTAINTY", 23, 34], ["clerical errors", "OBSERVATION", 296, 311]]], ["Typical rate for clerical errors in reporting PT results is historically about 1%.", [["clerical errors", "PROBLEM", 17, 32]]], ["While clerical errors do not reveal lack of sensitivity or specificity of the test method, they have an equal impact on treatment, infection control, and disease control efforts.", [["infection", "DISEASE", 131, 140], ["the test method", "TEST", 74, 89], ["treatment", "TREATMENT", 120, 129], ["infection control", "TREATMENT", 131, 148], ["disease control efforts", "TREATMENT", 154, 177], ["infection", "OBSERVATION", 131, 140]]], ["Laboratories that do not meet expected performance on PT challenges due to clerical errors must investigate and correct the processes from which these errors arose.DiscussionCorresponding author: Daniel C. Edson; dedson@api-pt.com.", [["PT challenges", "TREATMENT", 54, 67], ["clerical errors", "PROBLEM", 75, 90]]]], "c9d2805a6e2d11bc2fbe0a66fd4900e2456c7e78": [["Also called lecture-based learning (LBL), this traditional teaching method has obvious shortcomings.", [["this traditional teaching method", "TREATMENT", 42, 74]]], ["Consequently, exploring a new teaching mode to promote students' acquisition of knowledge and skills has become an important current topic.IntroductionIn the early 1990s, Eric Mazur proposed the peer teaching method, the earliest form of flipping the classroom [3] .", [["a new teaching mode", "TREATMENT", 24, 43]]], ["In 2000, Baker recommended using online tools to guide classroom teaching [5] .", [["classroom teaching", "TREATMENT", 55, 73]]], ["Bergmann and Sams [6] , two high school chemistry teachers, started FCs in 2007.", [["Bergmann", "CELL", 0, 8]]], ["The FC is a novel teaching method that differs from traditional teaching.", [["traditional teaching", "TREATMENT", 52, 72]]], ["The focus on the FC is the student's accountability for their own learning, and a necessary reflective approach.", [["a necessary reflective approach", "TREATMENT", 80, 111]]], ["At present, the world is experiencing a serious epidemic caused by the coronavirus disease 2019 (COVID- 19) , and there is an extreme shortage of medical workers.", [["coronavirus disease", "DISEASE", 71, 90], ["the coronavirus disease", "PROBLEM", 67, 90], ["coronavirus disease", "OBSERVATION", 71, 90]]], ["A large volume of medical workers went to assist with the COVID-19 impact, but their numbers were still insufficient.", [["the COVID-19 impact", "TREATMENT", 54, 73], ["large", "OBSERVATION_MODIFIER", 2, 7], ["volume", "OBSERVATION_MODIFIER", 8, 14]]], ["Nurses are a necessary element of the treatment process.", [["the treatment process", "TREATMENT", 34, 55]]], ["To perform their roles, nurses were required substantial professional knowledge to face a variety of potential problems.", [["potential problems", "PROBLEM", 101, 119]]], ["However, the current didactic teaching delivery method does not help nursing students foster the ability to reason critically and apply theory to clinical situations [12] .", [["the current didactic teaching delivery method", "TREATMENT", 9, 54]]], ["Therefore, scholars have begun to seeking other effective methods to promote student enthusiasm and efficiency in nursing teaching [2, [13] [14] [15] .", [["[13] [14", "SIMPLE_CHEMICAL", 135, 143]]], ["However, the existing studies have not strictly treated the randomized controlled trial (RCT) as an inclusion criterion [20] [21] [22] .", [["[20] [21] [22]", "SIMPLE_CHEMICAL", 120, 134], ["the existing studies", "TEST", 9, 29]]], ["Excluding non-RCTs is a great way to improve the quality of the meta-analysis.IntroductionThe FC has been widely applied in various nursing education courses.", [["the meta-analysis", "TEST", 60, 77], ["IntroductionThe FC", "TREATMENT", 78, 96]]], ["There has been a systematic review, with a meta-analysis indicating that the flipped approach positively affects nursing students' skill competence [22] .", [["a systematic review", "TEST", 15, 34], ["a meta-analysis", "TEST", 41, 56]]], ["Since theory is the basis of practice, faculties usually set up theory courses in advance of practical operation to teach theoretical knowledge and furnish a theoretical basis.", [["practical operation", "TREATMENT", 93, 112]]], ["It is therefore necessary to conduct a meta-analysis to quantitatively analyze existing evidence in RCTs.", [["a meta-analysis", "TEST", 37, 52]]], ["Examples of search strategies are as follows: 1) The search strings were run in PubMed: (((flipped OR inverted)) AND (class OR learn)) AND (nursing[MeSH Terms] OR nurse education); 2) For Embase we used the strings: (flipped \ufffd OR inverted \ufffd ) AND (class \ufffd OR learn \ufffd ) AND (nursing \ufffd OR 'nurse education'); 3) In Chinese databases, the search terms were used as (flipped classroom OR inverted classroom) AND nursing.Inclusion criteriaAbstracts of all articles were used for preliminary screening, and obtained full articles for further screening.", [["preliminary screening", "TEST", 474, 495], ["further screening", "TEST", 528, 545]]], ["The inclusion criteria that met requirements were as follows: 1) The study must be designed as a randomized controlled trial; 2) The subjects were nursing undergraduates, higher and middle vocational students in schools rather than in hospitals; 3) The course of the study was related to nursing.", [["The study", "TEST", 65, 74], ["a randomized controlled trial", "TREATMENT", 95, 124], ["the study", "TEST", 263, 272]]], ["4) The experimental group received flipped teaching, consisting self-learning by video before class and problem-solving activities in class; 5) The control group received traditional lecture-based learning (LBL) method which was typically used in general classroom; 6) Objective-based assessment, such as theoretical knowledge test, was applied to evaluate students' learning outcomes and quantitative theory score was taken as an outcome; 7) Published articles were in Chinese.", [["flipped teaching", "TREATMENT", 35, 51], ["traditional lecture", "TREATMENT", 171, 190], ["learning (LBL) method", "TREATMENT", 197, 218], ["based assessment", "TEST", 279, 295], ["theoretical knowledge test", "TEST", 305, 331], ["quantitative theory score", "TEST", 389, 414]]], ["Articles would be excluded as long as met one of the criteria: 1) The study wasn't reported as a randomized controlled trial; 2) The subjects were interns or nurses in hospitals; 3) The control group did not use traditional teaching; 4) It didn't evaluate the theoretical scores as primary outcomes or had incomplete data; 5) The full text could not be obtained; 6) It was duplicate.Inclusion criteriaTwo searchers (CXR and XJC) screened the articles respectively.", [["CXR", "PROTEIN", 416, 419], ["The study", "TEST", 66, 75], ["traditional teaching", "TREATMENT", 212, 232], ["Inclusion criteriaTwo searchers", "TEST", 383, 414], ["CXR", "TEST", 416, 419]]], ["All results after screening would be taken into account.", [["screening", "TEST", 18, 27]]], ["All discrepancies were discussed and determined by a third party.Data extraction and quality assessmentRelevant information in the included articles was extracted by two researchers independently.", [["Data extraction", "TEST", 65, 80], ["quality assessment", "TEST", 85, 103]]], ["The information was extracted in a table which mainly included first author, publication year, educational background of subjects, disciplines or curricula, duration of intervention, sample size of the experimental group and control group, and test score index.", [["intervention", "TREATMENT", 169, 181], ["test score index", "TEST", 244, 260], ["size", "OBSERVATION_MODIFIER", 190, 194]]], ["The potential risk of bias was assessed by multiple researchers using the Cochrane Collaboration's tool [23] independently.Statistical analysisIn this study, Review Manager 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and STATA 14.0 software (STATA Corporation, College Station, TX, USA) were used to work with data.", [["this study", "TEST", 146, 156]]], ["The standardized mean value (SMD) with 95% confidence interval (CI) was used as the effect measure to compare consecutive results from different scales to calculate each study.", [["CI", "TEST", 64, 66], ["each study", "TEST", 165, 175]]], ["The point estimates associated with the summary results for each study were shown in forest plots.", [["each study", "TEST", 60, 70]]], ["Heterogeneity of meta-analysis was evaluated by I 2 statistic.", [["Heterogeneity of meta-analysis", "PROBLEM", 0, 30]]], ["And I 2 statistic with values >50% indicated significant heterogeneity in this study.", [["values", "TEST", 23, 29], ["this study", "TEST", 74, 84], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["heterogeneity", "OBSERVATION", 57, 70]]], ["SMD was combined with 95% CI by using random effect model with heterogeneity or fixed effect model without heterogeneity.", [["random effect model", "PROBLEM", 38, 57], ["fixed effect model", "PROBLEM", 80, 98], ["heterogeneity", "PROBLEM", 107, 120], ["heterogeneity", "OBSERVATION", 63, 76], ["fixed effect", "OBSERVATION", 80, 92], ["without", "UNCERTAINTY", 99, 106], ["heterogeneity", "OBSERVATION_MODIFIER", 107, 120]]], ["If heterogeneity existed, a sensitivity analysis was performed to investigate the impact of each study on the overall estimate.", [["a sensitivity analysis", "TEST", 26, 48], ["each study", "TEST", 92, 102]]], ["Publication bias was detected by the funnel plots using STATA 14.0 software.Search resultsAfter systematically searching related databases, a total of 2,439 records were retrieved.", [["Publication bias", "TEST", 0, 16]]], ["After 1,284 records were removed because of duplication, 1,155 records remained.", [["duplication", "PROBLEM", 44, 55]]], ["A total of 1,059 records were excluded after screening titles and abstracts.", [["screening titles", "TEST", 45, 61]]], ["After reading the full text, 41 records were excluded as non-randomized controlled trials and 23 because of missing or incomplete results.", [["non-randomized controlled trials", "TREATMENT", 57, 89], ["missing or incomplete results", "PROBLEM", 108, 137]]], ["Consequently, only 32 records were included in this meta-analysis.", [["this meta-analysis", "TEST", 47, 65]]], ["The flow of articles, screened according to the exclusion and inclusion criteria is shown in Fig 1.Study characteristics and study qualityIn total, 32 articles were included.", [["the exclusion", "TEST", 44, 57], ["inclusion criteria", "TEST", 62, 80], ["Study characteristics", "TEST", 99, 120], ["study quality", "TEST", 125, 138], ["flow", "OBSERVATION_MODIFIER", 4, 8]]], ["These studies' authors are all Chinese, and all articles have been published in Chinese journals.", [["These studies", "TEST", 0, 13]]], ["The studies involved 4,389 participants, of which 2,197 and 2,192 belonged to the FC and LBL groups, respectively.", [["LBL", "CANCER", 89, 92], ["participants", "SPECIES", 27, 39], ["The studies", "TEST", 0, 11]]], ["The sample size varied from 56 to 448 participants.", [["participants", "SPECIES", 38, 50], ["The sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15], ["varied", "OBSERVATION_MODIFIER", 16, 22]]], ["Nine studies [31, 33, 34, 38, 41, 42, 45, 50, 52] applied the FC mode to basic nursing teaching.", [["Nine studies", "TEST", 0, 12], ["basic nursing teaching", "TREATMENT", 73, 95]]], ["Three studies [30, 37, 54] used the FC in obstetrics and gynecology nursing.", [["Three studies", "TEST", 0, 13]]], ["The length of the teaching intervention varied from 24 class hours to two semesters.", [["the teaching intervention", "TREATMENT", 14, 39], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The knowledge examination scores were used to evaluate students' theoretical knowledge.", [["The knowledge examination scores", "TEST", 0, 32]]], ["The baseline characteristics of the included studies are shown in Table 1 .", [["the included studies", "TEST", 32, 52]]], ["Funnel plots of the theoretical knowledge scores were used to assess publication bias, which was found to be present ( Fig 2) The risk of bias in all included articles is shown in Fig 3.", [["Funnel plots", "TEST", 0, 12], ["publication bias", "TEST", 69, 85]]], ["All included studies were RCTs, but only four illustrated their randomized sequence generation methods.", [["All included studies", "TEST", 0, 20], ["RCTs", "TEST", 26, 30]]], ["None of the studies describe their allocation concealment and the blinding of outcome assessments.", [["the studies", "TEST", 8, 19], ["outcome assessments", "TEST", 78, 97]]], ["Only one reported applying the blinding process to participants and personnel.", [["participants", "SPECIES", 51, 63]]], ["None of these studies were conducted in a way to indicate whether data were missing or excluded and whether there had been selective reporting.The effects of FC on theoretical knowledge scoresTheoretical knowledge scores were reported in all the included studies (2197 and 2192 in the FC and LBL groups, respectively).", [["these studies", "TEST", 8, 21], ["Theoretical knowledge scores", "PROBLEM", 192, 220], ["FC", "OBSERVATION_MODIFIER", 158, 160]]], ["The mean of the theoretical knowledge scores in the FC was 1.33 compared to the traditional classroom (95%CI: 1.02-1.64; P < 0.001).", [["CI", "TEST", 106, 108], ["P", "TEST", 121, 122], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["A meta-analysis ofPLOS ONEFlipped classroom improves nursing students' theoretical learning in China of students' feedback, as it pertains to cooperative spirit and self-management, were represented in two respective forest plots respectively (Fig 6) .", [["self-management", "TREATMENT", 165, 180]]], ["In general, student feedback from the FC group was better than that from the LBL group.How the FC affected different characteristicsPublication year, educational background, and subject were each considered a subgroup.", [["FC", "CANCER", 38, 40], ["LBL", "CANCER", 77, 80]]], ["Analysis revealed that in some segments of the subgroups, the theoretical scores of the FC group were higher than that of the LBL group.", [["FC", "CANCER", 88, 90], ["LBL", "CANCER", 126, 129], ["Analysis", "TEST", 0, 8], ["some", "OBSERVATION_MODIFIER", 26, 30], ["segments", "OBSERVATION_MODIFIER", 31, 39], ["subgroups", "OBSERVATION_MODIFIER", 47, 56], ["theoretical", "OBSERVATION_MODIFIER", 62, 73], ["scores", "OBSERVATION_MODIFIER", 74, 80], ["FC", "OBSERVATION_MODIFIER", 88, 90], ["higher", "OBSERVATION_MODIFIER", 102, 108]]], ["Moreover, there was significant heterogeneity among the different subgroups (I 2 > 50%), indicating that these three characteristics were irrelevant to heterogeneity.", [["significant heterogeneity", "PROBLEM", 20, 45], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["heterogeneity", "OBSERVATION", 32, 45], ["different", "OBSERVATION_MODIFIER", 56, 65], ["subgroups", "OBSERVATION_MODIFIER", 66, 75]]], ["This meta-analysis was limited by low reliability because these subgroups were unable to reduce the level of heterogeneity.Sensitivity analysisSensitivity analyses were conducted in this meta-analysis.", [["This meta-analysis", "TEST", 0, 18], ["low reliability", "PROBLEM", 34, 49], ["Sensitivity analysisSensitivity analyses", "TEST", 123, 163], ["this meta-analysis", "TEST", 182, 200], ["heterogeneity", "OBSERVATION", 109, 122]]], ["To assess the statistical stability of the results, the impact of a single dataset on the combined results was shown after removing a single study.", [["a single study", "TEST", 132, 146]]], ["The results of the sensitivity analyses of the FC and LBL are shown in Fig 7.", [["LBL", "CANCER", 54, 57], ["the sensitivity analyses", "TEST", 15, 39], ["the FC and LBL", "TEST", 43, 57]]], ["For the flipped classroom, there were no excluded studies.", [["no excluded", "UNCERTAINTY", 38, 49]]], ["The results pertaining to the theoretical scores were statistically stable (Estimate = 1.04, 95% CI: 0.98-1.11, P < 0.001).DiscussionThis 34-study meta-analysis of summarized Chinese nursing students' relevant outcomes, including theoretical test and skill scores.", [["the theoretical scores", "TEST", 26, 48], ["Estimate", "TEST", 76, 84], ["CI", "TEST", 97, 99], ["P", "TEST", 112, 113], ["theoretical test", "TEST", 230, 246], ["skill scores", "TEST", 251, 263], ["stable", "OBSERVATION_MODIFIER", 68, 74]]], ["The results of this study indicated that the FC mode produced a significantly higher theoretical scores than the LBL mode, with a mean theoretical knowledge score of 1.33 for the former.", [["this study", "TEST", 15, 25], ["the FC mode", "TEST", 41, 52], ["a significantly higher theoretical scores", "PROBLEM", 62, 103]]], ["These results are consistent with previous results in pharmaceutical [56] , dental [18] , and ophthalmology [57] education.", [["consistent with", "UNCERTAINTY", 18, 33]]], ["Furthermore, the results of this review showed that effects of the FC on undergraduate and higher vocational students were almost the same and that both which were better than LBL teaching.", [["this review", "TEST", 28, 39]]], ["It meant that using the FC was effective in different educational backgrounds.", [["the FC", "TREATMENT", 20, 26]]], ["There are some explanations for the more active student learning and the better effect of the FC over the LBL.", [["LBL", "DISEASE", 106, 109], ["LBL", "CANCER", 106, 109], ["the FC over the LBL", "TREATMENT", 90, 109]]], ["Some scholars have recognized the traditional classroom's limitations; hence, it is very important to change or improve LBL teaching, given that faculty members teaching experiences and the teaching methods that they choose influence students' learning feedback [58] .", [["LBL teaching", "TREATMENT", 120, 132]]], ["Inadequate teaching leads to low efficiency among teachers, which among teachers in students' inattention during class.", [["inattention", "DISEASE", 94, 105], ["low efficiency", "OBSERVATION_MODIFIER", 29, 43]]], ["The FC is one of several feasible teaching modes.", [["FC", "OBSERVATION", 4, 6]]], ["Based on various massive open online course (MOOC) platforms, the FC mode can be applied to numerous curricula, with students choosing an appropriate MOOC video for self-learning toward the overarching goal of improving their learning efficiency.", [["various massive open online course", "TREATMENT", 9, 43], ["MOOC) platforms", "TREATMENT", 45, 60], ["the FC mode", "TREATMENT", 62, 73], ["massive", "OBSERVATION_MODIFIER", 17, 24], ["open", "OBSERVATION", 25, 29]]], ["In this meta-analysis, the FC improved students' theoretical performance, but its effect was not as beneficial with respect to skill performance Therefore, instructional designers should make full use of MOOCs to further improve students' theoretical performance.PLOS ONEAs one of the most populous countries in the world, with unmet needs of nurse number and various quality of nursing education, China needs to equip itself to deal with a large complex healthcare system [65] .", [["MOOCs", "TREATMENT", 204, 209], ["nursing education", "TREATMENT", 379, 396]]], ["Besides, in China, the study load and duration of nursing programs are high.", [["the study load", "TEST", 19, 33], ["nursing programs", "TREATMENT", 50, 66]]], ["Moreover, Lee et al. [66] illustrated that nursing students need to study not only nursing but also other medical courses such as medical physics, microbiology, parasitology, and preventive medicine.", [["preventive medicine", "TREATMENT", 179, 198]]], ["However, Limited content can be learned in the restricted time, and it's very difficult for students to master a large volume of professional knowledge in such a short time.", [["large", "OBSERVATION_MODIFIER", 113, 118]]], ["This meta-analysis suggests that the flipped teaching mode significantly increases students' theoretical scores, comparing favorably with the LBL mode.", [["This meta-analysis", "TEST", 0, 18], ["the flipped teaching mode", "PROBLEM", 33, 58]]], ["In future, the FC mode is worth using in nursing education.PLOS ONEApart from the FC mode, there are other novel teaching modes, such as problem-based learning (PBL), case-based learning (CBL), and team-based learning (TBL).", [["PBL", "CELL_TYPE", 161, 164], ["novel teaching modes", "TREATMENT", 107, 127]]], ["PBL mode concentrates on the process of students discovering and solving problems [67] .", [["PBL", "CELL_TYPE", 0, 3]]], ["A variety of teaching models have been used in various areas of professional teaching.", [["teaching models", "TREATMENT", 13, 28], ["professional teaching", "TREATMENT", 64, 85]]], ["For instance, Hu [70] applied the mixed FC and PBL teaching mode Similarly, Elangovan et al. [71] integrated PBL and CBL in dental education.", [["PBL", "CELL", 109, 112], ["PBL", "CELL_TYPE", 109, 112], ["CBL", "PROTEIN", 117, 120], ["the mixed FC and PBL teaching mode", "TREATMENT", 30, 64], ["CBL in dental education", "TREATMENT", 117, 140]]], ["Moreover, a mixed mode that combined the FC with team-, case-, lecture-, and evidence-based learning in ophthalmology teaching yielded only improved independent learning among students, but also an awareness of cooperation and competition [72] .PLOS ONEThere are some strengths in this meta-analysis.", [["this meta-analysis", "TEST", 281, 299]]], ["Theoretical score is considered as the first outcome and skill score as second outcome to compare the effects of the FC and LBL in this review.", [["Theoretical score", "TEST", 0, 17]]], ["Besides, The FC mode in nursing education is popular and has been applied to ensure its effect.", [["nursing education", "TREATMENT", 24, 41]]], ["In this meta-analysis, all studies were RCTs and had different educational backgrounds, which were examined to judge whether different educational backgrounds would affect the effect of the new teaching mode.PLOS ONEThis meta-analysis had several limitations.", [["all studies", "TEST", 23, 34], ["RCTs", "TEST", 40, 44]]], ["First, with regard to the geographical generalizability of the results, only Chinese articles met the screening criteria and were included in this study; thus, this study is only able to evaluate the FC's implementation effect in China or Asia, as it would be difficult to a make such an assessment in other regions.", [["the screening criteria", "TEST", 98, 120], ["this study", "TEST", 142, 152], ["this study", "TEST", 160, 170], ["an assessment", "TEST", 285, 298]]], ["Second, the included studies had significant heterogeneity, which may have reduced the reliability of the analysis.", [["the included studies", "TEST", 8, 28], ["significant heterogeneity", "PROBLEM", 33, 58], ["the analysis", "TEST", 102, 114], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["heterogeneity", "OBSERVATION", 45, 58]]], ["Furthermore, study quality was uneven because of different teaching resources, levels and evaluation standards in different schools.", [["study quality", "TEST", 13, 26], ["evaluation", "TEST", 90, 100]]], ["Third, the funnel plot for theoretical scores revealed asymmetry, indicating a publication bias.ConclusionThe results of this meta-analysis suggest that compared to the LBL teaching method, FC mode significantly improved Chinese nursing students' theoretical scores.", [["the funnel plot", "TEST", 7, 22], ["theoretical scores", "TEST", 27, 45], ["asymmetry", "PROBLEM", 55, 64], ["a publication bias", "PROBLEM", 77, 95], ["this meta-analysis", "TEST", 121, 139], ["the LBL teaching method", "TREATMENT", 165, 188], ["asymmetry", "OBSERVATION", 55, 64], ["publication bias", "OBSERVATION", 79, 95]]], ["However, high heterogeneity and publication bias were present, which may have influenced the reliability of the FC effect in the context of nursing teaching.", [["high heterogeneity and publication bias", "PROBLEM", 9, 48], ["nursing teaching", "TREATMENT", 140, 156], ["high", "OBSERVATION_MODIFIER", 9, 13], ["heterogeneity", "OBSERVATION", 14, 27]]], ["High-quality, multi-regional studies should be feature in future analysis.ConclusionSupporting information S1", [["multi-regional studies", "TEST", 14, 36], ["future analysis", "TEST", 58, 73]]]], "afc020f334c233b7281d9533a3108639bf7d9bcf": [["Angiotensin-converting enzyme (ACE) and its homologue angiotensinconverting enzyme 2 (ACE2) are critical counter-regulatory enzymes of the renin-angiotensin system, and have been implicated in cardiac function, renal disease, diabetes, atherosclerosis and acute lung injury.", [["cardiac", "ANATOMY", 193, 200], ["renal", "ANATOMY", 211, 216], ["lung", "ANATOMY", 262, 266], ["Angiotensin", "CHEMICAL", 0, 11], ["angiotensin", "CHEMICAL", 145, 156], ["renal disease", "DISEASE", 211, 224], ["diabetes", "DISEASE", 226, 234], ["atherosclerosis", "DISEASE", 236, 251], ["acute lung injury", "DISEASE", 256, 273], ["Angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 0, 29], ["ACE", "GENE_OR_GENE_PRODUCT", 31, 34], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 54, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 139, 156], ["cardiac", "ORGAN", 193, 200], ["renal", "ORGAN", 211, 216], ["lung", "ORGAN", 262, 266], ["Angiotensin-converting enzyme", "PROTEIN", 0, 29], ["ACE", "PROTEIN", 31, 34], ["homologue angiotensinconverting enzyme 2", "PROTEIN", 44, 84], ["ACE2", "PROTEIN", 86, 90], ["regulatory enzymes", "PROTEIN", 113, 131], ["renin", "PROTEIN", 139, 144], ["Angiotensin", "TEST", 0, 11], ["enzyme", "TEST", 23, 29], ["ACE", "TEST", 31, 34], ["its homologue angiotensinconverting enzyme", "TEST", 40, 82], ["ACE2", "TEST", 86, 90], ["critical counter", "TEST", 96, 112], ["the renin", "TEST", 135, 144], ["renal disease", "PROBLEM", 211, 224], ["diabetes", "PROBLEM", 226, 234], ["atherosclerosis", "PROBLEM", 236, 251], ["acute lung injury", "PROBLEM", 256, 273], ["cardiac", "ANATOMY", 193, 200], ["function", "OBSERVATION", 201, 209], ["renal", "ANATOMY", 211, 216], ["disease", "OBSERVATION", 217, 224], ["diabetes", "OBSERVATION", 226, 234], ["atherosclerosis", "OBSERVATION", 236, 251], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["lung", "ANATOMY", 262, 266], ["injury", "OBSERVATION", 267, 273]]], ["Both ACE and ACE2 have catalytic activity that is chloride sensitive and is caused by the presence of the CL1 and CL2 chloride-binding sites in ACE and the CL1 site in ACE2.", [["chloride", "CHEMICAL", 50, 58], ["chloride", "CHEMICAL", 118, 126], ["chloride", "CHEMICAL", 50, 58], ["chloride", "CHEMICAL", 118, 126], ["ACE", "GENE_OR_GENE_PRODUCT", 5, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["chloride", "SIMPLE_CHEMICAL", 50, 58], ["CL1", "GENE_OR_GENE_PRODUCT", 106, 109], ["CL2", "GENE_OR_GENE_PRODUCT", 114, 117], ["ACE", "GENE_OR_GENE_PRODUCT", 144, 147], ["CL1", "GENE_OR_GENE_PRODUCT", 156, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 168, 172], ["ACE", "PROTEIN", 5, 8], ["ACE2", "PROTEIN", 13, 17], ["CL1 and CL2 chloride-binding sites", "DNA", 106, 140], ["ACE", "PROTEIN", 144, 147], ["CL1 site", "DNA", 156, 164], ["ACE2", "PROTEIN", 168, 172], ["Both ACE", "TREATMENT", 0, 8], ["ACE2", "TREATMENT", 13, 17], ["the CL1", "PROBLEM", 102, 109], ["CL2 chloride", "TREATMENT", 114, 126], ["binding sites", "PROBLEM", 127, 140], ["ACE", "TREATMENT", 144, 147], ["catalytic activity", "OBSERVATION", 23, 41], ["CL1", "ANATOMY", 106, 109], ["CL1", "ANATOMY", 156, 159]]], ["The chloride regulation of activity is also substrate dependent.", [["chloride", "CHEMICAL", 4, 12], ["chloride", "CHEMICAL", 4, 12], ["chloride", "SIMPLE_CHEMICAL", 4, 12], ["activity", "OBSERVATION_MODIFIER", 27, 35], ["dependent", "OBSERVATION_MODIFIER", 54, 63]]], ["Site-directed mutagenesis was employed to elucidate which of the CL1 and CL2 site residues are responsible for chloride sensitivity.", [["chloride", "CHEMICAL", 111, 119], ["chloride", "CHEMICAL", 111, 119], ["CL1", "GENE_OR_GENE_PRODUCT", 65, 68], ["CL2", "GENE_OR_GENE_PRODUCT", 73, 76], ["chloride", "SIMPLE_CHEMICAL", 111, 119], ["CL1 and CL2 site residues", "DNA", 65, 90], ["the CL1 and CL2 site residues", "PROBLEM", 61, 90], ["chloride sensitivity", "PROBLEM", 111, 131], ["CL1", "ANATOMY", 65, 68]]], ["The CL1 site residues Arg186, Trp279 and Arg489 of testicular ACE and the equivalent ACE2 residues Arg169, Trp271 and Lys481 were found to be critical to chloride sensitivity.", [["testicular", "ANATOMY", 51, 61], ["chloride", "CHEMICAL", 154, 162], ["Arg", "CHEMICAL", 22, 25], ["Trp279", "CHEMICAL", 30, 36], ["Arg", "CHEMICAL", 99, 102], ["Trp271", "CHEMICAL", 107, 113], ["Lys481", "CHEMICAL", 118, 124], ["chloride", "CHEMICAL", 154, 162], ["CL1", "GENE_OR_GENE_PRODUCT", 4, 7], ["Arg186", "AMINO_ACID", 22, 28], ["Trp279", "GENE_OR_GENE_PRODUCT", 30, 36], ["Arg489", "AMINO_ACID", 41, 47], ["testicular ACE", "GENE_OR_GENE_PRODUCT", 51, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["Arg169", "AMINO_ACID", 99, 105], ["Trp271", "GENE_OR_GENE_PRODUCT", 107, 113], ["Lys481", "AMINO_ACID", 118, 124], ["chloride", "SIMPLE_CHEMICAL", 154, 162], ["CL1 site", "DNA", 4, 12], ["testicular ACE", "PROTEIN", 51, 65], ["ACE2", "PROTEIN", 85, 89], ["Arg", "TEST", 22, 25], ["Trp279", "TEST", 30, 36], ["testicular ACE", "TREATMENT", 51, 65], ["the equivalent ACE2 residues Arg", "TEST", 70, 102], ["Trp271", "TEST", 107, 113], ["testicular", "ANATOMY", 51, 61]]], ["Arg522 of testicular ACE was also confirmed to be vital to the chloride regulation mediated by the CL2 site.", [["testicular", "ANATOMY", 10, 20], ["chloride", "CHEMICAL", 63, 71], ["chloride", "CHEMICAL", 63, 71], ["Arg522", "GENE_OR_GENE_PRODUCT", 0, 6], ["testicular", "ORGAN", 10, 20], ["ACE", "GENE_OR_GENE_PRODUCT", 21, 24], ["chloride", "SIMPLE_CHEMICAL", 63, 71], ["CL2", "GENE_OR_GENE_PRODUCT", 99, 102], ["testicular ACE", "PROTEIN", 10, 24], ["CL2 site", "DNA", 99, 107], ["testicular ACE", "TREATMENT", 10, 24], ["the chloride regulation", "TREATMENT", 59, 82], ["testicular", "ANATOMY", 10, 20]]], ["In addition, Arg514 of ACE2 was identified as a residue critical to substrate selectivity, with the R514Q mutant, relative to the wild-type, possessing a fourfold greater selectivity for the formation of the vasodilator angiotensin-(1-7) from the vasoconstrictor angiotensin II.", [["Arg514", "CHEMICAL", 13, 19], ["angiotensin-(1-7)", "CHEMICAL", 220, 237], ["angiotensin II", "CHEMICAL", 263, 277], ["Arg", "CHEMICAL", 13, 16], ["Arg514", "SIMPLE_CHEMICAL", 13, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["R514Q", "GENE_OR_GENE_PRODUCT", 100, 105], ["angiotensin-(1-7", "GENE_OR_GENE_PRODUCT", 220, 236], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 263, 277], ["ACE2", "PROTEIN", 23, 27], ["R514Q mutant", "PROTEIN", 100, 112], ["vasoconstrictor angiotensin II", "PROTEIN", 247, 277], ["ACE2", "TEST", 23, 27], ["the vasodilator angiotensin", "TREATMENT", 204, 231], ["the vasoconstrictor angiotensin II", "TREATMENT", 243, 277], ["vasodilator angiotensin", "OBSERVATION", 208, 231], ["vasoconstrictor angiotensin", "OBSERVATION", 247, 274]]], ["The enhancement of angiotensin II cleavage by R514Q ACE2 was a result of a 2.5-fold increase in V max compared with the wild-type.", [["angiotensin II", "CHEMICAL", 19, 33], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 19, 33], ["R514Q ACE2", "GENE_OR_GENE_PRODUCT", 46, 56], ["angiotensin II", "PROTEIN", 19, 33], ["R514Q ACE2", "PROTEIN", 46, 56], ["angiotensin II cleavage", "PROBLEM", 19, 42], ["a 2.5-fold increase in V max", "PROBLEM", 73, 101], ["enhancement", "OBSERVATION_MODIFIER", 4, 15], ["angiotensin II cleavage", "OBSERVATION", 19, 42], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["V max", "OBSERVATION_MODIFIER", 96, 101]]], ["Inhibition of ACE2 was also found to be chloride sensitive, as for testicular ACE, with residues Arg169 and Arg514 of ACE2 identified as influencing the potency of the ACE2-specific inhibitor MLN-4760.", [["testicular", "ANATOMY", 67, 77], ["chloride", "CHEMICAL", 40, 48], ["MLN-4760", "CHEMICAL", 192, 200], ["chloride", "CHEMICAL", 40, 48], ["Arg", "CHEMICAL", 97, 100], ["Arg514", "CHEMICAL", 108, 114], ["MLN-4760", "CHEMICAL", 192, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["chloride", "SIMPLE_CHEMICAL", 40, 48], ["testicular", "ORGAN", 67, 77], ["ACE", "GENE_OR_GENE_PRODUCT", 78, 81], ["Arg169", "AMINO_ACID", 97, 103], ["Arg514", "AMINO_ACID", 108, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["ACE2", "GENE_OR_GENE_PRODUCT", 168, 172], ["MLN-4760", "SIMPLE_CHEMICAL", 192, 200], ["ACE2", "PROTEIN", 14, 18], ["testicular ACE", "PROTEIN", 67, 81], ["ACE2", "PROTEIN", 118, 122], ["ACE2", "PROTEIN", 168, 172], ["Inhibition of ACE2", "TEST", 0, 18], ["chloride", "TEST", 40, 48], ["testicular ACE", "TEST", 67, 81], ["residues Arg", "TEST", 88, 100], ["ACE2", "TEST", 118, 122], ["the ACE2", "TEST", 164, 172], ["testicular", "ANATOMY", 67, 77]]], ["Consequently, important insights into the chloride sensitivity, substrate selectivity and inhibition of testicular ACE and ACE2 were elucidated. has two homologous domains (N-and C-domains), and each of these contains an active site. tACE only possesses a single catalytic domain, which corresponds to the C-domain of sACE.", [["testicular", "ANATOMY", 104, 114], ["chloride", "CHEMICAL", 42, 50], ["tACE", "CHEMICAL", 234, 238], ["chloride", "CHEMICAL", 42, 50], ["chloride", "SIMPLE_CHEMICAL", 42, 50], ["testicular ACE", "GENE_OR_GENE_PRODUCT", 104, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 123, 127], ["sACE", "GENE_OR_GENE_PRODUCT", 318, 322], ["testicular ACE", "PROTEIN", 104, 118], ["ACE2", "PROTEIN", 123, 127], ["N-and C-domains", "PROTEIN", 173, 188], ["tACE", "PROTEIN", 234, 238], ["catalytic domain", "PROTEIN", 263, 279], ["C-domain", "PROTEIN", 306, 314], ["sACE", "PROTEIN", 318, 322], ["the chloride sensitivity", "TEST", 38, 62], ["testicular ACE and ACE2", "TREATMENT", 104, 127], ["an active site", "PROBLEM", 218, 232], ["tACE", "TREATMENT", 234, 238], ["a single catalytic domain", "PROBLEM", 254, 279], ["testicular", "ANATOMY", 104, 114], ["active", "OBSERVATION", 221, 227], ["single", "OBSERVATION_MODIFIER", 256, 262], ["catalytic domain", "OBSERVATION", 263, 279], ["sACE", "OBSERVATION_MODIFIER", 318, 322]]]], "PMC6483994": [["IntroductionGenes encoding epigenetic modifiers are among the most frequently mutated in hematopoietic malignancies.1,2 It has been suggested that dysfunctions in these genes, such as TET2, DNMT3A, and IDH1/2, promote leukemogenesis by blocking the differentiation of hematopoietic stem and progenitor cells (HSPCs).3\u20137 Our previous studies identified Mixed Lineage Leukemia 3 (MLL3, officially known as KMT2C) on chromosome 7q as a tumor suppressor gene.8 Haploinsufficiency of Mll3 impairs HSPC differentiation and leads to (myelodysplastic syndrome) MDS-like phenotypes.", [["hematopoietic malignancies", "ANATOMY", 89, 115], ["hematopoietic stem", "ANATOMY", 268, 286], ["progenitor cells", "ANATOMY", 291, 307], ["HSPCs", "ANATOMY", 309, 314], ["chromosome 7q", "ANATOMY", 414, 427], ["tumor", "ANATOMY", 433, 438], ["HSPC", "ANATOMY", 492, 496], ["hematopoietic malignancies", "DISEASE", 89, 115], ["1,2", "CHEMICAL", 116, 119], ["leukemogenesis", "DISEASE", 218, 232], ["tumor", "DISEASE", 433, 438], ["myelodysplastic syndrome", "DISEASE", 527, 551], ["MDS", "DISEASE", 553, 556], ["hematopoietic malignancies", "CANCER", 89, 115], ["TET2", "GENE_OR_GENE_PRODUCT", 184, 188], ["DNMT3A", "GENE_OR_GENE_PRODUCT", 190, 196], ["IDH1/2", "GENE_OR_GENE_PRODUCT", 202, 208], ["hematopoietic stem and progenitor cells", "CELL", 268, 307], ["HSPCs", "CELL", 309, 314], ["Mixed Lineage Leukemia 3", "GENE_OR_GENE_PRODUCT", 352, 376], ["MLL3", "GENE_OR_GENE_PRODUCT", 378, 382], ["KMT2C", "GENE_OR_GENE_PRODUCT", 404, 409], ["chromosome 7q", "CELLULAR_COMPONENT", 414, 427], ["tumor", "CANCER", 433, 438], ["Mll3", "GENE_OR_GENE_PRODUCT", 479, 483], ["HSPC", "CELL", 492, 496], ["TET2", "DNA", 184, 188], ["DNMT3A", "DNA", 190, 196], ["IDH1", "DNA", 202, 206], ["hematopoietic stem and progenitor cells", "CELL_TYPE", 268, 307], ["HSPCs", "CELL_TYPE", 309, 314], ["MLL3", "DNA", 378, 382], ["KMT2C", "DNA", 404, 409], ["chromosome 7q", "DNA", 414, 427], ["tumor suppressor gene", "DNA", 433, 454], ["Mll3", "PROTEIN", 479, 483], ["IntroductionGenes encoding epigenetic modifiers", "TREATMENT", 0, 47], ["hematopoietic malignancies", "PROBLEM", 89, 115], ["dysfunctions in these genes", "PROBLEM", 147, 174], ["TET2, DNMT3A", "PROBLEM", 184, 196], ["IDH1/2", "PROBLEM", 202, 208], ["hematopoietic stem", "TREATMENT", 268, 286], ["Our previous studies", "TEST", 320, 340], ["Mixed Lineage Leukemia", "PROBLEM", 352, 374], ["a tumor suppressor gene", "TREATMENT", 431, 454], ["Haploinsufficiency of Mll3 impairs HSPC differentiation", "PROBLEM", 457, 512], ["myelodysplastic syndrome)", "PROBLEM", 527, 552], ["MDS-like phenotypes", "PROBLEM", 553, 572], ["hematopoietic malignancies", "OBSERVATION", 89, 115], ["dysfunctions", "OBSERVATION", 147, 159], ["hematopoietic stem", "OBSERVATION", 268, 286], ["Mixed", "OBSERVATION_MODIFIER", 352, 357], ["Lineage Leukemia", "OBSERVATION", 358, 374], ["tumor suppressor", "OBSERVATION", 433, 449], ["Haploinsufficiency", "OBSERVATION", 457, 475], ["impairs HSPC differentiation", "OBSERVATION", 484, 512], ["myelodysplastic syndrome", "OBSERVATION", 527, 551]]], ["Mll3 (or Mll4), H3K4 mono- and dimethyltransferase, forms the COMPASS-like complex with an H3K27 demethylase Utx (Ubiquitously transcribed tetratricopeptide repeat on chromosome X, officially named as KDM6A) and other components.9\u201312 Therefore, the COMPASS-like complex can regulate target gene expressions by simultaneously modifying both H3K4 and H3K27.13,14IntroductionInterestingly, UTX is highly frequently mutated in human blood malignancies and solid cancers.15\u201320 For example, UTX is mutated in approximately 10% chronic myelomonocytic leukemia (CMML) and CMML-derived acute myeloid leukemia (AML) patients and 20% acute lymphoblastic leukemia (ALL) patients.5,14,21UTX is essential for multiple biological processes including stem cell self-renewal, embryogenesis, and posterior development.22\u201325 In cancer biology, UTX is considered as a tumor suppressor gene of various cancers.", [["blood malignancies", "ANATOMY", 429, 447], ["solid cancers", "ANATOMY", 452, 465], ["chronic myelomonocytic leukemia", "ANATOMY", 521, 552], ["CMML", "ANATOMY", 554, 558], ["CMML", "ANATOMY", 564, 568], ["acute myeloid leukemia", "ANATOMY", 577, 599], ["AML", "ANATOMY", 601, 604], ["acute lymphoblastic leukemia", "ANATOMY", 623, 651], ["ALL", "ANATOMY", 653, 656], ["stem cell", "ANATOMY", 735, 744], ["cancer", "ANATOMY", 809, 815], ["tumor", "ANATOMY", 848, 853], ["cancers", "ANATOMY", 881, 888], ["blood malignancies", "DISEASE", 429, 447], ["solid cancers", "DISEASE", 452, 465], ["UTX", "CHEMICAL", 485, 488], ["chronic myelomonocytic leukemia", "DISEASE", 521, 552], ["CMML", "DISEASE", 554, 558], ["CMML", "DISEASE", 564, 568], ["acute myeloid leukemia", "DISEASE", 577, 599], ["AML", "DISEASE", 601, 604], ["acute lymphoblastic leukemia", "DISEASE", 623, 651], ["ALL", "DISEASE", 653, 656], ["5,14,21UTX", "CHEMICAL", 667, 677], ["cancer", "DISEASE", 809, 815], ["UTX", "CHEMICAL", 825, 828], ["tumor", "DISEASE", 848, 853], ["cancers", "DISEASE", 881, 888], ["5,14,21UTX", "CHEMICAL", 667, 677], ["Mll3", "GENE_OR_GENE_PRODUCT", 0, 4], ["Mll4", "GENE_OR_GENE_PRODUCT", 9, 13], ["H3K4", "GENE_OR_GENE_PRODUCT", 16, 20], ["dimethyltransferase", "GENE_OR_GENE_PRODUCT", 31, 50], ["COMPASS", "GENE_OR_GENE_PRODUCT", 62, 69], ["H3K27 demethylase", "GENE_OR_GENE_PRODUCT", 91, 108], ["Utx", "GENE_OR_GENE_PRODUCT", 109, 112], ["tetratricopeptide repeat on chromosome X", "GENE_OR_GENE_PRODUCT", 139, 179], ["KDM6A", "GENE_OR_GENE_PRODUCT", 201, 206], ["COMPASS", "GENE_OR_GENE_PRODUCT", 249, 256], ["H3K4", "GENE_OR_GENE_PRODUCT", 340, 344], ["H3K27", "GENE_OR_GENE_PRODUCT", 349, 354], ["UTX", "GENE_OR_GENE_PRODUCT", 387, 390], ["human", "ORGANISM", 423, 428], ["blood malignancies", "CANCER", 429, 447], ["solid cancers", "CANCER", 452, 465], ["UTX", "GENE_OR_GENE_PRODUCT", 485, 488], ["chronic myelomonocytic leukemia", "CANCER", 521, 552], ["CMML", "CANCER", 554, 558], ["CMML-derived acute myeloid leukemia", "CANCER", 564, 599], ["AML", "CANCER", 601, 604], ["patients", "ORGANISM", 606, 614], ["acute lymphoblastic leukemia", "CANCER", 623, 651], ["ALL", "CANCER", 653, 656], ["patients", "ORGANISM", 658, 666], ["5,14,21UTX", "GENE_OR_GENE_PRODUCT", 667, 677], ["stem cell", "CELL", 735, 744], ["posterior", "MULTI-TISSUE_STRUCTURE", 778, 787], ["cancer", "CANCER", 809, 815], ["UTX", "GENE_OR_GENE_PRODUCT", 825, 828], ["tumor", "CANCER", 848, 853], ["cancers", "CANCER", 881, 888], ["Mll3", "PROTEIN", 0, 4], ["Mll4", "PROTEIN", 9, 13], ["H3K4", "PROTEIN", 16, 20], ["dimethyltransferase", "PROTEIN", 31, 50], ["COMPASS-like complex", "PROTEIN", 62, 82], ["H3K27 demethylase", "PROTEIN", 91, 108], ["Utx", "PROTEIN", 109, 112], ["Ubiquitously transcribed tetratricopeptide repeat", "DNA", 114, 163], ["chromosome X", "DNA", 167, 179], ["KDM6A", "DNA", 201, 206], ["COMPASS-like complex", "PROTEIN", 249, 269], ["H3K4", "PROTEIN", 340, 344], ["H3K27", "PROTEIN", 349, 354], ["UTX", "PROTEIN", 387, 390], ["UTX", "PROTEIN", 485, 488], ["5,14,21UTX", "PROTEIN", 667, 677], ["UTX", "DNA", 825, 828], ["tumor suppressor gene", "DNA", 848, 869], ["human", "SPECIES", 423, 428], ["patients", "SPECIES", 606, 614], ["patients", "SPECIES", 658, 666], ["human", "SPECIES", 423, 428], ["H3K4 mono", "TEST", 16, 25], ["dimethyltransferase", "TREATMENT", 31, 50], ["an H3K27 demethylase Utx", "TREATMENT", 88, 112], ["simultaneously modifying both H3K4 and H3K27", "TREATMENT", 310, 354], ["human blood malignancies", "PROBLEM", 423, 447], ["solid cancers", "PROBLEM", 452, 465], ["UTX", "PROBLEM", 485, 488], ["chronic myelomonocytic leukemia", "PROBLEM", 521, 552], ["CMML)", "PROBLEM", 554, 559], ["CMML", "PROBLEM", 564, 568], ["acute myeloid leukemia", "PROBLEM", 577, 599], ["AML)", "PROBLEM", 601, 605], ["20% acute lymphoblastic leukemia", "PROBLEM", 619, 651], ["multiple biological processes", "PROBLEM", 695, 724], ["embryogenesis", "PROBLEM", 759, 772], ["posterior development", "PROBLEM", 778, 799], ["UTX", "PROBLEM", 825, 828], ["a tumor suppressor gene of various cancers", "PROBLEM", 846, 888], ["solid cancers", "OBSERVATION", 452, 465], ["UTX", "OBSERVATION", 485, 488], ["chronic", "OBSERVATION_MODIFIER", 521, 528], ["myelomonocytic leukemia", "OBSERVATION", 529, 552], ["CMML", "OBSERVATION", 554, 558], ["CMML", "OBSERVATION", 564, 568], ["acute", "OBSERVATION_MODIFIER", 577, 582], ["myeloid leukemia", "OBSERVATION", 583, 599], ["acute", "OBSERVATION_MODIFIER", 623, 628], ["lymphoblastic leukemia", "OBSERVATION", 629, 651], ["essential for", "UNCERTAINTY", 681, 694], ["stem cell", "OBSERVATION", 735, 744], ["posterior", "ANATOMY_MODIFIER", 778, 787], ["cancer", "OBSERVATION", 809, 815], ["tumor", "OBSERVATION", 848, 853], ["various", "OBSERVATION_MODIFIER", 873, 880], ["cancers", "OBSERVATION", 881, 888]]], ["UTX knockout has been reported to promote pancreatic or lung cancer development.26,27 Also, its deficiency could lead to both myeloid and lymphoid malignancies.28\u201331 It is known that UTX is required for hematopoiesis.", [["pancreatic", "ANATOMY", 42, 52], ["lung cancer", "ANATOMY", 56, 67], ["myeloid", "ANATOMY", 126, 133], ["lymphoid malignancies", "ANATOMY", 138, 159], ["UTX", "CHEMICAL", 0, 3], ["pancreatic or lung cancer", "DISEASE", 42, 67], ["myeloid and lymphoid malignancies", "DISEASE", 126, 159], ["28\u201331", "CHEMICAL", 160, 165], ["UTX", "CHEMICAL", 183, 186], ["UTX", "GENE_OR_GENE_PRODUCT", 0, 3], ["pancreatic", "CANCER", 42, 52], ["lung cancer", "CANCER", 56, 67], ["myeloid", "CELL", 126, 133], ["lymphoid malignancies", "CANCER", 138, 159], ["UTX", "GENE_OR_GENE_PRODUCT", 183, 186], ["UTX", "PROTEIN", 0, 3], ["UTX", "PROTEIN", 183, 186], ["UTX knockout", "PROBLEM", 0, 12], ["pancreatic or lung cancer development", "PROBLEM", 42, 79], ["its deficiency", "PROBLEM", 92, 106], ["both myeloid and lymphoid malignancies", "PROBLEM", 121, 159], ["UTX", "PROBLEM", 183, 186], ["hematopoiesis", "PROBLEM", 203, 216], ["pancreatic", "ANATOMY", 42, 52], ["lung", "ANATOMY", 56, 60], ["cancer", "OBSERVATION", 61, 67], ["could lead to", "UNCERTAINTY", 107, 120], ["both", "OBSERVATION_MODIFIER", 121, 125], ["myeloid", "OBSERVATION", 126, 133], ["lymphoid malignancies", "OBSERVATION", 138, 159], ["UTX", "OBSERVATION", 183, 186], ["hematopoiesis", "OBSERVATION", 203, 216]]], ["Without it, the frequency and absolute number of both LT-HSCs and ST-HSCs increases due to the impaired cell differentiation.5,31IntroductionDifferentiation therapy has been approved as being effective for hematopoietic malignancies, such as all-trans-retinoic acid and arsenic trioxide for acute promyelocytic leukemia.32\u201334 Given the critical role of UTX in the regulation of HSPCs, we hypothesized that releasing the differentiation block due to UTX deficiencies could benefit patients with UTX mutations.", [["LT-HSCs", "ANATOMY", 54, 61], ["ST-HSCs", "ANATOMY", 66, 73], ["cell", "ANATOMY", 104, 108], ["hematopoietic malignancies", "ANATOMY", 206, 232], ["acute promyelocytic leukemia", "ANATOMY", 291, 319], ["HSPCs", "ANATOMY", 378, 383], ["hematopoietic malignancies", "DISEASE", 206, 232], ["all-trans-retinoic acid", "CHEMICAL", 242, 265], ["arsenic trioxide", "CHEMICAL", 270, 286], ["acute promyelocytic leukemia", "DISEASE", 291, 319], ["UTX", "CHEMICAL", 353, 356], ["UTX", "CHEMICAL", 449, 452], ["all-trans-retinoic acid", "CHEMICAL", 242, 265], ["arsenic trioxide", "CHEMICAL", 270, 286], ["LT-HSCs", "CELL", 54, 61], ["ST-HSCs", "CELL", 66, 73], ["cell", "CELL", 104, 108], ["hematopoietic malignancies", "CANCER", 206, 232], ["all-trans-retinoic acid", "SIMPLE_CHEMICAL", 242, 265], ["arsenic trioxide", "SIMPLE_CHEMICAL", 270, 286], ["acute promyelocytic leukemia", "CANCER", 291, 319], ["UTX", "GENE_OR_GENE_PRODUCT", 353, 356], ["HSPCs", "CELL", 378, 383], ["UTX", "GENE_OR_GENE_PRODUCT", 449, 452], ["patients", "ORGANISM", 480, 488], ["UTX", "GENE_OR_GENE_PRODUCT", 494, 497], ["LT", "PROTEIN", 54, 56], ["HSCs", "CELL_TYPE", 57, 61], ["HSCs", "CELL_TYPE", 69, 73], ["UTX", "PROTEIN", 353, 356], ["HSPCs", "CELL_TYPE", 378, 383], ["patients", "SPECIES", 480, 488], ["ST-HSCs", "PROBLEM", 66, 73], ["the impaired cell differentiation", "PROBLEM", 91, 124], ["IntroductionDifferentiation therapy", "TREATMENT", 129, 164], ["hematopoietic malignancies", "PROBLEM", 206, 232], ["all-trans-retinoic acid", "TREATMENT", 242, 265], ["arsenic trioxide", "TREATMENT", 270, 286], ["acute promyelocytic leukemia", "PROBLEM", 291, 319], ["UTX", "PROBLEM", 353, 356], ["the differentiation block", "PROBLEM", 416, 441], ["UTX deficiencies", "PROBLEM", 449, 465], ["UTX mutations", "PROBLEM", 494, 507], ["both", "ANATOMY_MODIFIER", 49, 53], ["LT", "ANATOMY", 54, 56], ["HSCs", "ANATOMY", 57, 61], ["HSCs", "ANATOMY", 69, 73], ["impaired cell differentiation", "OBSERVATION", 95, 124], ["acute", "OBSERVATION_MODIFIER", 291, 296], ["promyelocytic leukemia", "OBSERVATION", 297, 319], ["UTX", "OBSERVATION", 353, 356]]], ["To explore potential therapeutic strategies for malignancies with UTX deficiencies, we performed an epigenetic drug library screening.", [["malignancies", "ANATOMY", 48, 60], ["malignancies", "DISEASE", 48, 60], ["malignancies", "CANCER", 48, 60], ["UTX", "SIMPLE_CHEMICAL", 66, 69], ["therapeutic strategies", "TREATMENT", 21, 43], ["malignancies", "PROBLEM", 48, 60], ["UTX deficiencies", "PROBLEM", 66, 82], ["an epigenetic drug library screening", "TEST", 97, 133]]], ["We found that SP2509, a putative LSD1 inhibitor,35 specifically promoted the differentiation of UTX knockout HSPCs while sparing wild-type HSPCs.", [["HSPCs", "ANATOMY", 109, 114], ["HSPCs", "ANATOMY", 139, 144], ["SP2509", "CHEMICAL", 14, 20], ["SP2509", "CHEMICAL", 14, 20], ["SP2509", "SIMPLE_CHEMICAL", 14, 20], ["LSD1", "GENE_OR_GENE_PRODUCT", 33, 37], ["UTX", "GENE_OR_GENE_PRODUCT", 96, 99], ["HSPCs", "CELL", 109, 114], ["HSPCs", "CELL", 139, 144], ["LSD1", "PROTEIN", 33, 37], ["UTX knockout HSPCs", "CELL_TYPE", 96, 114], ["wild-type HSPCs", "CELL_TYPE", 129, 144], ["a putative LSD1 inhibitor", "TREATMENT", 22, 47], ["UTX knockout HSPCs", "TREATMENT", 96, 114]]], ["Mechanistically, UTX, likely through the COMPASS-like complex, facilitates the expression of differentiation-related genes and tumor suppressors associated with increased H3K4 methylation.", [["tumor", "ANATOMY", 127, 132], ["tumor", "DISEASE", 127, 132], ["UTX", "GENE_OR_GENE_PRODUCT", 17, 20], ["COMPASS", "GENE_OR_GENE_PRODUCT", 41, 48], ["tumor", "CANCER", 127, 132], ["H3K4", "GENE_OR_GENE_PRODUCT", 171, 175], ["UTX", "PROTEIN", 17, 20], ["COMPASS-like complex", "PROTEIN", 41, 61], ["H3K4", "PROTEIN", 171, 175], ["UTX", "PROBLEM", 17, 20], ["tumor suppressors", "PROBLEM", 127, 144], ["increased H3K4 methylation", "PROBLEM", 161, 187], ["UTX", "OBSERVATION", 17, 20], ["tumor", "OBSERVATION", 127, 132], ["increased", "OBSERVATION_MODIFIER", 161, 170], ["H3K4 methylation", "OBSERVATION", 171, 187]]], ["LSD1 is an H3K4 demethylase.36 LSD1 inhibition restores the balance in the H3K4 methylation of target genes in UTX-mutant cells and releases them from differentiation block.", [["UTX-mutant cells", "ANATOMY", 111, 127], ["LSD1", "GENE_OR_GENE_PRODUCT", 0, 4], ["H3K4 demethylase", "GENE_OR_GENE_PRODUCT", 11, 27], ["LSD1", "GENE_OR_GENE_PRODUCT", 31, 35], ["H3K4", "GENE_OR_GENE_PRODUCT", 75, 79], ["UTX", "GENE_OR_GENE_PRODUCT", 111, 114], ["cells", "CELL", 122, 127], ["LSD1", "PROTEIN", 0, 4], ["H3K4 demethylase", "PROTEIN", 11, 27], ["LSD1", "PROTEIN", 31, 35], ["H3K4", "PROTEIN", 75, 79], ["target genes", "DNA", 95, 107], ["UTX-mutant cells", "CELL_LINE", 111, 127], ["LSD1", "PROBLEM", 0, 4], ["an H3K4 demethylase", "PROBLEM", 8, 27], ["LSD1 inhibition", "TREATMENT", 31, 46], ["mutant cells", "PROBLEM", 115, 127], ["differentiation block", "PROBLEM", 151, 172], ["H3K4 demethylase", "OBSERVATION", 11, 27]]], ["Intriguingly, SP2509 had similar effects on UTX-null AML cells and extended the lifespan of animals with UTX-deficient-driven leukemia.Epigenetic drug library screening identified candidate small molecules for specifically promoting the differentiation of Utx-null HSPCs ::: ResultsGiven the functions of the tumor suppressor Utx in the differentiation of HSPCs through the modifications of histone 3, we decided to perform a high-throughput functional screening of an epigenetic drug library in wild-type (WT) and Utx-null HSPCs (Fig. 1a).", [["UTX-null AML cells", "ANATOMY", 44, 62], ["leukemia", "ANATOMY", 126, 134], ["HSPCs", "ANATOMY", 265, 270], ["tumor", "ANATOMY", 309, 314], ["HSPCs", "ANATOMY", 356, 361], ["HSPCs", "ANATOMY", 524, 529], ["SP2509", "CHEMICAL", 14, 20], ["AML", "DISEASE", 53, 56], ["UTX", "CHEMICAL", 105, 108], ["leukemia", "DISEASE", 126, 134], ["tumor", "DISEASE", 309, 314], ["SP2509", "CHEMICAL", 14, 20], ["SP2509", "SIMPLE_CHEMICAL", 14, 20], ["UTX-null AML cells", "CELL", 44, 62], ["UTX", "GENE_OR_GENE_PRODUCT", 105, 108], ["leukemia", "CANCER", 126, 134], ["HSPCs", "CELL", 265, 270], ["tumor", "CANCER", 309, 314], ["Utx", "GENE_OR_GENE_PRODUCT", 326, 329], ["HSPCs", "CELL", 356, 361], ["histone 3", "GENE_OR_GENE_PRODUCT", 391, 400], ["Utx", "GENE_OR_GENE_PRODUCT", 515, 518], ["HSPCs", "CELL", 524, 529], ["Fig. 1a", "CELL", 531, 538], ["UTX-null AML cells", "CELL_LINE", 44, 62], ["Utx-null HSPCs", "CELL_LINE", 256, 270], ["tumor suppressor Utx", "PROTEIN", 309, 329], ["HSPCs", "CELL_TYPE", 356, 361], ["histone 3", "PROTEIN", 391, 400], ["wild-type (WT) and Utx-null HSPCs", "CELL_LINE", 496, 529], ["UTX", "TEST", 44, 47], ["null AML cells", "PROBLEM", 48, 62], ["UTX-deficient", "PROBLEM", 105, 118], ["driven leukemia", "PROBLEM", 119, 134], ["Epigenetic drug library screening", "TEST", 135, 168], ["small molecules", "PROBLEM", 190, 205], ["the tumor suppressor Utx", "TREATMENT", 305, 329], ["an epigenetic drug library", "TREATMENT", 466, 492], ["Utx", "TEST", 515, 518], ["null AML cells", "OBSERVATION", 48, 62], ["driven leukemia", "OBSERVATION", 119, 134], ["tumor", "OBSERVATION", 309, 314], ["suppressor Utx", "OBSERVATION", 315, 329]]], ["We hypothesized that candidate small molecules could reverse the epigenetic abnormalities resulting from Utx loss and specifically release the differentiation block on Utx-deficient HSPCs. cKit+ HSPCs were isolated using MACS beads from wild-type (WT) or Utxf/f;Mx1-cre (KO) C57BL/6 mice37,38 7 days after pIpC treatment.", [["HSPCs", "ANATOMY", 182, 187], ["cKit+ HSPCs", "ANATOMY", 189, 200], ["pIpC", "CHEMICAL", 306, 310], ["Utx", "GENE_OR_GENE_PRODUCT", 105, 108], ["Utx", "GENE_OR_GENE_PRODUCT", 168, 171], ["HSPCs", "CELL", 182, 187], ["HSPCs", "CELL", 195, 200], ["Utxf/f", "ORGANISM", 255, 261], ["Mx1", "GENE_OR_GENE_PRODUCT", 262, 265], ["-cre (KO) C57BL/6 mice", "ORGANISM", 265, 287], ["Utx", "PROTEIN", 105, 108], ["Utx-deficient HSPCs", "CELL_LINE", 168, 187], ["cKit", "PROTEIN", 189, 193], ["HSPCs", "CELL_TYPE", 195, 200], ["Mx1", "PROTEIN", 262, 265], ["mice", "SPECIES", 283, 287], ["mice", "SPECIES", 283, 287], ["small molecules", "PROBLEM", 31, 46], ["the epigenetic abnormalities", "PROBLEM", 61, 89], ["Utx loss", "PROBLEM", 105, 113], ["the differentiation block", "PROBLEM", 139, 164], ["deficient HSPCs", "PROBLEM", 172, 187], ["cKit", "TEST", 189, 193], ["HSPCs", "PROBLEM", 195, 200], ["MACS beads", "TREATMENT", 221, 231], ["Utxf", "TEST", 255, 259], ["Mx1", "TEST", 262, 265], ["cre", "TEST", 266, 269], ["C57BL", "TEST", 275, 280], ["pIpC treatment", "TREATMENT", 306, 320], ["HSPCs", "ANATOMY", 195, 200]]], ["The epigenetic drug library has 276 compounds including a majority of currently available agonists and antagonists of epigenetic regulatory enzymes (Fig. 1b).", [["Fig. 1b", "GENE_OR_GENE_PRODUCT", 149, 156], ["epigenetic regulatory enzymes", "PROTEIN", 118, 147], ["Fig. 1b", "PROTEIN", 149, 156], ["agonists", "TREATMENT", 90, 98], ["antagonists", "TREATMENT", 103, 114], ["epigenetic regulatory enzymes", "TEST", 118, 147]]], ["The working concentrations of these drugs were 10 \u03bcM.Epigenetic drug library screening identified candidate small molecules for specifically promoting the differentiation of Utx-null HSPCs ::: ResultsThe outputs of the screen were stemness and differentiation status of HSPCs, measured by flow cytometry using cKit and Mac-1 staining, respectively.", [["HSPCs", "ANATOMY", 183, 188], ["HSPCs", "ANATOMY", 270, 275], ["HSPCs", "CELL", 183, 188], ["HSPCs", "CELL", 270, 275], ["Mac-1", "GENE_OR_GENE_PRODUCT", 319, 324], ["Utx-null HSPCs", "CELL_LINE", 174, 188], ["HSPCs", "CELL_TYPE", 270, 275], ["Mac", "PROTEIN", 319, 322], ["these drugs", "TREATMENT", 30, 41], ["Epigenetic drug library screening", "TEST", 53, 86], ["small molecules", "PROBLEM", 108, 123], ["the screen", "TEST", 215, 225], ["HSPCs", "TEST", 270, 275], ["flow cytometry", "TEST", 289, 303], ["cKit", "TEST", 310, 314], ["Mac", "TEST", 319, 322]]], ["To identify compounds specifically enhancing the differentiation of Utx KO HSPCs while sparing WT HSPCs, we ranked the compounds by differences in the mean fluorescence intensity (MFI) of Mac-1 or cKit staining between Utx WT and KO HSPCs (Fig. 1c, d).", [["Utx KO HSPCs", "ANATOMY", 68, 80], ["HSPCs", "ANATOMY", 98, 103], ["HSPCs", "ANATOMY", 233, 238], ["Utx KO HSPCs", "CELL", 68, 80], ["HSPCs", "CELL", 98, 103], ["Mac-1", "GENE_OR_GENE_PRODUCT", 188, 193], ["cKit", "GENE_OR_GENE_PRODUCT", 197, 201], ["KO HSPCs", "CELL", 230, 238], ["Utx KO HSPCs", "CELL_LINE", 68, 80], ["WT HSPCs", "CELL_TYPE", 95, 103], ["Mac", "PROTEIN", 188, 191], ["cKit", "PROTEIN", 197, 201], ["Utx WT", "CELL_LINE", 219, 225], ["KO HSPCs", "CELL_TYPE", 230, 238], ["Utx KO HSPCs", "TREATMENT", 68, 80], ["Mac", "TEST", 188, 191], ["cKit staining", "PROBLEM", 197, 210], ["Utx WT", "TEST", 219, 225]]], ["Consistent with previous reports that Utx deficiency blocks HSPC differentiation, vehicle-treated Utx KO HSPCs expressed lower levels of Mac-1, a myeloid cell marker, than WT HSPCs, indicating impaired differentiation in KO cells.", [["HSPC", "ANATOMY", 60, 64], ["Utx KO HSPCs", "ANATOMY", 98, 110], ["myeloid cell", "ANATOMY", 146, 158], ["HSPCs", "ANATOMY", 175, 180], ["KO cells", "ANATOMY", 221, 229], ["Utx", "GENE_OR_GENE_PRODUCT", 38, 41], ["HSPC", "CELL", 60, 64], ["vehicle", "SIMPLE_CHEMICAL", 82, 89], ["Utx KO HSPCs", "CELL", 98, 110], ["Mac-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["myeloid cell", "CELL", 146, 158], ["HSPCs", "CELL", 175, 180], ["KO cells", "CELL", 221, 229], ["Utx", "PROTEIN", 38, 41], ["HSPC", "CELL_TYPE", 60, 64], ["Utx KO HSPCs", "CELL_LINE", 98, 110], ["Mac", "PROTEIN", 137, 140], ["WT HSPCs", "CELL_TYPE", 172, 180], ["KO cells", "CELL_TYPE", 221, 229], ["Utx deficiency", "PROBLEM", 38, 52], ["HSPC differentiation", "PROBLEM", 60, 80], ["Mac", "TEST", 137, 140], ["a myeloid cell marker", "TEST", 144, 165], ["WT HSPCs", "TEST", 172, 180], ["impaired differentiation in KO cells", "PROBLEM", 193, 229], ["Utx deficiency", "OBSERVATION", 38, 52], ["Mac", "ANATOMY", 137, 140], ["myeloid cell marker", "OBSERVATION", 146, 165], ["impaired differentiation", "OBSERVATION", 193, 217], ["KO cells", "OBSERVATION", 221, 229]]], ["In contrast, Utx KO HSPCs expressed higher levels of cKit, a standard marker for HSPCs, than WT HSPCs.Epigenetic drug library screening identified candidate small molecules for specifically promoting the differentiation of Utx-null HSPCs ::: ResultsThe top three compounds that induced the most pronounced changes in Mac-1 expression between Utx KO and WT HSPCs were BIX01294, Bisindolylmaleimide IX, and SP2509 (Fig. 1c).", [["Utx KO HSPCs", "ANATOMY", 13, 25], ["HSPCs", "ANATOMY", 81, 86], ["HSPCs", "ANATOMY", 96, 101], ["HSPCs", "ANATOMY", 232, 237], ["HSPCs", "ANATOMY", 356, 361], ["BIX01294", "CHEMICAL", 367, 375], ["BIX01294", "CHEMICAL", 367, 375], ["Bisindolylmaleimide IX", "CHEMICAL", 377, 399], ["SP2509", "CHEMICAL", 405, 411], ["Utx KO HSPCs", "CELL", 13, 25], ["cKit", "GENE_OR_GENE_PRODUCT", 53, 57], ["HSPCs", "CELL", 81, 86], ["HSPCs", "CELL", 96, 101], ["HSPCs", "CELL", 232, 237], ["Mac-1", "GENE_OR_GENE_PRODUCT", 317, 322], ["Utx KO", "ORGANISM", 342, 348], ["HSPCs", "CELL", 356, 361], ["BIX01294", "SIMPLE_CHEMICAL", 367, 375], ["Bisindolylmaleimide IX", "GENE_OR_GENE_PRODUCT", 377, 399], ["Utx KO HSPCs", "CELL_LINE", 13, 25], ["cKit", "PROTEIN", 53, 57], ["HSPCs", "CELL_TYPE", 81, 86], ["WT HSPCs", "CELL_TYPE", 93, 101], ["Utx-null HSPCs", "CELL_LINE", 223, 237], ["Mac", "PROTEIN", 317, 320], ["WT HSPCs", "CELL_TYPE", 353, 361], ["cKit", "TEST", 53, 57], ["Epigenetic drug library screening", "TEST", 102, 135], ["small molecules", "PROBLEM", 157, 172], ["WT HSPCs", "TEST", 353, 361], ["Bisindolylmaleimide IX", "TREATMENT", 377, 399], ["most pronounced", "OBSERVATION_MODIFIER", 290, 305]]], ["BIX01294 is an inhibitor of histone methyltransferase G9a, and it therefore reduces H3K9m2 levels at an IC50 of 2.7 \u03bcM.39 Bisindolylmaleimide IX is a pan-PKC inhibitor, which can inhibit PKC-\u03b1, PKC-\u03b2I, PKC-\u03b2II, PKC-\u03b3, and PKC-\u03b5 with low nanomolar IC50.40 SP2509 is a selective inhibitor of the histone demethylase LSD1 with an IC50 of 3 nM.35,41 On the other hand, the top three compounds that mostly reduced cKit expression in Utx KO HSPCs compared to that in WT HSPCs were azacytidine, decitabine, and SP2509 (Fig. 1d).", [["Utx KO HSPCs", "ANATOMY", 428, 440], ["HSPCs", "ANATOMY", 464, 469], ["BIX01294", "CHEMICAL", 0, 8], ["SP2509", "CHEMICAL", 255, 261], ["azacytidine", "CHEMICAL", 475, 486], ["decitabine", "CHEMICAL", 488, 498], ["SP2509", "CHEMICAL", 504, 510], ["BIX01294", "CHEMICAL", 0, 8], ["Bisindolylmaleimide IX", "CHEMICAL", 122, 144], ["SP2509", "CHEMICAL", 255, 261], ["azacytidine", "CHEMICAL", 475, 486], ["decitabine", "CHEMICAL", 488, 498], ["SP2509", "CHEMICAL", 504, 510], ["BIX01294", "SIMPLE_CHEMICAL", 0, 8], ["histone methyltransferase", "GENE_OR_GENE_PRODUCT", 28, 53], ["G9a", "GENE_OR_GENE_PRODUCT", 54, 57], ["H3K9m2", "GENE_OR_GENE_PRODUCT", 84, 90], ["Bisindolylmaleimide IX", "GENE_OR_GENE_PRODUCT", 122, 144], ["pan-PKC", "GENE_OR_GENE_PRODUCT", 150, 157], ["PKC-\u03b1", "GENE_OR_GENE_PRODUCT", 187, 192], ["PKC-\u03b2I", "GENE_OR_GENE_PRODUCT", 194, 200], ["PKC-\u03b2II", "GENE_OR_GENE_PRODUCT", 202, 209], ["PKC-\u03b3", "GENE_OR_GENE_PRODUCT", 211, 216], ["PKC-\u03b5", "GENE_OR_GENE_PRODUCT", 222, 227], ["SP2509", "SIMPLE_CHEMICAL", 255, 261], ["histone demethylase", "GENE_OR_GENE_PRODUCT", 294, 313], ["LSD1", "GENE_OR_GENE_PRODUCT", 314, 318], ["cKit", "GENE_OR_GENE_PRODUCT", 409, 413], ["Utx KO HSPCs", "CELL", 428, 440], ["HSPCs", "CELL", 464, 469], ["azacytidine", "SIMPLE_CHEMICAL", 475, 486], ["decitabine", "SIMPLE_CHEMICAL", 488, 498], ["SP2509", "SIMPLE_CHEMICAL", 504, 510], ["histone methyltransferase", "PROTEIN", 28, 53], ["G9a", "PROTEIN", 54, 57], ["H3K9m2", "PROTEIN", 84, 90], ["PKC", "PROTEIN", 187, 190], ["\u03b1", "PROTEIN", 191, 192], ["PKC", "PROTEIN", 194, 197], ["\u03b2I", "PROTEIN", 198, 200], ["PKC", "PROTEIN", 202, 205], ["\u03b2II", "PROTEIN", 206, 209], ["PKC", "PROTEIN", 211, 214], ["\u03b3", "PROTEIN", 215, 216], ["PKC", "PROTEIN", 222, 225], ["histone demethylase", "PROTEIN", 294, 313], ["LSD1", "PROTEIN", 314, 318], ["cKit", "PROTEIN", 409, 413], ["Utx KO HSPCs", "CELL_LINE", 428, 440], ["WT HSPCs", "CELL_TYPE", 461, 469], ["an inhibitor of histone methyltransferase G9a", "TREATMENT", 12, 57], ["H3K9m2 levels", "PROBLEM", 84, 97], ["an IC50", "TEST", 101, 108], ["Bisindolylmaleimide IX", "TREATMENT", 122, 144], ["a pan-PKC inhibitor", "TREATMENT", 148, 167], ["PKC", "TEST", 187, 190], ["PKC", "TEST", 194, 197], ["PKC", "TEST", 202, 205], ["PKC", "TEST", 211, 214], ["PKC", "TEST", 222, 225], ["low nanomolar IC", "PROBLEM", 233, 249], ["a selective inhibitor", "TREATMENT", 265, 286], ["the histone demethylase LSD1", "TREATMENT", 290, 318], ["an IC50", "TEST", 324, 331], ["Utx KO HSPCs", "PROBLEM", 428, 440], ["azacytidine", "TREATMENT", 475, 486], ["decitabine", "TREATMENT", 488, 498], ["methyltransferase G9a", "OBSERVATION", 36, 57]]], ["Azacytidine and decitabine are already used in patients with various hematopoietic malignancies, and they induce differentiation of or directly kill leukemic blasts.42,43 The identification of azacytidine and decitabine validated our screening.", [["hematopoietic malignancies", "ANATOMY", 69, 95], ["leukemic blasts", "ANATOMY", 149, 164], ["Azacytidine", "CHEMICAL", 0, 11], ["decitabine", "CHEMICAL", 16, 26], ["hematopoietic malignancies", "DISEASE", 69, 95], ["leukemic blasts", "DISEASE", 149, 164], ["azacytidine", "CHEMICAL", 193, 204], ["decitabine", "CHEMICAL", 209, 219], ["Azacytidine", "CHEMICAL", 0, 11], ["decitabine", "CHEMICAL", 16, 26], ["azacytidine", "CHEMICAL", 193, 204], ["decitabine", "CHEMICAL", 209, 219], ["Azacytidine", "SIMPLE_CHEMICAL", 0, 11], ["decitabine", "SIMPLE_CHEMICAL", 16, 26], ["patients", "ORGANISM", 47, 55], ["malignancies", "CANCER", 83, 95], ["leukemic blasts", "CELL", 149, 164], ["azacytidine", "SIMPLE_CHEMICAL", 193, 204], ["decitabine", "SIMPLE_CHEMICAL", 209, 219], ["leukemic blasts", "CELL_TYPE", 149, 164], ["patients", "SPECIES", 47, 55], ["Azacytidine", "TREATMENT", 0, 11], ["decitabine", "TREATMENT", 16, 26], ["various hematopoietic malignancies", "PROBLEM", 61, 95], ["directly kill leukemic blasts", "PROBLEM", 135, 164], ["azacytidine", "TREATMENT", 193, 204], ["decitabine", "TREATMENT", 209, 219], ["our screening", "TEST", 230, 243], ["hematopoietic malignancies", "OBSERVATION", 69, 95], ["leukemic blasts", "OBSERVATION", 149, 164]]], ["However, we were more interested in the less studied SP2509, especially because it was the only compound identified to affect both Mac-1 and cKit expression.", [["SP2509", "CHEMICAL", 53, 59], ["SP2509", "CHEMICAL", 53, 59], ["SP2509", "SIMPLE_CHEMICAL", 53, 59], ["Mac-1", "GENE_OR_GENE_PRODUCT", 131, 136], ["cKit", "GENE_OR_GENE_PRODUCT", 141, 145], ["Mac", "PROTEIN", 131, 134], ["cKit", "PROTEIN", 141, 145]]], ["Actually, SP2509 was also the only candidate identified when the compounds were ranked by different proportions of cKit+ populations between Utx KO and WT HSPCs (Fig. 1e).", [["HSPCs", "ANATOMY", 155, 160], ["SP2509", "CHEMICAL", 10, 16], ["SP2509", "CHEMICAL", 10, 16], ["SP2509", "SIMPLE_CHEMICAL", 10, 16], ["cKit", "GENE_OR_GENE_PRODUCT", 115, 119], ["Utx KO", "CELL", 141, 147], ["HSPCs", "CELL", 155, 160], ["cKit", "PROTEIN", 115, 119], ["Utx KO", "CELL_LINE", 141, 147], ["WT HSPCs", "CELL_TYPE", 152, 160]]], ["Therefore, we focused on SP2509 in the subsequent studies.Validating SP2509 as a specific inducer of differentiation in Utx-deficient cells ::: ResultsTo validate the function of SP2509 on Utx KO HSPCs, we performed another independent experiment similar to the library screening (Fig. 1a).", [["Utx-deficient cells", "ANATOMY", 120, 139], ["Utx KO HSPCs", "ANATOMY", 189, 201], ["SP2509", "CHEMICAL", 25, 31], ["SP2509", "CHEMICAL", 69, 75], ["SP2509", "CHEMICAL", 179, 185], ["SP2509", "CHEMICAL", 25, 31], ["SP2509", "CHEMICAL", 69, 75], ["SP2509", "SIMPLE_CHEMICAL", 25, 31], ["SP2509", "SIMPLE_CHEMICAL", 69, 75], ["Utx", "GENE_OR_GENE_PRODUCT", 120, 123], ["cells", "CELL", 134, 139], ["SP2509", "SIMPLE_CHEMICAL", 179, 185], ["Utx KO HSPCs", "CELL", 189, 201], ["Utx-deficient cells", "CELL_LINE", 120, 139], ["Utx KO HSPCs", "CELL_LINE", 189, 201], ["the subsequent studies", "TEST", 35, 57], ["the library screening", "TEST", 258, 279]]], ["First, in vehicle-treated group, Utx KO HSPCs remained more cKit+ cells than that in Utx WT HSPCs (32.4% vs 23.4%; Fig. 2a), while less Mac-1+ cells in Utx KO HSPCs than that in WT HSPCs (56.2% vs 76.3%; Fig. 2b), indicating that Utx loss impaired the differentiation of HSPCs.", [["Utx KO HSPCs", "ANATOMY", 33, 45], ["cKit+ cells", "ANATOMY", 60, 71], ["Utx WT HSPCs", "ANATOMY", 85, 97], ["Mac-1+ cells", "ANATOMY", 136, 148], ["Utx KO HSPCs", "ANATOMY", 152, 164], ["HSPCs", "ANATOMY", 181, 186], ["HSPCs", "ANATOMY", 271, 276], ["Utx KO HSPCs", "CELL", 33, 45], ["cKit+ cells", "CELL", 60, 71], ["Utx WT HSPCs", "CELL", 85, 97], ["Mac-1", "GENE_OR_GENE_PRODUCT", 136, 141], ["Utx KO HSPCs", "CELL", 152, 164], ["HSPCs", "CELL", 181, 186], ["Utx", "GENE_OR_GENE_PRODUCT", 230, 233], ["HSPCs", "CELL", 271, 276], ["Utx KO HSPCs", "CELL_LINE", 33, 45], ["cKit+ cells", "CELL_TYPE", 60, 71], ["Utx WT HSPCs", "CELL_TYPE", 85, 97], ["Mac", "PROTEIN", 136, 139], ["Utx KO HSPCs", "CELL_TYPE", 152, 164], ["WT HSPCs", "CELL_TYPE", 178, 186], ["Utx", "PROTEIN", 230, 233], ["HSPCs", "CELL_TYPE", 271, 276], ["Utx", "TEST", 85, 88], ["HSPCs", "TEST", 92, 97], ["vs", "TEST", 105, 107], ["Fig.", "TEST", 115, 119], ["Mac", "TEST", 136, 139], ["HSPCs", "TEST", 159, 164], ["WT", "TEST", 178, 180], ["HSPCs", "TEST", 181, 186], ["vs", "TEST", 194, 196], ["Fig.", "TEST", 204, 208], ["Utx loss", "PROBLEM", 230, 238], ["Utx", "OBSERVATION", 230, 233]]], ["With SP2509 treatment, Utx WT HSPCs did not have much changes compared to vehicle-treated group.", [["HSPCs", "ANATOMY", 30, 35], ["SP2509", "CHEMICAL", 5, 11], ["SP2509", "CHEMICAL", 5, 11], ["SP2509", "SIMPLE_CHEMICAL", 5, 11], ["Utx WT HSPCs", "CELL", 23, 35], ["Utx WT HSPCs", "CELL_LINE", 23, 35], ["SP2509 treatment", "TREATMENT", 5, 21], ["Utx WT HSPCs", "TREATMENT", 23, 35]]], ["Twenty-six percent of SP2509-treated Utx WT HSPCs remained cKit+, whereas 69.7% became Mac-1+ (Fig. 2c, d).", [["HSPCs", "ANATOMY", 44, 49], ["SP2509", "CHEMICAL", 22, 28], ["SP2509", "CHEMICAL", 22, 28], ["SP2509", "SIMPLE_CHEMICAL", 22, 28], ["Utx WT HSPCs", "CELL", 37, 49], ["Mac-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["SP2509-treated Utx WT HSPCs", "CELL_LINE", 22, 49], ["cKit", "PROTEIN", 59, 63], ["HSPCs", "TEST", 44, 49], ["cKit", "TEST", 59, 63], ["Mac", "TEST", 87, 90]]], ["In striking contrast, only 9.38% of Utx KO HSPCs remained cKit+ after SP2509 treatment, which was approximately 2.5-fold lower than that in vehicle-treated KO HSPCs and significantly less than that in WT HSPCs (Fig. 2e, f).", [["Utx KO HSPCs", "ANATOMY", 36, 48], ["HSPCs", "ANATOMY", 159, 164], ["HSPCs", "ANATOMY", 204, 209], ["SP2509", "CHEMICAL", 70, 76], ["SP2509", "CHEMICAL", 70, 76], ["Utx KO HSPCs", "CELL", 36, 48], ["cKit", "GENE_OR_GENE_PRODUCT", 58, 62], ["SP2509", "SIMPLE_CHEMICAL", 70, 76], ["HSPCs", "CELL", 159, 164], ["HSPCs", "CELL", 204, 209], ["Utx KO HSPCs", "CELL_LINE", 36, 48], ["cKit", "PROTEIN", 58, 62], ["vehicle-treated KO HSPCs", "CELL_LINE", 140, 164], ["WT HSPCs", "CELL_TYPE", 201, 209], ["HSPCs", "TEST", 43, 48], ["cKit", "TEST", 58, 62], ["SP2509 treatment", "TREATMENT", 70, 86]]], ["Conversely, 90% of Utx KO HSPCs became Mac-1+ with SP2509 treatment, which was approximately one-fold higher than that in vehicle-treated Utx KO HSPCs and significantly more than that in WT HSPCs (Fig. 2g, h).", [["Utx KO HSPCs", "ANATOMY", 19, 31], ["Utx KO HSPCs", "ANATOMY", 138, 150], ["HSPCs", "ANATOMY", 190, 195], ["SP2509", "CHEMICAL", 51, 57], ["SP2509", "CHEMICAL", 51, 57], ["Utx KO HSPCs", "CELL", 19, 31], ["Mac-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["SP2509", "SIMPLE_CHEMICAL", 51, 57], ["Utx KO HSPCs", "CELL", 138, 150], ["HSPCs", "CELL", 190, 195], ["Utx KO HSPCs", "CELL_LINE", 19, 31], ["Mac", "PROTEIN", 39, 42], ["Utx KO HSPCs", "CELL_LINE", 138, 150], ["WT HSPCs", "CELL_TYPE", 187, 195], ["Mac", "TEST", 39, 42], ["SP2509 treatment", "TREATMENT", 51, 67]]], ["Consistently, the MFI of cKit staining in Utx KO HSPCs decreased from 2489 for vehicle treatment to 681 for SP2509 treatment, a 2.65-fold reduction, while there was no significant difference between vehicle- and SP2509-treated WT HSPCs (Fig. 2i, j).", [["Utx KO HSPCs", "ANATOMY", 42, 54], ["HSPCs", "ANATOMY", 230, 235], ["SP2509", "CHEMICAL", 108, 114], ["SP2509", "CHEMICAL", 212, 218], ["SP2509", "CHEMICAL", 108, 114], ["SP2509", "CHEMICAL", 212, 218], ["cKit", "GENE_OR_GENE_PRODUCT", 25, 29], ["Utx KO HSPCs", "CELL", 42, 54], ["SP2509", "SIMPLE_CHEMICAL", 108, 114], ["SP2509", "SIMPLE_CHEMICAL", 212, 218], ["HSPCs", "CELL", 230, 235], ["cKit", "PROTEIN", 25, 29], ["Utx KO HSPCs", "CELL_LINE", 42, 54], ["SP2509-treated WT HSPCs", "CELL_LINE", 212, 235], ["cKit staining", "TEST", 25, 38], ["HSPCs", "TEST", 49, 54], ["vehicle treatment", "TREATMENT", 79, 96], ["SP2509 treatment", "TREATMENT", 108, 124], ["a 2.65-fold reduction", "TREATMENT", 126, 147], ["vehicle", "TEST", 199, 206], ["no", "UNCERTAINTY", 165, 167], ["significant", "OBSERVATION_MODIFIER", 168, 179]]], ["The MFI of Mac-1 staining in Utx KO HSPCs increased from 1450 for vehicle treatment to 16,326 for SP2509 treatment, a 10.2-fold increase, which was dramatically more than the difference between vehicle- and SP2509-treated Utx WT HSPCs (Fig. 2k, l).", [["Utx KO HSPCs", "ANATOMY", 29, 41], ["HSPCs", "ANATOMY", 229, 234], ["SP2509", "CHEMICAL", 98, 104], ["SP2509", "CHEMICAL", 207, 213], ["SP2509", "CHEMICAL", 98, 104], ["SP2509", "CHEMICAL", 207, 213], ["Mac-1", "GENE_OR_GENE_PRODUCT", 11, 16], ["Utx KO HSPCs", "CELL", 29, 41], ["SP2509", "SIMPLE_CHEMICAL", 98, 104], ["SP2509", "SIMPLE_CHEMICAL", 207, 213], ["Utx WT HSPCs", "CELL", 222, 234], ["Mac", "PROTEIN", 11, 14], ["Utx KO HSPCs", "CELL_LINE", 29, 41], ["SP2509-treated Utx WT HSPCs", "CELL_LINE", 207, 234], ["Mac", "TEST", 11, 14], ["HSPCs", "TEST", 36, 41], ["vehicle treatment", "TREATMENT", 66, 83], ["SP2509 treatment", "TREATMENT", 98, 114], ["Utx WT HSPCs", "TREATMENT", 222, 234], ["Mac", "ANATOMY", 11, 14]]], ["Therefore, SP2509 was validated as a specific differentiation inducer for Utx KO HSPCs while sparing WT HSPCs.SP2509 treatment reversed the global effect of Utx deficiency on the transcriptome of HSPCs ::: ResultsTo understand the molecular mechanisms underlying the SP2509-induced differentiation of Utx KO HSPCs, we used RNA sequencing (RNA-seq) to analyze the transcriptomes of Utx WT and KO HSPCs treated with vehicle or SP2509.", [["Utx KO HSPCs", "ANATOMY", 74, 86], ["HSPCs", "ANATOMY", 104, 109], ["HSPCs", "ANATOMY", 196, 201], ["Utx KO HSPCs", "ANATOMY", 301, 313], ["HSPCs", "ANATOMY", 395, 400], ["SP2509", "CHEMICAL", 11, 17], ["SP2509", "CHEMICAL", 110, 116], ["Utx", "CHEMICAL", 157, 160], ["SP2509", "CHEMICAL", 267, 273], ["SP2509", "CHEMICAL", 425, 431], ["SP2509", "CHEMICAL", 11, 17], ["SP2509", "CHEMICAL", 110, 116], ["SP2509", "CHEMICAL", 267, 273], ["SP2509", "CHEMICAL", 425, 431], ["SP2509", "SIMPLE_CHEMICAL", 11, 17], ["Utx KO HSPCs", "CELL", 74, 86], ["HSPCs", "CELL", 104, 109], ["SP2509", "SIMPLE_CHEMICAL", 110, 116], ["Utx", "GENE_OR_GENE_PRODUCT", 157, 160], ["HSPCs", "CELL", 196, 201], ["SP2509", "SIMPLE_CHEMICAL", 267, 273], ["Utx KO HSPCs", "CELL", 301, 313], ["Utx WT", "CELL", 381, 387], ["KO HSPCs", "CELL", 392, 400], ["SP2509", "SIMPLE_CHEMICAL", 425, 431], ["Utx KO HSPCs", "CELL_LINE", 74, 86], ["WT HSPCs", "CELL_TYPE", 101, 109], ["Utx", "PROTEIN", 157, 160], ["HSPCs", "CELL_TYPE", 196, 201], ["SP2509", "PROTEIN", 267, 273], ["Utx KO HSPCs", "CELL_LINE", 301, 313], ["Utx WT", "CELL_LINE", 381, 387], ["KO HSPCs", "CELL_TYPE", 392, 400], ["Utx KO HSPCs", "TREATMENT", 74, 86], ["treatment", "TREATMENT", 117, 126], ["Utx deficiency", "PROBLEM", 157, 171], ["Utx KO HSPCs", "TREATMENT", 301, 313], ["RNA sequencing", "TEST", 323, 337], ["Utx WT", "TREATMENT", 381, 387], ["vehicle", "TREATMENT", 414, 421], ["Utx deficiency", "OBSERVATION", 157, 171]]], ["Cells were harvested after 12-h treatment to capture the direct effects of SP2509 treatment on gene expression.", [["Cells", "ANATOMY", 0, 5], ["SP2509", "CHEMICAL", 75, 81], ["SP2509", "CHEMICAL", 75, 81], ["Cells", "CELL", 0, 5], ["SP2509", "SIMPLE_CHEMICAL", 75, 81], ["treatment", "TREATMENT", 32, 41], ["SP2509 treatment", "TREATMENT", 75, 91], ["gene expression", "TREATMENT", 95, 110]]], ["In each group, there were three independent treated samples.", [["samples", "ANATOMY", 52, 59]]], ["Unsupervised grouping analysis showed that all of the three samples were grouped together in each group (Fig. 3a), indicating a high quality of the RNA-seq data.", [["samples", "ANATOMY", 60, 67], ["Unsupervised grouping analysis", "TEST", 0, 30]]], ["Principal component analysis (PCA) also revealed tight grouping of the three replicates in each group.", [["Principal component analysis (PCA)", "TEST", 0, 34], ["tight", "OBSERVATION_MODIFIER", 49, 54]]], ["The location of Utx WT and KO HSPCs treated with vehicle or SP2509 on the PCA plot clearly demonstrated the differences between Utx WT and KO HSPCs and those between vehicle- and SP2509-treated HSPCs (Fig. 3b).SP2509 treatment reversed the global effect of Utx deficiency on the transcriptome of HSPCs ::: ResultsInterestingly, compared to the differentially expressed genes in WT HSPCs, 177 genes were significantly downregulated in Utx KO HSPCs (p < 0.05, log2[KO/WT] < \u22121), while only 34 genes were significantly upregulated (Fig. 3c).", [["KO HSPCs", "ANATOMY", 27, 35], ["HSPCs", "ANATOMY", 142, 147], ["HSPCs", "ANATOMY", 194, 199], ["HSPCs", "ANATOMY", 296, 301], ["HSPCs", "ANATOMY", 381, 386], ["Utx KO HSPCs", "ANATOMY", 434, 446], ["SP2509", "CHEMICAL", 60, 66], ["SP2509", "CHEMICAL", 179, 185], ["SP2509", "CHEMICAL", 210, 216], ["Utx", "CHEMICAL", 257, 260], ["SP2509", "CHEMICAL", 60, 66], ["SP2509", "CHEMICAL", 179, 185], ["SP2509", "CHEMICAL", 210, 216], ["Utx WT", "ORGANISM", 16, 22], ["KO HSPCs", "CELL", 27, 35], ["SP2509", "SIMPLE_CHEMICAL", 60, 66], ["Utx WT", "CELL", 128, 134], ["KO HSPCs", "CELL", 139, 147], ["SP2509", "SIMPLE_CHEMICAL", 179, 185], ["HSPCs", "CELL", 194, 199], ["SP2509", "SIMPLE_CHEMICAL", 210, 216], ["Utx", "GENE_OR_GENE_PRODUCT", 257, 260], ["HSPCs", "CELL", 296, 301], ["HSPCs", "CELL", 381, 386], ["Utx KO HSPCs", "CELL", 434, 446], ["Utx WT", "CELL_LINE", 16, 22], ["KO HSPCs", "CELL_TYPE", 27, 35], ["Utx WT", "CELL_LINE", 128, 134], ["KO HSPCs", "CELL_TYPE", 139, 147], ["SP2509-treated HSPCs", "CELL_LINE", 179, 199], ["Utx", "PROTEIN", 257, 260], ["HSPCs", "CELL_TYPE", 296, 301], ["WT HSPCs", "CELL_TYPE", 378, 386], ["Utx KO HSPCs", "CELL_LINE", 434, 446], ["Utx WT", "TREATMENT", 16, 22], ["vehicle", "TREATMENT", 49, 56], ["HSPCs", "TEST", 142, 147], ["vehicle", "TEST", 166, 173], ["treatment", "TREATMENT", 217, 226], ["Utx deficiency", "PROBLEM", 257, 271], ["WT HSPCs", "TEST", 378, 386], ["HSPCs", "TEST", 441, 446], ["p", "TEST", 448, 449], ["log2[KO/WT", "TEST", 458, 468], ["Utx deficiency", "OBSERVATION", 257, 271]]], ["The overwhelming repression of gene expression is consistent with the histone modification functions of Utx and its associated COMPASS-like complex.", [["histone", "GENE_OR_GENE_PRODUCT", 70, 77], ["Utx", "GENE_OR_GENE_PRODUCT", 104, 107], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 127, 147], ["histone", "PROTEIN", 70, 77], ["Utx", "PROTEIN", 104, 107], ["COMPASS", "PROTEIN", 127, 134], ["gene expression", "PROBLEM", 31, 46], ["the histone modification functions of Utx", "PROBLEM", 66, 107], ["gene expression", "OBSERVATION", 31, 46], ["consistent with", "UNCERTAINTY", 50, 65], ["histone modification", "OBSERVATION", 70, 90], ["complex", "OBSERVATION_MODIFIER", 140, 147]]], ["Similar results were also observed in Mll3 (the core component of COMPASS-like complex)-deficient HSPCs.8SP2509 treatment reversed the global effect of Utx deficiency on the transcriptome of HSPCs ::: ResultsIn striking contrast, 99 genes in SP2509-treated Utx KO HSPCs were significantly upregulated (p < 0.05, log2[KO/WT] < \u22121) compared to those in vehicle-treated Utx KO HSPCs, while only nine genes were significantly downregulated (Fig. 3d).", [["HSPCs", "ANATOMY", 98, 103], ["HSPCs", "ANATOMY", 191, 196], ["HSPCs", "ANATOMY", 264, 269], ["HSPCs", "ANATOMY", 374, 379], [".8SP2509", "CHEMICAL", 103, 111], ["Utx", "CHEMICAL", 152, 155], ["SP2509", "CHEMICAL", 242, 248], ["SP2509", "CHEMICAL", 242, 248], ["Mll3", "GENE_OR_GENE_PRODUCT", 38, 42], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 66, 86], ["Utx", "GENE_OR_GENE_PRODUCT", 152, 155], ["HSPCs", "CELL", 191, 196], ["SP2509", "SIMPLE_CHEMICAL", 242, 248], ["Utx KO HSPCs", "CELL", 257, 269], ["Utx KO HSPCs", "CELL", 367, 379], ["Mll3", "PROTEIN", 38, 42], ["COMPASS", "PROTEIN", 66, 73], ["HSPCs", "CELL_TYPE", 98, 103], ["Utx", "PROTEIN", 152, 155], ["HSPCs", "CELL_TYPE", 191, 196], ["99 genes", "DNA", 230, 238], ["SP2509-treated Utx KO HSPCs", "CELL_LINE", 242, 269], ["Utx KO HSPCs", "CELL_LINE", 367, 379], ["COMPASS-like complex)", "TREATMENT", 66, 87], ["deficient HSPCs", "TREATMENT", 88, 103], ["treatment", "TREATMENT", 112, 121], ["Utx deficiency", "PROBLEM", 152, 166], ["HSPCs", "TEST", 264, 269], ["log2[KO/WT", "TEST", 312, 322], ["Utx deficiency", "OBSERVATION", 152, 166]]], ["Notably, the overwhelming upregulation of gene expression by SP2509 was directly contradictory to the effect of Utx loss in HSPCs.", [["HSPCs", "ANATOMY", 124, 129], ["SP2509", "CHEMICAL", 61, 67], ["SP2509", "CHEMICAL", 61, 67], ["SP2509", "GENE_OR_GENE_PRODUCT", 61, 67], ["Utx", "GENE_OR_GENE_PRODUCT", 112, 115], ["HSPCs", "CELL", 124, 129], ["Utx", "PROTEIN", 112, 115], ["HSPCs", "CELL_TYPE", 124, 129], ["Utx loss in HSPCs", "PROBLEM", 112, 129], ["gene expression", "OBSERVATION", 42, 57]]], ["Accordingly, the effects of SP2509 treatment on the global transcriptome was specific to Utx KO HSPCs, and the up- and downregulated genes in SP2509-treated vs vehicle-treated Utx WT HSPCs were largely balanced.SP2509 enhanced the expression of differentiation-related genes and tumor suppressors repressed in Utx KO HSPCs ::: ResultsTo understand the functions of SP2509-regulated genes, we performed gene set enrichment analysis (GSEA).", [["Utx KO HSPCs", "ANATOMY", 89, 101], ["HSPCs", "ANATOMY", 183, 188], ["tumor", "ANATOMY", 279, 284], ["Utx KO HSPCs", "ANATOMY", 310, 322], ["SP2509", "CHEMICAL", 28, 34], ["SP2509", "CHEMICAL", 142, 148], ["SP2509", "CHEMICAL", 211, 217], ["tumor", "DISEASE", 279, 284], ["SP2509", "CHEMICAL", 28, 34], ["SP2509", "CHEMICAL", 142, 148], ["SP2509", "CHEMICAL", 211, 217], ["SP2509", "SIMPLE_CHEMICAL", 28, 34], ["Utx KO HSPCs", "CELL", 89, 101], ["SP2509", "SIMPLE_CHEMICAL", 142, 148], ["vehicle", "SIMPLE_CHEMICAL", 160, 167], ["HSPCs", "CELL", 183, 188], ["SP2509", "SIMPLE_CHEMICAL", 211, 217], ["tumor", "CANCER", 279, 284], ["Utx KO HSPCs", "CELL", 310, 322], ["SP2509", "GENE_OR_GENE_PRODUCT", 365, 371], ["Utx KO HSPCs", "CELL_LINE", 89, 101], ["SP2509-treated vs vehicle-treated Utx WT HSPCs", "CELL_LINE", 142, 188], ["Utx KO HSPCs", "CELL_LINE", 310, 322], ["SP2509", "DNA", 365, 371], ["regulated genes", "DNA", 372, 387], ["SP2509 treatment", "TREATMENT", 28, 44], ["vehicle", "TREATMENT", 160, 167], ["Utx WT HSPCs", "TREATMENT", 176, 188], ["tumor suppressors", "PROBLEM", 279, 296], ["gene set enrichment analysis", "TEST", 402, 430], ["tumor suppressors", "OBSERVATION", 279, 296]]], ["Consistent with the differentiation block due to Utx deficiency44 (Fig. 2a\u2013d), hematopoietic cell lineage-related pathways and multiple immune-related pathways were the most enriched pathways among the downregulated genes in Utx KO HSPCs.", [["hematopoietic cell lineage", "ANATOMY", 79, 105], ["Utx KO HSPCs", "ANATOMY", 225, 237], ["Utx deficiency44", "GENE_OR_GENE_PRODUCT", 49, 65], ["hematopoietic cell lineage", "CELL", 79, 105], ["Utx KO HSPCs", "CELL", 225, 237], ["Utx deficiency44", "PROTEIN", 49, 65], ["hematopoietic cell lineage", "CELL_TYPE", 79, 105], ["downregulated genes", "DNA", 202, 221], ["Utx KO HSPCs", "CELL_LINE", 225, 237], ["the differentiation block", "PROBLEM", 16, 41], ["Utx deficiency44", "PROBLEM", 49, 65], ["hematopoietic cell lineage", "PROBLEM", 79, 105], ["multiple immune-related pathways", "PROBLEM", 127, 159], ["differentiation block", "OBSERVATION", 20, 41], ["hematopoietic cell lineage", "OBSERVATION", 79, 105], ["multiple", "OBSERVATION_MODIFIER", 127, 135]]], ["Transcriptional signatures produced by Utx KO (compared to Utx WT) were negatively correlated with the RPS14 pathway45-associated gene signature (normalized enrichment score [NES] = \u22121.717, false discovery rate [FDR] = 0.004).", [["Utx KO", "GENE_OR_GENE_PRODUCT", 39, 45], ["Utx", "GENE_OR_GENE_PRODUCT", 59, 62], ["RPS14", "GENE_OR_GENE_PRODUCT", 103, 108], ["Utx KO", "PROTEIN", 39, 45], ["RPS14 pathway45", "DNA", 103, 118], ["Transcriptional signatures", "TEST", 0, 26], ["Utx WT", "TEST", 59, 65], ["the RPS14", "TEST", 99, 108], ["gene signature", "TEST", 130, 144], ["false discovery rate", "TEST", 190, 210]]], ["Nevertheless, the transcriptional signatures in response to SP2509 treatment were positively correlation with the RPS14 pathway ([NES] = 1.694, [FDR] = 0.006) (Fig. 4a).", [["SP2509", "CHEMICAL", 60, 66], ["SP2509", "CHEMICAL", 60, 66], ["SP2509", "SIMPLE_CHEMICAL", 60, 66], ["RPS14", "GENE_OR_GENE_PRODUCT", 114, 119], ["RPS14", "PROTEIN", 114, 119], ["SP2509 treatment", "TREATMENT", 60, 76], ["the RPS14 pathway", "TEST", 110, 127], ["FDR", "TEST", 145, 148]]], ["Similarly, the hallmark IL2/STAT5 pathway-related gene set was negatively enriched in Utx KO HSPCs ([NES] = \u22121.561, [FDR] = 0.017).", [["Utx KO HSPCs", "ANATOMY", 86, 98], ["IL2", "GENE_OR_GENE_PRODUCT", 24, 27], ["STAT5", "GENE_OR_GENE_PRODUCT", 28, 33], ["Utx KO HSPCs", "CELL", 86, 98], ["IL2", "PROTEIN", 24, 27], ["STAT5", "PROTEIN", 28, 33], ["Utx KO HSPCs", "CELL_TYPE", 86, 98], ["the hallmark IL2/STAT5 pathway", "TREATMENT", 11, 41], ["HSPCs", "TEST", 93, 98], ["FDR", "TEST", 117, 120], ["hallmark", "OBSERVATION_MODIFIER", 15, 23], ["IL2", "OBSERVATION", 24, 27]]], ["In turn, this gene set was positively enriched in Utx KO HSPCs treated with SP2905 ([NES] = 1.410, [FDR] = 0.170) (Fig. 4b).", [["Utx KO HSPCs", "ANATOMY", 50, 62], ["SP2905", "CHEMICAL", 76, 82], ["SP2905", "CHEMICAL", 76, 82], ["Utx KO HSPCs", "CELL", 50, 62], ["SP2905", "SIMPLE_CHEMICAL", 76, 82], ["Utx KO HSPCs", "CELL_LINE", 50, 62]]], ["Further, the transcriptional signature of Utx KO HSPCs was negatively enriched in genes involved in the inflammatory response pathway (NES = \u22121.615, FDR q = 0.013), while the Bmi1_DN.V1_UP46 gene set, related to stemness, was enriched in SP2590-treated Utx KO HSPCs (NES = 1.651, FDR q = 0.010).", [["Utx KO HSPCs", "ANATOMY", 42, 54], ["Utx KO HSPCs", "ANATOMY", 253, 265], ["SP2590", "CHEMICAL", 238, 244], ["SP2590", "CHEMICAL", 238, 244], ["Utx", "GENE_OR_GENE_PRODUCT", 42, 45], ["HSPCs", "CELL", 49, 54], ["Bmi1_DN.V1_UP46", "GENE_OR_GENE_PRODUCT", 175, 190], ["SP2590", "SIMPLE_CHEMICAL", 238, 244], ["Utx KO HSPCs", "CELL", 253, 265], ["Utx KO HSPCs", "CELL_LINE", 42, 54], ["Bmi1_DN.V1", "DNA", 175, 185], ["UP46 gene set", "DNA", 186, 199], ["SP2590-treated Utx KO HSPCs", "CELL_LINE", 238, 265], ["Utx KO HSPCs", "PROBLEM", 42, 54], ["NES", "TEST", 135, 138], ["FDR", "TEST", 149, 152], ["NES", "TEST", 267, 270], ["FDR", "TEST", 280, 283], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116]]], ["Hence, Utx deficiency inhibited the expression of differentiation-related genes, which was reversed by SP2509 treatment.SP2509 enhanced the expression of differentiation-related genes and tumor suppressors repressed in Utx KO HSPCs ::: ResultsInterestingly, the transcriptional signature produced by Utx KO was negatively correlated with the tumor suppressor p53 pathway-related gene set ([NES] = \u22121.600, [FDR] = 0.017) and positively correlated with the Myc pathway-related gene set ([NES] = 1.876, [FDR] = 0.006), which might explain the functions of Utx in numerous human cancers.27,30,31,44,47 In contrast, the transcriptome in SP2509-treated KO HSPCs was significantly positively enriched in p53 pathway-related genes ([NES] = 1.859, [FDR] = 0.000) and negatively correlated with Myc pathway-related genes ([NES] = \u22122.490, [FDR] = 0.000) (Fig. 4e, f).", [["tumor", "ANATOMY", 188, 193], ["Utx KO HSPCs", "ANATOMY", 219, 231], ["tumor", "ANATOMY", 342, 347], ["cancers", "ANATOMY", 575, 582], ["HSPCs", "ANATOMY", 650, 655], ["SP2509", "CHEMICAL", 103, 109], ["SP2509", "CHEMICAL", 120, 126], ["tumor", "DISEASE", 188, 193], ["tumor", "DISEASE", 342, 347], ["human cancers", "DISEASE", 569, 582], ["SP2509", "CHEMICAL", 632, 638], ["SP2509", "CHEMICAL", 103, 109], ["SP2509", "CHEMICAL", 120, 126], ["SP2509", "CHEMICAL", 632, 638], ["Utx", "GENE_OR_GENE_PRODUCT", 7, 10], ["SP2509", "SIMPLE_CHEMICAL", 103, 109], ["SP2509", "SIMPLE_CHEMICAL", 120, 126], ["tumor", "CANCER", 188, 193], ["Utx KO HSPCs", "CELL", 219, 231], ["Utx", "GENE_OR_GENE_PRODUCT", 300, 303], ["tumor", "CANCER", 342, 347], ["p53", "GENE_OR_GENE_PRODUCT", 359, 362], ["Myc", "GENE_OR_GENE_PRODUCT", 455, 458], ["Utx", "GENE_OR_GENE_PRODUCT", 553, 556], ["human", "ORGANISM", 569, 574], ["cancers", "CANCER", 575, 582], ["SP2509", "SIMPLE_CHEMICAL", 632, 638], ["KO HSPCs", "CELL", 647, 655], ["p53", "GENE_OR_GENE_PRODUCT", 697, 700], ["Myc", "GENE_OR_GENE_PRODUCT", 785, 788], ["Utx", "PROTEIN", 7, 10], ["Utx KO HSPCs", "CELL_LINE", 219, 231], ["Utx KO", "PROTEIN", 300, 306], ["p53", "PROTEIN", 359, 362], ["Myc", "PROTEIN", 455, 458], ["Utx", "PROTEIN", 553, 556], ["SP2509-treated KO HSPCs", "CELL_LINE", 632, 655], ["p53", "PROTEIN", 697, 700], ["Myc", "PROTEIN", 785, 788], ["human", "SPECIES", 569, 574], ["human", "SPECIES", 569, 574], ["Utx deficiency", "PROBLEM", 7, 21], ["tumor suppressors", "PROBLEM", 188, 205], ["the tumor suppressor p53 pathway", "TEST", 338, 370], ["gene set", "TEST", 379, 387], ["FDR", "TEST", 406, 409], ["the Myc pathway", "TEST", 451, 466], ["FDR", "TEST", 501, 504], ["Utx in numerous human cancers", "PROBLEM", 553, 582], ["the transcriptome", "TEST", 611, 628], ["KO HSPCs", "TEST", 647, 655], ["p53 pathway", "TEST", 697, 708], ["FDR", "TEST", 740, 743], ["Myc pathway", "TEST", 785, 796], ["FDR", "TEST", 829, 832], ["Utx deficiency", "OBSERVATION", 7, 21], ["tumor suppressors", "OBSERVATION", 188, 205], ["Utx", "OBSERVATION", 553, 556], ["numerous", "OBSERVATION_MODIFIER", 560, 568], ["human cancers", "OBSERVATION", 569, 582]]], ["Additionally, the ribosome biogenesis-related gene set was positively enriched in Utx KO HSPCs ([NES] = 1.90, [FDR] = 0.12).", [["ribosome", "ANATOMY", 18, 26], ["Utx KO HSPCs", "ANATOMY", 82, 94], ["ribosome", "CELLULAR_COMPONENT", 18, 26], ["Utx KO HSPCs", "CELL_TYPE", 82, 94], ["the ribosome biogenesis", "TEST", 14, 37], ["HSPCs", "TEST", 89, 94], ["FDR", "TEST", 111, 114], ["ribosome biogenesis", "OBSERVATION", 18, 37]]], ["Conversely, this gene set was negatively enriched in SP2590-treated Utx KO HSPCs ([NES] = 1.90, [FDR] = \u22122.218) (Fig. 4f).", [["Utx KO HSPCs", "ANATOMY", 68, 80], ["SP2590", "CHEMICAL", 53, 59], ["SP2590", "CHEMICAL", 53, 59], ["SP2590", "SIMPLE_CHEMICAL", 53, 59], ["Utx KO HSPCs", "CELL", 68, 80], ["SP2590", "PROTEIN", 53, 59], ["Utx KO HSPCs", "CELL_LINE", 68, 80], ["FDR", "TEST", 97, 100]]], ["Thus, SP2509 treatment rescued the expression of tumor suppressors and oncogenes perturbed by Utx deficiency in HSPCs.SP2509 enhanced the expression of differentiation-related genes and tumor suppressors repressed in Utx KO HSPCs ::: ResultsQuantitative PCR analysis of selected differentiation-related genes, such as Car1, Car2, Gata1, and Gata2, from GSEA in Utx KO HSPCs confirmed significant decreased expression compared to that in Utx WT HSPCs (p < 0.01) (Fig. 4g).", [["tumor", "ANATOMY", 49, 54], ["HSPCs", "ANATOMY", 112, 117], ["tumor", "ANATOMY", 186, 191], ["Utx KO HSPCs", "ANATOMY", 217, 229], ["Utx KO HSPCs", "ANATOMY", 361, 373], ["Utx WT HSPCs", "ANATOMY", 437, 449], ["SP2509", "CHEMICAL", 6, 12], ["tumor", "DISEASE", 49, 54], ["SP2509", "CHEMICAL", 118, 124], ["tumor", "DISEASE", 186, 191], ["SP2509", "CHEMICAL", 6, 12], ["SP2509", "CHEMICAL", 118, 124], ["SP2509", "SIMPLE_CHEMICAL", 6, 12], ["tumor", "CANCER", 49, 54], ["Utx", "GENE_OR_GENE_PRODUCT", 94, 97], ["HSPCs", "CELL", 112, 117], ["SP2509", "SIMPLE_CHEMICAL", 118, 124], ["tumor", "CANCER", 186, 191], ["Utx KO HSPCs", "CELL", 217, 229], ["Car1", "GENE_OR_GENE_PRODUCT", 318, 322], ["Car2", "GENE_OR_GENE_PRODUCT", 324, 328], ["Gata1", "GENE_OR_GENE_PRODUCT", 330, 335], ["Gata2", "GENE_OR_GENE_PRODUCT", 341, 346], ["Utx KO HSPCs", "CELL", 361, 373], ["Utx WT HSPCs", "CELL", 437, 449], ["oncogenes", "DNA", 71, 80], ["Utx", "PROTEIN", 94, 97], ["HSPCs", "CELL_TYPE", 112, 117], ["Utx KO HSPCs", "CELL_LINE", 217, 229], ["Car1", "DNA", 318, 322], ["Car2", "DNA", 324, 328], ["Gata1", "DNA", 330, 335], ["Gata2", "DNA", 341, 346], ["GSEA", "DNA", 353, 357], ["Utx KO HSPCs", "CELL_LINE", 361, 373], ["Utx WT HSPCs", "CELL_LINE", 437, 449], ["SP2509 treatment", "TREATMENT", 6, 22], ["tumor suppressors", "TREATMENT", 49, 66], ["oncogenes", "TREATMENT", 71, 80], ["Utx deficiency", "PROBLEM", 94, 108], ["tumor suppressors", "PROBLEM", 186, 203], ["ResultsQuantitative PCR analysis", "TEST", 234, 266], ["Car1", "TEST", 318, 322], ["Car2", "TEST", 324, 328], ["Gata1", "TEST", 330, 335], ["HSPCs", "TEST", 368, 373], ["significant decreased expression", "PROBLEM", 384, 416], ["HSPCs", "TEST", 444, 449], ["tumor suppressors", "OBSERVATION", 49, 66], ["tumor suppressors", "OBSERVATION", 186, 203], ["significant", "OBSERVATION_MODIFIER", 384, 395], ["decreased", "OBSERVATION", 396, 405]]], ["Accordingly, SP2509-treated Utx KO HSPCs displayed significantly increased expression of selected differentiation-related genes and tumor suppressors including Bax compared to vehicle-treated Utx KO HSPCs (p < 0.05) (Fig. 4h).SP2509 treatment reversed the H3K4 methylation-mediated repression of differentiation-related genes and tumor suppressors in Utx KO HSPCs by inhibiting LSD1 ::: ResultsGiven the H3K4 methylation activity of Utx and its associated COMPASS-like complex and the H3K4 demethylation activity of LSD1, the putative target of SP2509,48 we further studied the mechanisms of SP2509-induced differentiation in Utx KO HSPCs.", [["Utx KO HSPCs", "ANATOMY", 28, 40], ["tumor", "ANATOMY", 132, 137], ["Utx KO HSPCs", "ANATOMY", 192, 204], ["tumor", "ANATOMY", 330, 335], ["Utx KO HSPCs", "ANATOMY", 351, 363], ["Utx KO HSPCs", "ANATOMY", 626, 638], ["SP2509", "CHEMICAL", 13, 19], ["tumor", "DISEASE", 132, 137], ["SP2509", "CHEMICAL", 226, 232], ["tumor", "DISEASE", 330, 335], ["SP2509", "CHEMICAL", 592, 598], ["SP2509", "CHEMICAL", 13, 19], ["SP2509", "CHEMICAL", 226, 232], ["SP2509,48", "CHEMICAL", 545, 554], ["SP2509", "CHEMICAL", 592, 598], ["SP2509", "SIMPLE_CHEMICAL", 13, 19], ["Utx KO HSPCs", "CELL", 28, 40], ["tumor", "CANCER", 132, 137], ["Bax", "GENE_OR_GENE_PRODUCT", 160, 163], ["vehicle", "SIMPLE_CHEMICAL", 176, 183], ["Utx KO HSPCs", "CELL", 192, 204], ["SP2509", "SIMPLE_CHEMICAL", 226, 232], ["H3K4", "GENE_OR_GENE_PRODUCT", 256, 260], ["tumor", "CANCER", 330, 335], ["Utx KO HSPCs", "CELL", 351, 363], ["LSD1", "GENE_OR_GENE_PRODUCT", 378, 382], ["H3K4", "GENE_OR_GENE_PRODUCT", 404, 408], ["Utx", "GENE_OR_GENE_PRODUCT", 433, 436], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 456, 476], ["H3K4", "GENE_OR_GENE_PRODUCT", 485, 489], ["LSD1", "GENE_OR_GENE_PRODUCT", 516, 520], ["SP2509,48", "SIMPLE_CHEMICAL", 545, 554], ["SP2509", "SIMPLE_CHEMICAL", 592, 598], ["Utx KO HSPCs", "CELL", 626, 638], ["SP2509-treated Utx KO HSPCs", "CELL_LINE", 13, 40], ["Bax", "PROTEIN", 160, 163], ["vehicle-treated Utx KO HSPCs", "CELL_LINE", 176, 204], ["H3K4", "PROTEIN", 256, 260], ["Utx KO HSPCs", "CELL_LINE", 351, 363], ["LSD1", "PROTEIN", 378, 382], ["H3K4", "PROTEIN", 404, 408], ["Utx", "PROTEIN", 433, 436], ["COMPASS-like complex", "PROTEIN", 456, 476], ["H3K4", "PROTEIN", 485, 489], ["LSD1", "PROTEIN", 516, 520], ["SP2509", "PROTEIN", 592, 598], ["Utx KO HSPCs", "CELL_LINE", 626, 638], ["SP2509", "TEST", 13, 19], ["selected differentiation", "PROBLEM", 89, 113], ["tumor suppressors", "TREATMENT", 132, 149], ["Bax", "TREATMENT", 160, 163], ["HSPCs", "TEST", 199, 204], ["treatment", "TREATMENT", 233, 242], ["the H3K4 methylation", "TREATMENT", 252, 272], ["tumor suppressors", "TREATMENT", 330, 347], ["the H3K4 methylation activity of Utx", "PROBLEM", 400, 436], ["its associated COMPASS-like complex", "PROBLEM", 441, 476], ["the H3K4 demethylation activity of LSD1", "PROBLEM", 481, 520], ["tumor suppressors", "OBSERVATION", 132, 149], ["tumor suppressors", "OBSERVATION", 330, 347], ["H3K4 demethylation", "OBSERVATION", 485, 503]]], ["As shown in western blot (Fig. 5a, b), the total H3K4m3 level was reduced in Utx KO HSPCs compared to that in Utx WT HSPCs.", [["Utx KO HSPCs", "ANATOMY", 77, 89], ["Utx WT HSPCs", "ANATOMY", 110, 122], ["b", "GENE_OR_GENE_PRODUCT", 35, 36], ["H3K4m3", "GENE_OR_GENE_PRODUCT", 49, 55], ["Utx KO HSPCs", "CELL", 77, 89], ["Utx WT HSPCs", "CELL", 110, 122], ["H3K4m3", "PROTEIN", 49, 55], ["Utx KO HSPCs", "CELL_LINE", 77, 89], ["Utx WT HSPCs", "CELL_LINE", 110, 122], ["the total H3K4m3 level", "TEST", 39, 61], ["Utx KO HSPCs", "TREATMENT", 77, 89]]], ["Although Utx itself does not have a direct H3K4-modifying activity, it associates with Mll3/4 in COMPASS-like complex, which are H3K4 mono- and dimethyltransferase.", [["Utx", "GENE_OR_GENE_PRODUCT", 9, 12], ["H3K4", "GENE_OR_GENE_PRODUCT", 43, 47], ["Mll3/4", "GENE_OR_GENE_PRODUCT", 87, 93], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 97, 117], ["H3K4", "GENE_OR_GENE_PRODUCT", 129, 133], ["Utx", "PROTEIN", 9, 12], ["H3K4", "PROTEIN", 43, 47], ["Mll3/4", "PROTEIN", 87, 93], ["COMPASS", "PROTEIN", 97, 104], ["H3K4 mono- and dimethyltransferase", "PROTEIN", 129, 163], ["a direct H3K4", "TREATMENT", 34, 47], ["H3K4 mono", "TEST", 129, 138]]], ["Actually, we did observe a significant reduction in H3K4m1 levels, but the levels of H3K4m2 were similar between Utx KO and WT HSPCs.", [["HSPCs", "ANATOMY", 127, 132], ["H3K4m1", "GENE_OR_GENE_PRODUCT", 52, 58], ["H3K4m2", "GENE_OR_GENE_PRODUCT", 85, 91], ["Utx KO", "CELL", 113, 119], ["HSPCs", "CELL", 127, 132], ["H3K4m1", "PROTEIN", 52, 58], ["H3K4m2", "PROTEIN", 85, 91], ["Utx KO", "CELL_LINE", 113, 119], ["WT HSPCs", "CELL_TYPE", 124, 132], ["a significant reduction in H3K4m1 levels", "PROBLEM", 25, 65], ["the levels", "TEST", 71, 81], ["H3K4m2", "TEST", 85, 91], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["reduction", "OBSERVATION_MODIFIER", 39, 48]]], ["Consistently, differentiation-related genes, such as Car1, Car2 and Gata1, and the tumor suppressor Bax, displayed reduced H3K4m1 levels in Utx KO HSPCs compared to those in WT HSPCs44 (Fig. 5c\u2013f), which led to the decreased expression levels of these genes (Fig. 4h).", [["tumor", "ANATOMY", 83, 88], ["Utx KO HSPCs", "ANATOMY", 140, 152], ["tumor", "DISEASE", 83, 88], ["Car1", "GENE_OR_GENE_PRODUCT", 53, 57], ["Car2", "GENE_OR_GENE_PRODUCT", 59, 63], ["Gata1", "GENE_OR_GENE_PRODUCT", 68, 73], ["tumor", "CANCER", 83, 88], ["Bax", "GENE_OR_GENE_PRODUCT", 100, 103], ["H3K4m1", "GENE_OR_GENE_PRODUCT", 123, 129], ["Utx KO HSPCs", "CELL", 140, 152], ["WT HSPCs44", "ORGANISM", 174, 184], ["Fig. 5c\u2013f)", "ORGANISM", 186, 196], ["Car1", "PROTEIN", 53, 57], ["Car2", "DNA", 59, 63], ["Gata1", "DNA", 68, 73], ["tumor suppressor Bax", "PROTEIN", 83, 103], ["H3K4m1", "PROTEIN", 123, 129], ["Utx KO HSPCs", "CELL_LINE", 140, 152], ["WT HSPCs44", "CELL_LINE", 174, 184], ["Gata1", "TREATMENT", 68, 73], ["the tumor suppressor Bax", "TREATMENT", 79, 103], ["reduced H3K4m1 levels", "PROBLEM", 115, 136], ["Utx KO HSPCs", "PROBLEM", 140, 152], ["the decreased expression levels", "PROBLEM", 211, 242], ["decreased", "OBSERVATION", 215, 224]]], ["Our results suggested that Utx loss might impair the H3K4 methyltransferase activities of Mll3/4.SP2509 treatment reversed the H3K4 methylation-mediated repression of differentiation-related genes and tumor suppressors in Utx KO HSPCs by inhibiting LSD1 ::: ResultsIn contrast, LSD1, the target of SP2509, is an H3K4 and H3K9 demethylase.", [["tumor", "ANATOMY", 201, 206], ["Utx KO HSPCs", "ANATOMY", 222, 234], ["Utx loss", "DISEASE", 27, 35], ["SP2509", "CHEMICAL", 97, 103], ["tumor", "DISEASE", 201, 206], ["SP2509", "CHEMICAL", 97, 103], ["Utx", "GENE_OR_GENE_PRODUCT", 27, 30], ["H3K4 methyltransferase", "GENE_OR_GENE_PRODUCT", 53, 75], ["Mll3/4", "GENE_OR_GENE_PRODUCT", 90, 96], ["SP2509", "SIMPLE_CHEMICAL", 97, 103], ["H3K4", "GENE_OR_GENE_PRODUCT", 127, 131], ["tumor", "CANCER", 201, 206], ["Utx KO HSPCs", "CELL", 222, 234], ["LSD1", "GENE_OR_GENE_PRODUCT", 249, 253], ["LSD1", "GENE_OR_GENE_PRODUCT", 278, 282], ["SP2509", "GENE_OR_GENE_PRODUCT", 298, 304], ["H3K4", "GENE_OR_GENE_PRODUCT", 312, 316], ["H3K9 demethylase", "GENE_OR_GENE_PRODUCT", 321, 337], ["Utx", "PROTEIN", 27, 30], ["H3K4", "PROTEIN", 53, 57], ["Mll3/4", "PROTEIN", 90, 96], ["H3K4", "PROTEIN", 127, 131], ["Utx KO HSPCs", "CELL_LINE", 222, 234], ["LSD1", "PROTEIN", 249, 253], ["LSD1", "PROTEIN", 278, 282], ["SP2509", "PROTEIN", 298, 304], ["H3K4", "PROTEIN", 312, 316], ["H3K9 demethylase", "PROTEIN", 321, 337], ["Utx loss", "PROBLEM", 27, 35], ["the H3K4 methyltransferase activities", "PROBLEM", 49, 86], ["treatment", "TREATMENT", 104, 113], ["the H3K4 methylation", "TREATMENT", 123, 143], ["tumor suppressors", "TREATMENT", 201, 218], ["an H3K4 and H3K9 demethylase", "PROBLEM", 309, 337], ["Utx", "OBSERVATION", 27, 30], ["H3K4 methyltransferase", "OBSERVATION", 53, 75], ["tumor suppressors", "OBSERVATION", 201, 218], ["H3K4", "OBSERVATION", 312, 316], ["H3K9 demethylase", "OBSERVATION", 321, 337]]], ["Indeed, LSD1 inhibition by SP2509 increased H3K4m3 levels in Utx KO HSPCs (Fig. 5a, b).", [["Utx KO HSPCs", "ANATOMY", 61, 73], ["SP2509", "CHEMICAL", 27, 33], ["SP2509", "CHEMICAL", 27, 33], ["LSD1", "GENE_OR_GENE_PRODUCT", 8, 12], ["SP2509", "SIMPLE_CHEMICAL", 27, 33], ["H3K4m3", "GENE_OR_GENE_PRODUCT", 44, 50], ["Utx KO HSPCs", "CELL", 61, 73], ["LSD1", "PROTEIN", 8, 12], ["H3K4m3", "PROTEIN", 44, 50], ["Utx KO HSPCs", "CELL_LINE", 61, 73], ["increased H3K4m3 levels", "PROBLEM", 34, 57]]], ["The total levels of H3K4m2 were not significantly changed in Utx KO HSPCs treated with SP2509, but the level of H3K4m1 was further reduced, suggesting that a majority of these loci might have been further methylated to H3K4m3.", [["Utx KO HSPCs", "ANATOMY", 61, 73], ["SP2509", "CHEMICAL", 87, 93], ["SP2509", "CHEMICAL", 87, 93], ["H3K4m2", "GENE_OR_GENE_PRODUCT", 20, 26], ["Utx KO HSPCs", "CELL", 61, 73], ["SP2509", "SIMPLE_CHEMICAL", 87, 93], ["H3K4m1", "GENE_OR_GENE_PRODUCT", 112, 118], ["H3K4m3", "GENE_OR_GENE_PRODUCT", 219, 225], ["H3K4m2", "PROTEIN", 20, 26], ["Utx KO HSPCs", "CELL_LINE", 61, 73], ["H3K4m1", "PROTEIN", 112, 118], ["H3K4m3", "DNA", 219, 225], ["The total levels of H3K4m2", "TEST", 0, 26], ["these loci", "PROBLEM", 170, 180]]], ["The level of H3K4m3 in Bax gene was reduced in Utx KO ES cells compared to that in Utx WT cells49 (Fig. 5g).", [["Utx KO ES cells", "ANATOMY", 47, 62], ["Utx WT cells49", "ANATOMY", 83, 97], ["H3K4m3", "GENE_OR_GENE_PRODUCT", 13, 19], ["Bax", "GENE_OR_GENE_PRODUCT", 23, 26], ["Utx KO ES cells", "CELL", 47, 62], ["Utx WT cells49", "CELL", 83, 97], ["H3K4m3", "PROTEIN", 13, 19], ["Bax gene", "DNA", 23, 31], ["Utx KO ES cells", "CELL_LINE", 47, 62], ["Utx WT cells49", "CELL_LINE", 83, 97], ["H3K4m3 in Bax gene", "TREATMENT", 13, 31], ["Utx KO ES cells", "PROBLEM", 47, 62]]], ["Interestingly, treatment with OG86, another LSD1 inhibitor, increased the binding of MLL4 to the promoter of BAX in leukemic cells50 (Fig. 5h), suggesting that LSD1 and the COMPASS-like complex might directly compete for binding on the promoters of differentiation-related genes and tumor suppressors.", [["leukemic cells50", "ANATOMY", 116, 132], ["tumor", "ANATOMY", 283, 288], ["OG86", "CHEMICAL", 30, 34], ["tumor", "DISEASE", 283, 288], ["OG86", "CHEMICAL", 30, 34], ["OG86", "SIMPLE_CHEMICAL", 30, 34], ["LSD1", "GENE_OR_GENE_PRODUCT", 44, 48], ["MLL4", "GENE_OR_GENE_PRODUCT", 85, 89], ["BAX", "GENE_OR_GENE_PRODUCT", 109, 112], ["leukemic cells50", "CANCER", 116, 132], ["LSD1", "GENE_OR_GENE_PRODUCT", 160, 164], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 173, 193], ["tumor", "CANCER", 283, 288], ["LSD1", "PROTEIN", 44, 48], ["MLL4", "PROTEIN", 85, 89], ["BAX", "PROTEIN", 109, 112], ["leukemic cells50", "PROTEIN", 116, 132], ["LSD1", "PROTEIN", 160, 164], ["COMPASS", "PROTEIN", 173, 180], ["promoters", "DNA", 236, 245], ["treatment", "TREATMENT", 15, 24], ["OG86", "TREATMENT", 30, 34], ["another LSD1 inhibitor", "TREATMENT", 36, 58], ["LSD1", "PROBLEM", 160, 164], ["tumor suppressors", "TREATMENT", 283, 300], ["leukemic cells50", "OBSERVATION", 116, 132], ["tumor suppressors", "OBSERVATION", 283, 300]]], ["Thus, LSD1 inhibition reversed the reduction in H3K4 methylation in Utx-deficient cells and increased the expression of differentiation-related genes and tumor suppressors.SP2509 treatment promoted the differentiation of Utx-deficient AML cells in vitro and in vivo and extended the survival of leukemic mice ::: ResultsWe further tested whether SP2509 would have similar inhibitory effect on Utx-deficient malignant cells as it did on Utx KO HSPCs.", [["Utx-deficient cells", "ANATOMY", 68, 87], ["tumor", "ANATOMY", 154, 159], ["Utx-deficient AML cells", "ANATOMY", 221, 244], ["malignant cells", "ANATOMY", 407, 422], ["Utx KO HSPCs", "ANATOMY", 436, 448], ["tumor", "DISEASE", 154, 159], ["SP2509", "CHEMICAL", 172, 178], ["AML", "DISEASE", 235, 238], ["SP2509", "CHEMICAL", 346, 352], ["SP2509", "CHEMICAL", 172, 178], ["SP2509", "CHEMICAL", 346, 352], ["LSD1", "GENE_OR_GENE_PRODUCT", 6, 10], ["H3K4", "GENE_OR_GENE_PRODUCT", 48, 52], ["Utx", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 82, 87], ["tumor", "CANCER", 154, 159], ["SP2509", "SIMPLE_CHEMICAL", 172, 178], ["Utx", "GENE_OR_GENE_PRODUCT", 221, 224], ["AML cells", "CELL", 235, 244], ["mice", "ORGANISM", 304, 308], ["SP2509", "SIMPLE_CHEMICAL", 346, 352], ["Utx", "GENE_OR_GENE_PRODUCT", 393, 396], ["malignant cells", "CELL", 407, 422], ["Utx KO HSPCs", "CELL", 436, 448], ["LSD1", "PROTEIN", 6, 10], ["H3K4", "PROTEIN", 48, 52], ["Utx-deficient cells", "CELL_LINE", 68, 87], ["Utx-deficient AML cells", "CELL_LINE", 221, 244], ["Utx-deficient malignant cells", "CELL_LINE", 393, 422], ["Utx KO HSPCs", "CELL_LINE", 436, 448], ["mice", "SPECIES", 304, 308], ["mice", "SPECIES", 304, 308], ["LSD1 inhibition", "PROBLEM", 6, 21], ["the reduction", "TREATMENT", 31, 44], ["H3K4 methylation in Utx", "TREATMENT", 48, 71], ["deficient cells", "PROBLEM", 72, 87], ["tumor suppressors", "TREATMENT", 154, 171], ["treatment", "TREATMENT", 179, 188], ["Utx-deficient AML cells", "TREATMENT", 221, 244], ["deficient malignant cells", "PROBLEM", 397, 422], ["reduction", "OBSERVATION_MODIFIER", 35, 44], ["H3K4 methylation", "OBSERVATION", 48, 64], ["deficient cells", "OBSERVATION", 72, 87], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["tumor suppressors", "OBSERVATION", 154, 171], ["AML cells", "OBSERVATION", 235, 244], ["leukemic mice", "OBSERVATION", 295, 308], ["malignant cells", "OBSERVATION", 407, 422]]], ["Utx\u2212/\u2212; shp53-mCherry;shNf1-GFP AML cells (from unpublished independent work) were treated with or without 10 \u03bcM SP2509 for 3 days.", [["shNf1-GFP AML cells", "ANATOMY", 22, 41], ["SP2509", "CHEMICAL", 113, 119], ["SP2509", "CHEMICAL", 113, 119], ["Utx\u2212", "GENE_OR_GENE_PRODUCT", 0, 4], ["shp53-mCherry", "GENE_OR_GENE_PRODUCT", 8, 21], ["shNf1", "GENE_OR_GENE_PRODUCT", 22, 27], ["Utx\u2212/\u2212; shp53-mCherry", "DNA", 0, 21], ["shNf1-GFP AML cells", "CELL_LINE", 22, 41], ["Utx\u2212", "TEST", 0, 4], ["\u2212", "TEST", 5, 6], ["shp53", "TEST", 8, 13], ["mCherry", "TEST", 14, 21], ["shNf1", "TEST", 22, 27], ["GFP AML cells", "PROBLEM", 28, 41], ["GFP AML cells", "OBSERVATION", 28, 41]]], ["By flow cytometry, we found that SP2509 treatment dramatically increased the expression of the differentiation marker Mac-1 in leukemia cells (Fig. 6a).", [["leukemia cells", "ANATOMY", 127, 141], ["SP2509", "CHEMICAL", 33, 39], ["leukemia", "DISEASE", 127, 135], ["SP2509", "CHEMICAL", 33, 39], ["SP2509", "SIMPLE_CHEMICAL", 33, 39], ["Mac-1", "GENE_OR_GENE_PRODUCT", 118, 123], ["leukemia cells", "CELL", 127, 141], ["Fig. 6a", "CELL", 143, 150], ["Mac-1", "PROTEIN", 118, 123], ["leukemia cells", "CELL_TYPE", 127, 141], ["flow cytometry", "TEST", 3, 17], ["SP2509 treatment", "TREATMENT", 33, 49], ["leukemia cells", "PROBLEM", 127, 141], ["leukemia cells", "OBSERVATION", 127, 141]]], ["The percentage of Mac-1+ population and the MFI of Mac-1 staining in SP2509-treated Utx-null AML cells were approximately two-fold higher than those in vehicle-treated cells.", [["Utx-null AML cells", "ANATOMY", 84, 102], ["cells", "ANATOMY", 168, 173], ["SP2509", "CHEMICAL", 69, 75], ["AML", "DISEASE", 93, 96], ["Mac-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["Mac-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["SP2509", "SIMPLE_CHEMICAL", 69, 75], ["Utx", "GENE_OR_GENE_PRODUCT", 84, 87], ["AML cells", "CELL", 93, 102], ["cells", "CELL", 168, 173], ["Mac", "PROTEIN", 18, 21], ["Mac", "PROTEIN", 51, 54], ["SP2509-treated Utx-null AML cells", "CELL_LINE", 69, 102], ["vehicle-treated cells", "CELL_LINE", 152, 173], ["Mac", "TEST", 18, 21], ["the MFI", "TEST", 40, 47], ["Mac", "TEST", 51, 54], ["staining", "TEST", 57, 65], ["SP2509", "TEST", 69, 75], ["Utx", "TEST", 84, 87], ["null AML cells", "PROBLEM", 88, 102], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["Mac", "OBSERVATION", 18, 21], ["Mac", "ANATOMY", 51, 54], ["null AML cells", "OBSERVATION", 88, 102]]], ["Accordingly, the expression of the stemness marker cKit was reduced by SP2509 (Fig. 6b).", [["SP2509", "CHEMICAL", 71, 77], ["SP2509", "CHEMICAL", 71, 77], ["cKit", "GENE_OR_GENE_PRODUCT", 51, 55], ["cKit", "PROTEIN", 51, 55], ["the stemness marker cKit", "TEST", 31, 55]]], ["Consistent with the release of differentiation block, SP2509 significantly repressed the growth of Utx-null AML cells (Fig. 6c).", [["Utx-null AML cells", "ANATOMY", 99, 117], ["SP2509", "CHEMICAL", 54, 60], ["AML", "DISEASE", 108, 111], ["SP2509", "CHEMICAL", 54, 60], ["SP2509", "SIMPLE_CHEMICAL", 54, 60], ["Utx", "GENE_OR_GENE_PRODUCT", 99, 102], ["Utx-null AML cells", "CELL_LINE", 99, 117], ["differentiation block", "PROBLEM", 31, 52], ["Utx", "TEST", 99, 102], ["null AML cells", "PROBLEM", 103, 117], ["growth", "OBSERVATION_MODIFIER", 89, 95], ["null AML cells", "OBSERVATION", 103, 117]]], ["Thus, similar to its function in premalignant Utx-deficient HSPCs, SP2509 inhibited Utx-null AML cells in vitro by promoting their differentiation.", [["HSPCs", "ANATOMY", 60, 65], ["Utx-null AML cells", "ANATOMY", 84, 102], ["SP2509", "CHEMICAL", 67, 73], ["AML", "DISEASE", 93, 96], ["SP2509", "CHEMICAL", 67, 73], ["Utx", "GENE_OR_GENE_PRODUCT", 46, 49], ["HSPCs", "CELL", 60, 65], ["SP2509", "SIMPLE_CHEMICAL", 67, 73], ["Utx", "GENE_OR_GENE_PRODUCT", 84, 87], ["premalignant Utx-deficient HSPCs", "CELL_LINE", 33, 65], ["Utx-null AML cells", "CELL_LINE", 84, 102], ["premalignant Utx", "PROBLEM", 33, 49], ["deficient HSPCs", "PROBLEM", 50, 65], ["Utx", "TEST", 84, 87], ["null AML cells", "PROBLEM", 88, 102], ["null AML cells", "OBSERVATION", 88, 102]]], ["These data validated our screening strategy to target Utx deficiency in malignant cells.SP2509 treatment promoted the differentiation of Utx-deficient AML cells in vitro and in vivo and extended the survival of leukemic mice ::: ResultsThen, the potential therapeutic effect of SP2509 on Utx-deficient AML was tested in vivo.", [["malignant cells", "ANATOMY", 72, 87], ["Utx-deficient AML cells", "ANATOMY", 137, 160], ["AML", "ANATOMY", 302, 305], ["SP2509", "CHEMICAL", 88, 94], ["AML", "DISEASE", 151, 154], ["SP2509", "CHEMICAL", 278, 284], ["AML", "DISEASE", 302, 305], ["SP2509", "CHEMICAL", 88, 94], ["SP2509", "CHEMICAL", 278, 284], ["Utx", "GENE_OR_GENE_PRODUCT", 54, 57], ["malignant cells", "CELL", 72, 87], ["SP2509", "SIMPLE_CHEMICAL", 88, 94], ["Utx", "GENE_OR_GENE_PRODUCT", 137, 140], ["AML cells", "CELL", 151, 160], ["mice", "ORGANISM", 220, 224], ["SP2509", "SIMPLE_CHEMICAL", 278, 284], ["Utx", "GENE_OR_GENE_PRODUCT", 288, 291], ["AML", "CANCER", 302, 305], ["Utx", "PROTEIN", 54, 57], ["malignant cells", "CELL_TYPE", 72, 87], ["Utx-deficient AML cells", "CELL_LINE", 137, 160], ["Utx", "PROTEIN", 288, 291], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 220, 224], ["our screening", "TEST", 21, 34], ["Utx deficiency in malignant cells", "PROBLEM", 54, 87], ["treatment", "TREATMENT", 95, 104], ["Utx-deficient AML cells", "TREATMENT", 137, 160], ["Utx", "TREATMENT", 288, 291], ["deficient AML", "PROBLEM", 292, 305], ["malignant cells", "OBSERVATION", 72, 87], ["AML cells", "OBSERVATION", 151, 160], ["leukemic mice", "OBSERVATION", 211, 224], ["therapeutic", "OBSERVATION_MODIFIER", 256, 267], ["AML", "OBSERVATION", 302, 305]]], ["Utx\u2212/\u2212; shp53-mCherry;shNf1-GFP AML cells were transplanted into sublethally irradiated congenic recipient mice.", [["shNf1-GFP AML cells", "ANATOMY", 22, 41], ["Utx\u2212", "GENE_OR_GENE_PRODUCT", 0, 4], ["shp53-mCherry", "GENE_OR_GENE_PRODUCT", 8, 21], ["shNf1", "GENE_OR_GENE_PRODUCT", 22, 27], ["mice", "ORGANISM", 107, 111], ["Utx\u2212/\u2212; shp53-mCherry", "DNA", 0, 21], ["shNf1-GFP AML cells", "CELL_LINE", 22, 41], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["Utx\u2212", "TEST", 0, 4], ["\u2212", "TEST", 5, 6], ["shp53", "TEST", 8, 13], ["mCherry", "TEST", 14, 21], ["shNf1", "TEST", 22, 27], ["GFP AML cells", "PROBLEM", 28, 41], ["GFP AML cells", "OBSERVATION", 28, 41], ["congenic recipient", "OBSERVATION", 88, 106]]], ["Seven days after transplantation, all of the recipient mice had similar proportions of GFP+-mCherry+ AML cells in their peripheral blood measured by flow cytometry.", [["GFP+-mCherry+ AML cells", "ANATOMY", 87, 110], ["peripheral blood", "ANATOMY", 120, 136], ["mice", "ORGANISM", 55, 59], ["GFP", "GENE_OR_GENE_PRODUCT", 87, 90], ["peripheral blood", "ORGANISM_SUBSTANCE", 120, 136], ["AML cells", "CELL_TYPE", 101, 110], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["transplantation", "TREATMENT", 17, 32], ["AML cells", "PROBLEM", 101, 110], ["their peripheral blood", "TEST", 114, 136], ["flow cytometry", "TEST", 149, 163], ["AML cells", "OBSERVATION", 101, 110], ["peripheral", "ANATOMY_MODIFIER", 120, 130], ["blood", "ANATOMY", 131, 136], ["flow cytometry", "OBSERVATION", 149, 163]]], ["These leukemic mice were randomly assigned into two groups: one was treated with 25 mg/kg SP2509 twice per week by intraperitoneal injection, while the other one was treated with vehicle.", [["intraperitoneal", "ANATOMY", 115, 130], ["SP2509", "CHEMICAL", 90, 96], ["SP2509", "CHEMICAL", 90, 96], ["mice", "ORGANISM", 15, 19], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 130], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["vehicle", "TREATMENT", 179, 186]]], ["These mice were monitored for disease progression by complete blood cell (CBC) count, blood smear staining, and flow cytometry (Fig. 6d).", [["blood cell", "ANATOMY", 62, 72], ["CBC", "ANATOMY", 74, 77], ["blood", "ANATOMY", 86, 91], ["mice", "ORGANISM", 6, 10], ["complete blood cell", "CELL", 53, 72], ["CBC", "CELL", 74, 77], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["disease progression", "PROBLEM", 30, 49], ["complete blood cell", "TEST", 53, 72], ["CBC", "TEST", 74, 77], ["count", "TEST", 79, 84], ["blood smear staining", "TEST", 86, 106], ["flow cytometry", "TEST", 112, 126]]], ["One week after treatment, we observed approximately 50% Mac-1+ AML cells in the peripheral blood of SP2509-treated mice compared to 25% in the peripheral blood of vehicle-treated mice (Fig. 6e).", [["Mac-1+ AML cells", "ANATOMY", 56, 72], ["peripheral blood", "ANATOMY", 80, 96], ["peripheral blood", "ANATOMY", 143, 159], ["AML", "DISEASE", 63, 66], ["SP2509", "CHEMICAL", 100, 106], ["SP2509", "CHEMICAL", 100, 106], ["Mac-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["peripheral blood", "ORGANISM_SUBSTANCE", 80, 96], ["SP2509", "SIMPLE_CHEMICAL", 100, 106], ["mice", "ORGANISM", 115, 119], ["peripheral blood", "ORGANISM_SUBSTANCE", 143, 159], ["vehicle", "SIMPLE_CHEMICAL", 163, 170], ["mice", "ORGANISM", 179, 183], ["Mac-1+ AML cells", "CELL_LINE", 56, 72], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 179, 183], ["treatment", "TREATMENT", 15, 24], ["Mac", "TEST", 56, 59], ["AML cells", "PROBLEM", 63, 72], ["the peripheral blood", "TEST", 76, 96], ["AML cells", "OBSERVATION", 63, 72], ["peripheral", "ANATOMY_MODIFIER", 80, 90], ["blood", "ANATOMY", 91, 96], ["peripheral", "ANATOMY_MODIFIER", 143, 153], ["blood", "ANATOMY", 154, 159]]], ["This differentiation-promoting effect of SP2509 was more obvious after a 2-week treatment.", [["SP2509", "CHEMICAL", 41, 47], ["SP2509", "CHEMICAL", 41, 47], ["SP2509", "SIMPLE_CHEMICAL", 41, 47], ["a 2-week treatment", "TREATMENT", 71, 89]]], ["The majority of AML cells were Mac-1+ in SP2509-treated mice, and the MFI of Mac-1 staining in SP2509-treated leukemic cells was approximately five-fold higher than that in vehicle-treated cells (Fig. 6f\u2013h).", [["AML cells", "ANATOMY", 16, 25], ["leukemic cells", "ANATOMY", 110, 124], ["cells", "ANATOMY", 189, 194], ["AML", "DISEASE", 16, 19], ["SP2509", "CHEMICAL", 41, 47], ["SP2509", "CHEMICAL", 95, 101], ["SP2509", "CHEMICAL", 41, 47], ["SP2509", "CHEMICAL", 95, 101], ["AML cells", "CELL", 16, 25], ["Mac-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["SP2509", "SIMPLE_CHEMICAL", 41, 47], ["mice", "ORGANISM", 56, 60], ["Mac-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["SP2509", "SIMPLE_CHEMICAL", 95, 101], ["leukemic cells", "CELL", 110, 124], ["cells", "CELL", 189, 194], ["AML cells", "CELL_TYPE", 16, 25], ["Mac", "PROTEIN", 31, 34], ["SP2509", "CELL_LINE", 41, 47], ["Mac", "PROTEIN", 77, 80], ["SP2509-treated leukemic cells", "CELL_LINE", 95, 124], ["vehicle-treated cells", "CELL_LINE", 173, 194], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["AML cells", "PROBLEM", 16, 25], ["Mac", "TEST", 31, 34], ["Mac", "TEST", 77, 80], ["leukemic cells", "PROBLEM", 110, 124], ["AML cells", "OBSERVATION", 16, 25], ["leukemic cells", "OBSERVATION", 110, 124]]], ["We did not observe significant weight loss in mice treated with SP2509, suggesting that SP2509 was well tolerated by the mice (data not shown).", [["weight loss", "DISEASE", 31, 42], ["SP2509", "CHEMICAL", 64, 70], ["SP2509", "CHEMICAL", 88, 94], ["SP2509", "CHEMICAL", 64, 70], ["SP2509", "CHEMICAL", 88, 94], ["mice", "ORGANISM", 46, 50], ["SP2509", "SIMPLE_CHEMICAL", 64, 70], ["SP2509", "SIMPLE_CHEMICAL", 88, 94], ["mice", "ORGANISM", 121, 125], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 121, 125], ["significant weight loss", "PROBLEM", 19, 42]]], ["These data demonstrated that SP2509 promoted the differentiation of Utx-mutated tumor cells in vivo.SP2509 treatment promoted the differentiation of Utx-deficient AML cells in vitro and in vivo and extended the survival of leukemic mice ::: ResultsMore importantly, SP2509 prevented the progression of AML in vivo.", [["Utx-mutated tumor cells", "ANATOMY", 68, 91], ["Utx-deficient AML cells", "ANATOMY", 149, 172], ["AML", "ANATOMY", 302, 305], ["SP2509", "CHEMICAL", 29, 35], ["tumor", "DISEASE", 80, 85], ["SP2509", "CHEMICAL", 100, 106], ["AML", "DISEASE", 163, 166], ["SP2509", "CHEMICAL", 266, 272], ["AML", "DISEASE", 302, 305], ["SP2509", "CHEMICAL", 29, 35], ["SP2509", "CHEMICAL", 100, 106], ["SP2509", "CHEMICAL", 266, 272], ["SP2509", "SIMPLE_CHEMICAL", 29, 35], ["Utx", "GENE_OR_GENE_PRODUCT", 68, 71], ["tumor cells", "CELL", 80, 91], ["SP2509", "SIMPLE_CHEMICAL", 100, 106], ["Utx", "GENE_OR_GENE_PRODUCT", 149, 152], ["AML cells", "CELL", 163, 172], ["mice", "ORGANISM", 232, 236], ["SP2509", "SIMPLE_CHEMICAL", 266, 272], ["AML", "CANCER", 302, 305], ["Utx-mutated tumor cells", "CELL_LINE", 68, 91], ["Utx-deficient AML cells", "CELL_LINE", 149, 172], ["mice", "SPECIES", 232, 236], ["mice", "SPECIES", 232, 236], ["These data", "TEST", 0, 10], ["Utx", "TREATMENT", 68, 71], ["mutated tumor cells", "PROBLEM", 72, 91], ["treatment", "TREATMENT", 107, 116], ["Utx-deficient AML cells", "TREATMENT", 149, 172], ["AML", "PROBLEM", 302, 305], ["tumor cells", "OBSERVATION", 80, 91], ["AML cells", "OBSERVATION", 163, 172], ["leukemic mice", "OBSERVATION", 223, 236], ["AML", "OBSERVATION", 302, 305]]], ["The tumor burden of recipient mice was measured using the percentage of GFP+-mCherry+ cells in peripheral blood.", [["tumor", "ANATOMY", 4, 9], ["GFP+-mCherry+ cells", "ANATOMY", 72, 91], ["peripheral blood", "ANATOMY", 95, 111], ["tumor", "DISEASE", 4, 9], ["tumor", "CANCER", 4, 9], ["mice", "ORGANISM", 30, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["peripheral blood", "ORGANISM_SUBSTANCE", 95, 111], ["GFP", "PROTEIN", 72, 75], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["The tumor burden of recipient mice", "PROBLEM", 0, 34], ["cells in peripheral blood", "PROBLEM", 86, 111], ["tumor", "OBSERVATION", 4, 9], ["burden", "OBSERVATION_MODIFIER", 10, 16], ["GFP+-mCherry+ cells", "OBSERVATION", 72, 91], ["peripheral", "ANATOMY_MODIFIER", 95, 105], ["blood", "ANATOMY", 106, 111]]], ["Utx-mutated AML was very aggressive, and leukemic cells progressively proliferated in vehicle-treated mice.", [["AML", "ANATOMY", 12, 15], ["leukemic cells", "ANATOMY", 41, 55], ["AML", "DISEASE", 12, 15], ["Utx", "GENE_OR_GENE_PRODUCT", 0, 3], ["AML", "CANCER", 12, 15], ["leukemic cells", "CELL", 41, 55], ["vehicle", "SIMPLE_CHEMICAL", 86, 93], ["mice", "ORGANISM", 102, 106], ["leukemic cells", "CELL_TYPE", 41, 55], ["mice", "SPECIES", 102, 106], ["mutated AML", "PROBLEM", 4, 15], ["very aggressive", "PROBLEM", 20, 35], ["leukemic cells", "PROBLEM", 41, 55], ["leukemic cells", "OBSERVATION", 41, 55]]], ["The tumor burden in this group increased from 2% to 70% in 2.5 weeks.", [["tumor", "ANATOMY", 4, 9], ["tumor", "DISEASE", 4, 9], ["tumor", "CANCER", 4, 9], ["The tumor burden", "PROBLEM", 0, 16], ["tumor", "OBSERVATION", 4, 9], ["burden", "OBSERVATION_MODIFIER", 10, 16], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["In contrast, tumor burden increased much slower in SP2509-treated mice, as only 20% AML cells detected in the peripheral blood after 2.5 weeks (Fig. 6i).", [["tumor", "ANATOMY", 13, 18], ["AML cells", "ANATOMY", 84, 93], ["peripheral blood", "ANATOMY", 110, 126], ["tumor", "DISEASE", 13, 18], ["SP2509", "CHEMICAL", 51, 57], ["AML", "DISEASE", 84, 87], ["SP2509", "CHEMICAL", 51, 57], ["tumor", "CANCER", 13, 18], ["SP2509", "SIMPLE_CHEMICAL", 51, 57], ["mice", "ORGANISM", 66, 70], ["AML cells", "CELL", 84, 93], ["peripheral blood", "ORGANISM_SUBSTANCE", 110, 126], ["AML cells", "CELL_TYPE", 84, 93], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["tumor burden", "PROBLEM", 13, 25], ["20% AML cells", "PROBLEM", 80, 93], ["tumor", "OBSERVATION", 13, 18], ["burden", "OBSERVATION_MODIFIER", 19, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["much", "OBSERVATION_MODIFIER", 36, 40], ["slower", "OBSERVATION_MODIFIER", 41, 47], ["AML cells", "OBSERVATION", 84, 93], ["peripheral", "ANATOMY_MODIFIER", 110, 120], ["blood", "ANATOMY", 121, 126]]], ["Interestingly, more leukemic cells in SP2509-treated mouse peripheral blood were observed than that in vehicle-treated mice 1 week after treatment.", [["leukemic cells", "ANATOMY", 20, 34], ["peripheral blood", "ANATOMY", 59, 75], ["SP2509", "CHEMICAL", 38, 44], ["SP2509", "CHEMICAL", 38, 44], ["leukemic cells", "CELL", 20, 34], ["SP2509", "SIMPLE_CHEMICAL", 38, 44], ["mouse", "ORGANISM", 53, 58], ["peripheral blood", "ORGANISM_SUBSTANCE", 59, 75], ["vehicle", "SIMPLE_CHEMICAL", 103, 110], ["mice", "ORGANISM", 119, 123], ["leukemic cells", "CELL_TYPE", 20, 34], ["SP2509", "CELL_LINE", 38, 44], ["mouse", "SPECIES", 53, 58], ["mice", "SPECIES", 119, 123], ["mouse", "SPECIES", 53, 58], ["mice", "SPECIES", 119, 123], ["more leukemic cells", "PROBLEM", 15, 34], ["SP2509", "TEST", 38, 44], ["mouse peripheral blood", "PROBLEM", 53, 75], ["treatment", "TREATMENT", 137, 146], ["leukemic cells", "OBSERVATION", 20, 34], ["peripheral", "ANATOMY_MODIFIER", 59, 69], ["blood", "ANATOMY", 70, 75]]], ["This caveat might be because of early proliferation associated with differentiation, which we observed within other AML models, such as IDH2-mutated AML.6 After 2.5-week treatment, whole blood cell count in vehicle-treated mice were 25\u201365k/\u03bcL, but those in SP2509-treated mice were largely normal (Fig. 6j).", [["AML", "ANATOMY", 116, 119], ["AML", "ANATOMY", 149, 152], ["whole blood cell", "ANATOMY", 181, 197], ["AML", "DISEASE", 116, 119], ["AML", "DISEASE", 149, 152], ["SP2509", "CHEMICAL", 257, 263], ["SP2509", "CHEMICAL", 257, 263], ["AML", "CANCER", 116, 119], ["IDH2", "GENE_OR_GENE_PRODUCT", 136, 140], ["AML", "CANCER", 149, 152], ["whole blood cell", "CELL", 181, 197], ["vehicle", "SIMPLE_CHEMICAL", 207, 214], ["mice", "ORGANISM", 223, 227], ["SP2509", "SIMPLE_CHEMICAL", 257, 263], ["mice", "ORGANISM", 272, 276], ["IDH2", "PROTEIN", 136, 140], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 272, 276], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 272, 276], ["early proliferation", "PROBLEM", 32, 51], ["IDH2-mutated AML", "PROBLEM", 136, 152], ["treatment", "TREATMENT", 170, 179], ["whole blood cell count", "TEST", 181, 203], ["might be because of", "UNCERTAINTY", 12, 31], ["early", "OBSERVATION_MODIFIER", 32, 37], ["proliferation", "OBSERVATION", 38, 51], ["normal", "OBSERVATION", 290, 296]]], ["Furthmore, all of the vehicle-treated mice died within 17 days after treatment, while five out of six SP2509-treated mice survived over 3 weeks (Fig. 6k).", [["SP2509", "CHEMICAL", 102, 108], ["SP2509", "CHEMICAL", 102, 108], ["mice", "ORGANISM", 38, 42], ["SP2509", "SIMPLE_CHEMICAL", 102, 108], ["mice", "ORGANISM", 117, 121], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 117, 121], ["treatment", "TREATMENT", 69, 78]]], ["The surviving mice had few blast cells in their peripheral blood (Fig. 6l).", [["blast cells", "ANATOMY", 27, 38], ["peripheral blood", "ANATOMY", 48, 64], ["mice", "ORGANISM", 14, 18], ["blast cells", "CELL", 27, 38], ["peripheral blood", "ORGANISM_SUBSTANCE", 48, 64], ["blast cells", "CELL_TYPE", 27, 38], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["few blast cells", "PROBLEM", 23, 38], ["few", "OBSERVATION_MODIFIER", 23, 26], ["blast cells", "OBSERVATION", 27, 38], ["peripheral", "ANATOMY_MODIFIER", 48, 58], ["blood", "ANATOMY", 59, 64]]], ["Thus, SP2509 exerted marked therapeutic effects on Utx-mutated tumors in vivo.SP2509 treatment promoted the differentiation of Utx-deficient AML cells in vitro and in vivo and extended the survival of leukemic mice ::: ResultsIn summary, Utx loss reduces H3K4 methylation, presumably through the COMPASS-like complex, and therefore represses the expression of differentiation-related genes and tumor suppressors, which leads to a differentiation block in HSPCs eventually giving rise to tumorigenesis (Fig. 7a).", [["tumors", "ANATOMY", 63, 69], ["Utx-deficient AML cells", "ANATOMY", 127, 150], ["tumor", "ANATOMY", 394, 399], ["HSPCs", "ANATOMY", 455, 460], ["SP2509", "CHEMICAL", 6, 12], ["tumors", "DISEASE", 63, 69], ["SP2509", "CHEMICAL", 78, 84], ["AML", "DISEASE", 141, 144], ["tumor", "DISEASE", 394, 399], ["SP2509", "CHEMICAL", 6, 12], ["SP2509", "CHEMICAL", 78, 84], ["SP2509", "SIMPLE_CHEMICAL", 6, 12], ["Utx", "GENE_OR_GENE_PRODUCT", 51, 54], ["tumors", "CANCER", 63, 69], ["SP2509", "SIMPLE_CHEMICAL", 78, 84], ["Utx", "GENE_OR_GENE_PRODUCT", 127, 130], ["AML cells", "CELL", 141, 150], ["mice", "ORGANISM", 210, 214], ["Utx", "GENE_OR_GENE_PRODUCT", 238, 241], ["H3K4", "GENE_OR_GENE_PRODUCT", 255, 259], ["COMPASS", "GENE_OR_GENE_PRODUCT", 296, 303], ["tumor", "CANCER", 394, 399], ["HSPCs", "CELL", 455, 460], ["Utx-deficient AML cells", "CELL_LINE", 127, 150], ["Utx", "PROTEIN", 238, 241], ["H3K4", "PROTEIN", 255, 259], ["COMPASS-like complex", "PROTEIN", 296, 316], ["HSPCs", "CELL_TYPE", 455, 460], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 210, 214], ["Utx", "TREATMENT", 51, 54], ["mutated tumors in vivo", "PROBLEM", 55, 77], ["treatment", "TREATMENT", 85, 94], ["Utx-deficient AML cells", "TREATMENT", 127, 150], ["Utx loss", "PROBLEM", 238, 246], ["H3K4 methylation", "PROBLEM", 255, 271], ["tumor suppressors", "TREATMENT", 394, 411], ["a differentiation block", "PROBLEM", 428, 451], ["marked", "OBSERVATION_MODIFIER", 21, 27], ["therapeutic", "OBSERVATION_MODIFIER", 28, 39], ["tumors", "OBSERVATION", 63, 69], ["AML cells", "OBSERVATION", 141, 150], ["leukemic mice", "OBSERVATION", 201, 214], ["H3K4 methylation", "OBSERVATION", 255, 271], ["tumor suppressors", "OBSERVATION", 394, 411]]], ["LSD1 competes with MLL3/4 on the promoters of these genes.", [["LSD1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MLL3/4", "GENE_OR_GENE_PRODUCT", 19, 25], ["LSD1", "PROTEIN", 0, 4], ["MLL3/4", "DNA", 19, 25], ["promoters", "DNA", 33, 42]]], ["Thus, the inhibition of LSD1 by SP2509 reverses the reduction in H3K4 methylation in Utx-deficient cells, which gives rise to an increased expression of differentiation-related genes and tumor suppressors and specifically promotes the differentiation of Utx-mutated cells (Fig. 7b).DiscussionAccumulating evidence suggests that epigenetic abnormalities are common and critical for human cancers, especially hematopoietic malignancies.", [["Utx-deficient cells", "ANATOMY", 85, 104], ["tumor", "ANATOMY", 187, 192], ["cells", "ANATOMY", 266, 271], ["cancers", "ANATOMY", 387, 394], ["hematopoietic malignancies", "ANATOMY", 407, 433], ["SP2509", "CHEMICAL", 32, 38], ["tumor", "DISEASE", 187, 192], ["cancers", "DISEASE", 387, 394], ["hematopoietic malignancies", "DISEASE", 407, 433], ["SP2509", "CHEMICAL", 32, 38], ["LSD1", "GENE_OR_GENE_PRODUCT", 24, 28], ["SP2509", "SIMPLE_CHEMICAL", 32, 38], ["H3K4", "GENE_OR_GENE_PRODUCT", 65, 69], ["Utx", "GENE_OR_GENE_PRODUCT", 85, 88], ["cells", "CELL", 99, 104], ["tumor", "CANCER", 187, 192], ["Utx-", "GENE_OR_GENE_PRODUCT", 254, 258], ["cells", "CELL", 266, 271], ["human", "ORGANISM", 381, 386], ["cancers", "CANCER", 387, 394], ["hematopoietic malignancies", "CANCER", 407, 433], ["LSD1", "PROTEIN", 24, 28], ["H3K4", "PROTEIN", 65, 69], ["Utx-deficient cells", "CELL_LINE", 85, 104], ["Utx-mutated cells", "CELL_LINE", 254, 271], ["human", "SPECIES", 381, 386], ["human", "SPECIES", 381, 386], ["LSD1", "TEST", 24, 28], ["the reduction", "PROBLEM", 48, 61], ["H3K4 methylation in Utx", "TREATMENT", 65, 88], ["deficient cells", "PROBLEM", 89, 104], ["an increased expression of differentiation", "PROBLEM", 126, 168], ["tumor suppressors", "TREATMENT", 187, 204], ["Utx-mutated cells", "PROBLEM", 254, 271], ["epigenetic abnormalities", "PROBLEM", 328, 352], ["human cancers", "PROBLEM", 381, 394], ["hematopoietic malignancies", "PROBLEM", 407, 433], ["reduction", "OBSERVATION_MODIFIER", 52, 61], ["H3K4 methylation", "OBSERVATION", 65, 81], ["deficient cells", "OBSERVATION", 89, 104], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["tumor suppressors", "OBSERVATION", 187, 204], ["cancers", "OBSERVATION", 387, 394], ["hematopoietic malignancies", "OBSERVATION", 407, 433]]], ["Many cancer-associated epigenetic alterations promote tumorigenesis by impairing the differentiation of tissue stem and/or progenitor cells.", [["cancer", "ANATOMY", 5, 11], ["tissue stem", "ANATOMY", 104, 115], ["progenitor cells", "ANATOMY", 123, 139], ["cancer", "DISEASE", 5, 11], ["cancer", "CANCER", 5, 11], ["tissue stem", "CELL", 104, 115], ["progenitor cells", "CELL", 123, 139], ["tissue stem and/or progenitor cells", "CELL_TYPE", 104, 139], ["Many cancer", "PROBLEM", 0, 11], ["epigenetic alterations", "PROBLEM", 23, 45], ["progenitor cells", "PROBLEM", 123, 139], ["cancer", "OBSERVATION", 5, 11], ["tumorigenesis", "OBSERVATION", 54, 67], ["progenitor cells", "OBSERVATION", 123, 139]]], ["Thus, differentiation therapy would be especially effective for cancers involving epigenetic dysregulation.", [["cancers", "ANATOMY", 64, 71], ["cancers", "DISEASE", 64, 71], ["cancers", "CANCER", 64, 71], ["differentiation therapy", "TREATMENT", 6, 29], ["cancers", "PROBLEM", 64, 71], ["epigenetic dysregulation", "PROBLEM", 82, 106]]], ["Since any given epigenetic modification, including histone methylation, can regulate the expression of a number of targets, the direct reversal of epigenetic abnormalities due to a driver epigenetic modifier would be more efficient than targeting individual targets.", [["histone", "GENE_OR_GENE_PRODUCT", 51, 58], ["histone", "PROTEIN", 51, 58], ["epigenetic modification", "TREATMENT", 16, 39], ["histone methylation", "TREATMENT", 51, 70], ["epigenetic abnormalities", "PROBLEM", 147, 171], ["a driver epigenetic modifier", "TREATMENT", 179, 207]]], ["The balance between epigenetic writers and erasers provides opportunities to identify therapeutic targets specific for cancers with given epigenetic abnormalities.DiscussionUTX, an H3K27 demethylase and a key component of the COMPASS-like complex, is a putative tumor suppressor in multiple human cancers.", [["cancers", "ANATOMY", 119, 126], ["tumor", "ANATOMY", 262, 267], ["cancers", "ANATOMY", 297, 304], ["cancers", "DISEASE", 119, 126], ["tumor", "DISEASE", 262, 267], ["human cancers", "DISEASE", 291, 304], ["cancers", "CANCER", 119, 126], ["H3K27 demethylase", "GENE_OR_GENE_PRODUCT", 181, 198], ["COMPASS", "GENE_OR_GENE_PRODUCT", 226, 233], ["tumor", "CANCER", 262, 267], ["human", "ORGANISM", 291, 296], ["cancers", "CANCER", 297, 304], ["DiscussionUTX", "PROTEIN", 163, 176], ["H3K27 demethylase", "PROTEIN", 181, 198], ["COMPASS-like complex", "PROTEIN", 226, 246], ["human", "SPECIES", 291, 296], ["human", "SPECIES", 291, 296], ["cancers", "PROBLEM", 119, 126], ["epigenetic abnormalities", "PROBLEM", 138, 162], ["an H3K27 demethylase", "TREATMENT", 178, 198], ["a putative tumor suppressor", "TREATMENT", 251, 278], ["multiple human cancers", "PROBLEM", 282, 304], ["H3K27 demethylase", "OBSERVATION", 181, 198], ["tumor suppressor", "OBSERVATION", 262, 278], ["multiple", "OBSERVATION_MODIFIER", 282, 290], ["human cancers", "OBSERVATION", 291, 304]]], ["Our study, as well as previous reports, showed that UTX deficiency impairs the differentiation of HSPCs.", [["HSPCs", "ANATOMY", 98, 103], ["UTX", "CHEMICAL", 52, 55], ["UTX", "CHEMICAL", 52, 55], ["UTX", "GENE_OR_GENE_PRODUCT", 52, 55], ["HSPCs", "CELL", 98, 103], ["UTX", "PROTEIN", 52, 55], ["HSPCs", "CELL_TYPE", 98, 103], ["Our study", "TEST", 0, 9], ["UTX deficiency", "PROBLEM", 52, 66], ["UTX deficiency", "OBSERVATION", 52, 66]]], ["In this study, we screened an epigenetic drug library using Utx KO and WT HSPCs.", [["HSPCs", "ANATOMY", 74, 79], ["Utx KO", "CELL", 60, 66], ["WT HSPCs", "CELL", 71, 79], ["Utx KO and WT HSPCs", "CELL_LINE", 60, 79], ["this study", "TEST", 3, 13]]], ["We found that SP2509, an inhibitor of the H3K4 and H3K9 demethylase LSD1, specifically promoted the differentiation of Utx-null HSPCs while sparing Utx WT HSPCs.", [["Utx-null HSPCs", "ANATOMY", 119, 133], ["Utx WT HSPCs", "ANATOMY", 148, 160], ["SP2509", "CHEMICAL", 14, 20], ["SP2509", "CHEMICAL", 14, 20], ["SP2509", "SIMPLE_CHEMICAL", 14, 20], ["H3K4", "GENE_OR_GENE_PRODUCT", 42, 46], ["H3K9 demethylase", "GENE_OR_GENE_PRODUCT", 51, 67], ["LSD1", "GENE_OR_GENE_PRODUCT", 68, 72], ["Utx", "GENE_OR_GENE_PRODUCT", 119, 122], ["HSPCs", "CELL", 128, 133], ["Utx WT HSPCs", "CELL", 148, 160], ["H3K4", "PROTEIN", 42, 46], ["H3K9 demethylase", "PROTEIN", 51, 67], ["LSD1", "PROTEIN", 68, 72], ["Utx-null HSPCs", "CELL_LINE", 119, 133], ["Utx WT HSPCs", "CELL_TYPE", 148, 160], ["the H3K4 and H3K9 demethylase LSD1", "TREATMENT", 38, 72], ["Utx", "TREATMENT", 119, 122], ["null HSPCs", "PROBLEM", 123, 133], ["H3K9 demethylase", "OBSERVATION", 51, 67]]], ["Based on the effect of SP2509 on Utx-deficient premalignant cells, we further tested it in Utx-mutated tumor cells in vitro and in vivo.", [["premalignant cells", "ANATOMY", 47, 65], ["Utx-mutated tumor cells", "ANATOMY", 91, 114], ["SP2509", "CHEMICAL", 23, 29], ["tumor", "DISEASE", 103, 108], ["SP2509", "CHEMICAL", 23, 29], ["SP2509", "SIMPLE_CHEMICAL", 23, 29], ["Utx", "GENE_OR_GENE_PRODUCT", 33, 36], ["premalignant cells", "CELL", 47, 65], ["Utx", "GENE_OR_GENE_PRODUCT", 91, 94], ["tumor cells", "CELL", 103, 114], ["Utx-deficient premalignant cells", "CELL_LINE", 33, 65], ["Utx-mutated tumor cells", "CELL_LINE", 91, 114], ["Utx", "TREATMENT", 33, 36], ["deficient premalignant cells", "PROBLEM", 37, 65], ["mutated tumor cells", "PROBLEM", 95, 114], ["premalignant cells", "OBSERVATION", 47, 65], ["tumor cells", "OBSERVATION", 103, 114]]], ["Notably, SP2509 had similar differentiation-promoting effect on AML cells, and, more importantly, it inhibited leukemia progression in vivo and significantly extended the lifespan of mice with AML.", [["AML cells", "ANATOMY", 64, 73], ["leukemia", "ANATOMY", 111, 119], ["AML", "ANATOMY", 193, 196], ["SP2509", "CHEMICAL", 9, 15], ["AML", "DISEASE", 64, 67], ["leukemia", "DISEASE", 111, 119], ["AML", "DISEASE", 193, 196], ["SP2509", "CHEMICAL", 9, 15], ["SP2509", "SIMPLE_CHEMICAL", 9, 15], ["AML cells", "CELL", 64, 73], ["leukemia", "CANCER", 111, 119], ["mice", "ORGANISM", 183, 187], ["AML", "CANCER", 193, 196], ["AML cells", "CELL_TYPE", 64, 73], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["AML cells", "PROBLEM", 64, 73], ["leukemia progression", "PROBLEM", 111, 131], ["AML", "PROBLEM", 193, 196], ["AML cells", "OBSERVATION", 64, 73], ["leukemia", "OBSERVATION", 111, 119], ["AML", "OBSERVATION", 193, 196]]], ["Mechanistically, Utx mutations repress the expression of differentiation-related genes and tumor suppressors by impairing H3K4 methylation on these genes, while SP2509 inhibits LSD1 and reverses the impairments in H3K4 methylation in Utx-mutated cells.", [["tumor", "ANATOMY", 91, 96], ["cells", "ANATOMY", 246, 251], ["tumor", "DISEASE", 91, 96], ["SP2509", "CHEMICAL", 161, 167], ["SP2509", "CHEMICAL", 161, 167], ["Utx", "GENE_OR_GENE_PRODUCT", 17, 20], ["tumor", "CANCER", 91, 96], ["H3K4", "GENE_OR_GENE_PRODUCT", 122, 126], ["SP2509", "SIMPLE_CHEMICAL", 161, 167], ["LSD1", "GENE_OR_GENE_PRODUCT", 177, 181], ["H3K4", "GENE_OR_GENE_PRODUCT", 214, 218], ["cells", "CELL", 246, 251], ["Utx", "PROTEIN", 17, 20], ["H3K4", "PROTEIN", 122, 126], ["LSD1", "PROTEIN", 177, 181], ["H3K4", "PROTEIN", 214, 218], ["Utx-mutated cells", "CELL_LINE", 234, 251], ["Utx mutations", "PROBLEM", 17, 30], ["tumor suppressors", "TREATMENT", 91, 108], ["impairing H3K4 methylation", "PROBLEM", 112, 138], ["LSD1", "PROBLEM", 177, 181], ["the impairments", "PROBLEM", 195, 210], ["H3K4 methylation in Utx-mutated cells", "PROBLEM", 214, 251]]], ["Thus, we identified a highly specific inhibitor for abnormal cells with deficiencies in Utx and/or the COMPASS-like complex.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["Utx", "GENE_OR_GENE_PRODUCT", 88, 91], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 103, 123], ["abnormal cells", "CELL_TYPE", 52, 66], ["Utx", "PROTEIN", 88, 91], ["COMPASS-like complex", "PROTEIN", 103, 123], ["abnormal cells", "PROBLEM", 52, 66], ["deficiencies in Utx", "PROBLEM", 72, 91]]], ["Interestingly, SP2509 and some other LSD1 inhibitors have been suggested to be effective in some leukemias and other human cancers.41,51 SP2577, the clinical formulation of SP2509, is in a phase I clinical trial for patients with relapsed or refractory Ewing sarcoma.", [["leukemias", "ANATOMY", 97, 106], ["cancers", "ANATOMY", 123, 130], ["Ewing sarcoma", "ANATOMY", 253, 266], ["SP2509", "CHEMICAL", 15, 21], ["leukemias", "DISEASE", 97, 106], ["human cancers", "DISEASE", 117, 130], ["SP2577", "CHEMICAL", 137, 143], ["SP2509", "CHEMICAL", 173, 179], ["Ewing sarcoma", "DISEASE", 253, 266], ["SP2509", "CHEMICAL", 15, 21], ["SP2577", "CHEMICAL", 137, 143], ["SP2509", "CHEMICAL", 173, 179], ["SP2509", "SIMPLE_CHEMICAL", 15, 21], ["LSD1", "GENE_OR_GENE_PRODUCT", 37, 41], ["leukemias", "CANCER", 97, 106], ["human", "ORGANISM", 117, 122], ["cancers", "CANCER", 123, 130], ["SP2577", "SIMPLE_CHEMICAL", 137, 143], ["SP2509", "SIMPLE_CHEMICAL", 173, 179], ["patients", "ORGANISM", 216, 224], ["Ewing sarcoma", "CANCER", 253, 266], ["LSD1", "PROTEIN", 37, 41], ["human", "SPECIES", 117, 122], ["patients", "SPECIES", 216, 224], ["human", "SPECIES", 117, 122], ["some other LSD1 inhibitors", "PROBLEM", 26, 52], ["some leukemias", "PROBLEM", 92, 106], ["other human cancers", "PROBLEM", 111, 130], ["refractory Ewing sarcoma", "PROBLEM", 242, 266], ["suggested to be", "UNCERTAINTY", 63, 78], ["effective", "OBSERVATION_MODIFIER", 79, 88], ["leukemias", "OBSERVATION", 97, 106], ["cancers", "OBSERVATION", 123, 130], ["refractory", "OBSERVATION_MODIFIER", 242, 252], ["Ewing sarcoma", "OBSERVATION", 253, 266]]], ["Further validation of SP2509 and other inhibitors with similar functions in human cancer cells with UTX mutations or COMPASS-like complex dysfunctions would pave the way for their potential applications for the treatment of patients with such epigenetic abnormalities.Mice ::: MethodsUtxf/f mice (purchased from The Jackson Labratory, 024177) were crossed with Mx1-Cre mice (purchased from Jackson Lab, 005673).", [["cancer cells", "ANATOMY", 82, 94], ["SP2509", "CHEMICAL", 22, 28], ["cancer", "DISEASE", 82, 88], ["SP2509", "CHEMICAL", 22, 28], ["SP2509", "SIMPLE_CHEMICAL", 22, 28], ["human", "ORGANISM", 76, 81], ["cancer cells", "CELL", 82, 94], ["UTX", "GENE_OR_GENE_PRODUCT", 100, 103], ["COMPASS-like complex", "GENE_OR_GENE_PRODUCT", 117, 137], ["patients", "ORGANISM", 224, 232], ["Mice", "ORGANISM", 268, 272], ["MethodsUtxf/f mice", "ORGANISM", 277, 295], ["Mx1", "GENE_OR_GENE_PRODUCT", 361, 364], ["Cre", "GENE_OR_GENE_PRODUCT", 365, 368], ["mice", "ORGANISM", 369, 373], ["human cancer cells", "CELL_TYPE", 76, 94], ["Mx1", "PROTEIN", 361, 364], ["human", "SPECIES", 76, 81], ["patients", "SPECIES", 224, 232], ["Mice", "SPECIES", 268, 272], ["mice", "SPECIES", 291, 295], ["mice", "SPECIES", 369, 373], ["human", "SPECIES", 76, 81], ["mice", "SPECIES", 291, 295], ["mice", "SPECIES", 369, 373], ["Further validation", "TEST", 0, 18], ["SP2509", "TREATMENT", 22, 28], ["other inhibitors", "TREATMENT", 33, 49], ["human cancer cells", "PROBLEM", 76, 94], ["UTX mutations", "PROBLEM", 100, 113], ["COMPASS-like complex dysfunctions", "PROBLEM", 117, 150], ["the treatment", "TREATMENT", 207, 220], ["such epigenetic abnormalities", "PROBLEM", 238, 267]]], ["The expression of Cre was induced by the intraperitoneal injection of pIpC (Sigma P1530, 10 mg/kg) into 5- to 6-week-old mice every other day for a total of 10 days.Isolation of HSPCs and cell culture ::: MethodsWBM cells were freshly isolated from Utxf/f and Utxf/f; Mx1-Cre mice, and then HSPCs were sorted with mouse CD117 magnetic microbeads (Miltenyi Biotec, 130-091-224).", [["intraperitoneal", "ANATOMY", 41, 56], ["HSPCs", "ANATOMY", 178, 183], ["cell", "ANATOMY", 188, 192], ["MethodsWBM cells", "ANATOMY", 205, 221], ["HSPCs", "ANATOMY", 291, 296], ["pIpC", "CHEMICAL", 70, 74], ["P1530", "CHEMICAL", 82, 87], ["Cre", "GENE_OR_GENE_PRODUCT", 18, 21], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 56], ["pIpC", "SIMPLE_CHEMICAL", 70, 74], ["Sigma P1530", "SIMPLE_CHEMICAL", 76, 87], ["mice", "ORGANISM", 121, 125], ["HSPCs", "CELL", 178, 183], ["cell", "CELL", 188, 192], ["MethodsWBM cells", "CELL", 205, 221], ["Utxf/f", "ORGANISM", 260, 266], ["Mx1", "GENE_OR_GENE_PRODUCT", 268, 271], ["-Cre mice", "ORGANISM", 271, 280], ["HSPCs", "CELL", 291, 296], ["mouse", "ORGANISM", 314, 319], ["CD117", "GENE_OR_GENE_PRODUCT", 320, 325], ["Cre", "PROTEIN", 18, 21], ["HSPCs", "CELL_TYPE", 178, 183], ["MethodsWBM cells", "CELL_LINE", 205, 221], ["Mx1", "PROTEIN", 268, 271], ["HSPCs", "CELL_TYPE", 291, 296], ["mouse CD117 magnetic microbeads", "CELL_LINE", 314, 345], ["Miltenyi Biotec", "PROTEIN", 347, 362], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 276, 280], ["mouse", "SPECIES", 314, 319], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 276, 280], ["mouse", "SPECIES", 314, 319], ["pIpC (Sigma P1530", "TREATMENT", 70, 87], ["cell culture", "TEST", 188, 200], ["MethodsWBM cells", "TEST", 205, 221], ["Utxf", "TEST", 249, 253], ["Utxf", "TEST", 260, 264], ["Mx1", "TEST", 268, 271], ["Cre mice", "TEST", 272, 280], ["HSPCs", "TEST", 291, 296], ["HSPCs", "ANATOMY", 178, 183]]], ["Primary mouse cells were cultured in BCM medium (50% IMDM + 50% DMEM + 10% FBS + 5% PS + 0.34% BME) with 10% Stem Cell Medium (SCM) including 10% FBS, IL3 (10 ng/mL; 1:1000), IL6 (10 ng/mL; 1:500), and SCF (50 ng/mL; 1:1000).Drug screening ::: MethodsThe epigenetics compound library (including 276 compounds) used for drug screening was purchased from Selleckchem (Catalog# L1900).", [["cells", "ANATOMY", 14, 19], ["FBS", "ANATOMY", 75, 78], ["Cell", "ANATOMY", 114, 118], ["SCM", "ANATOMY", 127, 130], ["FBS", "ANATOMY", 146, 149], ["BME", "CHEMICAL", 95, 98], ["mouse", "ORGANISM", 8, 13], ["cells", "CELL", 14, 19], ["FBS", "ORGANISM_SUBSTANCE", 75, 78], ["Stem Cell", "CELL", 109, 118], ["FBS", "ORGANISM_SUBSTANCE", 146, 149], ["IL3", "GENE_OR_GENE_PRODUCT", 151, 154], ["IL6", "GENE_OR_GENE_PRODUCT", 175, 178], ["SCF", "GENE_OR_GENE_PRODUCT", 202, 205], ["Primary mouse cells", "CELL_TYPE", 0, 19], ["IL3", "PROTEIN", 151, 154], ["IL6", "PROTEIN", 175, 178], ["SCF", "PROTEIN", 202, 205], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["Primary mouse cells", "PROBLEM", 0, 19], ["IMDM", "TEST", 53, 57], ["DMEM", "TEST", 64, 68], ["FBS", "TEST", 75, 78], ["PS", "TEST", 84, 86], ["BME", "TEST", 95, 98], ["Stem Cell Medium", "TEST", 109, 125], ["FBS", "TEST", 146, 149], ["IL3", "TEST", 151, 154], ["IL6", "TEST", 175, 178], ["SCF", "TEST", 202, 205], ["Methods", "TREATMENT", 244, 251], ["drug screening", "TEST", 319, 333], ["mouse cells", "OBSERVATION", 8, 19], ["Stem Cell Medium", "OBSERVATION", 109, 125]]], ["The compounds were generally provided in DMSO at 10 \u03bcM concentrations.", [["DMSO", "CHEMICAL", 41, 45], ["DMSO", "CHEMICAL", 41, 45], ["DMSO", "SIMPLE_CHEMICAL", 41, 45], ["DMSO", "TREATMENT", 41, 45]]], ["After HSPCs were isolated from bone marrow and cultured in vitro for 24 h, they were seeded at equal numbers in five low-attachment 96-well plates (the primary number of cells was 40,000 in 100 \u03bcL medium per well; in one 96-well plate, 60 wells were filled with cells, while other surrounding wells were filled with PBS).", [["HSPCs", "ANATOMY", 6, 11], ["bone marrow", "ANATOMY", 31, 42], ["cells", "ANATOMY", 170, 175], ["cells", "ANATOMY", 262, 267], ["HSPCs", "CELL", 6, 11], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 31, 42], ["cells", "CELL", 170, 175], ["cells", "CELL", 262, 267], ["HSPCs", "CELL_TYPE", 6, 11], ["bone marrow", "TEST", 31, 42], ["bone marrow", "ANATOMY", 31, 42]]], ["Then, 276 kinds of compounds at a final concentration of 10 \u03bcM were used separately (marked in pink), and DMSO was used to treat control cells (marked in gray).", [["cells", "ANATOMY", 137, 142], ["DMSO", "CHEMICAL", 106, 110], ["DMSO", "CHEMICAL", 106, 110], ["DMSO", "SIMPLE_CHEMICAL", 106, 110], ["cells", "CELL", 137, 142], ["control cells", "CELL_TYPE", 129, 142], ["DMSO", "TREATMENT", 106, 110], ["control cells", "PROBLEM", 129, 142]]], ["After 3 days of treatment, cell features were determined by flow cytometry.Flow cytometry ::: MethodsCells were stained with antibodies against Mac-1 (Clone: M1/70, BD101224) and cKit (Clone: 2B8, BD105812) after 3 days of treatment.", [["cell", "ANATOMY", 27, 31], ["cell", "CELL", 27, 31], ["MethodsCells", "SIMPLE_CHEMICAL", 94, 106], ["Mac-1", "GENE_OR_GENE_PRODUCT", 144, 149], ["Clone", "GENE_OR_GENE_PRODUCT", 151, 156], ["BD101224", "GENE_OR_GENE_PRODUCT", 165, 173], ["antibodies", "PROTEIN", 125, 135], ["Mac", "PROTEIN", 144, 147], ["M1", "PROTEIN", 158, 160], ["BD101224", "PROTEIN", 165, 173], ["cKit", "PROTEIN", 179, 183], ["treatment", "TREATMENT", 16, 25], ["cell features", "PROBLEM", 27, 40], ["flow cytometry", "TEST", 60, 74], ["antibodies", "TEST", 125, 135], ["Mac", "TEST", 144, 147], ["cKit", "TEST", 179, 183], ["treatment", "TREATMENT", 223, 232], ["flow cytometry", "OBSERVATION", 60, 74]]], ["All flow cytometry analyses were performed with an LSR Fortessa instrument (BD), and the data were analyzed using FlowJo software.RNA-sequencing analysis ::: MethodsRNA-seq libraries were prepared using NEBNext\u00ae Ultra\u2122 RNA Library Prep Kit for Illumina\u00ae and were sequenced with an Illumina HiSeq\u2122 X sequencing machine with 150-bp paired-end reads.", [["MethodsRNA-seq libraries", "DNA", 158, 182], ["150-bp paired-end reads", "DNA", 323, 346], ["All flow cytometry analyses", "TEST", 0, 27], ["the data", "TEST", 85, 93], ["RNA-sequencing analysis", "TEST", 130, 153], ["MethodsRNA-seq libraries", "TREATMENT", 158, 182], ["NEBNext", "TREATMENT", 203, 210], ["Illumina\u00ae", "TREATMENT", 244, 253], ["an Illumina HiSeq\u2122 X sequencing machine", "TREATMENT", 278, 317], ["flow cytometry", "OBSERVATION", 4, 18]]], ["The RNA-seq reads were aligned to a reference genome (GRCm38) by STAR_2.6.0a.52 Transcript abundance was normalized and measured in fragments per kb of exon per million fragments mapped (FPKM).", [["reference genome", "DNA", 36, 52], ["GRCm38", "DNA", 54, 60], ["STAR_2.6.0", "DNA", 65, 75], ["exon", "DNA", 152, 156], ["FPKM", "DNA", 187, 191], ["The RNA", "TEST", 0, 7], ["exon per million fragments", "PROBLEM", 152, 178]]], ["Differential gene expression was analyzed by DESeq2.53 Genes with absolute fold changes greater than 0.5 and FDR \u2264 0.05 were considered differentially expressed genes.", [["absolute fold changes", "PROBLEM", 66, 87], ["FDR", "TEST", 109, 112]]], ["Samples distances were calculated by PCA and the Euclidean distance.", [["Samples distances", "TEST", 0, 17]]], ["GSEA54,55 was employed to determine statistically significant similarities and differences between two given clusters by identifying a priori-defined gene sets.ChIP-seq data collection and visualization ::: MethodsData were downloaded from the GEO database under accession codes GSE63222,50 GSE101307,44 and GSE76692.49 In addition, data were visualized by Integrative Genomics Viewer56 (IGV).Western blotting ::: Methods1M cells were harvested and lysed in SDS buffer (50 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 150 mM NaCl, 1% NP-40, 40 mM DTT) followed by sonication with an Ultrasonic Cell Disruptor.", [["Methods1M cells", "ANATOMY", 414, 429], ["Cell", "ANATOMY", 585, 589], ["GSE63222,50 GSE101307,44", "CHEMICAL", 279, 303], ["GSE76692.49", "CHEMICAL", 308, 319], ["Tris-HCl", "CHEMICAL", 476, 484], ["NaCl", "CHEMICAL", 516, 520], ["NP-40", "CHEMICAL", 525, 530], ["Tris-HCl", "CHEMICAL", 476, 484], ["NaCl", "CHEMICAL", 516, 520], ["DTT", "CHEMICAL", 538, 541], ["Methods1M cells", "CELL", 414, 429], ["Tris-HCl", "SIMPLE_CHEMICAL", 476, 484], ["DTT", "SIMPLE_CHEMICAL", 538, 541], ["GSEA54,55", "DNA", 0, 9], ["priori-defined gene sets", "DNA", 135, 159], ["Methods1M cells", "CELL_LINE", 414, 429], ["GSE", "TEST", 291, 294], ["GSE", "TEST", 308, 311], ["Methods1M cells", "TREATMENT", 414, 429], ["Tris", "TEST", 476, 480], ["HCl", "TEST", 481, 484], ["pH", "TEST", 486, 488], ["SDS", "TEST", 504, 507], ["NaCl", "TEST", 516, 520], ["NP", "TEST", 525, 527], ["an Ultrasonic Cell Disruptor", "TREATMENT", 571, 599], ["Ultrasonic Cell Disruptor", "OBSERVATION", 574, 599]]], ["Then, lysate proteins were separated by 15% SDS\u2013PAGE gels and then transferred to PVDF membranes.", [["lysate", "ANATOMY", 6, 12], ["PVDF membranes", "ANATOMY", 82, 96], ["PVDF", "CHEMICAL", 82, 86], ["membranes", "CELLULAR_COMPONENT", 87, 96], ["lysate proteins", "PROTEIN", 6, 21], ["lysate proteins", "TREATMENT", 6, 21]]], ["Western blots were performed using antibodies against H3K4m1 (Abcam, ab8895), H3K4m2 (Abcam, ab7766), H3K4m3 (Abcam, ab8580), or total histone 3 (H3, HuaBio, EM30605).qPCR assay ::: MethodsExpression levels of genes (one set of the genes was selected from downregulated genes in the microarray data comparing the Utx KO group to the WT group, and the other set of genes was selected from upregulated genes in the microarray data comparing SP2509 treatment to vehicle treatment in the Utx KO group) were quantified by using SYBR Green Master Mix and the Quant Studio 3 Real-Time PCR System (Thermo Fisher Scientific). qPCR primer sequences are listed in Table 1.Leukemia modeling and in vivo treatment ::: MethodsAll animal studies were approved by the Institutional Animal Care and Use Committees of Sichuan University.", [["Leukemia", "ANATOMY", 661, 669], ["SP2509", "CHEMICAL", 439, 445], ["Leukemia", "DISEASE", 661, 669], ["SP2509", "CHEMICAL", 439, 445], ["H3K4m1", "GENE_OR_GENE_PRODUCT", 54, 60], ["Abcam", "GENE_OR_GENE_PRODUCT", 62, 67], ["ab8895", "GENE_OR_GENE_PRODUCT", 69, 75], ["H3K4m2", "GENE_OR_GENE_PRODUCT", 78, 84], ["Abcam, ab7766", "GENE_OR_GENE_PRODUCT", 86, 99], ["H3K4m3", "GENE_OR_GENE_PRODUCT", 102, 108], ["Abcam", "GENE_OR_GENE_PRODUCT", 110, 115], ["histone 3", "GENE_OR_GENE_PRODUCT", 135, 144], ["H3", "GENE_OR_GENE_PRODUCT", 146, 148], ["SP2509", "SIMPLE_CHEMICAL", 439, 445], ["Leukemia", "CANCER", 661, 669], ["H3K4m1", "PROTEIN", 54, 60], ["Abcam", "PROTEIN", 62, 67], ["ab8895", "PROTEIN", 69, 75], ["H3K4m2", "PROTEIN", 78, 84], ["Abcam", "PROTEIN", 86, 91], ["ab7766", "PROTEIN", 93, 99], ["H3K4m3", "PROTEIN", 102, 108], ["Abcam", "PROTEIN", 110, 115], ["ab8580", "PROTEIN", 117, 123], ["histone 3", "PROTEIN", 135, 144], ["H3", "PROTEIN", 146, 148], ["EM30605", "PROTEIN", 158, 165], ["downregulated genes", "DNA", 256, 275], ["upregulated genes", "DNA", 388, 405], ["qPCR primer sequences", "DNA", 617, 638], ["Western blots", "TEST", 0, 13], ["antibodies", "TEST", 35, 45], ["H3K4m1", "TEST", 54, 60], ["Abcam", "TEST", 62, 67], ["H3K4m2", "TEST", 78, 84], ["Abcam", "TEST", 86, 91], ["ab", "TEST", 93, 95], ["H3K4m3", "TEST", 102, 108], ["Abcam", "TEST", 110, 115], ["total histone", "TEST", 129, 142], ["HuaBio", "TEST", 150, 156], ["MethodsExpression levels of genes", "PROBLEM", 182, 215], ["vehicle treatment", "TREATMENT", 459, 476], ["qPCR primer sequences", "TEST", 617, 638], ["Leukemia modeling", "PROBLEM", 661, 678], ["Methods", "TREATMENT", 705, 712], ["All animal studies", "TEST", 712, 730]]], ["Approximately 2 \u00d7 106Utx\u2212/\u2212; shp53-mCherry;shNf1-GFP AML cells were transplanted by tail-vein injections into sublethally irradiated (4.5 Gy) 8-week-old female C57BL/6 mice.", [["shNf1-GFP AML cells", "ANATOMY", 43, 62], ["tail-vein", "ANATOMY", 84, 93], ["106Utx", "GENE_OR_GENE_PRODUCT", 18, 24], ["shp53-mCherry", "GENE_OR_GENE_PRODUCT", 29, 42], ["shNf1", "GENE_OR_GENE_PRODUCT", 43, 48], ["tail-vein", "MULTI-TISSUE_STRUCTURE", 84, 93], ["C57BL/6 mice", "ORGANISM", 160, 172], ["shp53", "PROTEIN", 29, 34], ["shNf1-GFP AML cells", "CELL_LINE", 43, 62], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 168, 172], ["shp53", "TEST", 29, 34], ["mCherry", "TEST", 35, 42], ["shNf1", "TEST", 43, 48], ["GFP AML cells", "TREATMENT", 49, 62], ["GFP AML cells", "OBSERVATION", 49, 62], ["tail", "ANATOMY", 84, 88], ["vein", "ANATOMY", 89, 93]]], ["Drug treatments were initiated on day 7 after the cells were transplanted, and six mice were treated in each group: vehicle vs 25 mg/kg SP2509.", [["cells", "ANATOMY", 50, 55], ["SP2509", "CHEMICAL", 136, 142], ["SP2509", "CHEMICAL", 136, 142], ["cells", "CELL", 50, 55], ["mice", "ORGANISM", 83, 87], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["Drug treatments", "TREATMENT", 0, 15]]], ["SP2509 in solvent buffer (20% PEG-40, 20% dimethyl sulfoxide, 60% sterile water) or vehicle was intraperitoneally administered twice per week (Tuesday and Thursday) for 3 weeks as previously administrated.41 The leukemia progression in recipient mice was monitored by CBC, flow cytometry, and blood smear once per week.", [["leukemia", "ANATOMY", 212, 220], ["blood", "ANATOMY", 293, 298], ["SP2509", "CHEMICAL", 0, 6], ["PEG-40", "CHEMICAL", 30, 36], ["dimethyl sulfoxide", "CHEMICAL", 42, 60], ["leukemia", "DISEASE", 212, 220], ["SP2509", "CHEMICAL", 0, 6], ["PEG-40", "CHEMICAL", 30, 36], ["dimethyl sulfoxide", "CHEMICAL", 42, 60], ["SP2509", "SIMPLE_CHEMICAL", 0, 6], ["PEG-40", "SIMPLE_CHEMICAL", 30, 36], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 42, 60], ["vehicle", "SIMPLE_CHEMICAL", 84, 91], ["leukemia", "CANCER", 212, 220], ["mice", "ORGANISM", 246, 250], ["CBC", "CELL", 268, 271], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 246, 250], ["solvent buffer", "TREATMENT", 10, 24], ["PEG", "TREATMENT", 30, 33], ["20% dimethyl sulfoxide", "TREATMENT", 38, 60], ["60% sterile water)", "TREATMENT", 62, 80], ["vehicle", "TREATMENT", 84, 91], ["The leukemia progression", "PROBLEM", 208, 232], ["CBC", "TEST", 268, 271], ["flow cytometry", "TEST", 273, 287], ["blood smear", "TEST", 293, 304], ["leukemia", "OBSERVATION", 212, 220], ["progression", "OBSERVATION_MODIFIER", 221, 232]]]], "747c9c3ab814444e24806776cdb7316e1e24a5bb": [["INTRODUCTIONHepatitis A virus (HAV) is a major cause of enterically transmitted hepatitis worldwide, posing a global burden estimated in 2005 at 119 million infections of which 31 million resulted in symptomatic illness and 34,000 in death.", [["HAV", "DISEASE", 31, 34], ["enterically transmitted hepatitis", "DISEASE", 56, 89], ["infections", "DISEASE", 157, 167], ["illness", "DISEASE", 212, 219], ["death", "DISEASE", 234, 239], ["INTRODUCTIONHepatitis A virus", "ORGANISM", 0, 29], ["HAV", "ORGANISM", 31, 34], ["INTRODUCTIONHepatitis A virus", "SPECIES", 0, 29], ["HAV", "SPECIES", 31, 34], ["A virus (HAV", "PROBLEM", 22, 34], ["enterically transmitted hepatitis worldwide", "PROBLEM", 56, 99], ["a global burden", "PROBLEM", 108, 123], ["symptomatic illness", "PROBLEM", 200, 219], ["virus", "OBSERVATION", 24, 29], ["hepatitis", "OBSERVATION", 80, 89], ["global", "OBSERVATION_MODIFIER", 110, 116], ["burden", "OBSERVATION_MODIFIER", 117, 123], ["symptomatic", "OBSERVATION_MODIFIER", 200, 211], ["illness", "OBSERVATION", 212, 219]]], ["1 The virus is transmitted faeco-orally, mainly through close contact with infected individuals or by consumption of contaminated food and drinking water.", [["The virus", "PROBLEM", 2, 11], ["virus", "OBSERVATION", 6, 11]]], ["The extreme environmental stability of the HAV particle contributes significantly to its transmission.", [["HAV", "ORGANISM", 43, 46], ["HAV", "SPECIES", 43, 46], ["the HAV particle", "PROBLEM", 39, 55], ["extreme", "OBSERVATION_MODIFIER", 4, 11], ["environmental", "OBSERVATION_MODIFIER", 12, 25], ["stability", "OBSERVATION_MODIFIER", 26, 35], ["HAV particle", "OBSERVATION_MODIFIER", 43, 55]]], ["2, 3 HAV epidemiology correlates with poor hygiene and living conditions.", [["HAV", "ORGANISM", 5, 8], ["HAV", "SPECIES", 5, 8]]], ["Consequently, virtually every adult in developing countries is seropositive due to childhood infection.", [["infection", "DISEASE", 93, 102], ["childhood infection", "PROBLEM", 83, 102], ["infection", "OBSERVATION", 93, 102]]], ["On the contrary, in regions with improved hygiene standards, infection is often postponed to later age.", [["infection", "DISEASE", 61, 70], ["infection", "PROBLEM", 61, 70], ["improved", "OBSERVATION_MODIFIER", 33, 41], ["hygiene", "OBSERVATION", 42, 49], ["infection", "OBSERVATION", 61, 70]]], ["In addition, disease severity is generally age-dependent: infections are usually mild or asymptomatic in young children, whereas at older age, hepatitis A frequently presents with classic symptoms of acute hepatitis (e.g., jaundice, fatigue, general malaise, etc.) and a higher incidence of fulminant hepatitis, which may require liver transplantation.", [["liver", "ANATOMY", 330, 335], ["infections", "DISEASE", 58, 68], ["hepatitis A", "DISEASE", 143, 154], ["acute hepatitis", "DISEASE", 200, 215], ["jaundice", "DISEASE", 223, 231], ["fatigue", "DISEASE", 233, 240], ["fulminant hepatitis", "DISEASE", 291, 310], ["children", "ORGANISM", 111, 119], ["hepatitis A", "ORGANISM", 143, 154], ["liver", "ORGAN", 330, 335], ["children", "SPECIES", 111, 119], ["hepatitis A", "SPECIES", 143, 154], ["disease severity", "PROBLEM", 13, 29], ["infections", "PROBLEM", 58, 68], ["hepatitis A", "PROBLEM", 143, 154], ["classic symptoms", "PROBLEM", 180, 196], ["acute hepatitis", "PROBLEM", 200, 215], ["jaundice", "PROBLEM", 223, 231], ["fatigue", "PROBLEM", 233, 240], ["general malaise", "PROBLEM", 242, 257], ["fulminant hepatitis", "PROBLEM", 291, 310], ["liver transplantation", "TREATMENT", 330, 351], ["disease", "OBSERVATION", 13, 20], ["infections", "OBSERVATION", 58, 68], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["asymptomatic", "OBSERVATION_MODIFIER", 89, 101], ["hepatitis", "OBSERVATION", 143, 152], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["hepatitis", "OBSERVATION", 206, 215], ["jaundice", "OBSERVATION", 223, 231], ["higher incidence", "OBSERVATION_MODIFIER", 271, 287], ["fulminant", "OBSERVATION_MODIFIER", 291, 300], ["hepatitis", "OBSERVATION", 301, 310], ["liver", "ANATOMY", 330, 335], ["transplantation", "OBSERVATION", 336, 351]]], ["4 Fulminant hepatitis occurs especially in those aged over 50 for which mortality rates up to 5.4% have been reported.", [["Fulminant hepatitis", "DISEASE", 2, 21], ["Fulminant hepatitis", "PROBLEM", 2, 21], ["mortality rates", "TEST", 72, 87], ["Fulminant", "OBSERVATION_MODIFIER", 2, 11], ["hepatitis", "OBSERVATION", 12, 21]]], ["5 Additionally, HAV superinfections in chronic liver disease patients (e.g., hepatitis B or C) are believed to increase morbidity and mortality, [6] [7] [8] although these findings are still subject to debate.", [["liver", "ANATOMY", 47, 52], ["HAV superinfections", "DISEASE", 16, 35], ["chronic liver disease", "DISEASE", 39, 60], ["hepatitis B", "DISEASE", 77, 88], ["HAV", "ORGANISM", 16, 19], ["liver", "ORGAN", 47, 52], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["HAV", "SPECIES", 16, 19], ["HAV superinfections in chronic liver disease", "PROBLEM", 16, 60], ["hepatitis B", "PROBLEM", 77, 88], ["HAV", "OBSERVATION_MODIFIER", 16, 19], ["superinfections", "OBSERVATION", 20, 35], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["liver", "ANATOMY", 47, 52], ["disease", "OBSERVATION", 53, 60]]], ["9 Since highly efficient vaccines that provide long-lasting immunity have become available, HAV mortality and morbidity has decreased dramatically.", [["HAV", "ORGANISM", 92, 95], ["HAV", "SPECIES", 92, 95], ["highly efficient vaccines", "TREATMENT", 8, 33], ["HAV mortality", "PROBLEM", 92, 105], ["morbidity", "PROBLEM", 110, 119], ["morbidity", "OBSERVATION", 110, 119], ["decreased", "OBSERVATION_MODIFIER", 124, 133], ["dramatically", "OBSERVATION_MODIFIER", 134, 146]]], ["8, 10 However, occasional outbreaks of hepatitis A, sometimes resulting in fatal outcomes, still occur in industrialized countries.", [["hepatitis A", "DISEASE", 39, 50], ["hepatitis A", "SPECIES", 39, 50], ["hepatitis A", "PROBLEM", 39, 50], ["hepatitis", "OBSERVATION", 39, 48]]], ["For instance, in the last decade, outbreaks have been linked to the consumption of contaminated green onions, semidried tomatoes, seafood, such as raw oysters and sushi, and other foodstuffs.", [["tomatoes", "ANATOMY", 120, 128], ["onions", "SPECIES", 102, 108], ["tomatoes", "SPECIES", 120, 128], ["green onions", "SPECIES", 96, 108], ["tomatoes", "SPECIES", 120, 128]]], ["[11] [12] [13] [14] As posited earlier, 15 research interest in the molecular biology and pathogenesis of HAV has decreased substantially since the availability of a safe and efficient vaccine.", [["HAV", "DISEASE", 106, 109], ["[11] [12] [13] [14] As", "CHEMICAL", 0, 22], ["[11] [12] [13] [14", "SIMPLE_CHEMICAL", 0, 18], ["HAV", "ORGANISM", 106, 109], ["HAV", "SPECIES", 106, 109], ["pathogenesis of HAV", "PROBLEM", 90, 109], ["a safe and efficient vaccine", "TREATMENT", 164, 192], ["HAV", "OBSERVATION", 106, 109], ["decreased", "OBSERVATION", 114, 123]]], ["Nonetheless, HAV remains an intriguing and poorly understood virus and hepatitis A is still a public health problem in many countries.", [["HAV", "DISEASE", 13, 16], ["hepatitis A", "DISEASE", 71, 82], ["HAV", "ORGANISM", 13, 16], ["hepatitis A", "ORGANISM", 71, 82], ["HAV", "SPECIES", 13, 16], ["hepatitis A", "SPECIES", 71, 82], ["hepatitis A", "PROBLEM", 71, 82], ["virus", "OBSERVATION", 61, 66], ["hepatitis", "OBSERVATION", 71, 80]]], ["Here, we will review key aspects of the biology of HAV with an emphasis on recent findings and the unique characteristics of the virus.", [["HAV", "DISEASE", 51, 54], ["HAV", "ORGANISM", 51, 54], ["HAV", "SPECIES", 51, 54], ["the virus", "PROBLEM", 125, 134]]], ["The potential clinical use of antivirals against HAV will be discussed as well.HAV GENOME ORGANIZATION AND REPLICATION CYCLEHAV is a nonenveloped, single-stranded RNA virus with a positive-sense genome.", [["HAV", "DISEASE", 49, 52], ["HAV", "ORGANISM", 49, 52], ["positive-sense genome", "DNA", 180, 201], ["HAV", "SPECIES", 49, 52], ["HAV", "SPECIES", 79, 82], ["antivirals", "TREATMENT", 30, 40], ["HAV", "PROBLEM", 49, 52], ["a nonenveloped", "PROBLEM", 131, 145], ["single-stranded RNA virus", "PROBLEM", 147, 172], ["GENOME ORGANIZATION", "OBSERVATION", 83, 102], ["REPLICATION CYCLEHAV", "OBSERVATION", 107, 127], ["nonenveloped", "OBSERVATION_MODIFIER", 133, 145], ["sense genome", "OBSERVATION", 189, 201]]], ["Despite the fact that HAV is classified within the family of the Picornaviridae, it exhibits quite some differences compared to other members of this family and is consequently the sole member of the genus Hepatovirus.", [["HAV", "DISEASE", 22, 25], ["HAV", "ORGANISM", 22, 25], ["Hepatovirus", "GENE_OR_GENE_PRODUCT", 206, 217], ["HAV", "SPECIES", 22, 25], ["the Picornaviridae", "TREATMENT", 61, 79], ["genus Hepatovirus", "ANATOMY", 200, 217]]], ["16 Based on phylogenetic analysis of full length VP1 sequences, the single HAV serotype is divided into six genotypes (I-VI).", [["VP1", "GENE_OR_GENE_PRODUCT", 49, 52], ["HAV", "ORGANISM", 75, 78], ["full length VP1 sequences", "DNA", 37, 62], ["HAV", "SPECIES", 75, 78], ["phylogenetic analysis", "TEST", 12, 33], ["full length VP1 sequences", "TEST", 37, 62], ["the single HAV serotype", "PROBLEM", 64, 87]]], ["17 Genotypes I to III are human and can be subdivided into subgenotypes A and B (and potentially subgenotype IC 18 ), whereas genotypes IV to VI are of simian origin.", [["human", "ORGANISM", 26, 31], ["B", "GENE_OR_GENE_PRODUCT", 78, 79], ["simian", "ORGANISM", 152, 158], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["simian origin", "OBSERVATION", 152, 165]]], ["17 The HAV genome (as shown in Fig. 1 ) is approximately 7.5 kb in length and consists of a 5 untranslated region (UTR), a single open reading frame (ORF) and a 3 -UTR with a polyadenosine tract.", [["polyadenosine", "CHEMICAL", 175, 188], ["polyadenosine", "CHEMICAL", 175, 188], ["HAV", "ORGANISM", 7, 10], ["HAV genome", "DNA", 7, 17], ["5 untranslated region", "DNA", 92, 113], ["UTR", "DNA", 115, 118], ["open reading frame", "DNA", 130, 148], ["ORF", "DNA", 150, 153], ["3 -UTR", "DNA", 161, 167], ["HAV", "SPECIES", 7, 10], ["length", "TEST", 67, 73], ["a 5 untranslated region (UTR)", "PROBLEM", 90, 119], ["a 3 -UTR", "TREATMENT", 159, 167], ["a polyadenosine tract", "TREATMENT", 173, 194], ["HAV genome", "OBSERVATION", 7, 17], ["approximately", "OBSERVATION_MODIFIER", 43, 56], ["7.5 kb", "OBSERVATION_MODIFIER", 57, 63], ["length", "OBSERVATION_MODIFIER", 67, 73]]], ["Like other picornaviruses, the HAV genome lacks a cap structure; instead a VPg protein (3B) is attached to the 5 end.", [["HAV", "ORGANISM", 31, 34], ["HAV genome", "DNA", 31, 41], ["VPg protein", "PROTEIN", 75, 86], ["3B", "PROTEIN", 88, 90], ["HAV", "SPECIES", 31, 34], ["other picornaviruses", "PROBLEM", 5, 25], ["a VPg protein (3B)", "TREATMENT", 73, 91], ["picornaviruses", "OBSERVATION", 11, 25], ["cap structure", "OBSERVATION_MODIFIER", 50, 63]]], ["In the 5 -UTR, six secondary structure domains can be found: domain I contains a hairpin structure, while the second domain comprises two stem loop structures followed by a polypyrimidine tract (pY1).", [["stem loop structures", "ANATOMY", 138, 158], ["polypyrimidine", "CHEMICAL", 173, 187], ["5 -UTR", "DNA", 7, 13], ["domain I", "PROTEIN", 61, 69], ["hairpin structure", "PROTEIN", 81, 98], ["stem loop structures", "PROTEIN", 138, 158], ["polypyrimidine tract", "PROTEIN", 173, 193], ["pY1", "PROTEIN", 195, 198], ["a hairpin structure", "PROBLEM", 79, 98], ["a polypyrimidine tract", "TREATMENT", 171, 193], ["hairpin structure", "OBSERVATION", 81, 98], ["two", "OBSERVATION_MODIFIER", 134, 137], ["stem loop", "OBSERVATION", 138, 147], ["polypyrimidine tract", "OBSERVATION", 173, 193]]], ["19 The remaining domains form the type III internal ribosome entry site (IRES) allowing capindependent translation of the viral genome.", [["type III internal ribosome entry site", "DNA", 34, 71], ["IRES", "DNA", 73, 77], ["viral genome", "DNA", 122, 134], ["the viral genome", "PROBLEM", 118, 134], ["type III", "OBSERVATION_MODIFIER", 34, 42], ["internal", "OBSERVATION_MODIFIER", 43, 51], ["ribosome", "OBSERVATION_MODIFIER", 52, 60], ["entry site", "OBSERVATION", 61, 71], ["viral genome", "OBSERVATION", 122, 134]]], ["The single ORF comprises the structural genes (VP1 to VP4 (= P1) and 2A) and the nonstructural genes (2B-2C and 3A-3D).", [["VP1 to VP4 (= P1)", "GENE_OR_GENE_PRODUCT", 47, 64], ["ORF", "DNA", 11, 14], ["structural genes", "DNA", 29, 45], ["VP1", "DNA", 47, 50], ["VP4", "DNA", 54, 57], ["P1", "DNA", 61, 63], ["2A", "DNA", 69, 71], ["nonstructural genes", "DNA", 81, 100], ["2B-2C and 3A-3D", "DNA", 102, 117], ["The single ORF", "PROBLEM", 0, 14], ["VP1", "TEST", 47, 50], ["VP4", "TEST", 54, 57], ["the nonstructural genes", "TEST", 77, 100]]], ["The short 3 -UTR contains two stem loops and/or a pseudoknot structure which are, together with domains I and II and the polypyrimidine tract of the 5 -UTR, crucial for viral RNA synthesis.", [["stem loops", "ANATOMY", 30, 40], ["polypyrimidine", "CHEMICAL", 121, 135], ["short 3 -UTR", "DNA", 4, 16], ["I and II", "PROTEIN", 104, 112], ["5 -UTR", "DNA", 149, 155], ["viral RNA", "RNA", 169, 178], ["a pseudoknot structure", "PROBLEM", 48, 70], ["domains I and II and the polypyrimidine tract", "PROBLEM", 96, 141], ["viral RNA synthesis", "PROBLEM", 169, 188], ["short", "OBSERVATION_MODIFIER", 4, 9], ["two", "OBSERVATION_MODIFIER", 26, 29], ["stem loops", "OBSERVATION", 30, 40], ["polypyrimidine tract", "OBSERVATION", 121, 141], ["viral RNA synthesis", "OBSERVATION", 169, 188]]], ["20A.", [["20A", "DNA", 0, 3]]], ["Receptor Binding and Cell EntryIn 1996, the HAV cellular receptor (HAVcr-1) was identified on African green monkey kidney cells (AGMK) as an attachment and probably functional receptor.", [["cellular", "ANATOMY", 48, 56], ["kidney cells", "ANATOMY", 115, 127], ["AGMK", "ANATOMY", 129, 133], ["Cell", "CELL", 21, 25], ["HAV cellular receptor", "GENE_OR_GENE_PRODUCT", 44, 65], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 67, 74], ["green monkey kidney cells", "CELL", 102, 127], ["AGMK", "CELL", 129, 133], ["HAV cellular receptor", "PROTEIN", 44, 65], ["HAVcr", "PROTEIN", 67, 72], ["African green monkey kidney cells", "CELL_TYPE", 94, 127], ["AGMK", "PROTEIN", 129, 133], ["green monkey", "SPECIES", 102, 114], ["African green monkey", "SPECIES", 94, 114], ["the HAV cellular receptor", "TEST", 40, 65], ["HAVcr", "TEST", 67, 72], ["kidney", "ANATOMY", 115, 121], ["probably", "UNCERTAINTY", 156, 164], ["functional receptor", "OBSERVATION", 165, 184]]], ["21 Consequently, the human homolog (HuHAVcr-1) was identified and characterized as a human HAV receptor.", [["human", "ORGANISM", 21, 26], ["HuHAVcr-1", "GENE_OR_GENE_PRODUCT", 36, 45], ["human", "ORGANISM", 85, 90], ["HAV receptor", "GENE_OR_GENE_PRODUCT", 91, 103], ["human homolog", "DNA", 21, 34], ["HuHAVcr", "PROTEIN", 36, 43], ["human HAV receptor", "PROTEIN", 85, 103], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 85, 90], ["the human homolog (HuHAVcr", "TREATMENT", 17, 43]]], ["22 HAVcr-1 is also known to be a marker for acute ischemic kidney injury (in this context referred to as kidney injury molecule 1 or KIM-1) 23 and a regulator of T-cell based immunity (in this context referred to as T-cell immunoglobulin and mucin domain-containing protein 1 or TIM-1).", [["kidney", "ANATOMY", 59, 65], ["kidney", "ANATOMY", 105, 111], ["T-cell", "ANATOMY", 162, 168], ["ischemic kidney injury", "DISEASE", 50, 72], ["kidney injury", "DISEASE", 105, 118], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 3, 10], ["kidney", "ORGAN", 59, 65], ["kidney injury molecule 1", "GENE_OR_GENE_PRODUCT", 105, 129], ["KIM-1) 23", "GENE_OR_GENE_PRODUCT", 133, 142], ["T-cell", "CELL", 162, 168], ["T-cell immunoglobulin", "GENE_OR_GENE_PRODUCT", 216, 237], ["mucin domain-containing protein 1", "GENE_OR_GENE_PRODUCT", 242, 275], ["TIM-1", "GENE_OR_GENE_PRODUCT", 279, 284], ["HAVcr", "PROTEIN", 3, 8], ["kidney injury molecule 1 or KIM-1) 23", "PROTEIN", 105, 142], ["T-cell immunoglobulin", "PROTEIN", 216, 237], ["mucin domain-containing protein 1", "PROTEIN", 242, 275], ["TIM-1", "PROTEIN", 279, 284], ["acute ischemic kidney injury", "PROBLEM", 44, 72], ["kidney injury molecule", "PROBLEM", 105, 127], ["T-cell immunoglobulin", "TREATMENT", 216, 237], ["mucin domain", "TEST", 242, 254], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["ischemic", "OBSERVATION", 50, 58], ["kidney", "ANATOMY", 59, 65], ["injury", "OBSERVATION", 66, 72], ["kidney", "ANATOMY", 105, 111], ["injury", "OBSERVATION", 112, 118]]], ["24 Nevertheless, since HAVcr-1 is also expressed on other organs, 22 it is likely that additional receptors are required for HAV attachment and entry.", [["organs", "ANATOMY", 58, 64], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 23, 30], ["organs", "ORGAN", 58, 64], ["HAV", "ORGANISM", 125, 128], ["HAVcr", "PROTEIN", 23, 28], ["HAV", "SPECIES", 125, 128], ["HAVcr", "TEST", 23, 28], ["HAV attachment", "PROBLEM", 125, 139]]], ["For instance, it has been suggested that TIM-3 promotes HAV entry without being a functional receptor.", [["TIM-3", "GENE_OR_GENE_PRODUCT", 41, 46], ["HAV", "ORGANISM", 56, 59], ["TIM-3", "PROTEIN", 41, 46], ["HAV", "SPECIES", 56, 59]]], ["25 In addition, HAVspecific IgA are reported to mediate infection of hepatocytes via the asialoglycoprotein receptor (ASGPR).", [["hepatocytes", "ANATOMY", 69, 80], ["infection", "DISEASE", 56, 65], ["IgA", "GENE_OR_GENE_PRODUCT", 28, 31], ["hepatocytes", "CELL", 69, 80], ["asialoglycoprotein receptor", "GENE_OR_GENE_PRODUCT", 89, 116], ["ASGPR", "GENE_OR_GENE_PRODUCT", 118, 123], ["HAVspecific IgA", "PROTEIN", 16, 31], ["hepatocytes", "CELL_TYPE", 69, 80], ["asialoglycoprotein receptor", "PROTEIN", 89, 116], ["ASGPR", "PROTEIN", 118, 123], ["HAVspecific IgA", "PROBLEM", 16, 31], ["IgA", "OBSERVATION", 28, 31], ["infection", "OBSERVATION", 56, 65], ["hepatocytes", "ANATOMY", 69, 80]]], ["26 This and the fact that IgA was also identified as a natural ligand for HAVcr-1 27 may explain why (and how) IgA-coated HAV can enter the hepatocytes through both HAVcr-1 and ASGPR, thereby promoting enterohepatic circulation and continuous (endogenous) reinfections of the liver.", [["hepatocytes", "ANATOMY", 140, 151], ["enterohepatic", "ANATOMY", 202, 215], ["liver", "ANATOMY", 276, 281], ["IgA", "GENE_OR_GENE_PRODUCT", 26, 29], ["HAVcr-1 27", "GENE_OR_GENE_PRODUCT", 74, 84], ["IgA", "GENE_OR_GENE_PRODUCT", 111, 114], ["HAV", "ORGANISM", 122, 125], ["hepatocytes", "CELL", 140, 151], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 165, 172], ["ASGPR", "GENE_OR_GENE_PRODUCT", 177, 182], ["liver", "ORGAN", 276, 281], ["IgA", "PROTEIN", 26, 29], ["HAVcr", "PROTEIN", 74, 79], ["IgA", "PROTEIN", 111, 114], ["hepatocytes", "CELL_TYPE", 140, 151], ["HAVcr", "PROTEIN", 165, 170], ["ASGPR", "PROTEIN", 177, 182], ["HAV", "SPECIES", 122, 125], ["HAVcr", "TEST", 74, 79], ["IgA-coated HAV", "PROBLEM", 111, 125], ["HAVcr", "TEST", 165, 170], ["ASGPR", "TEST", 177, 182], ["continuous (endogenous) reinfections of the liver", "PROBLEM", 232, 281], ["IgA", "OBSERVATION", 26, 29], ["hepatocytes", "ANATOMY", 140, 151], ["enterohepatic circulation", "ANATOMY", 202, 227], ["reinfections", "OBSERVATION", 256, 268], ["liver", "ANATOMY", 276, 281]]], ["28 This phenomenon is thought to play an essential role in prolonged and relapsing cases of hepatitis A. Only the emergence of avid IgG antibodies can break the cycle and eventually clear the infection.", [["hepatitis", "DISEASE", 92, 101], ["infection", "DISEASE", 192, 201], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 132, 146], ["IgG antibodies", "PROTEIN", 132, 146], ["hepatitis A.", "PROBLEM", 92, 104], ["avid IgG antibodies", "TREATMENT", 127, 146], ["the infection", "PROBLEM", 188, 201], ["thought to play", "UNCERTAINTY", 22, 37], ["hepatitis", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 192, 201]]], ["28B.", [["28B", "GENE_OR_GENE_PRODUCT", 0, 3], ["28B", "PROTEIN", 0, 3]]], ["Uptake and UncoatingFollowing receptor-mediated binding to the cell surface, the HAV particle is internalized.", [["cell surface", "ANATOMY", 63, 75], ["cell surface", "CELLULAR_COMPONENT", 63, 75], ["HAV", "ORGANISM", 81, 84], ["Uptake", "PROBLEM", 0, 6]]], ["This has been suggested to occur through receptor-mediated endocytosis since HAV infection can be inhibited by blockers of endosomal acidification such as monensin, ammonium chloride, and chloroquine.", [["endosomal", "ANATOMY", 123, 132], ["HAV infection", "DISEASE", 77, 90], ["monensin", "CHEMICAL", 155, 163], ["ammonium chloride", "CHEMICAL", 165, 182], ["chloroquine", "CHEMICAL", 188, 199], ["monensin", "CHEMICAL", 155, 163], ["ammonium chloride", "CHEMICAL", 165, 182], ["chloroquine", "CHEMICAL", 188, 199], ["HAV", "ORGANISM", 77, 80], ["endosomal", "CELLULAR_COMPONENT", 123, 132], ["monensin", "SIMPLE_CHEMICAL", 155, 163], ["ammonium chloride", "SIMPLE_CHEMICAL", 165, 182], ["chloroquine", "SIMPLE_CHEMICAL", 188, 199], ["HAV", "SPECIES", 77, 80], ["mediated endocytosis", "PROBLEM", 50, 70], ["HAV infection", "PROBLEM", 77, 90], ["endosomal acidification", "PROBLEM", 123, 146], ["monensin, ammonium chloride", "TREATMENT", 155, 182], ["chloroquine", "TREATMENT", 188, 199], ["infection", "OBSERVATION", 81, 90], ["endosomal acidification", "OBSERVATION", 123, 146]]], ["[29] [30] [31] [32] However, the precise mechanism remains unclear to date.", [["[29] [30] [31] [32]", "SIMPLE_CHEMICAL", 0, 19]]], ["Upon binding to its receptor the particle is destabilized, thus initiating the uncoating process and releasing the single-stranded RNA into the host cell cytoplasm.", [["cell cytoplasm", "ANATOMY", 149, 163], ["cell", "CELL", 149, 153], ["cytoplasm", "ORGANISM_SUBSTANCE", 154, 163], ["single-stranded RNA", "RNA", 115, 134], ["the uncoating process", "TREATMENT", 75, 96], ["destabilized", "OBSERVATION", 45, 57], ["host cell cytoplasm", "OBSERVATION", 144, 163]]], ["33 Uncoating has been reported to be a slow and asynchronous process with a reported duration of 4-10 hr, in contrast to under an hour for poliovirus.", [["poliovirus", "SPECIES", 139, 149], ["a slow and asynchronous process", "PROBLEM", 37, 68], ["poliovirus", "PROBLEM", 139, 149], ["poliovirus", "OBSERVATION", 139, 149]]], ["34 It has been proposed that this asynchronicity may be due to the fact that the HAV inoculum contains a heterogeneous mixture of mature virions and provirions.", [["virions", "ANATOMY", 137, 144], ["HAV", "DISEASE", 81, 84], ["HAV", "ORGANISM", 81, 84], ["HAV", "SPECIES", 81, 84], ["the HAV inoculum", "PROBLEM", 77, 93], ["may be due to", "UNCERTAINTY", 49, 62], ["HAV", "OBSERVATION_MODIFIER", 81, 84], ["inoculum", "OBSERVATION", 85, 93], ["heterogeneous", "OBSERVATION_MODIFIER", 105, 118], ["mixture", "OBSERVATION_MODIFIER", 119, 126], ["mature virions", "OBSERVATION", 130, 144]]], ["These provirions still require a maturation cleavage (of VP0 into VP2 and VP4, as discussed below) following entry, prior to uncoating, and might therefore uncoat more slowly than mature virions.", [["virions", "ANATOMY", 187, 194], ["VP2", "GENE_OR_GENE_PRODUCT", 66, 69], ["VP4", "GENE_OR_GENE_PRODUCT", 74, 77], ["VP0", "PROTEIN", 57, 60], ["VP2", "PROTEIN", 66, 69], ["VP4", "PROTEIN", 74, 77], ["a maturation cleavage", "TREATMENT", 31, 52], ["VP0 into VP2 and VP4", "TREATMENT", 57, 77]]], ["34, 35 During the uncoating process, dense, noninfectious HAV uncoating intermediates are formed.", [["HAV", "ORGANISM", 58, 61], ["HAV", "SPECIES", 58, 61], ["dense, noninfectious HAV uncoating intermediates", "PROBLEM", 37, 85], ["dense", "OBSERVATION_MODIFIER", 37, 42], ["noninfectious", "OBSERVATION_MODIFIER", 44, 57]]], ["Intriguingly, these particles do not appear to have an altered sedimentation profile, thereby differing from the typical picornaviral A particle.", [["an altered sedimentation profile", "PROBLEM", 52, 84], ["altered", "OBSERVATION_MODIFIER", 55, 62], ["sedimentation", "OBSERVATION", 63, 76]]], ["36 Finally, both low pH and Ca 2+ ions are reported to play an important role in HAV receptor binding, uncoating and during the maturation cleavage of provirions following virus entry (as described above).", [["Ca", "CHEMICAL", 28, 30], ["Ca 2+", "CHEMICAL", 28, 33], ["Ca 2+ ions", "SIMPLE_CHEMICAL", 28, 38], ["HAV receptor", "GENE_OR_GENE_PRODUCT", 81, 93], ["provirions", "GENE_OR_GENE_PRODUCT", 151, 161], ["HAV receptor", "PROTEIN", 81, 93], ["HAV", "SPECIES", 81, 84], ["Ca", "TEST", 28, 30], ["HAV receptor binding", "PROBLEM", 81, 101], ["the maturation cleavage of provirions", "TREATMENT", 124, 161], ["virus entry", "PROBLEM", 172, 183], ["low pH", "OBSERVATION_MODIFIER", 17, 23]]], ["31, 32, 35, 37 Upon completion of uncoating, the single-stranded RNA is released into the host cell by an unknown mechanism. r DEBING, NEYTS, AND THIBAUTC.", [["cell", "ANATOMY", 95, 99], ["host cell", "CELL", 90, 99], ["host cell", "CELL_TYPE", 90, 99], ["uncoating", "TREATMENT", 34, 43], ["the single-stranded RNA", "TREATMENT", 45, 68], ["host cell", "OBSERVATION", 90, 99]]], ["TranslationThe viral RNA, being released into the cytoplasm, is then translated into a single polyprotein.", [["cytoplasm", "ANATOMY", 50, 59], ["cytoplasm", "ORGANISM_SUBSTANCE", 50, 59], ["viral RNA", "RNA", 15, 24], ["The viral RNA", "PROBLEM", 11, 24], ["a single polyprotein", "TREATMENT", 85, 105], ["viral RNA", "OBSERVATION", 15, 24]]], ["Similar to other picornaviruses, HAV employs an IRES, located in the 5 UTR, to direct cap-independent translation of the viral genome using the host ribosomal machinery.", [["ribosomal", "ANATOMY", 149, 158], ["HAV", "ORGANISM", 33, 36], ["ribosomal", "CELLULAR_COMPONENT", 149, 158], ["IRES", "DNA", 48, 52], ["5 UTR", "DNA", 69, 74], ["viral genome", "DNA", 121, 133], ["HAV", "SPECIES", 33, 36], ["other picornaviruses", "PROBLEM", 11, 31], ["an IRES", "TREATMENT", 45, 52], ["picornaviruses", "OBSERVATION", 17, 31], ["viral genome", "OBSERVATION", 121, 133]]], ["Most picornaviruses affect the host cell protein synthesis to favor a more efficient translation of the viral mRNA.", [["cell", "ANATOMY", 36, 40], ["picornaviruses", "ORGANISM", 5, 19], ["host cell", "CELL", 31, 40], ["viral mRNA", "RNA", 104, 114], ["Most picornaviruses", "PROBLEM", 0, 19], ["the host cell protein synthesis", "PROBLEM", 27, 58], ["the viral mRNA", "PROBLEM", 100, 114], ["host cell protein synthesis", "OBSERVATION", 31, 58], ["viral mRNA", "OBSERVATION", 104, 114]]], ["This process is mediated by a proteolytic cleavage of eukaryotic initiation factor 4G (eIF4G), thereby inducing a complete shutdown of capped mRNA translation.", [["eukaryotic initiation factor 4G", "GENE_OR_GENE_PRODUCT", 54, 85], ["eIF4G", "GENE_OR_GENE_PRODUCT", 87, 92], ["eukaryotic initiation factor 4G", "PROTEIN", 54, 85], ["eIF4G", "PROTEIN", 87, 92], ["capped mRNA", "RNA", 135, 146], ["a proteolytic cleavage", "TREATMENT", 28, 50], ["capped mRNA translation", "PROBLEM", 135, 158], ["capped mRNA", "OBSERVATION", 135, 146]]], ["38 Intriguingly, unlike for other picornaviruses, it is thought that HAV IRES depends on eIF4G, as part of an intact eIF4F complex.", [["HAV", "ORGANISM", 69, 72], ["eIF4G", "GENE_OR_GENE_PRODUCT", 89, 94], ["eIF4F", "GENE_OR_GENE_PRODUCT", 117, 122], ["HAV IRES", "DNA", 69, 77], ["eIF4G", "PROTEIN", 89, 94], ["eIF4F complex", "PROTEIN", 117, 130], ["HAV", "SPECIES", 69, 72], ["other picornaviruses", "PROBLEM", 28, 48], ["HAV IRES", "PROBLEM", 69, 77], ["eIF4G", "TREATMENT", 89, 94], ["picornaviruses", "OBSERVATION", 34, 48], ["intact", "OBSERVATION", 110, 116], ["eIF4F complex", "OBSERVATION", 117, 130]]], ["39 The fact that HAV has to compete with an intact host cell machinery may also explain its poor replication in cell culture (see Section 5).", [["cell", "ANATOMY", 56, 60], ["cell culture", "ANATOMY", 112, 124], ["HAV", "ORGANISM", 17, 20], ["host cell", "CELL", 51, 60], ["cell culture", "CELL", 112, 124], ["HAV", "SPECIES", 17, 20], ["an intact host cell machinery", "TREATMENT", 41, 70], ["its poor replication in cell culture", "PROBLEM", 88, 124]]], ["However, a recent publication by Redondo et al. suggested that HAV IRES-driven translation can occur without intact eIF4G and that another factor may be crucial for this translation.", [["HAV", "ORGANISM", 63, 66], ["eIF4G", "GENE_OR_GENE_PRODUCT", 116, 121], ["HAV IRES", "DNA", 63, 71], ["eIF4G", "PROTEIN", 116, 121], ["HAV", "SPECIES", 63, 66], ["HAV IRES", "PROBLEM", 63, 71]]], ["38 Next, the translated polyprotein is processed co-and posttranslationally in a series of proteolytic cleavages into several functional precursor and mature proteins.", [["mature proteins", "PROTEIN", 151, 166], ["proteolytic cleavages", "TREATMENT", 91, 112]]], ["The primary posttranslational cleavage occurs at the junction between P1-2A and 2B (instead of the junction between P1 and 2A as for other picornaviruses) (Fig. 1 ).", [["P1-2A", "GENE_OR_GENE_PRODUCT", 70, 75], ["2B", "GENE_OR_GENE_PRODUCT", 80, 82], ["P1-2A and 2B", "DNA", 70, 82], ["P1", "PROTEIN", 116, 118], ["2A", "PROTEIN", 123, 125], ["The primary posttranslational cleavage", "PROBLEM", 0, 38], ["P1", "TEST", 70, 72], ["P1 and 2A", "TREATMENT", 116, 125], ["other picornaviruses", "PROBLEM", 133, 153], ["posttranslational cleavage", "OBSERVATION", 12, 38], ["junction", "ANATOMY_MODIFIER", 99, 107]]], ["40 All other processing steps (except the VP1-2A junction, as discussed below) are mediated by 3C pro and its functional precursor 3ABC pro .", [["VP1", "PROTEIN", 42, 45], ["3C pro", "PROTEIN", 95, 101], ["3ABC pro", "PROTEIN", 131, 139], ["the VP1-2A junction", "TREATMENT", 38, 57]]], ["41 This is different from other picornaviruses that may use L pro , 2A, 3C pro , and the 3CD pro precursor.", [["3C pro", "GENE_OR_GENE_PRODUCT", 72, 78], ["L pro , 2A, 3C pro", "PROTEIN", 60, 78], ["3CD pro precursor", "PROTEIN", 89, 106], ["different", "OBSERVATION_MODIFIER", 11, 20], ["picornaviruses", "OBSERVATION", 32, 46]]], ["42 Intriguingly, HAV protein 2A, unlike for other picornaviruses, has no proteolytic activity nor does it contain a ribosome-skipping sequence, 42 but seems to be implicated in morphogenesis (see Section 2,F).D. Regulating the Balance between Translation and ReplicationSince translation of viral proteins and RNA replication are competing processes, they must be balanced properly to allow efficient viral replication.", [["HAV protein 2A", "GENE_OR_GENE_PRODUCT", 17, 31], ["HAV protein 2A", "PROTEIN", 17, 31], ["ribosome-skipping sequence", "DNA", 116, 142], ["viral proteins", "PROTEIN", 291, 305], ["D.", "SPECIES", 209, 211], ["D.", "SPECIES", 209, 211], ["HAV protein 2A", "TEST", 17, 31], ["other picornaviruses", "PROBLEM", 44, 64], ["proteolytic activity", "PROBLEM", 73, 93], ["a ribosome-skipping sequence", "TEST", 114, 142], ["Replication", "TREATMENT", 259, 270], ["viral proteins", "TREATMENT", 291, 305], ["RNA replication", "TREATMENT", 310, 325], ["efficient viral replication", "TREATMENT", 391, 418], ["picornaviruses", "OBSERVATION", 50, 64], ["no", "UNCERTAINTY", 70, 72]]], ["43 In order to tip the balance from translation to replication, the poly(A)-binding protein (PABP), as part of the eIF4F complex, is cleaved by HAV 3C pro .", [["poly", "CHEMICAL", 68, 72], ["poly(A)-binding protein", "GENE_OR_GENE_PRODUCT", 68, 91], ["PABP", "GENE_OR_GENE_PRODUCT", 93, 97], ["eIF4F", "GENE_OR_GENE_PRODUCT", 115, 120], ["HAV 3C", "ORGANISM", 144, 150], ["poly(A)-binding protein", "PROTEIN", 68, 91], ["PABP", "PROTEIN", 93, 97], ["eIF4F complex", "PROTEIN", 115, 128], ["HAV 3C pro", "PROTEIN", 144, 154], ["the poly(A)-binding protein (PABP)", "TREATMENT", 64, 98]]], ["The N-terminal cleavage product of PABP was shown to have an improved RNA-binding capacity compared to uncleaved PABP and may act as a dominant negative for IRES-mediated translation, thus favoring viral RNA synthesis.", [["N", "CHEMICAL", 4, 5], ["PABP", "GENE_OR_GENE_PRODUCT", 35, 39], ["PABP", "GENE_OR_GENE_PRODUCT", 113, 117], ["N-terminal cleavage product", "PROTEIN", 4, 31], ["PABP", "PROTEIN", 35, 39], ["PABP", "PROTEIN", 113, 117], ["IRES", "DNA", 157, 161], ["viral RNA", "RNA", 198, 207], ["The N-terminal cleavage product of PABP", "TREATMENT", 0, 39], ["an improved RNA-binding capacity", "PROBLEM", 58, 90], ["uncleaved PABP", "PROBLEM", 103, 117], ["viral RNA synthesis", "PROBLEM", 198, 217], ["viral RNA synthesis", "OBSERVATION", 198, 217]]], ["44 Additionally, proteolytic cleavage of the poly(rC)-binding protein PCBP2, which interacts with the pyrimidine-rich tract pY1 in the HAV 5 -UTR, may also be implicated in regulating the balance between translation and viral RNA synthesis.", [["pyrimidine", "CHEMICAL", 102, 112], ["pyrimidine", "CHEMICAL", 102, 112], ["PCBP2", "GENE_OR_GENE_PRODUCT", 70, 75], ["HAV 5", "ORGANISM", 135, 140], ["poly(rC)-binding protein", "PROTEIN", 45, 69], ["PCBP2", "PROTEIN", 70, 75], ["pyrimidine-rich tract pY1", "PROTEIN", 102, 127], ["HAV 5 -UTR", "DNA", 135, 145], ["viral RNA", "RNA", 220, 229], ["proteolytic cleavage of the poly(rC)-binding protein PCBP2", "TREATMENT", 17, 75], ["the pyrimidine-rich tract", "TREATMENT", 98, 123], ["viral RNA synthesis", "PROBLEM", 220, 239], ["viral RNA synthesis", "OBSERVATION", 220, 239]]], ["19 Other enzymes that bind to the HAV IRES are polypyrimidine tract binding protein (PTB), glyceraldehyde 3-phosphate dehydrogenase, and La autoantigen, which respectively enhance, suppress, and suppress translation.", [["glyceraldehyde 3-phosphate", "CHEMICAL", 91, 117], ["glyceraldehyde 3-phosphate", "CHEMICAL", 91, 117], ["HAV", "ORGANISM", 34, 37], ["polypyrimidine tract binding protein", "GENE_OR_GENE_PRODUCT", 47, 83], ["PTB", "GENE_OR_GENE_PRODUCT", 85, 88], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 91, 131], ["HAV IRES", "DNA", 34, 42], ["polypyrimidine tract binding protein", "PROTEIN", 47, 83], ["PTB", "PROTEIN", 85, 88], ["glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 91, 131], ["La autoantigen", "PROTEIN", 137, 151], ["HAV", "SPECIES", 34, 37], ["Other enzymes", "TEST", 3, 16], ["the HAV IRES", "TEST", 30, 42], ["polypyrimidine tract binding protein", "TEST", 47, 83], ["PTB", "TEST", 85, 88], ["glyceraldehyde 3-phosphate dehydrogenase", "TEST", 91, 131], ["La autoantigen", "PROBLEM", 137, 151]]], ["[45] [46] [47]E. ReplicationAs for most RNA viruses, replication of the viral genome takes place in replication complexes that consist of rearranged cellular membranes containing both viral and host proteins.", [["cellular membranes", "ANATOMY", 149, 167], ["cellular membranes", "CELLULAR_COMPONENT", 149, 167], ["viral genome", "DNA", 72, 84], ["replication complexes", "PROTEIN", 100, 121], ["viral and host proteins", "PROTEIN", 184, 207], ["ReplicationAs", "TREATMENT", 17, 30], ["most RNA viruses", "PROBLEM", 35, 51], ["the viral genome", "TREATMENT", 68, 84], ["replication complexes", "TREATMENT", 100, 121], ["rearranged cellular membranes", "PROBLEM", 138, 167], ["viral genome", "OBSERVATION", 72, 84], ["cellular membranes", "OBSERVATION", 149, 167], ["host proteins", "OBSERVATION", 194, 207]]], ["Studies revealed important roles for 2BC precursor and 2C proteins in the membrane rearrangements forming the replication complexes.", [["membrane", "ANATOMY", 74, 82], ["2BC precursor", "GENE_OR_GENE_PRODUCT", 37, 50], ["2C", "GENE_OR_GENE_PRODUCT", 55, 57], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["2BC precursor and 2C proteins", "PROTEIN", 37, 66], ["replication complexes", "PROTEIN", 110, 131], ["2BC precursor", "PROBLEM", 37, 50], ["2C proteins", "TREATMENT", 55, 66], ["the membrane rearrangements", "TREATMENT", 70, 97], ["membrane rearrangements", "OBSERVATION", 74, 97], ["replication complexes", "OBSERVATION", 110, 131]]], ["These complexes are described as a tubular vesicular network and were thought to be of endoplasmatic reticulum (ER) origin.", [["tubular vesicular network", "ANATOMY", 35, 60], ["endoplasmatic reticulum", "ANATOMY", 87, 110], ["ER", "ANATOMY", 112, 114], ["tubular vesicular network", "MULTI-TISSUE_STRUCTURE", 35, 60], ["endoplasmatic reticulum", "CELLULAR_COMPONENT", 87, 110], ["ER", "GENE_OR_GENE_PRODUCT", 112, 114], ["a tubular vesicular network", "PROBLEM", 33, 60], ["endoplasmatic reticulum", "PROBLEM", 87, 110], ["complexes", "OBSERVATION", 6, 15], ["tubular", "ANATOMY_MODIFIER", 35, 42], ["vesicular network", "OBSERVATION", 43, 60], ["thought to be of", "UNCERTAINTY", 70, 86], ["endoplasmatic reticulum", "OBSERVATION", 87, 110], ["origin", "OBSERVATION_MODIFIER", 116, 122]]], ["48, 49 However, a recent publication described the mitochondrial localization of the 3ABC precursor protein suggesting that HAV replication complexes may be derived from the outer mitochondrial membrane.", [["mitochondrial", "ANATOMY", 51, 64], ["outer mitochondrial membrane", "ANATOMY", 174, 202], ["mitochondrial", "CELLULAR_COMPONENT", 51, 64], ["3ABC", "GENE_OR_GENE_PRODUCT", 85, 89], ["HAV", "ORGANISM", 124, 127], ["outer", "CELLULAR_COMPONENT", 174, 179], ["mitochondrial membrane", "CELLULAR_COMPONENT", 180, 202], ["3ABC precursor protein", "PROTEIN", 85, 107], ["HAV replication complexes", "PROTEIN", 124, 149], ["HAV", "SPECIES", 124, 127], ["HAV replication complexes", "PROBLEM", 124, 149], ["outer", "ANATOMY_MODIFIER", 174, 179], ["mitochondrial membrane", "OBSERVATION", 180, 202]]], ["50 In line with this hypothesis, exchanging the mitochondria-targeting 3A transmembrane domain for the ER-targeting poliovirus 3A transmembrane domain resulted in loss of replication competence.", [["mitochondria", "ANATOMY", 48, 60], ["mitochondria", "CELLULAR_COMPONENT", 48, 60], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["poliovirus 3A", "GENE_OR_GENE_PRODUCT", 116, 129], ["mitochondria-targeting 3A transmembrane domain", "PROTEIN", 48, 94], ["ER", "PROTEIN", 103, 105], ["poliovirus 3A transmembrane domain", "PROTEIN", 116, 150], ["this hypothesis", "PROBLEM", 16, 31], ["the mitochondria", "TEST", 44, 60], ["poliovirus 3A transmembrane domain", "TREATMENT", 116, 150], ["loss of replication competence", "PROBLEM", 163, 193], ["loss", "OBSERVATION_MODIFIER", 163, 167], ["replication competence", "OBSERVATION", 171, 193]]], ["51 Within the replication complexes, the viral genome is transcribed into antisense RNA, which subsequently serves as a template for the production of new viral genomes.", [["replication complexes", "PROTEIN", 14, 35], ["viral genome", "DNA", 41, 53], ["antisense RNA", "RNA", 74, 87], ["viral genomes", "DNA", 155, 168], ["the viral genome", "PROBLEM", 37, 53], ["new viral genomes", "PROBLEM", 151, 168], ["replication complexes", "OBSERVATION", 14, 35], ["viral genome", "OBSERVATION", 41, 53], ["new", "OBSERVATION_MODIFIER", 151, 154], ["viral genomes", "OBSERVATION", 155, 168]]], ["During this process, the 3D protein functions as an RNA-dependent RNA polymerase.", [["3D protein", "PROTEIN", 25, 35], ["RNA-dependent RNA polymerase", "PROTEIN", 52, 80], ["the 3D protein functions", "TEST", 21, 45], ["an RNA", "TEST", 49, 55], ["dependent RNA polymerase", "PROBLEM", 56, 80]]], ["The 3B (VPg) protein serves as a starting point for primer-independent transcription and is covalently linked to the 5 genome end.", [["3B", "GENE_OR_GENE_PRODUCT", 4, 6], ["VPg", "GENE_OR_GENE_PRODUCT", 8, 11], ["3B (VPg) protein", "PROTEIN", 4, 20], ["5 genome end", "DNA", 117, 129], ["The 3B (VPg) protein serves", "TREATMENT", 0, 27], ["primer-independent transcription", "TREATMENT", 52, 84]]], ["A conserved replication element near the 5 end of the 3D pol -coding sequence likely directs uridylylation of VPg by 3D pol , in such way priming VPg for initiation of RNA replication.", [["VPg", "GENE_OR_GENE_PRODUCT", 110, 113], ["3D pol", "GENE_OR_GENE_PRODUCT", 117, 123], ["VPg", "GENE_OR_GENE_PRODUCT", 146, 149], ["conserved replication element", "DNA", 2, 31], ["5 end", "DNA", 41, 46], ["3D pol -coding sequence", "DNA", 54, 77], ["VPg", "PROTEIN", 110, 113], ["3D pol", "PROTEIN", 117, 123], ["VPg", "PROTEIN", 146, 149], ["A conserved replication element", "TREATMENT", 0, 31], ["the 3D pol -coding sequence", "TREATMENT", 50, 77], ["VPg by 3D pol", "TREATMENT", 110, 123], ["RNA replication", "TREATMENT", 168, 183], ["replication element", "OBSERVATION", 12, 31]]], ["52 During replication, the 3A/3B junction remains uncleaved and the transmembrane protein 3A serves as an anchor tethering the growing HAV RNA strand and associated proteins to the membranes of the replication complex, 42, 53 as is the case for other picornaviruses.", [["membranes", "ANATOMY", 181, 190], ["3B", "GENE_OR_GENE_PRODUCT", 30, 32], ["transmembrane", "CELLULAR_COMPONENT", 68, 81], ["protein 3A", "GENE_OR_GENE_PRODUCT", 82, 92], ["membranes", "CELLULAR_COMPONENT", 181, 190], ["transmembrane protein 3A", "PROTEIN", 68, 92], ["HAV RNA strand", "RNA", 135, 149], ["replication complex", "PROTEIN", 198, 217], ["the 3A/3B junction", "TREATMENT", 23, 41], ["the transmembrane protein 3A", "PROBLEM", 64, 92], ["an anchor tethering", "PROBLEM", 103, 122], ["other picornaviruses", "PROBLEM", 245, 265], ["growing", "OBSERVATION_MODIFIER", 127, 134], ["HAV RNA strand", "OBSERVATION", 135, 149], ["replication", "OBSERVATION_MODIFIER", 198, 209], ["complex", "OBSERVATION_MODIFIER", 210, 217], ["picornaviruses", "OBSERVATION", 251, 265]]], ["54 It has also been reported that the 2C protein of HAV binds to the 3 end of the antisense RNA.", [["HAV", "ORGANISM", 52, 55], ["2C protein", "PROTEIN", 38, 48], ["3 end", "RNA", 69, 74], ["antisense RNA", "RNA", 82, 95], ["HAV", "SPECIES", 52, 55], ["HAV binds", "TREATMENT", 52, 61], ["antisense RNA", "OBSERVATION", 82, 95]]], ["In this way, protein 2C may be implicated in anchoring the negative sense RNA template to the membranes of the replication complex.", [["membranes", "ANATOMY", 94, 103], ["protein 2C", "GENE_OR_GENE_PRODUCT", 13, 23], ["membranes", "CELLULAR_COMPONENT", 94, 103], ["protein 2C", "PROTEIN", 13, 23], ["negative sense RNA template", "RNA", 59, 86], ["replication complex", "PROTEIN", 111, 130], ["protein 2C", "TREATMENT", 13, 23], ["replication complex", "OBSERVATION", 111, 130]]], ["55F.", [["55F", "DNA", 0, 3]]], ["Capsid AssemblyDespite the fact that the multitiered capsid assembly process is only poorly understood, HAV differs at various steps from other picornaviruses.", [["HAV", "ORGANISM", 104, 107], ["other picornaviruses", "PROBLEM", 138, 158], ["picornaviruses", "OBSERVATION", 144, 158]]], ["Following the initial cleavage at the 2A/2B junction by 3C pro (as discussed above), the N-terminal part of protein 2A coordinates proper folding of the P1-2A precursor protein.", [["N", "CHEMICAL", 89, 90], ["protein 2A", "GENE_OR_GENE_PRODUCT", 108, 118], ["P1-2A", "GENE_OR_GENE_PRODUCT", 153, 158], ["2A", "PROTEIN", 38, 40], ["3C pro", "PROTEIN", 56, 62], ["N-terminal part", "PROTEIN", 89, 104], ["protein 2A", "PROTEIN", 108, 118], ["P1-2A precursor protein", "PROTEIN", 153, 176], ["the initial cleavage at the 2A/2B junction", "TREATMENT", 10, 52], ["the N-terminal part of protein 2A", "TREATMENT", 85, 118]]], ["This precursor protein is then processed by 3C pro and its stable precursor 3ABC pro into VP0 (consisting of VP4 and VP2), pX precursor (consisting of VP1 and 2A), and mature VP3 protein.", [["VP0", "GENE_OR_GENE_PRODUCT", 90, 93], ["VP4", "GENE_OR_GENE_PRODUCT", 109, 112], ["VP2", "GENE_OR_GENE_PRODUCT", 117, 120], ["pX", "GENE_OR_GENE_PRODUCT", 123, 125], ["VP1", "GENE_OR_GENE_PRODUCT", 151, 154], ["2A", "GENE_OR_GENE_PRODUCT", 159, 161], ["VP3", "GENE_OR_GENE_PRODUCT", 175, 178], ["precursor protein", "PROTEIN", 5, 22], ["3C pro", "PROTEIN", 44, 50], ["3ABC pro", "PROTEIN", 76, 84], ["VP0", "PROTEIN", 90, 93], ["VP4", "PROTEIN", 109, 112], ["VP2", "PROTEIN", 117, 120], ["pX precursor", "PROTEIN", 123, 135], ["VP1", "PROTEIN", 151, 154], ["2A", "PROTEIN", 159, 161], ["mature VP3 protein", "PROTEIN", 168, 186], ["VP4", "TEST", 109, 112], ["VP2", "TEST", 117, 120], ["pX precursor", "TEST", 123, 135], ["VP1", "TEST", 151, 154], ["mature VP3 protein", "PROBLEM", 168, 186], ["stable", "OBSERVATION_MODIFIER", 59, 65], ["VP3 protein", "OBSERVATION", 175, 186]]], ["42, 56 These building blocks assemble into pentamers and subsequently associate with viral RNA to form preprovirions.", [["preprovirions", "GENE_OR_GENE_PRODUCT", 103, 116], ["viral RNA", "RNA", 85, 94], ["viral RNA", "PROBLEM", 85, 94], ["viral RNA", "OBSERVATION", 85, 94]]], ["In a final processing step, VP0 will be cleaved into VP4 and VP2 and precursor pX into VP1 and 2A, yielding mature virus particles with only VP1, VP2, and VP3 proteins.", [["VP0", "SIMPLE_CHEMICAL", 28, 31], ["VP4", "GENE_OR_GENE_PRODUCT", 53, 56], ["VP2", "GENE_OR_GENE_PRODUCT", 61, 64], ["VP1", "GENE_OR_GENE_PRODUCT", 87, 90], ["2A", "GENE_OR_GENE_PRODUCT", 95, 97], ["VP1", "GENE_OR_GENE_PRODUCT", 141, 144], ["VP2", "GENE_OR_GENE_PRODUCT", 146, 149], ["VP3", "GENE_OR_GENE_PRODUCT", 155, 158], ["VP0", "PROTEIN", 28, 31], ["VP4", "PROTEIN", 53, 56], ["VP2", "PROTEIN", 61, 64], ["precursor pX", "PROTEIN", 69, 81], ["VP1 and 2A", "PROTEIN", 87, 97], ["VP1, VP2, and VP3 proteins", "PROTEIN", 141, 167], ["VP0", "TREATMENT", 28, 31], ["VP4", "TEST", 53, 56], ["VP2", "TEST", 61, 64], ["VP1", "TEST", 87, 90], ["mature virus particles", "PROBLEM", 108, 130], ["VP1", "TEST", 141, 144], ["VP2", "TEST", 146, 149], ["virus", "OBSERVATION", 115, 120], ["VP3", "ANATOMY", 155, 158]]], ["The processing of pX is mediated by a yet unknown cellular protease.", [["cellular", "ANATOMY", 50, 58], ["pX", "GENE_OR_GENE_PRODUCT", 18, 20], ["cellular", "CELL", 50, 58], ["pX", "PROTEIN", 18, 20], ["cellular protease", "PROTEIN", 50, 67], ["cellular protease", "OBSERVATION", 50, 67]]], ["57 Although the cleavage can be performed by extracellular enzymes like factor Xa and trypsin, 58, 59 maturation can also be executed by the lysosomal proteinase cathepsin L. This may indicate a role for lysosomal proteinases in maturation cleavage and potential targeting of HAV provirions to the early lysosomes for maturation cleavage.", [["extracellular", "ANATOMY", 45, 58], ["lysosomal", "ANATOMY", 204, 213], ["lysosomes", "ANATOMY", 304, 313], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["factor Xa", "GENE_OR_GENE_PRODUCT", 72, 81], ["trypsin", "GENE_OR_GENE_PRODUCT", 86, 93], ["cathepsin L.", "GENE_OR_GENE_PRODUCT", 162, 174], ["lysosomal proteinases", "GENE_OR_GENE_PRODUCT", 204, 225], ["HAV provirions", "ORGANISM", 276, 290], ["lysosomes", "CELLULAR_COMPONENT", 304, 313], ["extracellular enzymes", "PROTEIN", 45, 66], ["factor Xa", "PROTEIN", 72, 81], ["trypsin", "PROTEIN", 86, 93], ["lysosomal proteinase", "PROTEIN", 141, 161], ["lysosomal proteinases", "PROTEIN", 204, 225], ["HAV", "SPECIES", 276, 279], ["extracellular enzymes", "TEST", 45, 66], ["trypsin", "TEST", 86, 93], ["the lysosomal proteinase cathepsin L.", "TREATMENT", 137, 174], ["lysosomal proteinases", "PROBLEM", 204, 225], ["maturation cleavage", "TREATMENT", 229, 248], ["HAV provirions", "TREATMENT", 276, 290], ["maturation cleavage", "PROBLEM", 318, 337]]], ["59 On the other hand, VP0 processing is thought to be a self-catalytic process that is dependent on the presence of encapsidated RNA.", [["VP0", "GENE_OR_GENE_PRODUCT", 22, 25], ["VP0", "PROTEIN", 22, 25], ["encapsidated RNA", "RNA", 116, 132], ["VP0 processing", "PROBLEM", 22, 36], ["a self-catalytic process", "PROBLEM", 54, 78], ["encapsidated RNA", "PROBLEM", 116, 132], ["thought to be", "UNCERTAINTY", 40, 53], ["catalytic process", "OBSERVATION", 61, 78], ["dependent", "OBSERVATION_MODIFIER", 87, 96], ["encapsidated RNA", "OBSERVATION", 116, 132]]], ["60 The resulting VP4 is rather small compared to other picornaviruses and lacks an N-terminal myristoylation signal.", [["N", "CHEMICAL", 83, 84], ["VP4", "GENE_OR_GENE_PRODUCT", 17, 20], ["VP4", "PROTEIN", 17, 20], ["N-terminal myristoylation signal", "PROTEIN", 83, 115], ["The resulting VP4", "PROBLEM", 3, 20], ["other picornaviruses", "PROBLEM", 49, 69], ["an N-terminal myristoylation signal", "PROBLEM", 80, 115], ["VP4", "OBSERVATION", 17, 20], ["small", "OBSERVATION_MODIFIER", 31, 36], ["picornaviruses", "OBSERVATION", 55, 69], ["terminal", "OBSERVATION_MODIFIER", 85, 93], ["myristoylation signal", "OBSERVATION", 94, 115]]], ["61 Note that the mature VP4 protein has never been identified in purified virus stocks and its role in capsid formation remains unclear.", [["capsid", "ANATOMY", 103, 109], ["VP4", "GENE_OR_GENE_PRODUCT", 24, 27], ["capsid", "CELLULAR_COMPONENT", 103, 109], ["mature VP4 protein", "PROTEIN", 17, 35], ["the mature VP4 protein", "PROBLEM", 13, 35], ["purified virus stocks", "TREATMENT", 65, 86], ["capsid formation", "PROBLEM", 103, 119], ["virus stocks", "OBSERVATION", 74, 86], ["capsid formation", "OBSERVATION", 103, 119]]], ["ReleaseHAV is an enterically transmitted virus that replicates mostly in hepatocytes before it is excreted via the bile into the faeces.", [["hepatocytes", "ANATOMY", 73, 84], ["bile", "ANATOMY", 115, 119], ["faeces", "ANATOMY", 129, 135], ["ReleaseHAV", "CHEMICAL", 0, 10], ["ReleaseHAV", "GENE_OR_GENE_PRODUCT", 0, 10], ["hepatocytes", "CELL", 73, 84], ["bile", "MULTI-TISSUE_STRUCTURE", 115, 119], ["faeces", "ORGANISM_SUBSTANCE", 129, 135], ["hepatocytes", "CELL_TYPE", 73, 84], ["an enterically transmitted virus", "PROBLEM", 14, 46], ["virus", "OBSERVATION", 41, 46], ["hepatocytes", "ANATOMY", 73, 84], ["bile", "ANATOMY", 115, 119], ["faeces", "ANATOMY", 129, 135]]], ["Despite the fact that the exact details of HAV release remain elusive, the mechanism seems to differ depending on the cell type infected and is thought to involve either a vesicle-mediated cellular protein transport pathway or specialized hepatocellular transport proteins involved in bile secretion.", [["cell", "ANATOMY", 118, 122], ["vesicle", "ANATOMY", 172, 179], ["cellular", "ANATOMY", 189, 197], ["hepatocellular", "ANATOMY", 239, 253], ["bile", "ANATOMY", 285, 289], ["HAV", "ORGANISM", 43, 46], ["cell type", "CELL", 118, 127], ["vesicle", "CELLULAR_COMPONENT", 172, 179], ["cellular", "CELL", 189, 197], ["hepatocellular", "MULTI-TISSUE_STRUCTURE", 239, 253], ["bile", "MULTI-TISSUE_STRUCTURE", 285, 289], ["hepatocellular transport proteins", "PROTEIN", 239, 272], ["HAV release", "TREATMENT", 43, 54], ["specialized hepatocellular transport proteins", "PROBLEM", 227, 272], ["bile secretion", "PROBLEM", 285, 299], ["hepatocellular", "ANATOMY", 239, 253], ["bile", "ANATOMY", 285, 289]]], ["62 Blank and colleagues demonstrated that following infection of polarized human intestinal epithelial Caco-2 cells, release of progeny virus was largely restricted to the apical membrane.", [["intestinal epithelial Caco-2 cells", "ANATOMY", 81, 115], ["apical membrane", "ANATOMY", 172, 187], ["infection", "DISEASE", 52, 61], ["human", "ORGANISM", 75, 80], ["intestinal epithelial Caco-2 cells", "CELL", 81, 115], ["apical membrane", "CELLULAR_COMPONENT", 172, 187], ["polarized human intestinal epithelial Caco-2 cells", "CELL_LINE", 65, 115], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["polarized human intestinal epithelial Caco", "PROBLEM", 65, 107], ["progeny virus", "PROBLEM", 128, 141], ["intestinal", "ANATOMY", 81, 91], ["epithelial Caco", "OBSERVATION", 92, 107], ["progeny virus", "OBSERVATION", 128, 141], ["apical", "ANATOMY_MODIFIER", 172, 178], ["membrane", "ANATOMY_MODIFIER", 179, 187]]], ["62 In this way, virus is secreted mainly into the intestinal lumen resulting in an amplification of the HAV inoculum in the intestines and thus an increased viral shedding and spreading of the virus.", [["intestinal lumen", "ANATOMY", 50, 66], ["intestines", "ANATOMY", 124, 134], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 50, 66], ["HAV", "ORGANISM", 104, 107], ["intestines", "ORGAN", 124, 134], ["HAV", "SPECIES", 104, 107], ["virus", "PROBLEM", 16, 21], ["the HAV inoculum in the intestines", "PROBLEM", 100, 134], ["an increased viral shedding", "PROBLEM", 144, 171], ["the virus", "PROBLEM", 189, 198], ["virus", "OBSERVATION", 16, 21], ["intestinal lumen", "ANATOMY", 50, 66], ["HAV", "OBSERVATION_MODIFIER", 104, 107], ["inoculum", "OBSERVATION", 108, 116], ["intestines", "ANATOMY", 124, 134], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["viral shedding", "OBSERVATION", 157, 171], ["virus", "OBSERVATION", 193, 198]]], ["However, it is still unclear by which mechanism HAV reaches the blood stream.", [["blood stream", "ANATOMY", 64, 76], ["HAV", "ORGANISM", 48, 51], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["HAV", "SPECIES", 48, 51]]], ["A role for transcytosis by M cells present in Peyer's patches in the ileum has been suggested, a mechanism that was found for poliovirus and reovirus as well.", [["M cells", "ANATOMY", 27, 34], ["Peyer's patches", "ANATOMY", 46, 61], ["ileum", "ANATOMY", 69, 74], ["M cells", "CELL", 27, 34], ["Peyer's patches", "ORGANISM", 46, 61], ["ileum", "MULTI-TISSUE_STRUCTURE", 69, 74], ["reovirus", "ORGANISM", 141, 149], ["M cells", "CELL_TYPE", 27, 34], ["poliovirus", "SPECIES", 126, 136], ["transcytosis", "PROBLEM", 11, 23], ["poliovirus", "PROBLEM", 126, 136], ["reovirus", "PROBLEM", 141, 149], ["ileum", "ANATOMY", 69, 74]]], ["62 Another study described that infection of polarized human hepatocytes occurred most efficiently via the basolateral plasma membrane, after which more than 95% of progeny virus was exported through the basolateral membrane (into the bloodstream), rather than through the apical membrane (into the bile channels).", [["hepatocytes", "ANATOMY", 61, 72], ["basolateral plasma membrane", "ANATOMY", 107, 134], ["basolateral membrane", "ANATOMY", 204, 224], ["bloodstream", "ANATOMY", 235, 246], ["apical membrane", "ANATOMY", 273, 288], ["bile channels", "ANATOMY", 299, 312], ["infection", "DISEASE", 32, 41], ["human", "ORGANISM", 55, 60], ["hepatocytes", "CELL", 61, 72], ["basolateral", "CELLULAR_COMPONENT", 107, 118], ["plasma membrane", "CELLULAR_COMPONENT", 119, 134], ["progeny virus", "ORGANISM", 165, 178], ["basolateral membrane", "CELLULAR_COMPONENT", 204, 224], ["apical membrane", "CELLULAR_COMPONENT", 273, 288], ["bile", "MULTI-TISSUE_STRUCTURE", 299, 303], ["polarized human hepatocytes", "CELL_TYPE", 45, 72], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["Another study", "TEST", 3, 16], ["infection of polarized human hepatocytes", "PROBLEM", 32, 72], ["progeny virus", "PROBLEM", 165, 178], ["infection", "OBSERVATION", 32, 41], ["basolateral", "ANATOMY_MODIFIER", 107, 118], ["plasma membrane", "OBSERVATION", 119, 134], ["progeny virus", "OBSERVATION", 165, 178], ["basolateral", "ANATOMY_MODIFIER", 204, 215], ["membrane", "ANATOMY_MODIFIER", 216, 224], ["bloodstream", "ANATOMY", 235, 246], ["apical", "ANATOMY_MODIFIER", 273, 279], ["membrane", "ANATOMY_MODIFIER", 280, 288], ["bile channels", "ANATOMY", 299, 312]]], ["63 This contrasts with the in vivo observation that bile and faecal titers are considerably higher than serum titers.", [["bile", "ANATOMY", 52, 56], ["faecal", "ANATOMY", 61, 67], ["serum", "ANATOMY", 104, 109], ["bile", "SIMPLE_CHEMICAL", 52, 56], ["faecal", "ORGANISM_SUBSTANCE", 61, 67], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["bile and faecal titers", "TEST", 52, 74], ["serum titers", "TEST", 104, 116], ["bile", "ANATOMY", 52, 56], ["faecal titers", "OBSERVATION", 61, 74]]], ["15, 64 Reuptake and transcytosis of progeny virus by the hepatocytes into the bile channels is suggested as the mechanism for enteric secretion.H. Particle StructureHAV is a nonenveloped icosahedral particle of approximately 27 nm in diameter.", [["hepatocytes", "ANATOMY", 57, 68], ["bile channels", "ANATOMY", 78, 91], ["progeny virus", "ORGANISM", 36, 49], ["hepatocytes", "CELL", 57, 68], ["bile", "MULTI-TISSUE_STRUCTURE", 78, 82], ["hepatocytes", "CELL_TYPE", 57, 68], ["transcytosis of progeny virus", "PROBLEM", 20, 49], ["enteric secretion", "PROBLEM", 126, 143], ["progeny virus", "OBSERVATION", 36, 49], ["hepatocytes", "ANATOMY", 57, 68], ["bile channels", "ANATOMY", 78, 91], ["Particle StructureHAV", "OBSERVATION", 147, 168], ["nonenveloped", "OBSERVATION_MODIFIER", 174, 186], ["icosahedral", "OBSERVATION_MODIFIER", 187, 198], ["particle", "OBSERVATION_MODIFIER", 199, 207], ["approximately", "OBSERVATION_MODIFIER", 211, 224], ["27 nm", "OBSERVATION_MODIFIER", 225, 230], ["diameter", "OBSERVATION_MODIFIER", 234, 242]]], ["65 The mature capsid is composed of 12 pentamers each consisting of five copies of VP1, VP2, and VP3.", [["VP1", "GENE_OR_GENE_PRODUCT", 83, 86], ["VP2", "GENE_OR_GENE_PRODUCT", 88, 91], ["VP3", "GENE_OR_GENE_PRODUCT", 97, 100], ["VP1", "PROTEIN", 83, 86], ["VP2", "PROTEIN", 88, 91], ["VP3", "PROTEIN", 97, 100], ["The mature capsid", "TREATMENT", 3, 20], ["VP1", "TEST", 83, 86], ["VP2", "TEST", 88, 91], ["VP3", "TEST", 97, 100], ["mature", "OBSERVATION_MODIFIER", 7, 13], ["capsid", "OBSERVATION", 14, 20]]], ["Unlike for other picornaviruses, VP4 appears not to be present in mature HAV particles (see Section 2,F).", [["VP4", "GENE_OR_GENE_PRODUCT", 33, 36], ["HAV", "ORGANISM", 73, 76], ["VP4", "PROTEIN", 33, 36], ["HAV", "SPECIES", 73, 76], ["other picornaviruses", "PROBLEM", 11, 31], ["VP4", "PROBLEM", 33, 36], ["picornaviruses", "OBSERVATION", 17, 31], ["not to be", "UNCERTAINTY", 45, 54]]], ["Attempts to produce high-resolution images of HAV particles remained unsuccessful so far.", [["HAV", "ORGANISM", 46, 49], ["HAV", "SPECIES", 46, 49], ["HAV particles", "PROBLEM", 46, 59]]], ["A 2006 review 15 showed a medium-resolution image obtained by cryo-electron microscopy suggesting the absence of the well-defined canyon surrounding the fivefold axis, in this way differing from other picornaviruses.", [["canyon", "ORGANISM_SUBDIVISION", 130, 136], ["a medium-resolution image", "TEST", 24, 49], ["cryo-electron microscopy", "TEST", 62, 86], ["other picornaviruses", "PROBLEM", 195, 215], ["well-defined", "OBSERVATION_MODIFIER", 117, 129], ["canyon", "OBSERVATION", 130, 136], ["fivefold axis", "ANATOMY", 153, 166], ["picornaviruses", "OBSERVATION", 201, 215]]], ["HAV has a limited number of neutralization antigenic sites.", [["HAV", "DISEASE", 0, 3], ["HAV", "ORGANISM", 0, 3], ["neutralization antigenic sites", "DNA", 28, 58], ["HAV", "SPECIES", 0, 3], ["neutralization antigenic sites", "TREATMENT", 28, 58], ["neutralization", "OBSERVATION_MODIFIER", 28, 42], ["antigenic sites", "OBSERVATION", 43, 58]]], ["The immunodominant antigenic site is composed of VP1 and VP3 residues and is conformationdependent.", [["VP1", "GENE_OR_GENE_PRODUCT", 49, 52], ["VP3", "GENE_OR_GENE_PRODUCT", 57, 60], ["VP1 and VP3 residues", "PROTEIN", 49, 69], ["The immunodominant antigenic site", "PROBLEM", 0, 33], ["VP1 and VP3 residues", "PROBLEM", 49, 69], ["immunodominant", "OBSERVATION_MODIFIER", 4, 18], ["antigenic site", "OBSERVATION", 19, 33], ["VP3 residues", "OBSERVATION", 57, 69]]], ["66 A second antigenic site is the glycophorin A binding site by which HAV can bind to erythrocytes, causing hemagglutination.", [["erythrocytes", "ANATOMY", 86, 98], ["glycophorin A", "GENE_OR_GENE_PRODUCT", 34, 47], ["HAV", "ORGANISM", 70, 73], ["erythrocytes", "CELL", 86, 98], ["glycophorin A binding site", "DNA", 34, 60], ["erythrocytes", "CELL_TYPE", 86, 98], ["HAV", "SPECIES", 70, 73], ["A second antigenic site", "PROBLEM", 3, 26], ["the glycophorin A binding site", "PROBLEM", 30, 60], ["hemagglutination", "PROBLEM", 108, 124], ["antigenic site", "OBSERVATION", 12, 26], ["hemagglutination", "OBSERVATION", 108, 124]]], ["This process is optimal at acidic pH, but is impaired at physiological pH.", [["impaired at physiological pH", "PROBLEM", 45, 73], ["impaired", "OBSERVATION", 45, 53]]], ["This suggests that HAV has evolved to escape erythrocyte binding and consequent clearance.", [["erythrocyte", "ANATOMY", 45, 56], ["HAV", "ORGANISM", 19, 22], ["erythrocyte", "CELL", 45, 56], ["HAV", "SPECIES", 19, 22], ["HAV", "PROBLEM", 19, 22], ["escape erythrocyte binding", "PROBLEM", 38, 64], ["HAV", "OBSERVATION", 19, 22], ["escape erythrocyte binding", "OBSERVATION", 38, 64]]], ["67, 68 Indeed, a mutant of this binding site displayed increased clearance from the blood and lower overall fitness, suggesting evolutionary constraints and explaining the low level of antigenic variability of the glycophorin A binding site.", [["blood", "ANATOMY", 84, 89], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["glycophorin A", "GENE_OR_GENE_PRODUCT", 214, 227], ["glycophorin A binding site", "DNA", 214, 240], ["this binding site", "PROBLEM", 27, 44], ["increased clearance", "PROBLEM", 55, 74], ["the blood and lower overall fitness", "PROBLEM", 80, 115], ["evolutionary constraints", "PROBLEM", 128, 152], ["the glycophorin A binding site", "PROBLEM", 210, 240], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["clearance", "OBSERVATION", 65, 74], ["blood", "ANATOMY", 84, 89], ["evolutionary constraints", "OBSERVATION", 128, 152]]], ["68IMMUNE EVASION MECHANISMSHepatitis A is clinically characterized by a prolonged asymptomatic phase before clinical illness becomes apparent and a very limited type I interferon response (only in week 1-2 after HAV challenge).", [["type I interferon", "GENE_OR_GENE_PRODUCT", 161, 178], ["HAV", "ORGANISM", 212, 215], ["interferon", "PROTEIN", 168, 178], ["HAV", "SPECIES", 212, 215], ["a prolonged asymptomatic phase", "PROBLEM", 70, 100], ["clinical illness", "PROBLEM", 108, 124], ["a very limited type I interferon response", "PROBLEM", 146, 187]]], ["69 HAV replication remains largely undetected by the immune system for several weeks after infection and intrahepatic RNA was shown to persist for over 48 weeks in experimentally infected chimpanzees.", [["immune system", "ANATOMY", 53, 66], ["infection", "DISEASE", 91, 100], ["HAV", "ORGANISM", 3, 6], ["immune system", "ANATOMICAL_SYSTEM", 53, 66], ["chimpanzees", "ORGANISM", 188, 199], ["intrahepatic RNA", "RNA", 105, 121], ["HAV", "SPECIES", 3, 6], ["HAV replication", "PROBLEM", 3, 18], ["infection", "PROBLEM", 91, 100], ["intrahepatic RNA", "PROBLEM", 105, 121], ["experimentally infected chimpanzees", "PROBLEM", 164, 199], ["infection", "OBSERVATION", 91, 100], ["intrahepatic", "ANATOMY", 105, 117], ["infected chimpanzees", "OBSERVATION", 179, 199]]], ["69 To this end, HAV employs several strategies to evade the host immune response that are rather different from those used by other picornaviruses.A. Targeting MAVS and TRIFOne of these evasion tactics is to ablate the innate immunity's alarming system that induces IFN expression.", [["HAV", "ORGANISM", 16, 19], ["MAVS", "GENE_OR_GENE_PRODUCT", 160, 164], ["IFN", "GENE_OR_GENE_PRODUCT", 266, 269], ["MAVS", "PROTEIN", 160, 164], ["IFN", "PROTEIN", 266, 269], ["HAV", "SPECIES", 16, 19], ["MAVS", "OBSERVATION", 160, 164]]], ["HAV was shown to inhibit double-stranded RNA (ds RNA)-induced IFN\u03b2 gene expression 70 by interfering with the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA-5) signaling pathways (Fig. 2) .", [["melanoma", "ANATOMY", 153, 161], ["HAV", "ORGANISM", 0, 3], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 62, 66], ["retinoic acid-inducible gene I", "GENE_OR_GENE_PRODUCT", 110, 140], ["RIG-I", "GENE_OR_GENE_PRODUCT", 142, 147], ["melanoma differentiation-associated gene 5", "GENE_OR_GENE_PRODUCT", 153, 195], ["MDA-5", "GENE_OR_GENE_PRODUCT", 197, 202], ["double-stranded RNA", "RNA", 25, 44], ["ds RNA", "RNA", 46, 52], ["IFN\u03b2", "PROTEIN", 62, 66], ["retinoic acid-inducible gene I", "DNA", 110, 140], ["RIG-I", "DNA", 142, 147], ["melanoma differentiation-associated gene 5", "DNA", 153, 195], ["HAV", "SPECIES", 0, 3], ["double-stranded RNA (ds RNA", "TREATMENT", 25, 52], ["the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation", "PROBLEM", 106, 177], ["MDA", "TEST", 197, 200], ["melanoma", "OBSERVATION", 153, 161]]], ["71 RIG-I recognizes single-stranded 5 -triphosphate RNA, while MDA-5 detects single-and double-stranded picornaviral RNA covalently linked to VPg.", [["5 -triphosphate", "CHEMICAL", 36, 51], ["MDA-5", "CHEMICAL", 63, 68], ["5 -triphosphate", "CHEMICAL", 36, 51], ["MDA-5", "CHEMICAL", 63, 68], ["RIG-I", "GENE_OR_GENE_PRODUCT", 3, 8], ["single-stranded 5 -triphosphate", "SIMPLE_CHEMICAL", 20, 51], ["MDA-5", "GENE_OR_GENE_PRODUCT", 63, 68], ["VPg", "GENE_OR_GENE_PRODUCT", 142, 145], ["RIG-I", "DNA", 3, 8], ["single-stranded 5 -triphosphate RNA", "RNA", 20, 55], ["MDA", "PROTEIN", 63, 66], ["picornaviral RNA", "RNA", 104, 120], ["VPg", "PROTEIN", 142, 145], ["triphosphate RNA", "TEST", 39, 55], ["MDA", "TEST", 63, 66], ["double-stranded picornaviral RNA", "TREATMENT", 88, 120], ["VPg", "PROBLEM", 142, 145]]], ["72 Both RIG-I and MDA-5 use an adaptor protein called mitochondrial antiviral signaling protein (MAVS, also known as IPS-1, VISA, or Cardif) that is localized on the outer membrane of the mitochondria.", [["mitochondrial", "ANATOMY", 54, 67], ["outer membrane", "ANATOMY", 166, 180], ["mitochondria", "ANATOMY", 188, 200], ["RIG-I", "GENE_OR_GENE_PRODUCT", 8, 13], ["MDA-5", "GENE_OR_GENE_PRODUCT", 18, 23], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["antiviral signaling protein", "GENE_OR_GENE_PRODUCT", 68, 95], ["MAVS", "GENE_OR_GENE_PRODUCT", 97, 101], ["IPS-1", "GENE_OR_GENE_PRODUCT", 117, 122], ["VISA", "GENE_OR_GENE_PRODUCT", 124, 128], ["Cardif", "GENE_OR_GENE_PRODUCT", 133, 139], ["outer membrane", "CELLULAR_COMPONENT", 166, 180], ["mitochondria", "CELLULAR_COMPONENT", 188, 200], ["RIG", "PROTEIN", 8, 11], ["MDA", "PROTEIN", 18, 21], ["adaptor protein", "PROTEIN", 31, 46], ["mitochondrial antiviral signaling protein", "PROTEIN", 54, 95], ["MAVS", "PROTEIN", 97, 101], ["IPS", "PROTEIN", 117, 120], ["1", "PROTEIN", 121, 122], ["VISA", "PROTEIN", 124, 128], ["Cardif", "PROTEIN", 133, 139], ["MDA", "TEST", 18, 21], ["an adaptor protein", "TEST", 28, 46], ["mitochondrial antiviral signaling protein (MAVS", "PROBLEM", 54, 101], ["IPS", "TEST", 117, 120], ["VISA", "PROBLEM", 124, 128], ["antiviral signaling protein", "OBSERVATION", 68, 95], ["mitochondria", "ANATOMY", 188, 200]]], ["50 Upon activation by RIG-I or MDA-5, MAVS recruits and activates TANK-binding kinase 1 (TBK1) and inhibitor of NF-\u03baB kinase \u03b5 (IKK\u03b5).", [["MDA-5", "CHEMICAL", 31, 36], ["RIG-I", "GENE_OR_GENE_PRODUCT", 22, 27], ["MDA-5", "GENE_OR_GENE_PRODUCT", 31, 36], ["MAVS", "GENE_OR_GENE_PRODUCT", 38, 42], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 66, 87], ["TBK1", "GENE_OR_GENE_PRODUCT", 89, 93], ["NF-\u03baB kinase \u03b5", "GENE_OR_GENE_PRODUCT", 112, 126], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 128, 132], ["RIG-I", "PROTEIN", 22, 27], ["MDA", "PROTEIN", 31, 34], ["MAVS", "PROTEIN", 38, 42], ["TANK-binding kinase 1", "PROTEIN", 66, 87], ["TBK1", "PROTEIN", 89, 93], ["NF-\u03baB kinase \u03b5", "PROTEIN", 112, 126], ["IKK\u03b5", "PROTEIN", 128, 132], ["MDA", "TEST", 31, 34], ["TANK-binding kinase", "TEST", 66, 85], ["TBK1", "TEST", 89, 93], ["NF", "TEST", 112, 114]]], ["TBK1 and IKK\u03b5 are both responsible for the phosphorylation of IFN regulatory factor 3 (IRF-3), eventually leading to IRF-3 dimerization, nuclear translocation, and induction of IFN\u03b2 transcription.", [["nuclear", "ANATOMY", 137, 144], ["TBK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 9, 13], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 62, 85], ["IRF-3", "GENE_OR_GENE_PRODUCT", 87, 92], ["IRF-3", "GENE_OR_GENE_PRODUCT", 117, 122], ["nuclear", "CELLULAR_COMPONENT", 137, 144], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 177, 181], ["TBK1", "PROTEIN", 0, 4], ["IKK\u03b5", "PROTEIN", 9, 13], ["IFN regulatory factor 3", "PROTEIN", 62, 85], ["IRF-3", "PROTEIN", 87, 92], ["IRF-3", "PROTEIN", 117, 122], ["IFN\u03b2", "PROTEIN", 177, 181], ["TBK1", "TEST", 0, 4], ["IKK", "TEST", 9, 12], ["the phosphorylation of IFN regulatory factor", "PROBLEM", 39, 83], ["IRF", "TEST", 87, 90], ["IRF", "PROBLEM", 117, 120], ["nuclear translocation", "PROBLEM", 137, 158], ["IFN\u03b2 transcription", "TREATMENT", 177, 195]]], ["HAV proteins 3ABC pro50 and 2B 72 have been described to interfere with MAVS, thereby disrupting the innate cellular antiviral defense mechanism.", [["cellular", "ANATOMY", 108, 116], ["HAV", "ORGANISM", 0, 3], ["3ABC", "GENE_OR_GENE_PRODUCT", 13, 17], ["2B 72", "GENE_OR_GENE_PRODUCT", 28, 33], ["MAVS", "GENE_OR_GENE_PRODUCT", 72, 76], ["cellular", "CELL", 108, 116], ["HAV proteins", "PROTEIN", 0, 12], ["pro50", "PROTEIN", 18, 23], ["2B 72", "PROTEIN", 28, 33], ["MAVS", "PROTEIN", 72, 76], ["HAV", "SPECIES", 0, 3], ["HAV proteins", "TEST", 0, 12], ["MAVS", "PROBLEM", 72, 76], ["cellular antiviral defense", "OBSERVATION", 108, 134]]], ["Precursor protein 3ABC is a stable polyprotein processing intermediate that requires both the 3A and the 3C pro domain for the cleavage and inactivation of MAVS.", [["3ABC", "GENE_OR_GENE_PRODUCT", 18, 22], ["MAVS", "GENE_OR_GENE_PRODUCT", 156, 160], ["3ABC", "PROTEIN", 18, 22], ["3A", "PROTEIN", 94, 96], ["3C pro domain", "PROTEIN", 105, 118], ["MAVS", "PROTEIN", 156, 160], ["Precursor protein 3ABC", "TEST", 0, 22], ["a stable polyprotein processing", "PROBLEM", 26, 57], ["the 3C pro domain", "TREATMENT", 101, 118], ["the cleavage", "TREATMENT", 123, 135], ["MAVS", "PROBLEM", 156, 160], ["stable", "OBSERVATION_MODIFIER", 28, 34], ["polyprotein", "OBSERVATION", 35, 46]]], ["The transmembrane domain of protein 3A ascertains mitochondrial localization while the 3C pro catalytic site performs the actual proteolytic cleavage of MAVS.", [["transmembrane", "ANATOMY", 4, 17], ["mitochondrial", "ANATOMY", 50, 63], ["protein 3A", "GENE_OR_GENE_PRODUCT", 28, 38], ["mitochondrial", "CELLULAR_COMPONENT", 50, 63], ["MAVS", "GENE_OR_GENE_PRODUCT", 153, 157], ["transmembrane domain", "PROTEIN", 4, 24], ["protein 3A", "PROTEIN", 28, 38], ["3C pro catalytic site", "PROTEIN", 87, 108], ["MAVS", "PROTEIN", 153, 157], ["mitochondrial localization", "TEST", 50, 76], ["the 3C pro catalytic site", "TREATMENT", 83, 108]]], ["Mere 3C pro , lacking the 3A domain, is incapable to perform this proteolysis.", [["Mere 3C pro", "PROTEIN", 0, 11], ["3A domain", "PROTEIN", 26, 35], ["this proteolysis", "PROBLEM", 61, 77]]], ["50 In addition, it has been demonstrated that protein 2B suppressed both MAVS functioning and the kinase activities of TBK1 and IKK\u03b5, thus synergistically suppressing RIG-I/MDA-5 signaling, although the exact mechanism still remains to be elucidated.", [["protein 2B", "GENE_OR_GENE_PRODUCT", 46, 56], ["MAVS", "GENE_OR_GENE_PRODUCT", 73, 77], ["TBK1", "GENE_OR_GENE_PRODUCT", 119, 123], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 128, 132], ["RIG-I", "GENE_OR_GENE_PRODUCT", 167, 172], ["MDA-5", "GENE_OR_GENE_PRODUCT", 173, 178], ["protein 2B", "PROTEIN", 46, 56], ["MAVS", "PROTEIN", 73, 77], ["TBK1", "PROTEIN", 119, 123], ["IKK\u03b5", "PROTEIN", 128, 132], ["MDA", "PROTEIN", 173, 176], ["protein 2B", "PROBLEM", 46, 56], ["the kinase activities", "TEST", 94, 115], ["TBK1", "TEST", 119, 123], ["IKK\u03b5", "TEST", 128, 132], ["protein 2B", "OBSERVATION", 46, 56]]], ["72 Toll-like receptor 3 (TLR3) provides an additional recognition mechanism for dsRNA.", [["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 3, 23], ["TLR3", "GENE_OR_GENE_PRODUCT", 25, 29], ["Toll-like receptor 3", "PROTEIN", 3, 23], ["TLR3", "PROTEIN", 25, 29], ["dsRNA", "PROBLEM", 80, 85]]], ["Activation also results in IRF-3 phosphorylation and induction of IFN\u03b2 transcription, but unlike RIG-I and MDA-5, the downstream action of TLR3 is mediated through TRIF (Toll/IL-1 receptor domain-containing adaptor inducing IFN\u03b2), which activates the TBK1 and IKK\u03b5 kinases.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 27, 32], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 66, 70], ["RIG-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["MDA-5", "GENE_OR_GENE_PRODUCT", 107, 112], ["TLR3", "GENE_OR_GENE_PRODUCT", 139, 143], ["TRIF", "GENE_OR_GENE_PRODUCT", 164, 168], ["Toll/IL-1 receptor domain-containing adaptor inducing IFN\u03b2", "GENE_OR_GENE_PRODUCT", 170, 228], ["TBK1", "GENE_OR_GENE_PRODUCT", 251, 255], ["IKK\u03b5 kinases", "GENE_OR_GENE_PRODUCT", 260, 272], ["IRF-3", "PROTEIN", 27, 32], ["IFN\u03b2", "PROTEIN", 66, 70], ["MDA-5", "PROTEIN", 107, 112], ["TLR3", "PROTEIN", 139, 143], ["TRIF", "PROTEIN", 164, 168], ["Toll/IL-1 receptor domain", "PROTEIN", 170, 195], ["IFN\u03b2", "PROTEIN", 224, 228], ["TBK1", "PROTEIN", 251, 255], ["IKK\u03b5 kinases", "PROTEIN", 260, 272], ["IRF", "TEST", 27, 30], ["IFN\u03b2 transcription", "TREATMENT", 66, 84], ["MDA", "TEST", 107, 110], ["TRIF (Toll/IL-1 receptor domain", "TREATMENT", 164, 195], ["the TBK1", "TEST", 247, 255]]], ["A recent study reported the proteolytic cleavage of TRIF by the 3CD precursor.", [["TRIF", "GENE_OR_GENE_PRODUCT", 52, 56], ["TRIF", "PROTEIN", 52, 56], ["3CD precursor", "PROTEIN", 64, 77], ["A recent study", "TEST", 0, 14], ["the proteolytic cleavage of TRIF", "TREATMENT", 24, 56]]], ["73 In analogy with the specificity of 3ABC pro -induced cleavage of MAVS, 3C pro without the 3D domain is not capable of performing this cleavage.", [["3ABC", "SIMPLE_CHEMICAL", 38, 42], ["MAVS", "GENE_OR_GENE_PRODUCT", 68, 72], ["3ABC pro", "PROTEIN", 38, 46], ["MAVS", "PROTEIN", 68, 72], ["3C pro", "PROTEIN", 74, 80], ["3D domain", "PROTEIN", 93, 102], ["3ABC pro", "TREATMENT", 38, 46], ["MAVS", "PROBLEM", 68, 72], ["3C pro", "TREATMENT", 74, 80], ["this cleavage", "TREATMENT", 132, 145]]], ["This suggests that the 3D pol sequence is required to modify the substrate specificity without requiring the catalytic polymerase activity.", [["3D pol sequence", "DNA", 23, 38], ["catalytic polymerase", "PROTEIN", 109, 129], ["the 3D pol sequence", "TEST", 19, 38]]], ["In addition, proteolytic cleavage of TRIF cannot be performed by the 3ABC intermediate.", [["TRIF", "GENE_OR_GENE_PRODUCT", 37, 41], ["TRIF", "PROTEIN", 37, 41], ["proteolytic cleavage of TRIF", "TREATMENT", 13, 41]]], ["73 Cleavage of TRIF and MAVS has been reported for other picornaviruses as well, for example, coxsackievirus B3 (MAVS and TRIF) 74 and enterovirus 71 (TRIF).", [["TRIF", "GENE_OR_GENE_PRODUCT", 15, 19], ["MAVS", "GENE_OR_GENE_PRODUCT", 24, 28], ["coxsackievirus B3", "ORGANISM", 94, 111], ["MAVS", "GENE_OR_GENE_PRODUCT", 113, 117], ["TRIF) 74", "GENE_OR_GENE_PRODUCT", 122, 130], ["enterovirus 71", "ORGANISM", 135, 149], ["TRIF", "GENE_OR_GENE_PRODUCT", 151, 155], ["TRIF", "PROTEIN", 15, 19], ["MAVS", "PROTEIN", 24, 28], ["coxsackievirus B3 (MAVS and TRIF) 74", "PROTEIN", 94, 130], ["enterovirus 71", "PROTEIN", 135, 149], ["TRIF", "PROTEIN", 151, 155], ["coxsackievirus B3", "SPECIES", 94, 111], ["TRIF", "TREATMENT", 15, 19], ["MAVS", "TREATMENT", 24, 28], ["other picornaviruses", "PROBLEM", 51, 71], ["TRIF", "TEST", 122, 126], ["enterovirus", "PROBLEM", 135, 146]]], ["75 Unlike for HAV, 3C pro of both viruses appeared to be sufficient for proteolysis.", [["HAV", "ORGANISM", 14, 17], ["HAV", "SPECIES", 14, 17], ["HAV", "PROBLEM", 14, 17], ["both viruses", "PROBLEM", 29, 41], ["proteolysis", "PROBLEM", 72, 83], ["viruses", "OBSERVATION", 34, 41], ["proteolysis", "OBSERVATION", 72, 83]]], ["Interestingly, both MAVS and TRIF are also cleaved by the HCV NS3/4A protease.", [["MAVS", "GENE_OR_GENE_PRODUCT", 20, 24], ["TRIF", "GENE_OR_GENE_PRODUCT", 29, 33], ["HCV", "ORGANISM", 58, 61], ["NS3/4A protease", "GENE_OR_GENE_PRODUCT", 62, 77], ["MAVS", "PROTEIN", 20, 24], ["TRIF", "PROTEIN", 29, 33], ["HCV NS3/4A protease", "PROTEIN", 58, 77], ["HCV", "SPECIES", 58, 61], ["TRIF", "TREATMENT", 29, 33], ["the HCV NS3/4A protease", "TREATMENT", 54, 77], ["MAVS", "OBSERVATION", 20, 24]]], ["Despite the fact that the HAV and HCV proteases differ in cleavage specificity and are phylogenetically unrelated, they target the same pair of adaptor proteins, which may be considered a remarkable example of convergent evolution.", [["HAV", "ORGANISM", 26, 29], ["HCV", "ORGANISM", 34, 37], ["HAV and HCV proteases", "PROTEIN", 26, 47], ["adaptor proteins", "PROTEIN", 144, 160], ["HAV", "SPECIES", 26, 29], ["HCV", "SPECIES", 34, 37], ["the HAV and HCV proteases", "PROBLEM", 22, 47]]], ["73B.", [["73B", "PROTEIN", 0, 3]]], ["Coding BiasesA second immune evasion strategy employed by HAV can be found in its codon bias or nonuniform usage of codons during translation.", [["HAV", "ORGANISM", 58, 61], ["HAV", "SPECIES", 58, 61], ["Coding BiasesA second immune evasion strategy", "TREATMENT", 0, 45]]], ["76 Due to the lack of mechanisms to induce cellular shut off, HAV has to compete with host mRNA for translation (as described above).", [["cellular", "ANATOMY", 43, 51], ["cellular", "CELL", 43, 51], ["HAV", "ORGANISM", 62, 65], ["host mRNA", "RNA", 86, 95], ["HAV", "SPECIES", 62, 65]]], ["Within this context, HAV has strategically adopted a codon bias toward rare codons, resulting in a highly deoptimized coding usage.", [["HAV", "ORGANISM", 21, 24], ["HAV", "SPECIES", 21, 24], ["rare codons", "PROBLEM", 71, 82]]], ["77, 78 This phenomenon contributes considerably to the low replication efficiency of HAV in several ways and seems to serve multiple purposes: first, the deoptimized codon use may reflect a strategy by which rare tRNAs are preferred over abundant tRNAs thereby avoiding competition with cellular tRNAs in the absence of an adequate host cell translation shut off.", [["cellular", "ANATOMY", 287, 295], ["cell", "ANATOMY", 337, 341], ["HAV", "DISEASE", 85, 88], ["HAV", "ORGANISM", 85, 88], ["cellular", "CELL", 287, 295], ["cell", "CELL", 337, 341], ["cellular tRNAs", "RNA", 287, 301], ["HAV", "SPECIES", 85, 88], ["This phenomenon", "PROBLEM", 7, 22], ["the deoptimized codon", "TREATMENT", 150, 171], ["rare tRNAs", "PROBLEM", 208, 218], ["cellular tRNAs", "TREATMENT", 287, 301], ["low replication", "OBSERVATION_MODIFIER", 55, 70], ["cellular tRNAs", "OBSERVATION", 287, 301], ["adequate", "OBSERVATION_MODIFIER", 323, 331], ["host cell translation", "OBSERVATION", 332, 353]]], ["77 Second, due to a decreased translation and replication rate, the virus is capable of keeping the cellular amount of dsRNA to a minimum, thus escaping the host cell antiviral response.", [["cellular", "ANATOMY", 100, 108], ["cell", "ANATOMY", 162, 166], ["cellular", "CELL", 100, 108], ["host cell", "CELL", 157, 166], ["a decreased translation", "PROBLEM", 18, 41], ["replication rate", "TREATMENT", 46, 62], ["the virus", "PROBLEM", 64, 73], ["decreased", "OBSERVATION", 20, 29], ["amount", "OBSERVATION_MODIFIER", 109, 115], ["host cell antiviral response", "OBSERVATION", 157, 185]]], ["78 In addition, CpG-containing codons are particularly suppressed in the HAV coding sequence.", [["CpG", "CHEMICAL", 16, 19], ["CpG-containing codons", "DNA", 16, 37], ["HAV coding sequence", "DNA", 73, 92], ["HAV", "SPECIES", 73, 76], ["CpG-containing codons", "TREATMENT", 16, 37]]], ["79, 80 This particular codon deoptimization is proposed to be associated with the recognition of unmethylated CpG by the innate immunity as a pathogen marker, contrary to the methylated CpG pairs of the host.", [["CpG", "CHEMICAL", 110, 113], ["CpG", "CHEMICAL", 186, 189], ["unmethylated CpG", "DNA", 97, 113], ["methylated CpG pairs", "DNA", 175, 195], ["This particular codon deoptimization", "TREATMENT", 7, 43], ["unmethylated CpG", "TREATMENT", 97, 113], ["a pathogen marker", "TREATMENT", 140, 157]]], ["Also in this way, HAV can evade the attention of the immune system.", [["immune system", "ANATOMY", 53, 66], ["HAV", "ORGANISM", 18, 21], ["immune system", "ANATOMICAL_SYSTEM", 53, 66], ["HAV", "SPECIES", 18, 21]]], ["Third, the use of rare codons, usually grouped in clusters, is important for translation kinetics as such cluster may lead to a transient translation stop, a phenomenon known as ribosome stalling.", [["ribosome", "ANATOMY", 178, 186], ["ribosome", "CELLULAR_COMPONENT", 178, 186], ["rare codons", "PROBLEM", 18, 29], ["translation kinetics", "TREATMENT", 77, 97], ["a transient translation", "PROBLEM", 126, 149], ["a phenomenon", "PROBLEM", 156, 168], ["rare", "OBSERVATION_MODIFIER", 18, 22], ["codons", "OBSERVATION", 23, 29], ["ribosome stalling", "OBSERVATION", 178, 195]]], ["81 It has been suggested that this transient stop may be an important prerequisite for proper folding of HAV structural proteins thereby contributing to the low antigenic variability and extreme environmental stability of HAV.", [["HAV", "DISEASE", 222, 225], ["HAV", "ORGANISM", 105, 108], ["HAV", "ORGANISM", 222, 225], ["HAV structural proteins", "PROTEIN", 105, 128], ["HAV", "SPECIES", 105, 108], ["HAV", "SPECIES", 222, 225], ["HAV structural proteins", "PROBLEM", 105, 128], ["the low antigenic variability", "PROBLEM", 153, 182], ["HAV", "PROBLEM", 222, 225], ["environmental stability", "OBSERVATION", 195, 218]]], ["77, 78, 82 Consequently, when HAV is adapted to replicate in vitro under circumstances of chemically induced cellular shut off, the resulting strains (with a \"re-deoptimized\" coding sequence) display reduced environmental stability.", [["cellular", "ANATOMY", 109, 117], ["HAV", "ORGANISM", 30, 33], ["cellular", "CELL", 109, 117], ["re-deoptimized\" coding sequence", "DNA", 159, 190], ["HAV", "SPECIES", 30, 33], ["the resulting strains", "PROBLEM", 128, 149], ["reduced environmental stability", "PROBLEM", 200, 231], ["reduced", "OBSERVATION_MODIFIER", 200, 207], ["environmental stability", "OBSERVATION", 208, 231]]], ["83 Given the preference of HAV for reduced RNA replication and translation levels, it is now comprehensible why HAV would employ such inefficient type III IRES 84, 85 : a very efficient IRES would not be compatible with escaping innate immunity and with the many ribosome stalls during translation.", [["ribosome", "ANATOMY", 263, 271], ["HAV", "ORGANISM", 27, 30], ["HAV", "ORGANISM", 112, 115], ["IRES", "DNA", 186, 190], ["HAV", "SPECIES", 27, 30], ["HAV", "SPECIES", 112, 115], ["reduced RNA replication", "TREATMENT", 35, 58], ["translation levels", "TEST", 63, 81], ["a very efficient IRES", "PROBLEM", 169, 190], ["ribosome stalls", "OBSERVATION", 263, 278]]], ["83 In conclusion, the coding biases found in the HAV genome may result from evolutionary pressures toward (i) environmental stability (and thus controlled translation kinetics to obtain a resilient viral particle) and (ii) evading the host immune system.", [["HAV", "ORGANISM", 49, 52], ["HAV genome", "DNA", 49, 59], ["HAV", "SPECIES", 49, 52], ["the coding biases", "PROBLEM", 18, 35], ["the HAV genome", "PROBLEM", 45, 59], ["evolutionary pressures", "TEST", 76, 98], ["a resilient viral particle", "TREATMENT", 186, 212]]], ["79 Additional insights into the mechanisms at action would prove very valuable with regards to our understanding of virus evolution and virus-host interplay.C. Modulation of Regulatory T-Cell ActivityIn addition to manipulation of the innate immunity, HAV also modifies the adaptive immunity through its receptor binding.", [["Cell", "ANATOMY", 187, 191], ["HAV", "ORGANISM", 252, 255], ["HAV", "SPECIES", 252, 255], ["virus evolution", "PROBLEM", 116, 131], ["the innate immunity", "TREATMENT", 231, 250], ["the adaptive immunity", "TREATMENT", 270, 291], ["Regulatory T-Cell Activity", "OBSERVATION", 174, 200]]], ["HAVcr-1 is a phosphatidylserine (PtdSer) receptor and functions as a potent T-cell costimulatory molecule that regulates activation of and tolerance induction (thus suppressing autoimmune responses) in T cells.", [["T-cell", "ANATOMY", 76, 82], ["T cells", "ANATOMY", 202, 209], ["phosphatidylserine", "CHEMICAL", 13, 31], ["phosphatidylserine", "CHEMICAL", 13, 31], ["Ser", "CHEMICAL", 36, 39], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 0, 7], ["phosphatidylserine", "SIMPLE_CHEMICAL", 13, 31], ["PtdSer) receptor", "GENE_OR_GENE_PRODUCT", 33, 49], ["T-cell", "CELL", 76, 82], ["T cells", "CELL", 202, 209], ["HAVcr", "PROTEIN", 0, 5], ["phosphatidylserine (PtdSer) receptor", "PROTEIN", 13, 49], ["T-cell costimulatory molecule", "PROTEIN", 76, 105], ["T cells", "CELL_TYPE", 202, 209], ["HAVcr", "TEST", 0, 5], ["a phosphatidylserine (PtdSer) receptor", "TREATMENT", 11, 49], ["a potent T-cell costimulatory molecule", "TREATMENT", 67, 105], ["tolerance induction", "TREATMENT", 139, 158], ["suppressing autoimmune responses", "PROBLEM", 165, 197]]], ["24 A recent study reported that HAVcr-1 is constitutively expressed on regulatory T (Treg) cells.", [["regulatory T (Treg) cells", "ANATOMY", 71, 96], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 32, 39], ["regulatory T (Treg) cells", "CELL", 71, 96], ["HAVcr", "PROTEIN", 32, 37], ["regulatory T (Treg) cells", "CELL_TYPE", 71, 96], ["A recent study", "TEST", 3, 17], ["HAVcr", "TEST", 32, 37]]], ["86 The function of these specialized T cells is to limit the magnitude of the immune response to diverse pathogens in such way avoiding a hyperactive immune response and subsequent collateral (tissue) damage.", [["T cells", "ANATOMY", 37, 44], ["collateral", "ANATOMY", 181, 191], ["tissue", "ANATOMY", 193, 199], ["T cells", "CELL", 37, 44], ["tissue", "TISSUE", 193, 199], ["T cells", "CELL_TYPE", 37, 44], ["these specialized T cells", "PROBLEM", 19, 44], ["diverse pathogens", "PROBLEM", 97, 114], ["a hyperactive immune response", "PROBLEM", 136, 165], ["subsequent collateral (tissue) damage", "PROBLEM", 170, 207], ["hyperactive immune response", "OBSERVATION", 138, 165], ["collateral", "OBSERVATION_MODIFIER", 181, 191]]], ["87 Several microorganisms activate Treg in order to limit inflammation and tissue injury, as is the case for chronic HBV and HCV infections.", [["Treg", "ANATOMY", 35, 39], ["tissue", "ANATOMY", 75, 81], ["inflammation", "DISEASE", 58, 70], ["tissue injury", "DISEASE", 75, 88], ["chronic HBV and HCV infections", "DISEASE", 109, 139], ["Treg", "CELL", 35, 39], ["tissue", "TISSUE", 75, 81], ["HBV", "ORGANISM", 117, 120], ["HCV", "ORGANISM", 125, 128], ["Treg", "CELL_TYPE", 35, 39], ["HBV", "SPECIES", 117, 120], ["HCV", "SPECIES", 125, 128], ["Several microorganisms activate", "PROBLEM", 3, 34], ["Treg", "TREATMENT", 35, 39], ["inflammation", "PROBLEM", 58, 70], ["tissue injury", "PROBLEM", 75, 88], ["chronic HBV", "PROBLEM", 109, 120], ["HCV infections", "PROBLEM", 125, 139], ["inflammation", "OBSERVATION", 58, 70], ["tissue", "ANATOMY", 75, 81], ["injury", "OBSERVATION", 82, 88], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["HBV", "OBSERVATION", 117, 120], ["HCV", "OBSERVATION", 125, 128]]], ["87 Conversely, binding of HAV to its receptor inhibits Treg cell functioning.", [["Treg cell", "ANATOMY", 55, 64], ["HAV", "ORGANISM", 26, 29], ["Treg cell", "CELL", 55, 64], ["HAV", "SPECIES", 26, 29], ["Treg cell functioning", "TREATMENT", 55, 76], ["cell functioning", "OBSERVATION", 60, 76]]], ["86 In this way, the host is overwhelmed by anti-self-responses since Treg cells normally suppress autoimmune reactions, allowing HAV to escape the attention of the immune system.", [["Treg cells", "ANATOMY", 69, 79], ["immune system", "ANATOMY", 164, 177], ["autoimmune reactions", "DISEASE", 98, 118], ["Treg cells", "CELL", 69, 79], ["HAV", "ORGANISM", 129, 132], ["immune system", "ANATOMICAL_SYSTEM", 164, 177], ["Treg cells", "CELL_TYPE", 69, 79], ["HAV", "SPECIES", 129, 132], ["Treg cells", "TREATMENT", 69, 79], ["autoimmune reactions", "PROBLEM", 98, 118]]], ["In addition, HAV inhibits the production of transforming growth factor \u03b2 by Treg cells, thereby blocking T-effector-mediated anti-HAV responses.", [["Treg cells", "ANATOMY", 76, 86], ["HAV", "ORGANISM", 13, 16], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 44, 72], ["Treg cells", "CELL", 76, 86], ["T-effector", "GENE_OR_GENE_PRODUCT", 105, 115], ["transforming growth factor \u03b2", "PROTEIN", 44, 72], ["Treg cells", "CELL_TYPE", 76, 86], ["HAV", "SPECIES", 13, 16], ["transforming growth factor", "PROBLEM", 44, 70]]], ["Complementary, HAV stimulates IL-22 production that limits immune-mediated liver damage.", [["liver", "ANATOMY", 75, 80], ["liver damage", "DISEASE", 75, 87], ["HAV", "ORGANISM", 15, 18], ["IL-22", "GENE_OR_GENE_PRODUCT", 30, 35], ["liver", "ORGAN", 75, 80], ["HAV", "SPECIES", 15, 18], ["immune-mediated liver damage", "PROBLEM", 59, 87], ["liver", "ANATOMY", 75, 80], ["damage", "OBSERVATION", 81, 87]]], ["86 Taken together, by inhibiting Treg function, HAV creates an environment that favors viral replication and establishment of infection.", [["Treg", "ANATOMY", 33, 37], ["infection", "DISEASE", 126, 135], ["Treg", "CELL", 33, 37], ["HAV", "ORGANISM", 48, 51], ["HAV", "SPECIES", 48, 51], ["viral replication", "TREATMENT", 87, 104], ["infection", "PROBLEM", 126, 135], ["viral replication", "OBSERVATION", 87, 104], ["infection", "OBSERVATION", 126, 135]]], ["These findings may also provide an explanation why HAV may elicit autoimmune hepatitis and extrahepatic manifestations including autoimmune hemolytic anemia, even though these complications are rare.", [["extrahepatic", "ANATOMY", 91, 103], ["HAV", "DISEASE", 51, 54], ["autoimmune hepatitis", "DISEASE", 66, 86], ["autoimmune hemolytic anemia", "DISEASE", 129, 156], ["HAV", "ORGANISM", 51, 54], ["extrahepatic", "ORGAN", 91, 103], ["HAV", "SPECIES", 51, 54], ["autoimmune hepatitis", "PROBLEM", 66, 86], ["extrahepatic manifestations", "PROBLEM", 91, 118], ["autoimmune hemolytic anemia", "PROBLEM", 129, 156], ["these complications", "PROBLEM", 170, 189], ["autoimmune", "OBSERVATION_MODIFIER", 66, 76], ["hepatitis", "OBSERVATION", 77, 86], ["extrahepatic", "ANATOMY", 91, 103], ["autoimmune", "OBSERVATION_MODIFIER", 129, 139], ["hemolytic", "OBSERVATION_MODIFIER", 140, 149]]], ["88A LINK BETWEEN HEPATITIS A AND ATOPYThe hygiene hypothesis states that the uprising of atopic disease, including asthma, allergic rhinitis, and atopic dermatitis in industrialized countries is due to the increased hygiene.", [["atopic disease", "DISEASE", 89, 103], ["asthma", "DISEASE", 115, 121], ["allergic rhinitis", "DISEASE", 123, 140], ["atopic dermatitis", "DISEASE", 146, 163], ["atopic disease", "PROBLEM", 89, 103], ["asthma", "PROBLEM", 115, 121], ["allergic rhinitis", "PROBLEM", 123, 140], ["atopic dermatitis", "PROBLEM", 146, 163], ["the increased hygiene", "PROBLEM", 202, 223], ["HEPATITIS", "OBSERVATION", 17, 26], ["atopic disease", "OBSERVATION", 89, 103], ["asthma", "OBSERVATION", 115, 121], ["allergic rhinitis", "OBSERVATION", 123, 140], ["atopic dermatitis", "OBSERVATION", 146, 163], ["increased", "OBSERVATION_MODIFIER", 206, 215], ["hygiene", "OBSERVATION", 216, 223]]], ["89 As HAV serostatus can be regarded as a hygiene marker, its correlation with atopy was studied.", [["HAV", "ORGANISM", 6, 9], ["HAV", "SPECIES", 6, 9]]], ["It has been reported by several groups that HAV infection is negatively correlated with hay fever, asthma, and other atopic diseases.", [["HAV infection", "DISEASE", 44, 57], ["hay fever", "DISEASE", 88, 97], ["asthma", "DISEASE", 99, 105], ["atopic diseases", "DISEASE", 117, 132], ["HAV", "ORGANISM", 44, 47], ["HAV", "SPECIES", 44, 47], ["HAV infection", "PROBLEM", 44, 57], ["fever", "PROBLEM", 92, 97], ["asthma", "PROBLEM", 99, 105], ["other atopic diseases", "PROBLEM", 111, 132], ["infection", "OBSERVATION", 48, 57], ["asthma", "OBSERVATION", 99, 105], ["atopic diseases", "OBSERVATION", 117, 132]]], ["89, 90 However, other studies were unable to replicate such effect.", [["other studies", "TEST", 16, 29]]], ["91, 92 In addition, McIntire et al. described that previous HAV infection may protect against atopy in individuals carrying a six amino acid insertion (designated 157insMTTTVP) in the gene encoding HAVcr-1 (which is present in 46-64% of the population).", [["HAV infection", "DISEASE", 60, 73], ["atopy", "DISEASE", 94, 99], ["amino acid", "CHEMICAL", 130, 140], ["amino acid", "CHEMICAL", 130, 140], ["HAV", "ORGANISM", 60, 63], ["amino acid", "AMINO_ACID", 130, 140], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 198, 205], ["HAVcr", "PROTEIN", 198, 203], ["HAV", "SPECIES", 60, 63], ["previous HAV infection", "PROBLEM", 51, 73], ["a six amino acid insertion", "TREATMENT", 124, 150], ["infection", "OBSERVATION", 64, 73]]], ["94, 95 In addition, 157insMTTTVP appears to increase the susceptibility to severe HAV infection.", [["MTTTVP", "CHEMICAL", 26, 32], ["HAV infection", "DISEASE", 82, 95], ["HAV", "ORGANISM", 82, 85], ["157insMTTTVP", "PROTEIN", 20, 32], ["HAV", "SPECIES", 82, 85], ["severe HAV infection", "PROBLEM", 75, 95], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["HAV", "OBSERVATION_MODIFIER", 82, 85], ["infection", "OBSERVATION", 86, 95]]], ["96 A double mechanistic basis was suggested to (partially) explain this observation: (i) HAV binds more efficiently to the 157insMTTTVPcarrying HAVcr-1, resulting in a more effective receptor and (ii) natural killer T cells expressing this long form of HAVcr-1 were more cytolytic against HAV-infected hepatocytes.", [["natural killer T cells", "ANATOMY", 201, 223], ["hepatocytes", "ANATOMY", 302, 313], ["HAV-infected", "DISEASE", 289, 301], ["HAV", "ORGANISM", 89, 92], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 144, 151], ["natural killer T cells", "CELL", 201, 223], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 253, 260], ["HAV", "ORGANISM", 289, 292], ["hepatocytes", "CELL", 302, 313], ["157insMTTTVPcarrying HAVcr-1", "DNA", 123, 151], ["natural killer T cells", "CELL_TYPE", 201, 223], ["HAVcr", "PROTEIN", 253, 258], ["HAV-infected hepatocytes", "CELL_TYPE", 289, 313], ["HAV", "SPECIES", 89, 92], ["HAV", "SPECIES", 289, 292], ["HAV binds", "PROBLEM", 89, 98], ["natural killer T cells", "TREATMENT", 201, 223], ["HAVcr", "TEST", 253, 258], ["HAV", "PROBLEM", 289, 292], ["infected hepatocytes", "PROBLEM", 293, 313], ["infected", "OBSERVATION", 293, 301], ["hepatocytes", "ANATOMY", 302, 313]]], ["96 Thus, the 157insMTTTVP may protect from atopy, but predispose to severe HAV infections.A LINK BETWEEN HEPATITIS A AND ATOPYIn conclusion, a possible relationship between a previous HAV infection, protection from atopic disease and HAVcr-1 polymorphisms is still subject of debate, but represents an interesting area of research.", [["atopy", "DISEASE", 43, 48], ["HAV infections", "DISEASE", 75, 89], ["HAV infection", "DISEASE", 184, 197], ["atopic disease", "DISEASE", 215, 229], ["HAV", "ORGANISM", 75, 78], ["HAV", "ORGANISM", 184, 187], ["HAVcr-1", "GENE_OR_GENE_PRODUCT", 234, 241], ["157insMTTTVP", "PROTEIN", 13, 25], ["HAV", "SPECIES", 75, 78], ["HAV", "SPECIES", 184, 187], ["atopy", "PROBLEM", 43, 48], ["severe HAV infections", "PROBLEM", 68, 89], ["a previous HAV infection", "PROBLEM", 173, 197], ["atopic disease", "PROBLEM", 215, 229], ["HAVcr", "TEST", 234, 239], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["HAV", "OBSERVATION_MODIFIER", 75, 78], ["infections", "OBSERVATION", 79, 89], ["HEPATITIS", "OBSERVATION", 105, 114], ["HAV", "OBSERVATION_MODIFIER", 184, 187], ["infection", "OBSERVATION", 188, 197], ["atopic disease", "OBSERVATION", 215, 229]]], ["If HAV truly has a protecting effect, several questions should be addressed: does infection need to occur during childhood?", [["infection", "DISEASE", 82, 91], ["HAV", "ORGANISM", 3, 6], ["HAV", "SPECIES", 3, 6], ["infection", "PROBLEM", 82, 91]]], ["Has vaccination a similar effect?", [["vaccination", "TREATMENT", 4, 15]]], ["Can this relationship be used in finding a therapeutic target for atopy?", [["atopy", "DISEASE", 66, 71], ["atopy", "PROBLEM", 66, 71]]], ["Insights into this relationship may prove crucial in combating the rise of atopic disease in industrialized countries.CELL CULTUREUnlike for most picornaviruses, culturing wild-type (wt) HAV in cell culture has proven to be quite a challenge as these strains replicate only very marginally in vitro (e.g., reference 97).", [["cell culture", "ANATOMY", 194, 206], ["atopic disease", "DISEASE", 75, 89], ["wild-type (wt) HAV", "ORGANISM", 172, 190], ["cell", "CELL", 194, 198], ["HAV", "SPECIES", 187, 190], ["atopic disease", "PROBLEM", 75, 89], ["CELL CULTUREUnlike", "TEST", 118, 136], ["most picornaviruses", "PROBLEM", 141, 160], ["culturing", "TEST", 162, 171], ["HAV in cell culture", "TEST", 187, 206], ["these strains", "PROBLEM", 245, 258], ["atopic disease", "OBSERVATION", 75, 89]]], ["HAV can be adapted to growth in cell culture through serial passaging; a process that introduces cell culture adapting mutations stepwise into the viral genome.", [["cell culture", "ANATOMY", 32, 44], ["cell culture", "ANATOMY", 97, 109], ["HAV", "ORGANISM", 0, 3], ["cell culture", "CELL", 32, 44], ["cell", "CELL", 97, 101], ["viral genome", "DNA", 147, 159], ["HAV", "SPECIES", 0, 3], ["cell culture", "TEST", 32, 44], ["serial passaging", "TREATMENT", 53, 69], ["cell culture", "TREATMENT", 97, 109], ["viral genome", "OBSERVATION", 147, 159]]], ["Such mutations have been found in the P2 region (especially in 2B and 2C) 98, 99 and in the 5 -UTR, 100, 101 but also in other parts of the genome.", [["P2 region", "DNA", 38, 47], ["5 -UTR", "DNA", 92, 98], ["Such mutations", "PROBLEM", 0, 14], ["P2", "ANATOMY", 38, 40], ["region", "ANATOMY_MODIFIER", 41, 47], ["genome", "OBSERVATION", 140, 146]]], ["98 Intriguingly, these cell culture adapting mutations result in HAV strains that are highly attenuated in vivo (e.g., references 102, 103).", [["cell", "ANATOMY", 23, 27], ["cell", "CELL", 23, 27], ["HAV", "ORGANISM", 65, 68], ["HAV", "SPECIES", 65, 68], ["these cell culture", "TEST", 17, 35], ["HAV strains", "PROBLEM", 65, 76]]], ["A major advance in culturing HAV was the selection of a Huh7 cell line (designated Huh7-A-I) that allows genetically stable growth of wt HAV without the accumulation of cell culture adapting mutations.", [["Huh7 cell line", "ANATOMY", 56, 70], ["Huh7-A-I", "ANATOMY", 83, 91], ["cell", "ANATOMY", 169, 173], ["HAV", "ORGANISM", 29, 32], ["Huh7 cell line", "CELL", 56, 70], ["Huh7-A-I", "CELL", 83, 91], ["HAV", "ORGANISM", 137, 140], ["cell", "CELL", 169, 173], ["Huh7 cell line", "CELL_LINE", 56, 70], ["Huh7", "CELL_LINE", 83, 87], ["I", "CELL_LINE", 90, 91], ["HAV", "SPECIES", 29, 32], ["HAV", "SPECIES", 137, 140], ["culturing HAV", "PROBLEM", 19, 32], ["a Huh7 cell line", "TREATMENT", 54, 70], ["Huh7", "TEST", 83, 87], ["wt HAV", "PROBLEM", 134, 140], ["cell culture", "TEST", 169, 181], ["Huh7 cell line", "OBSERVATION", 56, 70], ["stable", "OBSERVATION_MODIFIER", 117, 123], ["growth", "OBSERVATION_MODIFIER", 124, 130], ["cell", "OBSERVATION", 169, 173]]], ["104 Although wt HAV does not induce a cytopathic effect (CPE) in cell culture, cytopathic strains may arise during prolonged serial passaging.", [["cell culture", "ANATOMY", 65, 77], ["HAV", "ORGANISM", 16, 19], ["cell culture", "CELL", 65, 77], ["HAV", "SPECIES", 16, 19], ["wt HAV", "PROBLEM", 13, 19], ["a cytopathic effect (CPE)", "PROBLEM", 36, 61], ["cell culture", "TEST", 65, 77], ["cytopathic strains", "PROBLEM", 79, 97], ["prolonged serial passaging", "TREATMENT", 115, 141], ["cytopathic", "OBSERVATION_MODIFIER", 38, 48]]], ["105 , 106 CPE appears to be cell type specific and is mostly found in monkey kidney cell lines like FRhK-4 and BS-C-1.", [["cell", "ANATOMY", 28, 32], ["kidney cell lines", "ANATOMY", 77, 94], ["FRhK-4", "ANATOMY", 100, 106], ["BS-C-1", "ANATOMY", 111, 117], ["cell", "CELL", 28, 32], ["monkey", "ORGANISM", 70, 76], ["kidney cell lines", "CELL", 77, 94], ["FRhK-4", "CELL", 100, 106], ["BS-C-1", "CELL", 111, 117], ["monkey kidney cell lines", "CELL_LINE", 70, 94], ["FRhK-4", "CELL_LINE", 100, 106], ["BS-C-1", "CELL_LINE", 111, 117], ["FRhK", "TEST", 100, 104], ["BS", "TEST", 111, 113], ["kidney", "ANATOMY", 77, 83], ["cell lines", "OBSERVATION", 84, 94]]], ["These selected virus strains induce apoptosis through ribosomal RNA degradation by RNase L 107, 108 and consequent caspase activation.", [["ribosomal", "ANATOMY", 54, 63], ["ribosomal", "CELLULAR_COMPONENT", 54, 63], ["RNase L 107", "GENE_OR_GENE_PRODUCT", 83, 94], ["caspase", "GENE_OR_GENE_PRODUCT", 115, 122], ["ribosomal RNA", "RNA", 54, 67], ["RNase L 107", "PROTEIN", 83, 94], ["caspase", "PROTEIN", 115, 122], ["These selected virus strains", "PROBLEM", 0, 28], ["apoptosis", "PROBLEM", 36, 45], ["ribosomal RNA degradation", "PROBLEM", 54, 79], ["RNase", "TEST", 83, 88], ["consequent caspase activation", "TREATMENT", 104, 133], ["ribosomal RNA", "OBSERVATION", 54, 67]]], ["109 Interestingly, it seems possible to induce CPE with cell culture adapted noncytopathic strains under specific conditions of lower temperature (<34 \u2022 C) and decreased cell density, both in FRhK-4 and human A549 cells.", [["cell", "ANATOMY", 56, 60], ["cell", "ANATOMY", 170, 174], ["FRhK-4", "ANATOMY", 192, 198], ["A549 cells", "ANATOMY", 209, 219], ["cell", "CELL", 56, 60], ["cell", "CELL", 170, 174], ["FRhK-4", "CELL", 192, 198], ["human", "ORGANISM", 203, 208], ["A549 cells", "CELL", 209, 219], ["FRhK-4", "CELL_LINE", 192, 198], ["human A549 cells", "CELL_LINE", 203, 219], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["CPE", "PROBLEM", 47, 50], ["cell culture", "TEST", 56, 68], ["noncytopathic strains", "PROBLEM", 77, 98], ["lower temperature", "TEST", 128, 145], ["decreased cell density", "PROBLEM", 160, 182], ["FRhK", "TEST", 192, 196], ["seems possible", "UNCERTAINTY", 22, 36], ["lower temperature", "OBSERVATION_MODIFIER", 128, 145], ["decreased cell density", "OBSERVATION", 160, 182], ["A549 cells", "OBSERVATION", 209, 219]]], ["110 Similarly, we observed CPE for the PA21 strain (genotype IIIa) in FRhK-4 cells under these conditions (unpublished results).THE NEED FOR ANTIVIRALS?Despite the availability of an efficient vaccine, an antiviral drug against HAV would be of great use.", [["FRhK-4 cells", "ANATOMY", 70, 82], ["HAV", "DISEASE", 228, 231], ["PA21", "GENE_OR_GENE_PRODUCT", 39, 43], ["FRhK-4 cells", "CELL", 70, 82], ["HAV", "ORGANISM", 228, 231], ["FRhK-4 cells", "CELL_LINE", 70, 82], ["HAV", "SPECIES", 228, 231], ["CPE", "PROBLEM", 27, 30], ["the PA21 strain (genotype IIIa", "PROBLEM", 35, 65], ["FRhK", "TEST", 70, 74], ["ANTIVIRALS", "TREATMENT", 141, 151], ["an efficient vaccine", "TREATMENT", 180, 200], ["an antiviral drug", "TREATMENT", 202, 219]]], ["First, since HAV growth in vitro is rather limited, the production of vaccines remains a painstaking process, which in part explains the high cost.", [["HAV", "ORGANISM", 13, 16], ["HAV", "SPECIES", 13, 16], ["HAV growth", "PROBLEM", 13, 23], ["vaccines", "TREATMENT", 70, 78], ["a painstaking process", "PROBLEM", 87, 108], ["growth", "OBSERVATION_MODIFIER", 17, 23], ["high cost", "OBSERVATION", 137, 146]]], ["15 This cost is particularly a problem in relatively poor regions with improved hygiene where infections occur at later age and consequently are more severe.", [["infections", "DISEASE", 94, 104], ["infections", "PROBLEM", 94, 104], ["relatively", "OBSERVATION_MODIFIER", 42, 52], ["poor", "OBSERVATION_MODIFIER", 53, 57], ["improved", "OBSERVATION_MODIFIER", 71, 79], ["hygiene", "OBSERVATION", 80, 87], ["infections", "OBSERVATION", 94, 104], ["more severe", "OBSERVATION_MODIFIER", 145, 156]]], ["4 Second, antivirals could shorten the period of illness and decrease symptoms and associated economic costs in infected unvaccinated patients.", [["illness", "DISEASE", 49, 56], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["antivirals", "TREATMENT", 10, 20], ["illness", "PROBLEM", 49, 56], ["decrease symptoms", "PROBLEM", 61, 78], ["economic", "OBSERVATION_MODIFIER", 94, 102], ["infected", "OBSERVATION_MODIFIER", 112, 120]]], ["Early treatment of these infected unvaccinated persons may also prevent severe cases of fulminant hepatitis.", [["fulminant hepatitis", "DISEASE", 88, 107], ["persons", "ORGANISM", 47, 54], ["persons", "SPECIES", 47, 54], ["Early treatment", "TREATMENT", 0, 15], ["these infected unvaccinated persons", "TREATMENT", 19, 54], ["fulminant hepatitis", "PROBLEM", 88, 107], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["fulminant", "OBSERVATION_MODIFIER", 88, 97], ["hepatitis", "OBSERVATION", 98, 107]]], ["Third, an antiviral could be a useful tool in rapidly containing epidemics.", [["an antiviral", "TREATMENT", 7, 19]]], ["Lastly, the potential emergence of vaccine-escape variants has been reported recently; 18 an anti-HAV drug could therefore be instrumental in halting the spread of such virus strains.", [["HAV", "SPECIES", 98, 101], ["vaccine", "TREATMENT", 35, 42], ["escape variants", "PROBLEM", 43, 58], ["an anti-HAV drug", "TREATMENT", 90, 106], ["such virus strains", "PROBLEM", 164, 182]]], ["In conclusion, there is certainly a need for antiviral drugs for hepatitis A, given that they are safe, efficacious, and preferably cheap.THE NEED FOR ANTIVIRALS?Research into HAV antiviral drug discovery was mostly performed during the late eighties and early nineties.", [["hepatitis A", "DISEASE", 65, 76], ["HAV", "ORGANISM", 176, 179], ["hepatitis A", "SPECIES", 65, 76], ["HAV", "SPECIES", 176, 179], ["antiviral drugs", "TREATMENT", 45, 60], ["hepatitis A", "PROBLEM", 65, 76], ["ANTIVIRALS", "TREATMENT", 151, 161], ["antiviral drug", "OBSERVATION", 180, 194]]], ["Afterwards, research efforts and funding waned due to the introduction of vaccines, 15 although some interesting work has been done on amantadine and 3C pro inhibitors in the last decade.", [["amantadine", "CHEMICAL", 135, 145], ["amantadine", "CHEMICAL", 135, 145], ["amantadine", "SIMPLE_CHEMICAL", 135, 145], ["the introduction of vaccines", "TREATMENT", 54, 82], ["amantadine", "TREATMENT", 135, 145], ["3C pro inhibitors", "TREATMENT", 150, 167]]], ["An overview of the most relevant inhibitors is presented here (also see Table I ).A. InterferonIn 1984, IFN\u03b2 was already demonstrated to efficiently inhibit the replication of HAV in human embryo fibroblasts.", [["embryo fibroblasts", "ANATOMY", 189, 207], ["InterferonIn 1984", "CHEMICAL", 85, 102], ["IFN\u03b2", "CHEMICAL", 104, 108], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 104, 108], ["HAV", "ORGANISM", 176, 179], ["human", "ORGANISM", 183, 188], ["embryo fibroblasts", "CELL", 189, 207], ["IFN\u03b2", "PROTEIN", 104, 108], ["human embryo fibroblasts", "CELL_TYPE", 183, 207], ["human", "SPECIES", 183, 188], ["HAV", "SPECIES", 176, 179], ["human", "SPECIES", 183, 188], ["HAV in human embryo fibroblasts", "PROBLEM", 176, 207], ["human embryo fibroblasts", "OBSERVATION", 183, 207]]], ["111 HAV-infected cells were completely cleared following five passages with 1000 IU/mL of IFN\u03b2.", [["cells", "ANATOMY", 17, 22], ["HAV-infected", "DISEASE", 4, 16], ["HAV", "ORGANISM", 4, 7], ["cells", "CELL", 17, 22], ["IFN", "PROTEIN", 90, 93], ["HAV", "SPECIES", 4, 7], ["infected cells", "PROBLEM", 8, 22], ["IFN", "TREATMENT", 90, 93], ["infected cells", "OBSERVATION", 8, 22]]], ["Later, another study reported an effective concentration 50 (EC 50 , minimal concentration required to reduce virus replication by 50%) of 90 IU/mL and a selectivity index (SI = 50% cytotoxic concentration (CC 50 )/EC 50 ) of more than 100 for IFN\u03b1-2a.", [["IFN\u03b1-2a", "GENE_OR_GENE_PRODUCT", 244, 251], ["IFN\u03b1", "PROTEIN", 244, 248], ["another study", "TEST", 7, 20], ["virus replication", "TREATMENT", 110, 127], ["a selectivity index", "TEST", 152, 171], ["SI", "TEST", 173, 175], ["cytotoxic concentration", "TEST", 182, 205]]], ["112 In addition to the in vitro activity, a case study describes the in vivo efficacy of IFN\u03b2 in three patients with fulminant hepatitis A and one patient with severe hepatic failure due to HAV.", [["hepatic", "ANATOMY", 167, 174], ["IFN\u03b2", "CHEMICAL", 89, 93], ["fulminant hepatitis A", "DISEASE", 117, 138], ["hepatic failure", "DISEASE", 167, 182], ["HAV", "DISEASE", 190, 193], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 89, 93], ["patients", "ORGANISM", 103, 111], ["patient", "ORGANISM", 147, 154], ["hepatic", "ORGAN", 167, 174], ["HAV", "ORGANISM", 190, 193], ["IFN\u03b2", "PROTEIN", 89, 93], ["patients", "SPECIES", 103, 111], ["patient", "SPECIES", 147, 154], ["HAV", "SPECIES", 190, 193], ["a case study", "TEST", 42, 54], ["fulminant hepatitis A", "PROBLEM", 117, 138], ["severe hepatic failure", "PROBLEM", 160, 182], ["HAV", "PROBLEM", 190, 193], ["fulminant", "OBSERVATION_MODIFIER", 117, 126], ["hepatitis", "OBSERVATION", 127, 136], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["hepatic", "ANATOMY", 167, 174], ["failure", "OBSERVATION", 175, 182]]], ["Following a treatment with 3 million units per day, liver functioning ameliorated and all four patients survived.", [["liver", "ANATOMY", 52, 57], ["liver", "ORGAN", 52, 57], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["a treatment", "TREATMENT", 10, 21], ["liver functioning ameliorated", "TREATMENT", 52, 81], ["liver", "ANATOMY", 52, 57]]], ["113 However, in addition to its high price and parenteral administration, the clinical use of IFN is associated with severe side effects hampering usage in less developed regions.B. AmantadineAmantadine was initially thought to inhibit HAV by increasing the intravesicular pH.", [["intravesicular", "ANATOMY", 258, 272], ["IFN", "CHEMICAL", 94, 97], ["AmantadineAmantadine", "CHEMICAL", 182, 202], ["HAV", "DISEASE", 236, 239], ["B.", "ORGANISM", 179, 181], ["AmantadineAmantadine", "SIMPLE_CHEMICAL", 182, 202], ["HAV", "ORGANISM", 236, 239], ["intravesicular", "IMMATERIAL_ANATOMICAL_ENTITY", 258, 272], ["IFN", "PROTEIN", 94, 97], ["HAV", "SPECIES", 236, 239], ["its high price", "TREATMENT", 28, 42], ["parenteral administration", "TREATMENT", 47, 72], ["IFN", "TREATMENT", 94, 97], ["severe side effects", "PROBLEM", 117, 136], ["B. AmantadineAmantadine", "TREATMENT", 179, 202], ["HAV", "PROBLEM", 236, 239], ["the intravesicular pH", "PROBLEM", 254, 275], ["less developed", "OBSERVATION_MODIFIER", 156, 170], ["intravesicular pH", "OBSERVATION", 258, 275]]], ["However, its antiviral effect required an extended incubation when compared to NH 4 Cl and other lipophilic amines (e.g., methylamine, dansylcadaverine).", [["NH 4 Cl", "CHEMICAL", 79, 86], ["amines", "CHEMICAL", 108, 114], ["methylamine", "CHEMICAL", 122, 133], ["dansylcadaverine", "CHEMICAL", 135, 151], ["NH 4 Cl", "CHEMICAL", 79, 86], ["amines", "CHEMICAL", 108, 114], ["methylamine", "CHEMICAL", 122, 133], ["dansylcadaverine", "CHEMICAL", 135, 151], ["NH 4 Cl", "SIMPLE_CHEMICAL", 79, 86], ["lipophilic amines", "SIMPLE_CHEMICAL", 97, 114], ["methylamine", "SIMPLE_CHEMICAL", 122, 133], ["dansylcadaverine", "SIMPLE_CHEMICAL", 135, 151], ["an extended incubation", "TREATMENT", 39, 61], ["other lipophilic amines", "TREATMENT", 91, 114], ["methylamine", "TREATMENT", 122, 133], ["dansylcadaverine", "TREATMENT", 135, 151], ["antiviral effect", "OBSERVATION", 13, 29]]], ["29 In line with these findings, inhibition of HAV IRES-dependent translation was later reported as a mechanism of action (MOA).", [["HAV", "ORGANISM", 46, 49], ["HAV IRES", "DNA", 46, 54], ["HAV", "SPECIES", 46, 49], ["HAV IRES", "TREATMENT", 46, 54]]], ["114 A follow-up study confirmed the moderate activity of amantadine in cell-based assays.", [["cell", "ANATOMY", 71, 75], ["amantadine", "CHEMICAL", 57, 67], ["amantadine", "CHEMICAL", 57, 67], ["amantadine", "SIMPLE_CHEMICAL", 57, 67], ["cell", "CELL", 71, 75], ["A follow-up study", "TEST", 4, 21], ["amantadine", "TREATMENT", 57, 67], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["activity", "OBSERVATION_MODIFIER", 45, 53]]], ["115 In addition, an increased effect was observed when amantadine was combined with IFN\u03b1 or IL-29 (IFN\u03bb1).", [["amantadine", "CHEMICAL", 55, 65], ["amantadine", "CHEMICAL", 55, 65], ["amantadine", "SIMPLE_CHEMICAL", 55, 65], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-29", "GENE_OR_GENE_PRODUCT", 92, 97], ["IFN\u03bb1", "GENE_OR_GENE_PRODUCT", 99, 104], ["IFN\u03b1", "PROTEIN", 84, 88], ["IL-29", "PROTEIN", 92, 97], ["IFN\u03bb1", "PROTEIN", 99, 104], ["an increased effect", "PROBLEM", 17, 36], ["amantadine", "TREATMENT", 55, 65], ["IFN", "TREATMENT", 84, 87], ["IL", "TEST", 92, 94], ["increased", "OBSERVATION_MODIFIER", 20, 29]]], ["115, 116 However, in addition to a fairly limited effect in vitro (EC 50 of 58 \u03bcM and a SI around 5 117 ), pharmacokinetic studies demonstrated maximum plasma concentrations (C max ) following a multiple dosage scheme well below the reported EC 50 , 118 limiting its use in a clinical context.C. The Curious Case of Guanidine HClFor guanidine HCl, a protein 2C-targeting enterovirus inhibitor, mixed results were reported.", [["plasma", "ANATOMY", 152, 158], ["Guanidine HCl", "CHEMICAL", 316, 329], ["guanidine HCl", "CHEMICAL", 333, 346], ["Guanidine HCl", "CHEMICAL", 316, 329], ["guanidine HCl", "CHEMICAL", 333, 346], ["EC", "CELL", 67, 69], ["plasma", "ORGANISM_SUBSTANCE", 152, 158], ["EC", "CELL", 242, 244], ["C", "GENE_OR_GENE_PRODUCT", 293, 294], ["Guanidine HCl", "SIMPLE_CHEMICAL", 316, 329], ["guanidine HCl", "SIMPLE_CHEMICAL", 333, 346], ["enterovirus", "ORGANISM", 371, 382], ["a SI", "TEST", 86, 90], ["pharmacokinetic studies", "TEST", 107, 130], ["maximum plasma concentrations", "PROBLEM", 144, 173], ["a multiple dosage scheme", "TREATMENT", 193, 217], ["Guanidine HCl", "TREATMENT", 316, 329], ["guanidine HCl", "TREATMENT", 333, 346], ["a protein 2C", "TREATMENT", 348, 360], ["enterovirus inhibitor", "TREATMENT", 371, 392]]], ["The earliest publication detected no inhibition at 1 and 2 mM, 119 but other groups found moderate inhibition (around 50%) following treatment with 3 mM 120 or 2.5 mM.", [["moderate inhibition", "PROBLEM", 90, 109], ["treatment", "TREATMENT", 133, 142], ["moderate", "OBSERVATION_MODIFIER", 90, 98], ["inhibition", "OBSERVATION", 99, 109]]], ["107 Cho and colleagues reported reversible inhibition at 2 mM but also reported enhancement of replication at 0.1-1 mM.", [["Cho", "CHEMICAL", 4, 7], ["reversible inhibition", "PROBLEM", 32, 53], ["enhancement of replication", "PROBLEM", 80, 106], ["reversible", "OBSERVATION_MODIFIER", 32, 42], ["inhibition", "OBSERVATION_MODIFIER", 43, 53], ["enhancement", "OBSERVATION_MODIFIER", 80, 91], ["replication", "OBSERVATION_MODIFIER", 95, 106]]], ["121 Conversely to these results, Yi et al. reported strong inhibition of viral replication at concentrations as low as 0.1 mM.", [["viral replication", "PROBLEM", 73, 90], ["viral replication", "OBSERVATION", 73, 90], ["low", "OBSERVATION_MODIFIER", 112, 115]]], ["99 Several factors may explain the inconsistency of these data: (i) mutations in the different viral genomes studied, specifically in the 2C region;C. The Curious Case of Guanidine HCl(ii) the cell type used in the antiviral assay; (iii) the multiplicity of infection (MOI), which was found to be an important determinant for the antiviral activity 107 ; and (iv) the detection method employed.D. Miscellaneous Small Molecule Inhibitors of the HAV Replication CycleOnly limited information is available on other compounds with anti-HAV activity.", [["cell", "ANATOMY", 193, 197], ["Guanidine HCl", "CHEMICAL", 171, 184], ["infection", "DISEASE", 258, 267], ["Guanidine HCl", "CHEMICAL", 171, 184], ["Guanidine HCl", "SIMPLE_CHEMICAL", 171, 184], ["cell type", "CELL", 193, 202], ["HAV", "ORGANISM", 444, 447], ["viral genomes", "DNA", 95, 108], ["C.", "SPECIES", 148, 150], ["mutations in the different viral genomes", "PROBLEM", 68, 108], ["Guanidine HCl(ii) the cell type", "TREATMENT", 171, 202], ["the antiviral assay", "TEST", 211, 230], ["infection", "PROBLEM", 258, 267], ["the antiviral activity", "TEST", 326, 348], ["Small Molecule Inhibitors", "TREATMENT", 411, 436], ["the HAV Replication", "TREATMENT", 440, 459], ["viral genomes", "OBSERVATION", 95, 108], ["infection", "OBSERVATION", 258, 267], ["Small", "OBSERVATION_MODIFIER", 411, 416], ["Molecule Inhibitors", "OBSERVATION", 417, 436]]], ["Early steps of the replication cycle can be blocked by iota-carrageenan, which probably functions as an inhibitor of virus attachment and receptor binding.", [["iota-carrageenan", "CHEMICAL", 55, 71], ["iota-carrageenan", "CHEMICAL", 55, 71], ["iota-carrageenan", "SIMPLE_CHEMICAL", 55, 71], ["the replication cycle", "TREATMENT", 15, 36], ["virus attachment", "PROBLEM", 117, 133], ["receptor binding", "PROBLEM", 138, 154]]], ["122 Atropine, at 1.7 mM, proved to moderately reduce HAV replication by targeting the early steps of the HAV replication cycle as well (attachment and possibly uncoating).", [["Atropine", "CHEMICAL", 4, 12], ["Atropine", "CHEMICAL", 4, 12], ["Atropine", "SIMPLE_CHEMICAL", 4, 12], ["HAV", "ORGANISM", 53, 56], ["HAV", "ORGANISM", 105, 108], ["HAV", "SPECIES", 53, 56], ["HAV", "SPECIES", 105, 108], ["Atropine", "TREATMENT", 4, 12], ["HAV replication", "TREATMENT", 53, 68]]], ["123 Due to toxicity and limited antiviral activity, the clinical potential of both compounds is low.", [["toxicity", "DISEASE", 11, 19], ["toxicity", "PROBLEM", 11, 19], ["limited antiviral activity", "PROBLEM", 24, 50], ["toxicity", "OBSERVATION", 11, 19], ["antiviral activity", "OBSERVATION", 32, 50], ["both", "OBSERVATION_MODIFIER", 78, 82], ["compounds", "OBSERVATION", 83, 92], ["low", "OBSERVATION_MODIFIER", 96, 99]]], ["For glycyrrhizin, an aqueous extract of the licorice root, an EC 50 of 325\u03bcM and a SI of 15 were reported.", [["aqueous extract", "ANATOMY", 21, 36], ["licorice root", "ANATOMY", 44, 57], ["EC", "ANATOMY", 62, 64], ["glycyrrhizin", "CHEMICAL", 4, 16], ["aqueous extract of the licorice", "CHEMICAL", 21, 52], ["glycyrrhizin", "CHEMICAL", 4, 16], ["glycyrrhizin", "SIMPLE_CHEMICAL", 4, 16], ["aqueous extract", "ORGANISM_SUBSTANCE", 21, 36], ["licorice root", "MULTI-TISSUE_STRUCTURE", 44, 57], ["EC", "CELL", 62, 64], ["licorice", "SPECIES", 44, 52], ["glycyrrhizin", "TREATMENT", 4, 16], ["an EC", "TEST", 59, 64], ["licorice root", "ANATOMY", 44, 57]]], ["117, 124 Subsequent studies suggested inhibition of membrane penetration as the putative MOA.", [["membrane", "ANATOMY", 52, 60], ["membrane", "CELLULAR_COMPONENT", 52, 60], ["Subsequent studies", "TEST", 9, 27], ["membrane penetration", "PROBLEM", 52, 72], ["membrane penetration", "OBSERVATION", 52, 72]]], ["124 In addition to its anti-HAV activity, glycyrrhizin proved also to be active against a relatively large panel of other viruses, including HBV, HCV, HSV, and HIV, with several proposed mechanisms of action, as reviewed by Fiore et al. 125 However, glycyrrhizin may cause pseudohyperaldosteronism due to its aldosterone-like effects.", [["glycyrrhizin", "CHEMICAL", 42, 54], ["HBV, HCV, HSV, and HIV", "DISEASE", 141, 163], ["glycyrrhizin", "CHEMICAL", 250, 262], ["pseudohyperaldosteronism", "DISEASE", 273, 297], ["aldosterone", "CHEMICAL", 309, 320], ["glycyrrhizin", "CHEMICAL", 42, 54], ["glycyrrhizin", "CHEMICAL", 250, 262], ["aldosterone", "CHEMICAL", 309, 320], ["glycyrrhizin", "SIMPLE_CHEMICAL", 42, 54], ["HBV", "ORGANISM", 141, 144], ["HCV", "ORGANISM", 146, 149], ["HSV", "ORGANISM", 151, 154], ["glycyrrhizin", "SIMPLE_CHEMICAL", 250, 262], ["aldosterone", "SIMPLE_CHEMICAL", 309, 320], ["HIV", "SPECIES", 160, 163], ["HBV", "SPECIES", 141, 144], ["HCV", "SPECIES", 146, 149], ["HSV", "SPECIES", 151, 154], ["HIV", "SPECIES", 160, 163], ["glycyrrhizin", "TREATMENT", 42, 54], ["other viruses", "PROBLEM", 116, 129], ["HBV", "PROBLEM", 141, 144], ["HCV", "PROBLEM", 146, 149], ["HSV", "PROBLEM", 151, 154], ["HIV", "PROBLEM", 160, 163], ["glycyrrhizin", "TREATMENT", 250, 262], ["pseudohyperaldosteronism", "PROBLEM", 273, 297], ["its aldosterone", "PROBLEM", 305, 320], ["viruses", "OBSERVATION", 122, 129]]], ["In addition, the compound is readily metabolized following oral and intravenous administration and the attained plasma concentrations are considerably lower than the reported EC 50 , 126 hampering clinical use for treatment of HAV-infected patients.D. Miscellaneous Small Molecule Inhibitors of the HAV Replication CycleProbably the most potent small molecules reported thus far are 4 ,6-dichloroflavan and 4 ,6-dichloroisoflavan (EC 50 values of 6 nM).", [["oral", "ANATOMY", 59, 63], ["intravenous", "ANATOMY", 68, 79], ["plasma", "ANATOMY", 112, 118], ["EC", "ANATOMY", 175, 177], ["HAV-infected", "DISEASE", 227, 239], ["4 ,6-dichloroflavan", "CHEMICAL", 383, 402], ["4 ,6-dichloroisoflavan", "CHEMICAL", 407, 429], ["4 ,6-dichloroflavan", "CHEMICAL", 383, 402], ["4 ,6-dichloroisoflavan", "CHEMICAL", 407, 429], ["oral", "ORGANISM_SUBDIVISION", 59, 63], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["plasma", "ORGANISM_SUBSTANCE", 112, 118], ["EC", "CELL", 175, 177], ["HAV", "ORGANISM", 227, 230], ["patients", "ORGANISM", 240, 248], ["HAV", "ORGANISM", 299, 302], ["4 ,6-dichloroflavan", "SIMPLE_CHEMICAL", 383, 402], ["4 ,6-dichloroisoflavan", "SIMPLE_CHEMICAL", 407, 429], ["EC", "SIMPLE_CHEMICAL", 431, 433], ["patients", "SPECIES", 240, 248], ["HAV", "SPECIES", 227, 230], ["oral and intravenous administration", "TREATMENT", 59, 94], ["the attained plasma concentrations", "TEST", 99, 133], ["treatment", "TREATMENT", 214, 223], ["HAV", "PROBLEM", 227, 230], ["Small Molecule Inhibitors", "TREATMENT", 266, 291], ["the HAV Replication", "TREATMENT", 295, 314], ["dichloroflavan", "TREATMENT", 388, 402], ["metabolized", "OBSERVATION_MODIFIER", 37, 48], ["infected", "OBSERVATION", 231, 239], ["Small", "OBSERVATION_MODIFIER", 266, 271], ["Molecule Inhibitors", "OBSERVATION", 272, 291], ["HAV Replication", "OBSERVATION", 299, 314], ["most potent", "OBSERVATION_MODIFIER", 333, 344], ["small molecules", "OBSERVATION", 345, 360]]], ["127 Inhibition of cell entry or viral uncoating were posited as possible mechanisms of action for the antiviral activity against HAV.", [["cell", "ANATOMY", 18, 22], ["HAV", "DISEASE", 129, 132], ["cell", "CELL", 18, 22], ["HAV", "ORGANISM", 129, 132], ["HAV", "SPECIES", 129, 132], ["cell entry", "TREATMENT", 18, 28], ["viral uncoating", "PROBLEM", 32, 47], ["the antiviral activity", "TREATMENT", 98, 120], ["HAV", "PROBLEM", 129, 132], ["viral uncoating", "OBSERVATION", 32, 47]]], ["These drugs were also found to be effective against rhinoviruses and poliovirus in vitro.", [["rhinoviruses", "DISEASE", 52, 64], ["rhinoviruses", "ORGANISM", 52, 64], ["poliovirus", "ORGANISM", 69, 79], ["poliovirus", "SPECIES", 69, 79], ["These drugs", "TREATMENT", 0, 11], ["rhinoviruses", "PROBLEM", 52, 64], ["poliovirus", "PROBLEM", 69, 79], ["poliovirus", "OBSERVATION", 69, 79]]], ["127 However, 4 ,6-dichloroflavan failed to protect volunteers from experimental rhinovirus infection when administered both orally or intranasally, 128, 129 raising doubts concerning its in vivo efficacy against HAV as well.D. Miscellaneous Small Molecule Inhibitors of the HAV Replication CycleOther early stage inhibitors include chlorpromazine and chloroquine.", [["4 ,6-dichloroflavan", "CHEMICAL", 13, 32], ["rhinovirus infection", "DISEASE", 80, 100], ["HAV", "DISEASE", 212, 215], ["chlorpromazine", "CHEMICAL", 332, 346], ["chloroquine", "CHEMICAL", 351, 362], ["4 ,6-dichloroflavan", "CHEMICAL", 13, 32], ["chlorpromazine", "CHEMICAL", 332, 346], ["chloroquine", "CHEMICAL", 351, 362], ["4 ,6-dichloroflavan", "SIMPLE_CHEMICAL", 13, 32], ["volunteers", "ORGANISM", 51, 61], ["rhinovirus", "ORGANISM", 80, 90], ["HAV", "ORGANISM", 212, 215], ["HAV", "ORGANISM", 274, 277], ["chlorpromazine", "SIMPLE_CHEMICAL", 332, 346], ["chloroquine", "SIMPLE_CHEMICAL", 351, 362], ["HAV", "SPECIES", 212, 215], ["dichloroflavan", "TREATMENT", 18, 32], ["experimental rhinovirus infection", "PROBLEM", 67, 100], ["HAV", "PROBLEM", 212, 215], ["Small Molecule Inhibitors", "TREATMENT", 241, 266], ["the HAV Replication CycleOther early stage inhibitors", "TREATMENT", 270, 323], ["chlorpromazine", "TREATMENT", 332, 346], ["chloroquine", "TREATMENT", 351, 362], ["rhinovirus infection", "OBSERVATION", 80, 100], ["Small", "OBSERVATION_MODIFIER", 241, 246], ["Molecule Inhibitors", "OBSERVATION", 247, 266]]], ["31 The former is thought to block endocytosis of nonclathrin-coated vesicles, while the latter inhibits endosome acidification.", [["vesicles", "ANATOMY", 68, 76], ["endosome", "ANATOMY", 104, 112], ["vesicles", "CELLULAR_COMPONENT", 68, 76], ["endosome", "CELLULAR_COMPONENT", 104, 112], ["nonclathrin", "PROTEIN", 49, 60], ["block endocytosis of nonclathrin-coated vesicles", "PROBLEM", 28, 76], ["endosome acidification", "PROBLEM", 104, 126], ["thought to", "UNCERTAINTY", 17, 27], ["endosome acidification", "OBSERVATION", 104, 126]]], ["31 Monensin, another endosome acidification blocker, yielded minor to extensive inhibition of HAV replication in different studies.", [["endosome", "ANATOMY", 21, 29], ["Monensin", "CHEMICAL", 3, 11], ["Monensin", "CHEMICAL", 3, 11], ["Monensin", "SIMPLE_CHEMICAL", 3, 11], ["endosome", "CELLULAR_COMPONENT", 21, 29], ["HAV", "ORGANISM", 94, 97], ["HAV", "SPECIES", 94, 97], ["Monensin", "TREATMENT", 3, 11], ["another endosome acidification blocker", "TREATMENT", 13, 51], ["HAV replication", "TREATMENT", 94, 109], ["HAV replication", "OBSERVATION", 94, 109]]], ["30, 31, 62 In addition to early stage inhibitors, several other HAV inhibitors were identified to target different steps of the intracellular replication process including RNA synthesis, translation, and capsid assembly.", [["intracellular", "ANATOMY", 128, 141], ["HAV", "ORGANISM", 64, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 141], ["HAV", "SPECIES", 64, 67], ["early stage inhibitors", "TREATMENT", 26, 48], ["several other HAV inhibitors", "TREATMENT", 50, 78], ["the intracellular replication process", "TREATMENT", 124, 161], ["RNA synthesis", "TREATMENT", 172, 185], ["intracellular replication", "OBSERVATION", 128, 153], ["RNA synthesis", "OBSERVATION", 172, 185]]], ["For instance, ribavirin was demonstrated to have a moderate effect at 100 \u03bcM, 130 showing an EC 50 of 94 \u03bcM and a selectivity index of around 4.", [["EC", "ANATOMY", 93, 95], ["ribavirin", "CHEMICAL", 14, 23], ["ribavirin", "CHEMICAL", 14, 23], ["ribavirin", "SIMPLE_CHEMICAL", 14, 23], ["EC", "CELL", 93, 95], ["ribavirin", "TREATMENT", 14, 23], ["an EC", "TEST", 90, 95], ["a selectivity index", "TEST", 112, 131], ["moderate", "OBSERVATION_MODIFIER", 51, 59]]], ["117 Improved anti-HAV activity was reported for pyrazofurin, an orotidine 5 -monophosphate decarboxylase inhibitor, but further development was halted due to toxicity (interference with nucleotide metabolism).", [["pyrazofurin", "CHEMICAL", 48, 59], ["orotidine 5 -monophosphate", "CHEMICAL", 64, 90], ["toxicity", "DISEASE", 158, 166], ["nucleotide", "CHEMICAL", 186, 196], ["pyrazofurin", "CHEMICAL", 48, 59], ["orotidine 5 -monophosphate", "CHEMICAL", 64, 90], ["nucleotide", "CHEMICAL", 186, 196], ["pyrazofurin", "SIMPLE_CHEMICAL", 48, 59], ["orotidine 5 -monophosphate decarboxylase", "SIMPLE_CHEMICAL", 64, 104], ["nucleotide", "SIMPLE_CHEMICAL", 186, 196], ["pyrazofurin", "TREATMENT", 48, 59], ["an orotidine", "TREATMENT", 61, 73], ["monophosphate decarboxylase inhibitor", "TREATMENT", 77, 114], ["toxicity", "PROBLEM", 158, 166], ["nucleotide metabolism", "TREATMENT", 186, 207]]], ["117 Protamine reduced HAV replication with 97% at 100 \u03bcg/mL and was suggested to function as a RNA polymerase inhibitor.", [["Protamine", "CHEMICAL", 4, 13], ["Protamine", "CHEMICAL", 4, 13], ["Protamine", "SIMPLE_CHEMICAL", 4, 13], ["HAV", "ORGANISM", 22, 25], ["HAV", "SPECIES", 22, 25], ["Protamine reduced HAV replication", "TREATMENT", 4, 37], ["a RNA polymerase inhibitor", "TREATMENT", 93, 119]]], ["123 In addition, inhibitors of oxidative phosphorylation and 2-deoxy-D-glucose, a glycolysis inhibitor, were identified as inhibitors of HAV replication by unknown mechanisms.", [["2-deoxy-D-glucose", "CHEMICAL", 61, 78], ["2-deoxy-D-glucose", "CHEMICAL", 61, 78], ["2-deoxy-D-glucose", "SIMPLE_CHEMICAL", 61, 78], ["HAV", "ORGANISM", 137, 140], ["HAV", "SPECIES", 137, 140], ["inhibitors", "TREATMENT", 17, 27], ["oxidative phosphorylation", "TREATMENT", 31, 56], ["a glycolysis inhibitor", "TREATMENT", 80, 102], ["HAV replication", "TREATMENT", 137, 152]]], ["30 Other inhibitors include brefeldin A 62, 107 and cycloheximide, 107 inhibitors of ER-to-golgi transport and protein synthesis, respectively.", [["brefeldin A 62, 107", "CHEMICAL", 28, 47], ["cycloheximide", "CHEMICAL", 52, 65], ["brefeldin A 62", "CHEMICAL", 28, 42], ["cycloheximide", "CHEMICAL", 52, 65], ["brefeldin A 62", "SIMPLE_CHEMICAL", 28, 42], ["cycloheximide", "SIMPLE_CHEMICAL", 52, 65], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["golgi", "SIMPLE_CHEMICAL", 91, 96], ["ER", "PROTEIN", 85, 87], ["cycloheximide", "TREATMENT", 52, 65]]], ["A moderate anti-HAV activity was also reported for amphotericin B 131 and methisoprinol, 132 drugs used against fungal infections and as an immunomodulator in the treatment of subacute sclerosing panencephalitis, respectively.", [["amphotericin B 131", "CHEMICAL", 51, 69], ["methisoprinol", "CHEMICAL", 74, 87], ["fungal infections", "DISEASE", 112, 129], ["sclerosing panencephalitis", "DISEASE", 185, 211], ["amphotericin B 131", "CHEMICAL", 51, 69], ["methisoprinol", "CHEMICAL", 74, 87], ["amphotericin B 131", "SIMPLE_CHEMICAL", 51, 69], ["methisoprinol", "SIMPLE_CHEMICAL", 74, 87], ["A moderate anti-HAV activity", "PROBLEM", 0, 28], ["amphotericin B", "TREATMENT", 51, 65], ["methisoprinol", "TREATMENT", 74, 87], ["132 drugs", "TREATMENT", 89, 98], ["fungal infections", "PROBLEM", 112, 129], ["an immunomodulator", "TREATMENT", 137, 155], ["subacute sclerosing panencephalitis", "PROBLEM", 176, 211], ["moderate", "OBSERVATION_MODIFIER", 2, 10], ["anti-HAV activity", "OBSERVATION", 11, 28], ["subacute", "OBSERVATION_MODIFIER", 176, 184], ["sclerosing panencephalitis", "OBSERVATION", 185, 211]]], ["However, no data are available on the MOA.D. Miscellaneous Small Molecule Inhibitors of the HAV Replication CycleIn recent years, several new anti-HAV compounds were synthesized, but the antiviral activity remained rather limited.", [["HAV", "ORGANISM", 92, 95], ["Small Molecule Inhibitors", "TREATMENT", 59, 84], ["several new anti-HAV compounds", "PROBLEM", 130, 160], ["the antiviral activity", "TEST", 183, 205], ["new", "OBSERVATION_MODIFIER", 138, 141]]], ["[133] [134] [135] Other papers reported highly potent inhibitors of HAV replication, but did not report toxicity data, making it impossible to judge whether or not these are selective inhibitors.", [["toxicity", "DISEASE", 104, 112], ["[133] [134] [135", "SIMPLE_CHEMICAL", 0, 16], ["HAV", "ORGANISM", 68, 71], ["HAV", "SPECIES", 68, 71], ["HAV replication", "PROBLEM", 68, 83], ["toxicity data", "PROBLEM", 104, 117], ["selective inhibitors", "TREATMENT", 174, 194]]], ["[136] [137] [138]E. Rational Design of 3C pro InhibitorsConsiderable efforts have been undertaken to rationally design and develop inhibitors for HAV and human enterovirus 3C pro and the related coronavirus 3C-like protease (3CL pro ).", [["HAV", "ORGANISM", 146, 149], ["human enterovirus 3C", "ORGANISM", 154, 174], ["coronavirus 3C", "ORGANISM", 195, 209], ["human enterovirus 3C pro", "PROTEIN", 154, 178], ["coronavirus 3C-like protease", "PROTEIN", 195, 223], ["3CL pro", "PROTEIN", 225, 232], ["human", "SPECIES", 154, 159], ["HAV", "SPECIES", 146, 149], ["human enterovirus 3C", "SPECIES", 154, 174], ["3C pro Inhibitors", "TREATMENT", 39, 56], ["inhibitors", "TREATMENT", 131, 141], ["HAV", "TREATMENT", 146, 149], ["human enterovirus 3C pro", "TREATMENT", 154, 178], ["the related coronavirus 3C", "TREATMENT", 183, 209]]], ["139 These enzymes have a topology comparable to that of the chymotrypsin-like serine proteases, but are in fact cysteine proteases.", [["serine", "CHEMICAL", 78, 84], ["cysteine", "CHEMICAL", 112, 120], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 60, 72], ["enzymes", "PROTEIN", 10, 17], ["chymotrypsin", "PROTEIN", 60, 72], ["serine proteases", "PROTEIN", 78, 94], ["cysteine proteases", "PROTEIN", 112, 130], ["These enzymes", "TEST", 4, 17], ["the chymotrypsin", "TEST", 56, 72], ["serine proteases", "PROBLEM", 78, 94], ["cysteine proteases", "OBSERVATION", 112, 130]]], ["139 Consequently, the general research strategy is to introduce thiolreactive groups into the catalytic site.", [["catalytic site", "PROTEIN", 94, 108]]], ["Several of such protease inhibitors have been developed over the years, both modified peptides and nonpeptidic analogs.", [["such protease inhibitors", "TREATMENT", 11, 35], ["nonpeptidic analogs", "TREATMENT", 99, 118], ["nonpeptidic analogs", "OBSERVATION", 99, 118]]], ["Despite the fact that the modified peptides are easier to design (by merely mimicking the natural protease substrate), nonpeptidic and peptidomimetic inactivators are preferred, since they can be modified in order to increase stability and cellular and gastrointestinal uptake, properties that are difficult to attain for peptides.", [["cellular", "ANATOMY", 240, 248], ["gastrointestinal", "ANATOMY", 253, 269], ["cellular", "CELL", 240, 248], ["gastrointestinal", "ORGAN", 253, 269], ["the modified peptides", "PROBLEM", 22, 43], ["the natural protease substrate", "TREATMENT", 86, 116], ["nonpeptidic and peptidomimetic inactivators", "PROBLEM", 119, 162], ["cellular and gastrointestinal uptake", "PROBLEM", 240, 276], ["peptidomimetic inactivators", "OBSERVATION", 135, 162], ["stability", "OBSERVATION_MODIFIER", 226, 235], ["gastrointestinal uptake", "OBSERVATION", 253, 276]]], ["A similar approach has already been applied to rhino-and enterovirus 3C pro and resulted in the molecule rupintrivir that was halted after unsuccessful phase II clinical trials.", [["enterovirus 3C", "ORGANISM", 57, 71], ["A similar approach", "TREATMENT", 0, 18], ["rhino", "TREATMENT", 47, 52], ["enterovirus 3C pro", "TREATMENT", 57, 75], ["the molecule rupintrivir", "TREATMENT", 92, 116]]], ["140 The first HAV 3C pro inhibitors developed were modified peptides based on the acetyl-Leu-Ala-Ala sequence, serving as competitors for the natural peptide substrate Leu-Arg-Thr.", [["140", "CHEMICAL", 0, 3], ["acetyl-Leu-Ala-Ala", "CHEMICAL", 82, 100], ["Leu-Arg-Thr", "CHEMICAL", 168, 179], ["acetyl-Leu-Ala-Ala", "CHEMICAL", 82, 100], ["Leu-Arg-Thr", "CHEMICAL", 168, 179], ["HAV 3C", "ORGANISM", 14, 20], ["acetyl-Leu-Ala-Ala", "SIMPLE_CHEMICAL", 82, 100], ["Leu-Arg-Thr", "SIMPLE_CHEMICAL", 168, 179], ["HAV", "SPECIES", 14, 17], ["The first HAV 3C pro inhibitors", "TREATMENT", 4, 35], ["modified peptides", "TREATMENT", 51, 68], ["the acetyl", "TEST", 78, 88]]], ["141 Based on these findings, peptidyl aldehyde and monofluoromethylketone (FMK) inhibitors were developed.", [["peptidyl aldehyde", "CHEMICAL", 29, 46], ["monofluoromethylketone", "CHEMICAL", 51, 73], ["FMK", "CHEMICAL", 75, 78], ["peptidyl aldehyde", "CHEMICAL", 29, 46], ["monofluoromethylketone", "CHEMICAL", 51, 73], ["FMK", "CHEMICAL", 75, 78], ["peptidyl aldehyde", "SIMPLE_CHEMICAL", 29, 46], ["monofluoromethylketone", "SIMPLE_CHEMICAL", 51, 73], ["FMK", "SIMPLE_CHEMICAL", 75, 78], ["these findings", "TEST", 13, 27], ["peptidyl aldehyde", "TREATMENT", 29, 46], ["monofluoromethylketone (FMK) inhibitors", "TREATMENT", 51, 90]]], ["142, 143 Resolving the crystal structure of HAV 3C pro in complex with a peptidyl FMK inhibitor indicated that the inhibitor covalently binds the catalytic cysteine.", [["cysteine", "CHEMICAL", 156, 164], ["peptidyl FMK", "SIMPLE_CHEMICAL", 73, 85], ["cysteine", "AMINO_ACID", 156, 164], ["HAV 3C pro", "PROTEIN", 44, 54], ["HAV 3C pro", "TREATMENT", 44, 54], ["a peptidyl FMK inhibitor", "TREATMENT", 71, 95], ["the inhibitor", "TREATMENT", 111, 124], ["the catalytic cysteine", "TREATMENT", 142, 164]]], ["144 One of these peptidyl FMK inhibitors was also tested ex vivo and was shown to reduce HAV replication by 96%.", [["peptidyl FMK", "SIMPLE_CHEMICAL", 17, 29], ["HAV", "ORGANISM", 89, 92], ["HAV", "SPECIES", 89, 92], ["these peptidyl FMK inhibitors", "TREATMENT", 11, 40], ["peptidyl FMK", "OBSERVATION", 17, 29]]], ["143 However, cellular uptake appeared to be a major problem.", [["cellular", "ANATOMY", 13, 21], ["cellular", "CELL", 13, 21], ["cellular uptake", "PROBLEM", 13, 28], ["a major problem", "PROBLEM", 44, 59], ["cellular uptake", "OBSERVATION", 13, 28], ["major", "OBSERVATION_MODIFIER", 46, 51], ["problem", "OBSERVATION", 52, 59]]], ["In addition, several azaglutamine derivatives were found to be irreversible peptidic inhibitors.", [["azaglutamine", "CHEMICAL", 21, 33], ["azaglutamine", "CHEMICAL", 21, 33], ["azaglutamine derivatives", "SIMPLE_CHEMICAL", 21, 45], ["several azaglutamine derivatives", "TREATMENT", 13, 45], ["irreversible peptidic inhibitors", "PROBLEM", 63, 95], ["irreversible", "OBSERVATION_MODIFIER", 63, 75], ["peptidic inhibitors", "OBSERVATION", 76, 95]]], ["145 On the other hand, several nonpeptidic antagonists were reported as well.", [["several nonpeptidic antagonists", "TREATMENT", 23, 54]]], ["Asymetric azodicarboxamides were found to be irreversible inhibitors of HAV and HRV 3C pro .", [["azodicarboxamides", "CHEMICAL", 10, 27], ["azodicarboxamides", "CHEMICAL", 10, 27], ["Asymetric azodicarboxamides", "SIMPLE_CHEMICAL", 0, 27], ["HAV", "ORGANISM", 72, 75], ["HAV", "SPECIES", 72, 75], ["Asymetric azodicarboxamides", "TREATMENT", 0, 27], ["irreversible inhibitors of HAV", "PROBLEM", 45, 75]]], ["146 Serine and threonine \u03b2-lactones also inhibited HAV 3C pro .", [["threonine", "CHEMICAL", 15, 24], ["Serine", "CHEMICAL", 4, 10], ["threonine \u03b2-lactones", "CHEMICAL", 15, 35], ["Serine", "AMINO_ACID", 4, 10], ["threonine \u03b2-lactones", "SIMPLE_CHEMICAL", 15, 35], ["HAV 3C pro", "PROTEIN", 51, 61], ["HAV 3C", "SPECIES", 51, 57], ["threonine \u03b2-lactones", "TREATMENT", 15, 35]]], ["147, 148 Other inhibitors include monophenyl pseudoxazolones of glycine (IC 50 of 4-6 \u03bcM) 149 and cathepsin K inhibitor-based ketoglutamines.", [["monophenyl pseudoxazolones", "CHEMICAL", 34, 60], ["glycine", "CHEMICAL", 64, 71], ["ketoglutamines", "CHEMICAL", 126, 140], ["monophenyl pseudoxazolones", "CHEMICAL", 34, 60], ["glycine", "CHEMICAL", 64, 71], ["ketoglutamines", "CHEMICAL", 126, 140], ["monophenyl pseudoxazolones", "SIMPLE_CHEMICAL", 34, 60], ["glycine", "SIMPLE_CHEMICAL", 64, 71], ["cathepsin K inhibitor-based ketoglutamines", "SIMPLE_CHEMICAL", 98, 140], ["Other inhibitors", "TREATMENT", 9, 25], ["monophenyl pseudoxazolones of glycine (IC", "TREATMENT", 34, 75], ["cathepsin K inhibitor", "TREATMENT", 98, 119], ["ketoglutamines", "TREATMENT", 126, 140]]], ["150 Lastly, halopyridinyl esters were reported as the most potent nonpeptide HAV 3C pro inhibitors thus far with IC 50 's as low as 53 nM.", [["halopyridinyl esters", "CHEMICAL", 12, 32], ["halopyridinyl esters", "CHEMICAL", 12, 32], ["halopyridinyl esters", "SIMPLE_CHEMICAL", 12, 32], ["3C pro inhibitors", "TREATMENT", 81, 98], ["IC", "TEST", 113, 115]]], ["151 Although recent publications in this field seem to focus increasingly on HRV 3C pro and coronavirus 3CL pro , 152 it would be wise not to neglect possible anti-HAV activity for potential future (off-label) use of a marketed HRV or coronavirus protease inhibitor for severe HAV infections.F. RNA InterferenceRNA interference (RNAi) has been suggested as a future treatment of severe HAV infections.", [["HAV infections", "DISEASE", 277, 291], ["HAV infections", "DISEASE", 386, 400], ["coronavirus", "ORGANISM", 235, 246], ["HAV", "ORGANISM", 277, 280], ["HAV", "ORGANISM", 386, 389], ["coronavirus", "SPECIES", 235, 246], ["HAV", "SPECIES", 277, 280], ["HAV", "SPECIES", 386, 389], ["recent publications in this field", "PROBLEM", 13, 46], ["HRV 3C pro", "TREATMENT", 77, 87], ["coronavirus 3CL pro", "TREATMENT", 92, 111], ["anti-HAV activity", "PROBLEM", 159, 176], ["a marketed HRV", "TREATMENT", 217, 231], ["coronavirus protease inhibitor", "TREATMENT", 235, 265], ["severe HAV infections", "PROBLEM", 270, 291], ["a future treatment", "TREATMENT", 357, 375], ["severe HAV infections", "PROBLEM", 379, 400], ["infections", "OBSERVATION", 281, 291], ["severe", "OBSERVATION_MODIFIER", 379, 385], ["HAV", "OBSERVATION_MODIFIER", 386, 389], ["infections", "OBSERVATION", 390, 400]]], ["153 Small interfering RNA (siRNA) targeting nonstructural genes can effectively block replication.", [["nonstructural genes", "DNA", 44, 63], ["Small interfering RNA (siRNA) targeting nonstructural genes", "PROBLEM", 4, 63], ["Small", "OBSERVATION_MODIFIER", 4, 9], ["interfering RNA", "OBSERVATION", 10, 25]]], ["153, 154 Inhibition was also reported when targeting domains IIIC and V of the HAV IRES.", [["HAV", "ORGANISM", 79, 82], ["HAV IRES", "DNA", 79, 87], ["HAV", "SPECIES", 79, 82]]], ["155 Three consecutive applications of siRNA over 14 days resulted in a 3 log 10 infectivity titer reduction in persistently infected cells.", [["cells", "ANATOMY", 133, 138], ["cells", "CELL", 133, 138], ["persistently infected cells", "CELL_TYPE", 111, 138], ["Three consecutive applications of siRNA", "TREATMENT", 4, 43], ["a 3 log 10 infectivity titer reduction", "TREATMENT", 69, 107], ["persistently infected cells", "PROBLEM", 111, 138], ["persistently", "OBSERVATION_MODIFIER", 111, 123], ["infected cells", "OBSERVATION", 124, 138]]], ["However, resistance emerged fairly quickly through mutation of the target site, necessitating combination of different siRNAs.", [["target site", "DNA", 67, 78], ["different siRNAs", "PROBLEM", 109, 125], ["different siRNAs", "OBSERVATION", 109, 125]]], ["154 Once clinical RNAi therapy would be an established treatment for other (infectious) diseases, it would be interesting to further explore this for hepatitis A. However, such clinical applications of RNAi are currently still at the experimental stage.G. Novel Antiviral AssaysWe recently reported the development of three assays to screen for and identify small molecule inhibitors of HAV replication.", [["infectious) diseases", "DISEASE", 76, 96], ["hepatitis", "DISEASE", 150, 159], ["HAV", "ORGANISM", 387, 390], ["hepatitis A.", "SPECIES", 150, 162], ["HAV", "SPECIES", 387, 390], ["clinical RNAi therapy", "TREATMENT", 9, 30], ["an established treatment", "TREATMENT", 40, 64], ["other (infectious) diseases", "PROBLEM", 69, 96], ["hepatitis A.", "PROBLEM", 150, 162], ["RNAi", "PROBLEM", 202, 206], ["Antiviral Assays", "TEST", 262, 278], ["small molecule inhibitors", "TREATMENT", 358, 383], ["HAV replication", "TREATMENT", 387, 402], ["Antiviral Assays", "OBSERVATION", 262, 278]]], ["156 A CPE reduction assay based on the cell culture adapted HM175/18f strain (genotype IB) is amendable to high-throughput screening.", [["cell", "ANATOMY", 39, 43], ["cell", "CELL", 39, 43], ["HM175", "ORGANISM", 60, 65], ["18f strain", "ORGANISM", 66, 76], ["A CPE reduction assay", "TEST", 4, 25], ["the cell culture", "TEST", 35, 51], ["genotype IB", "TEST", 78, 89]]], ["RT-qPCR-based virus yield assays for HM175/18f and genotype IIIA strain PA21 were developed as well, allowing for confirmation and further characterization of the antiviral activity of selected molecules.", [["HM175", "ORGANISM", 37, 42], ["PA21", "SIMPLE_CHEMICAL", 72, 76], ["RT-qPCR", "TEST", 0, 7], ["assays", "TEST", 26, 32], ["HM175", "TEST", 37, 42], ["genotype IIIA strain PA21", "PROBLEM", 51, 76], ["confirmation", "TEST", 114, 126], ["further characterization", "TEST", 131, 155], ["antiviral activity", "OBSERVATION", 163, 181]]], ["The known inhibitors IFN\u03b1 and amantadine were used to validate these assays.", [["IFN\u03b1", "CHEMICAL", 21, 25], ["amantadine", "CHEMICAL", 30, 40], ["amantadine", "CHEMICAL", 30, 40], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 21, 25], ["amantadine", "SIMPLE_CHEMICAL", 30, 40], ["IFN\u03b1", "PROTEIN", 21, 25], ["The known inhibitors IFN\u03b1", "TREATMENT", 0, 25], ["amantadine", "TREATMENT", 30, 40], ["these assays", "TEST", 63, 75]]], ["Using these assays, three enterovirus inhibitors with different targets were evaluated for anti-HAV activity.", [["enterovirus", "ORGANISM", 26, 37], ["anti-HAV", "PROTEIN", 91, 99], ["these assays", "TEST", 6, 18], ["three enterovirus inhibitors", "TREATMENT", 20, 48], ["different targets", "TREATMENT", 54, 71], ["anti-HAV activity", "TREATMENT", 91, 108]]], ["Pleconaril, a known capsid binder, 140 yielded (not unexpectedly) a very limited activity; inhibition by rupintrivir, a 3C pro inhibitor, proved to be strain-dependent 156 ; and enviroxime, a direct inhibitor of phosphatidylinositol-4-kinase III\u03b2 (PI4KIII\u03b2) that induces resistance mutations in enterovirus protein 3A, 157 was inactive in all three systems.", [["Pleconaril", "CHEMICAL", 0, 10], ["rupintrivir", "CHEMICAL", 105, 116], ["enviroxime", "CHEMICAL", 178, 188], ["Pleconaril", "CHEMICAL", 0, 10], ["rupintrivir", "CHEMICAL", 105, 116], ["enviroxime", "CHEMICAL", 178, 188], ["phosphatidylinositol", "CHEMICAL", 212, 232], ["Pleconaril", "SIMPLE_CHEMICAL", 0, 10], ["rupintrivir", "SIMPLE_CHEMICAL", 105, 116], ["enviroxime", "SIMPLE_CHEMICAL", 178, 188], ["phosphatidylinositol-4-kinase III\u03b2", "GENE_OR_GENE_PRODUCT", 212, 246], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 248, 256], ["enterovirus protein 3A", "GENE_OR_GENE_PRODUCT", 295, 317], ["phosphatidylinositol-4-kinase III\u03b2", "PROTEIN", 212, 246], ["PI4KIII\u03b2", "PROTEIN", 248, 256], ["enterovirus protein 3A", "PROTEIN", 295, 317], ["Pleconaril", "TREATMENT", 0, 10], ["a known capsid binder", "TREATMENT", 12, 33], ["a 3C pro inhibitor", "TREATMENT", 118, 136], ["enviroxime", "TREATMENT", 178, 188], ["phosphatidylinositol", "TEST", 212, 232], ["kinase III\u03b2 (PI4KIII\u03b2", "TREATMENT", 235, 256], ["resistance mutations in enterovirus protein 3A", "PROBLEM", 271, 317], ["capsid binder", "OBSERVATION", 20, 33]]], ["Recently, PI4KIII\u03b2 has been identified as an essential host factor in the replication strategy of enteroviruses.", [["enteroviruses", "DISEASE", 98, 111], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 10, 18], ["enteroviruses", "ORGANISM", 98, 111], ["PI4KIII\u03b2", "PROTEIN", 10, 18], ["an essential host factor", "PROBLEM", 42, 66], ["enteroviruses", "PROBLEM", 98, 111], ["essential", "OBSERVATION_MODIFIER", 45, 54], ["host", "OBSERVATION_MODIFIER", 55, 59], ["enteroviruses", "OBSERVATION", 98, 111]]], ["Following recruitment by enterovirus protein 3A to ER-derived organelle membranes, a phosphatidylinositol-4phosphate-rich environment is created, promoting viral RNA replication.", [["organelle membranes", "ANATOMY", 62, 81], ["phosphatidylinositol-4phosphate", "CHEMICAL", 85, 116], ["phosphatidylinositol", "CHEMICAL", 85, 105], ["phosphate", "CHEMICAL", 107, 116], ["enterovirus protein 3A", "GENE_OR_GENE_PRODUCT", 25, 47], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["organelle membranes", "CELLULAR_COMPONENT", 62, 81], ["phosphatidylinositol-4phosphate", "SIMPLE_CHEMICAL", 85, 116], ["enterovirus protein 3A", "PROTEIN", 25, 47], ["ER", "PROTEIN", 51, 53], ["a phosphatidylinositol", "TREATMENT", 83, 105], ["phosphate-rich environment", "TREATMENT", 107, 133], ["viral RNA replication", "TREATMENT", 156, 177], ["viral RNA replication", "OBSERVATION", 156, 177]]], ["The observation that r DEBING, NEYTS, AND THIBAUT HAV protein 3A is targeted toward the outer mitochondrial membrane instead of the ER, 50 together with the observed lack of activity for enviroxime in two different cell lines, 156 suggests that PI4KIII\u03b2 kinase activity does not play a role in HAV replication.H. Small Animal ModelsA small animal model would be an additional prerequisite for the development and validation of anti-HAV compounds.", [["outer mitochondrial membrane", "ANATOMY", 88, 116], ["cell lines", "ANATOMY", 215, 225], ["enviroxime", "CHEMICAL", 187, 197], ["enviroxime", "CHEMICAL", 187, 197], ["HAV protein 3A", "GENE_OR_GENE_PRODUCT", 50, 64], ["outer", "CELLULAR_COMPONENT", 88, 93], ["mitochondrial membrane", "CELLULAR_COMPONENT", 94, 116], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["enviroxime", "SIMPLE_CHEMICAL", 187, 197], ["cell lines", "CELL", 215, 225], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 245, 253], ["HAV", "ORGANISM", 294, 297], ["HAV protein 3A", "PROTEIN", 50, 64], ["ER", "PROTEIN", 132, 134], ["cell lines", "CELL_LINE", 215, 225], ["PI4KIII\u03b2", "PROTEIN", 245, 253], ["HAV", "SPECIES", 294, 297], ["r DEBING, NEYTS, AND THIBAUT HAV protein 3A", "PROBLEM", 21, 64], ["enviroxime", "TREATMENT", 187, 197], ["PI4KIII\u03b2 kinase activity", "PROBLEM", 245, 269], ["HAV replication", "TREATMENT", 294, 309], ["H. Small Animal ModelsA small animal model", "PROBLEM", 310, 352], ["anti-HAV compounds", "TREATMENT", 427, 445], ["cell lines", "OBSERVATION", 215, 225], ["Small", "OBSERVATION_MODIFIER", 313, 318], ["small", "OBSERVATION_MODIFIER", 334, 339]]], ["The host range of HAV is restricted to humans and several nonhuman primates, for example, tamarins and chimpanzees.", [["HAV", "DISEASE", 18, 21], ["HAV", "ORGANISM", 18, 21], ["humans", "ORGANISM", 39, 45], ["primates", "ORGANISM", 67, 75], ["tamarins", "ORGANISM", 90, 98], ["chimpanzees", "ORGANISM", 103, 114], ["humans", "SPECIES", 39, 45], ["tamarins", "SPECIES", 90, 98], ["HAV", "SPECIES", 18, 21], ["humans", "SPECIES", 39, 45], ["host range", "OBSERVATION_MODIFIER", 4, 14]]], ["158 Some efforts have been undertaken toward the development of small animal models, for example, virus adaptation to mouse cell lines or infection of guinea pigs.", [["cell lines", "ANATOMY", 124, 134], ["infection", "DISEASE", 138, 147], ["mouse", "ORGANISM", 118, 123], ["cell lines", "CELL", 124, 134], ["guinea pigs", "ORGANISM", 151, 162], ["mouse cell lines", "CELL_LINE", 118, 134], ["mouse", "SPECIES", 118, 123], ["guinea pigs", "SPECIES", 151, 162], ["mouse", "SPECIES", 118, 123], ["guinea pigs", "SPECIES", 151, 162], ["small animal models", "PROBLEM", 64, 83], ["virus adaptation", "TREATMENT", 98, 114], ["mouse cell lines", "TREATMENT", 118, 134], ["infection of guinea pigs", "PROBLEM", 138, 162], ["small", "OBSERVATION_MODIFIER", 64, 69], ["mouse cell lines", "OBSERVATION", 118, 134], ["infection", "OBSERVATION", 138, 147], ["guinea pigs", "OBSERVATION", 151, 162]]], ["159, 160 However, so far no robust model for clinical hepatitis A is available.", [["hepatitis A", "DISEASE", 54, 65], ["hepatitis A", "SPECIES", 54, 65], ["clinical hepatitis A", "PROBLEM", 45, 65], ["hepatitis", "OBSERVATION", 54, 63]]], ["Very recently, it has been found that the chimeric SCID/Alb-uPA mouse model, which supports the engraftment and proliferation of transplanted human hepatocytes, is susceptible to HAV infection (Pang D., personal communication).", [["hepatocytes", "ANATOMY", 148, 159], ["HAV infection", "DISEASE", 179, 192], ["Alb", "GENE_OR_GENE_PRODUCT", 56, 59], ["uPA", "GENE_OR_GENE_PRODUCT", 60, 63], ["human", "ORGANISM", 142, 147], ["hepatocytes", "CELL", 148, 159], ["HAV", "ORGANISM", 179, 182], ["Alb", "PROTEIN", 56, 59], ["uPA", "PROTEIN", 60, 63], ["transplanted human hepatocytes", "CELL_TYPE", 129, 159], ["mouse", "SPECIES", 64, 69], ["human", "SPECIES", 142, 147], ["mouse", "SPECIES", 64, 69], ["human", "SPECIES", 142, 147], ["HAV", "SPECIES", 179, 182], ["the chimeric SCID", "TEST", 38, 55], ["Alb-uPA mouse model", "TREATMENT", 56, 75], ["the engraftment", "PROBLEM", 92, 107], ["transplanted human hepatocytes", "PROBLEM", 129, 159], ["HAV infection", "PROBLEM", 179, 192], ["engraftment", "OBSERVATION", 96, 107], ["transplanted human hepatocytes", "OBSERVATION", 129, 159], ["infection", "OBSERVATION", 183, 192]]], ["Despite the fact that these results still need to be published, they could represent a major leap forward for anti-HAV research.CONCLUSIONDespite the fact that hepatitis A is a vaccine-preventable disease and infections are usually mild, continued attention for this pathogen is warranted.", [["hepatitis A", "DISEASE", 160, 171], ["infections", "DISEASE", 209, 219], ["hepatitis A", "ORGANISM", 160, 171], ["hepatitis A", "SPECIES", 160, 171], ["anti-HAV", "TREATMENT", 110, 118], ["hepatitis A", "PROBLEM", 160, 171], ["a vaccine", "TREATMENT", 175, 184], ["preventable disease", "PROBLEM", 185, 204], ["infections", "PROBLEM", 209, 219], ["this pathogen", "PROBLEM", 262, 275], ["hepatitis", "OBSERVATION", 160, 169], ["infections", "OBSERVATION", 209, 219]]], ["Outbreaks and occasional cases of fatal fulminant hepatitis A still occur and as the age of infection shifts upwards, the severity of the infection increases as well.", [["fulminant hepatitis A", "DISEASE", 40, 61], ["infection", "DISEASE", 92, 101], ["infection", "DISEASE", 138, 147], ["fatal fulminant hepatitis", "PROBLEM", 34, 59], ["infection shifts upwards", "PROBLEM", 92, 116], ["the infection", "PROBLEM", 134, 147], ["fatal", "OBSERVATION_MODIFIER", 34, 39], ["fulminant", "OBSERVATION_MODIFIER", 40, 49], ["hepatitis", "OBSERVATION", 50, 59], ["infection", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 138, 147]]], ["Morbidity and mortality may also increase in patients with chronic liver disease, for example, due to HBV or HCV.", [["liver", "ANATOMY", 67, 72], ["chronic liver disease", "DISEASE", 59, 80], ["patients", "ORGANISM", 45, 53], ["liver", "ORGAN", 67, 72], ["HBV", "ORGANISM", 102, 105], ["HCV", "ORGANISM", 109, 112], ["patients", "SPECIES", 45, 53], ["HBV", "SPECIES", 102, 105], ["HCV", "SPECIES", 109, 112], ["Morbidity", "PROBLEM", 0, 9], ["chronic liver disease", "PROBLEM", 59, 80], ["HBV", "PROBLEM", 102, 105], ["HCV", "PROBLEM", 109, 112], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["liver", "ANATOMY", 67, 72], ["disease", "OBSERVATION", 73, 80], ["HCV", "OBSERVATION", 109, 112]]], ["Additionally, a recent report warned for the potential emergence of vaccine-escape variants.", [["vaccine", "TREATMENT", 68, 75], ["escape variants", "PROBLEM", 76, 91]]], ["18 Taken together, these reasons warrant continuation and expansion of the current vaccination programs, but also the development of antiviral drugs against HAV, even though this may not be particularly interesting from a commercial point of view.", [["HAV", "DISEASE", 157, 160], ["HAV", "ORGANISM", 157, 160], ["HAV", "SPECIES", 157, 160], ["the current vaccination programs", "TREATMENT", 71, 103], ["antiviral drugs", "TREATMENT", 133, 148], ["HAV", "PROBLEM", 157, 160]]], ["So far no potent or selective inhibitors have been reported.", [["selective inhibitors", "TREATMENT", 20, 40], ["potent", "OBSERVATION_MODIFIER", 10, 16]]], ["We therefore propose to focus antiviral efforts on marketed drugs and antivirals that are currently in clinical development.", [["antiviral efforts", "TREATMENT", 30, 47], ["marketed drugs", "TREATMENT", 51, 65], ["antivirals", "TREATMENT", 70, 80]]], ["Off-label use of such drug would be a much appreciated therapy.", [["such drug", "TREATMENT", 17, 26], ["a much appreciated therapy", "TREATMENT", 36, 62]]], ["In fact, we are currently employing our CPE reduction assay for screening of a library of FDAapproved/marketed drugs and with promising results so far.", [["our CPE reduction", "TREATMENT", 36, 53], ["FDAapproved/marketed drugs", "TREATMENT", 90, 116]]], ["Also on the fundamental biology level, HAV remains a largely understudied virus, despite many interesting features.", [["HAV", "DISEASE", 39, 42], ["HAV", "ORGANISM", 39, 42], ["HAV", "SPECIES", 39, 42], ["a largely understudied virus", "PROBLEM", 51, 79], ["virus", "OBSERVATION", 74, 79]]], ["Further investigation could provide unique insights into pathogenesis, tissue tropism determinants, and replication strategies for HAV and picornaviruses in general.", [["tissue", "ANATOMY", 71, 77], ["HAV and picornaviruses", "DISEASE", 131, 153], ["tissue", "TISSUE", 71, 77], ["HAV", "ORGANISM", 131, 134], ["HAV", "SPECIES", 131, 134], ["Further investigation", "TEST", 0, 21], ["replication strategies", "TREATMENT", 104, 126], ["HAV", "PROBLEM", 131, 134], ["picornaviruses", "PROBLEM", 139, 153]]]], "PMC6920530": [["Evolution and comparative genomics ::: Chromosome 1: Olduvai protein domain (NBPF gene) family ::: IntroductionThe initial name \u2018Neuroblastoma Breakpoint gene Family\u2019 (NBPF) was given because the first identified member of the family was found to be deleted in an individual with neuroblastoma [19].", [["neuroblastoma", "ANATOMY", 280, 293], ["Neuroblastoma", "DISEASE", 129, 142], ["neuroblastoma", "DISEASE", 280, 293], ["Chromosome 1", "GENE_OR_GENE_PRODUCT", 39, 51], ["Olduvai protein domain", "GENE_OR_GENE_PRODUCT", 53, 75], ["NBPF", "GENE_OR_GENE_PRODUCT", 77, 81], ["Neuroblastoma", "CANCER", 129, 142], ["neuroblastoma", "CANCER", 280, 293], ["Chromosome 1", "DNA", 39, 51], ["Olduvai protein domain", "DNA", 53, 75], ["NBPF gene", "DNA", 77, 86], ["NBPF", "DNA", 168, 172], ["Chromosome", "TEST", 39, 49], ["neuroblastoma", "PROBLEM", 280, 293], ["neuroblastoma", "OBSERVATION", 280, 293]]], ["NBPF gene family members include variable numbers of tandemly repeated DUF1220 domains within their coding sequences.", [["NBPF", "GENE_OR_GENE_PRODUCT", 0, 4], ["DUF1220", "GENE_OR_GENE_PRODUCT", 71, 78], ["NBPF gene family members", "DNA", 0, 24], ["DUF1220 domains", "DNA", 71, 86], ["coding sequences", "DNA", 100, 116], ["tandemly repeated DUF1220 domains", "TREATMENT", 53, 86]]], ["Since the name DUF1220 was initially a working designation assigned by the Pfam database curators, Sikela and van Roy [20] have proposed to rename the domain Olduvai.", [["DUF1220", "GENE_OR_GENE_PRODUCT", 15, 22], ["DUF1220", "DNA", 15, 22]]], ["The different NBPF core duplicon genes are distributed along chromosome 1 in 16 copies, of which 6 are in tandem and 10 are dispersed [21].", [["chromosome 1", "ANATOMY", 61, 73], ["NBPF", "GENE_OR_GENE_PRODUCT", 14, 18], ["chromosome 1", "CELLULAR_COMPONENT", 61, 73], ["NBPF core duplicon genes", "DNA", 14, 38], ["chromosome 1", "DNA", 61, 73], ["The different NBPF core duplicon genes", "PROBLEM", 0, 38], ["different", "OBSERVATION_MODIFIER", 4, 13], ["NBPF", "OBSERVATION_MODIFIER", 14, 18], ["core", "OBSERVATION_MODIFIER", 19, 23], ["duplicon genes", "OBSERVATION", 24, 38]]], ["The macaque genome has three copies of NBPF genes, while mice and other mammals have no clear orthologs.", [["macaque", "ORGANISM", 4, 11], ["NBPF", "GENE_OR_GENE_PRODUCT", 39, 43], ["mice", "ORGANISM", 57, 61], ["macaque genome", "DNA", 4, 18], ["NBPF genes", "DNA", 39, 49], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["clear orthologs", "PROBLEM", 88, 103], ["macaque genome", "OBSERVATION", 4, 18]]], ["A possible ancestral gene is PDE4DIP, which includes a single Olduvai domain [22].", [["PDE4DIP", "GENE_OR_GENE_PRODUCT", 29, 36], ["PDE4DIP", "DNA", 29, 36], ["Olduvai domain", "DNA", 62, 76], ["a single Olduvai domain", "TREATMENT", 53, 76], ["possible", "UNCERTAINTY", 2, 10], ["ancestral gene", "OBSERVATION", 11, 25]]], ["The Olduvai domain copy number has particularly expanded in humans.", [["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["expanded", "OBSERVATION_MODIFIER", 48, 56]]], ["It increased from a single domain in mouse to 30\u201335 copies in new and old world monkeys and up to 300 domains in humans [22].", [["mouse", "ORGANISM", 37, 42], ["monkeys", "ORGANISM", 80, 87], ["humans", "ORGANISM", 113, 119], ["mouse", "SPECIES", 37, 42], ["humans", "SPECIES", 113, 119], ["mouse", "SPECIES", 37, 42], ["humans", "SPECIES", 113, 119], ["increased", "OBSERVATION_MODIFIER", 3, 12]]], ["Based on sequence similarity, the domain structure of Olduvai can be divided into six primary subtypes including CON 1, 2 and 3 and HLS 1, 2 and 3 [16, 22, 23].", [["Olduvai", "GENE_OR_GENE_PRODUCT", 54, 61], ["Olduvai", "PROTEIN", 54, 61], ["sequence similarity", "TEST", 9, 28], ["CON", "TEST", 113, 116], ["HLS", "TEST", 132, 135]]], ["The comparative analysis of Olduvai-domain-containing NBPF genes in primates has shown that NBPF genes evolve under strong positive selection [13, 16].Expression and subcellular localization ::: Chromosome 1: Olduvai protein domain (NBPF gene) family ::: Introduction", [["subcellular", "ANATOMY", 166, 177], ["NBPF", "GENE_OR_GENE_PRODUCT", 54, 58], ["primates", "ORGANISM", 68, 76], ["NBPF", "GENE_OR_GENE_PRODUCT", 92, 96], ["Chromosome 1", "GENE_OR_GENE_PRODUCT", 195, 207], ["Olduvai protein domain", "GENE_OR_GENE_PRODUCT", 209, 231], ["NBPF", "GENE_OR_GENE_PRODUCT", 233, 237], ["Olduvai-domain", "DNA", 28, 42], ["NBPF genes", "DNA", 54, 64], ["NBPF genes", "DNA", 92, 102], ["Chromosome 1", "DNA", 195, 207], ["Olduvai protein domain", "DNA", 209, 231], ["NBPF gene", "DNA", 233, 242], ["The comparative analysis", "TEST", 0, 24], ["Olduvai-domain", "TREATMENT", 28, 42], ["NBPF genes", "PROBLEM", 92, 102], ["Chromosome", "TEST", 195, 205]]]], "83b1fe07b42e0d0297b889629beec59d53557caf": [["MACROPHAGE DEVELOPMENTMacrophages originate from bone marrow stem cells.", [["bone marrow stem cells", "ANATOMY", 49, 71], ["bone marrow stem cells", "CELL", 49, 71], ["bone marrow stem cells", "CELL_TYPE", 49, 71], ["MACROPHAGE DEVELOPMENTMacrophages", "PROBLEM", 0, 33], ["bone marrow stem cells", "PROBLEM", 49, 71], ["bone", "ANATOMY", 49, 53], ["marrow stem cells", "OBSERVATION", 54, 71]]], ["About 6 d are required for a monoblast to develop into a pro-monocyte and then into a monocyte under the influence of colony stimulating factor(s).", [["monoblast", "ANATOMY", 29, 38], ["pro-monocyte", "ANATOMY", 57, 69], ["monocyte", "ANATOMY", 86, 94], ["monoblast", "CANCER", 29, 38], ["pro-monocyte", "CELL", 57, 69], ["monocyte", "CELL", 86, 94], ["colony stimulating factor", "GENE_OR_GENE_PRODUCT", 118, 143], ["monocyte", "CELL_TYPE", 86, 94], ["colony stimulating factor", "PROTEIN", 118, 143], ["a pro-monocyte", "TREATMENT", 55, 69]]], ["Monocytes enter the blood stream where they constitute a major phagocytic cellular component in the chicken's blood.", [["Monocytes", "ANATOMY", 0, 9], ["blood stream", "ANATOMY", 20, 32], ["cellular", "ANATOMY", 74, 82], ["blood", "ANATOMY", 110, 115], ["Monocytes", "CELL", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["phagocytic cellular", "CELL", 63, 82], ["chicken", "ORGANISM", 100, 107], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["Monocytes", "CELL_TYPE", 0, 9], ["chicken", "SPECIES", 100, 107], ["chicken", "SPECIES", 100, 107], ["Monocytes", "TEST", 0, 9], ["the blood stream", "TEST", 16, 32], ["a major phagocytic cellular component", "PROBLEM", 55, 92], ["major", "OBSERVATION_MODIFIER", 57, 62], ["phagocytic cellular", "OBSERVATION", 63, 82], ["component", "OBSERVATION_MODIFIER", 83, 92]]], ["The second developmental stage of blood monocytes is the macrophages, and they are present in a variety of the body's tissues.", [["blood monocytes", "ANATOMY", 34, 49], ["macrophages", "ANATOMY", 57, 68], ["body", "ANATOMY", 111, 115], ["tissues", "ANATOMY", 118, 125], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["monocytes", "ORGANISM_SUBSTANCE", 40, 49], ["macrophages", "CELL", 57, 68], ["body's", "TISSUE", 111, 117], ["tissues", "TISSUE", 118, 125], ["blood monocytes", "CELL_TYPE", 34, 49], ["macrophages", "CELL_TYPE", 57, 68], ["blood monocytes", "PROBLEM", 34, 49], ["second", "OBSERVATION_MODIFIER", 4, 10], ["developmental", "OBSERVATION_MODIFIER", 11, 24], ["stage", "OBSERVATION_MODIFIER", 25, 30], ["blood monocytes", "OBSERVATION", 34, 49], ["macrophages", "OBSERVATION_MODIFIER", 57, 68], ["variety", "OBSERVATION_MODIFIER", 96, 103], ["body's", "ANATOMY_MODIFIER", 111, 117], ["tissues", "ANATOMY", 118, 125]]], ["It takes about 3 d for blood monocytes, after their arrival into the bloodstream, to seed various tissues and organs.", [["blood monocytes", "ANATOMY", 23, 38], ["bloodstream", "ANATOMY", 69, 80], ["tissues", "ANATOMY", 98, 105], ["organs", "ANATOMY", 110, 116], ["blood monocytes", "CELL", 23, 38], ["tissues", "TISSUE", 98, 105], ["organs", "ORGAN", 110, 116], ["blood monocytes", "CELL_TYPE", 23, 38], ["blood monocytes", "TEST", 23, 38], ["bloodstream", "ANATOMY", 69, 80], ["organs", "ANATOMY", 110, 116]]], ["Macrophages are, therefore, tissue forms of blood monocytes.", [["Macrophages", "ANATOMY", 0, 11], ["tissue", "ANATOMY", 28, 34], ["blood monocytes", "ANATOMY", 44, 59], ["Macrophages", "CELL", 0, 11], ["tissue", "TISSUE", 28, 34], ["blood monocytes", "CELL", 44, 59], ["Macrophages", "CELL_TYPE", 0, 11], ["blood monocytes", "CELL_TYPE", 44, 59], ["blood monocytes", "TEST", 44, 59], ["blood monocytes", "OBSERVATION", 44, 59]]], ["Tissue macrophages can be found in the lungs where they are called alveolar macrophages.", [["Tissue macrophages", "ANATOMY", 0, 18], ["lungs", "ANATOMY", 39, 44], ["alveolar macrophages", "ANATOMY", 67, 87], ["Tissue macrophages", "CELL", 0, 18], ["lungs", "ORGAN", 39, 44], ["alveolar macrophages", "CELL", 67, 87], ["macrophages", "CELL_TYPE", 7, 18], ["alveolar macrophages", "CELL_TYPE", 67, 87], ["Tissue macrophages", "TEST", 0, 18], ["macrophages", "OBSERVATION", 7, 18], ["lungs", "ANATOMY", 39, 44], ["alveolar macrophages", "OBSERVATION", 67, 87]]], ["Only about 30% of the alveolar macrophages that are present in the lungs have their direct derivation from blood monocytes; the other 70% of alveolar macrophages develop by cell division inside the lungs.", [["alveolar macrophages", "ANATOMY", 22, 42], ["lungs", "ANATOMY", 67, 72], ["blood monocytes", "ANATOMY", 107, 122], ["alveolar macrophages", "ANATOMY", 141, 161], ["cell", "ANATOMY", 173, 177], ["lungs", "ANATOMY", 198, 203], ["alveolar macrophages", "CELL", 22, 42], ["lungs", "ORGAN", 67, 72], ["blood monocytes", "ORGANISM_SUBSTANCE", 107, 122], ["alveolar macrophages", "CELL", 141, 161], ["cell", "CELL", 173, 177], ["lungs", "ORGAN", 198, 203], ["alveolar macrophages", "CELL_TYPE", 22, 42], ["blood monocytes", "CELL_TYPE", 107, 122], ["alveolar macrophages", "CELL_TYPE", 141, 161], ["blood monocytes", "TEST", 107, 122], ["alveolar macrophages", "PROBLEM", 141, 161], ["30%", "OBSERVATION_MODIFIER", 11, 14], ["alveolar", "ANATOMY_MODIFIER", 22, 30], ["macrophages", "OBSERVATION", 31, 42], ["lungs", "ANATOMY", 67, 72], ["blood monocytes", "OBSERVATION", 107, 122], ["alveolar", "ANATOMY_MODIFIER", 141, 149], ["macrophages", "OBSERVATION", 150, 161], ["cell division", "OBSERVATION", 173, 186], ["lungs", "ANATOMY", 198, 203]]], ["On the other hand, almost 100% of Kupffer cells, the macrophages found in the liver, are derived directly from blood monocytes.", [["Kupffer cells", "ANATOMY", 34, 47], ["macrophages", "ANATOMY", 53, 64], ["liver", "ANATOMY", 78, 83], ["blood monocytes", "ANATOMY", 111, 126], ["Kupffer cells", "CELL", 34, 47], ["macrophages", "CELL", 53, 64], ["liver", "ORGAN", 78, 83], ["blood monocytes", "ORGANISM_SUBSTANCE", 111, 126], ["Kupffer cells", "CELL_TYPE", 34, 47], ["macrophages", "CELL_TYPE", 53, 64], ["blood monocytes", "CELL_TYPE", 111, 126], ["blood monocytes", "TEST", 111, 126], ["Kupffer cells", "OBSERVATION", 34, 47], ["macrophages", "OBSERVATION", 53, 64], ["liver", "ANATOMY", 78, 83], ["blood monocytes", "OBSERVATION", 111, 126]]], ["Macrophages are also present in bones where they are called osteoblasts.", [["Macrophages", "ANATOMY", 0, 11], ["bones", "ANATOMY", 32, 37], ["osteoblasts", "ANATOMY", 60, 71], ["Macrophages", "CELL", 0, 11], ["bones", "ORGAN", 32, 37], ["osteoblasts", "CELL", 60, 71], ["Macrophages", "CELL_TYPE", 0, 11], ["osteoblasts", "CELL_TYPE", 60, 71], ["Macrophages", "PROBLEM", 0, 11], ["osteoblasts", "PROBLEM", 60, 71], ["bones", "ANATOMY", 32, 37], ["osteoblasts", "OBSERVATION", 60, 71]]], ["They are present in the brain as microglia cells and in the connective tissues where they are called histiocytes.", [["brain", "ANATOMY", 24, 29], ["microglia cells", "ANATOMY", 33, 48], ["connective tissues", "ANATOMY", 60, 78], ["histiocytes", "ANATOMY", 101, 112], ["brain", "ORGAN", 24, 29], ["microglia cells", "CELL", 33, 48], ["connective tissues", "TISSUE", 60, 78], ["histiocytes", "CELL", 101, 112], ["microglia cells", "CELL_TYPE", 33, 48], ["histiocytes", "PROBLEM", 101, 112], ["brain", "ANATOMY", 24, 29], ["microglia cells", "OBSERVATION", 33, 48], ["connective tissues", "ANATOMY", 60, 78], ["histiocytes", "OBSERVATION", 101, 112]]], ["Some of our studies involving chicken bone marrow stem cell differentiation have shown that such cells are fully capable of differentiating into several types of cells lineages including macrophages ( Figure 1A , B, and C), even Therefore, I have not attempted to present an up-to-date review of literature on this topic.", [["bone marrow stem cell", "ANATOMY", 38, 59], ["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 162, 167], ["macrophages", "ANATOMY", 187, 198], ["chicken", "ORGANISM", 30, 37], ["bone marrow stem cell", "CELL", 38, 59], ["cells", "CELL", 97, 102], ["cells", "CELL", 162, 167], ["macrophages", "CELL", 187, 198], ["Figure 1A", "CELL", 201, 210], ["B", "GENE_OR_GENE_PRODUCT", 213, 214], ["macrophages", "CELL_TYPE", 187, 198], ["chicken", "SPECIES", 30, 37], ["chicken", "SPECIES", 30, 37], ["our studies", "TEST", 8, 19], ["chicken bone marrow stem cell differentiation", "PROBLEM", 30, 75], ["such cells", "PROBLEM", 92, 102], ["cells lineages", "PROBLEM", 162, 176], ["macrophages", "TEST", 187, 198], ["Figure 1A", "TEST", 201, 210], ["bone", "ANATOMY", 38, 42], ["marrow stem cell differentiation", "OBSERVATION", 43, 75], ["several types", "OBSERVATION_MODIFIER", 145, 158], ["cells lineages", "OBSERVATION", 162, 176]]], ["Rather, I have summarized some salient research accomplishments made by our research group over the years in the area of avian macrophage biology and function. at day of hatch or prior to hatching.", [["macrophage", "ANATOMY", 127, 137], ["avian", "ORGANISM", 121, 126], ["macrophage", "CELL", 127, 137], ["avian macrophage", "OBSERVATION", 121, 137]]], ["When we compared broilers with White Leghorn layers for the ability of embryonic hemopoietic progenitors to differentiate into macrophage lineage cells, we found that starting with the same numbers of bone marrow stem cells, broilers produced significantly lower numbers of macrophage-type colonies than White Leghorn chickens.", [["embryonic hemopoietic progenitors", "ANATOMY", 71, 104], ["macrophage lineage cells", "ANATOMY", 127, 151], ["bone marrow stem cells", "ANATOMY", 201, 223], ["macrophage-type colonies", "ANATOMY", 274, 298], ["broilers", "ORGANISM", 17, 25], ["Leghorn layers", "MULTI-TISSUE_STRUCTURE", 37, 51], ["embryonic hemopoietic progenitors", "CELL", 71, 104], ["macrophage lineage cells", "CELL", 127, 151], ["bone marrow stem cells", "CELL", 201, 223], ["broilers", "ORGANISM", 225, 233], ["macrophage-type colonies", "CELL", 274, 298], ["Leghorn chickens", "ORGANISM", 310, 326], ["embryonic hemopoietic progenitors", "CELL_TYPE", 71, 104], ["macrophage lineage cells", "CELL_TYPE", 127, 151], ["bone marrow stem cells", "CELL_TYPE", 201, 223], ["macrophage-type colonies", "CELL_LINE", 274, 298], ["broilers", "SPECIES", 17, 25], ["chickens", "SPECIES", 318, 326], ["Leghorn", "SPECIES", 37, 44], ["White Leghorn chickens", "SPECIES", 304, 326], ["White Leghorn layers", "TREATMENT", 31, 51], ["embryonic hemopoietic progenitors", "TREATMENT", 71, 104], ["type colonies", "PROBLEM", 285, 298], ["White Leghorn chickens", "PROBLEM", 304, 326], ["embryonic hemopoietic progenitors", "OBSERVATION", 71, 104], ["macrophage lineage cells", "OBSERVATION", 127, 151], ["bone", "ANATOMY", 201, 205], ["marrow stem cells", "OBSERVATION", 206, 223], ["significantly", "OBSERVATION_MODIFIER", 243, 256], ["lower", "OBSERVATION_MODIFIER", 257, 262], ["numbers", "OBSERVATION_MODIFIER", 263, 270], ["macrophage", "ANATOMY", 274, 284]]], ["This difference may be one indication of why broiler type chickens are perceived as being a little more susceptible perinatally than are White Leghorn type chickens (Nicolas-Bolnet et al., 1995) .MACROPHAGE ACTIVATION AND SOURCEIn addition to developmental maturation, cells of the mononuclear phagocytic system (MPS) lineage such as monocytes and macrophages also undergo functional maturation.", [["cells", "ANATOMY", 269, 274], ["mononuclear phagocytic system", "ANATOMY", 282, 311], ["MPS) lineage", "ANATOMY", 313, 325], ["monocytes", "ANATOMY", 334, 343], ["macrophages", "ANATOMY", 348, 359], ["broiler type chickens", "ORGANISM", 45, 66], ["Leghorn type chickens", "ORGANISM", 143, 164], ["cells", "CELL", 269, 274], ["mononuclear phagocytic system", "CELL", 282, 311], ["MPS) lineage", "CELL", 313, 325], ["monocytes", "CELL", 334, 343], ["macrophages", "CELL", 348, 359], ["mononuclear phagocytic system (MPS) lineage", "CELL_TYPE", 282, 325], ["monocytes", "CELL_TYPE", 334, 343], ["macrophages", "CELL_TYPE", 348, 359], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 156, 164], ["chickens", "SPECIES", 58, 66], ["White Leghorn type chickens", "SPECIES", 137, 164], ["developmental maturation", "PROBLEM", 243, 267], ["mononuclear phagocytic", "OBSERVATION", 282, 304], ["functional maturation", "OBSERVATION", 373, 394]]], ["In the murine system, resident macrophages isolated from the peritoneal cavity can be primed and activated in response to biological signals such as \u03b3interferon and lipopolysaccharide (LPS).", [["macrophages", "ANATOMY", 31, 42], ["peritoneal cavity", "ANATOMY", 61, 78], ["\u03b3interferon", "CHEMICAL", 149, 160], ["lipopolysaccharide", "CHEMICAL", 165, 183], ["LPS", "CHEMICAL", 185, 188], ["murine", "ORGANISM", 7, 13], ["macrophages", "CELL", 31, 42], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 61, 78], ["\u03b3interferon", "SIMPLE_CHEMICAL", 149, 160], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 165, 183], ["LPS", "SIMPLE_CHEMICAL", 185, 188], ["resident macrophages", "CELL_TYPE", 22, 42], ["murine", "SPECIES", 7, 13], ["\u03b3interferon and lipopolysaccharide (LPS)", "TREATMENT", 149, 189], ["macrophages", "OBSERVATION", 31, 42], ["peritoneal cavity", "ANATOMY", 61, 78]]], ["In chickens, however, there are no (or just a few) resident macrophages present in the abdominal cavity.", [["macrophages", "ANATOMY", 60, 71], ["abdominal cavity", "ANATOMY", 87, 103], ["chickens", "ORGANISM", 3, 11], ["macrophages", "CELL", 60, 71], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 87, 103], ["resident macrophages", "CELL_TYPE", 51, 71], ["chickens", "SPECIES", 3, 11], ["chickens", "SPECIES", 3, 11], ["chickens", "OBSERVATION", 3, 11], ["macrophages", "OBSERVATION", 60, 71], ["abdominal cavity", "ANATOMY", 87, 103]]], ["Therefore, as a result of an active inflammatory response at a tissue site such as the abdominal cavity, monocytes can be recruited into the tissues (Qureshi et al., 1986; Qureshi and Dietert, 1995) .", [["tissue site", "ANATOMY", 63, 74], ["abdominal cavity", "ANATOMY", 87, 103], ["monocytes", "ANATOMY", 105, 114], ["tissues", "ANATOMY", 141, 148], ["tissue", "TISSUE", 63, 69], ["abdominal cavity", "ORGAN", 87, 103], ["monocytes", "CELL", 105, 114], ["tissues", "TISSUE", 141, 148], ["monocytes", "CELL_TYPE", 105, 114], ["an active inflammatory response", "PROBLEM", 26, 57], ["a tissue site", "PROBLEM", 61, 74], ["active", "OBSERVATION_MODIFIER", 29, 35], ["inflammatory", "OBSERVATION", 36, 48], ["abdominal cavity", "ANATOMY", 87, 103], ["monocytes", "OBSERVATION", 105, 114], ["tissues", "ANATOMY", 141, 148]]], ["Macrophages can then be purified from the inflammatory abdominal exudate cells (AEC) by adherence to glass (coverslips) or plastic (Petri dish) surfaces.", [["Macrophages", "ANATOMY", 0, 11], ["abdominal exudate cells", "ANATOMY", 55, 78], ["AEC", "ANATOMY", 80, 83], ["Macrophages", "CELL", 0, 11], ["inflammatory abdominal exudate cells", "CELL", 42, 78], ["AEC", "CELL", 80, 83], ["Macrophages", "CELL_TYPE", 0, 11], ["inflammatory abdominal exudate cells", "CELL_TYPE", 42, 78], ["AEC", "CELL_TYPE", 80, 83], ["Macrophages", "PROBLEM", 0, 11], ["the inflammatory abdominal exudate cells", "PROBLEM", 38, 78], ["glass (coverslips)", "TREATMENT", 101, 119], ["plastic (Petri dish) surfaces", "TREATMENT", 123, 152], ["inflammatory", "OBSERVATION_MODIFIER", 42, 54], ["abdominal", "ANATOMY", 55, 64], ["exudate cells", "OBSERVATION", 65, 78]]], ["It has been shown that Sephadex-elicited macrophages are very phagocytic Abbreviation Key: AEC = abdominal exudate cells; CD14 = LPSbinding molecule; iNOS = inducible isoform nitric oxide synthase; LPS = lipopolysaccharide; MPS = mononuclear phagocytic system; NO = nitric oxide; NOS = nitric oxide synthase; TLR = toll-like receptor. for particulate antigens such sheep red blood cells or bacteria (Qureshi et al., 1986) .", [["macrophages", "ANATOMY", 41, 52], ["abdominal exudate cells", "ANATOMY", 97, 120], ["red blood cells", "ANATOMY", 371, 386], ["nitric oxide", "CHEMICAL", 175, 187], ["LPS", "CHEMICAL", 198, 201], ["lipopolysaccharide", "CHEMICAL", 204, 222], ["NO", "CHEMICAL", 261, 263], ["nitric oxide", "CHEMICAL", 266, 278], ["nitric oxide", "CHEMICAL", 286, 298], ["nitric oxide", "CHEMICAL", 175, 187], ["NO", "CHEMICAL", 261, 263], ["nitric oxide", "CHEMICAL", 266, 278], ["nitric oxide", "CHEMICAL", 286, 298], ["Sephadex", "SIMPLE_CHEMICAL", 23, 31], ["macrophages", "CELL", 41, 52], ["abdominal exudate cells", "CELL", 97, 120], ["CD14", "GENE_OR_GENE_PRODUCT", 122, 126], ["LPSbinding molecule", "GENE_OR_GENE_PRODUCT", 129, 148], ["iNOS", "GENE_OR_GENE_PRODUCT", 150, 154], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 175, 196], ["LPS", "SIMPLE_CHEMICAL", 198, 201], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 204, 222], ["MPS", "SIMPLE_CHEMICAL", 224, 227], ["NO", "SIMPLE_CHEMICAL", 261, 263], ["nitric oxide", "SIMPLE_CHEMICAL", 266, 278], ["NOS = nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 280, 307], ["TLR", "GENE_OR_GENE_PRODUCT", 309, 312], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 315, 333], ["sheep", "ORGANISM", 365, 370], ["red blood cells", "CELL", 371, 386], ["macrophages", "CELL_TYPE", 41, 52], ["AEC", "CELL_TYPE", 91, 94], ["abdominal exudate cells", "CELL_TYPE", 97, 120], ["CD14", "PROTEIN", 122, 126], ["LPSbinding molecule", "PROTEIN", 129, 148], ["iNOS", "PROTEIN", 150, 154], ["isoform nitric oxide synthase", "PROTEIN", 167, 196], ["NOS", "PROTEIN", 280, 283], ["nitric oxide synthase", "PROTEIN", 286, 307], ["TLR", "PROTEIN", 309, 312], ["toll-like receptor", "PROTEIN", 315, 333], ["sheep red blood cells", "CELL_TYPE", 365, 386], ["sheep", "SPECIES", 365, 370], ["sheep", "SPECIES", 365, 370], ["Sephadex", "TEST", 23, 31], ["macrophages", "PROBLEM", 41, 52], ["AEC", "TEST", 91, 94], ["abdominal exudate cells", "TEST", 97, 120], ["CD14", "TEST", 122, 126], ["LPSbinding molecule", "TEST", 129, 148], ["iNOS", "TEST", 150, 154], ["inducible isoform nitric oxide synthase", "TREATMENT", 157, 196], ["LPS", "TEST", 198, 201], ["lipopolysaccharide", "TEST", 204, 222], ["MPS", "TEST", 224, 227], ["mononuclear phagocytic system", "TEST", 230, 259], ["nitric oxide", "TREATMENT", 266, 278], ["nitric oxide synthase", "TREATMENT", 286, 307], ["particulate antigens such sheep red blood cells", "PROBLEM", 339, 386], ["bacteria", "PROBLEM", 390, 398], ["abdominal", "ANATOMY", 97, 106]]], ["However, Sephadex-elicited macrophages are not capable of performing certain specialized effector functions such as tumor cell killing.", [["macrophages", "ANATOMY", 27, 38], ["tumor cell", "ANATOMY", 116, 126], ["tumor", "DISEASE", 116, 121], ["macrophages", "CELL", 27, 38], ["tumor cell", "CELL", 116, 126], ["Sephadex-elicited macrophages", "CELL_LINE", 9, 38], ["Sephadex", "TEST", 9, 17], ["macrophages", "PROBLEM", 27, 38], ["tumor cell killing", "PROBLEM", 116, 134], ["macrophages", "OBSERVATION", 27, 38], ["tumor cell killing", "OBSERVATION", 116, 134]]], ["Our studies have shown that one can drive Sephadexelicited macrophages towards tumoricidal pathways by providing biological signals such as bacterial LPS and lymphokines (Qureshi and Miller, 1991a) .", [["macrophages", "ANATOMY", 59, 70], ["Sephadexelicited macrophages", "CELL", 42, 70], ["LPS", "GENE_OR_GENE_PRODUCT", 150, 153], ["Sephadexelicited macrophages", "CELL_LINE", 42, 70], ["lymphokines", "PROTEIN", 158, 169], ["Our studies", "TEST", 0, 11], ["bacterial LPS", "TREATMENT", 140, 153]]], ["Therefore, as with the murine macrophages, chicken macrophages could also be defined as undergoing at least three different stages of functional maturation, i.e., responsive, primed, and activated macrophages.", [["macrophages", "ANATOMY", 30, 41], ["macrophages", "ANATOMY", 51, 62], ["macrophages", "ANATOMY", 197, 208], ["murine", "ORGANISM", 23, 29], ["macrophages", "CELL", 30, 41], ["chicken", "ORGANISM", 43, 50], ["macrophages", "CELL", 51, 62], ["macrophages", "CELL", 197, 208], ["murine macrophages", "CELL_TYPE", 23, 41], ["chicken macrophages", "CELL_TYPE", 43, 62], ["activated macrophages", "CELL_TYPE", 187, 208], ["murine", "SPECIES", 23, 29], ["chicken", "SPECIES", 43, 50], ["chicken", "SPECIES", 43, 50], ["the murine macrophages", "TREATMENT", 19, 41], ["chicken macrophages", "PROBLEM", 43, 62], ["functional maturation", "OBSERVATION", 134, 155]]], ["There are studies in the literature describing the antigenic uptake/trapping function of spleen-and liver-sourced macrophages during embryonic development.", [["spleen", "ANATOMY", 89, 95], ["liver", "ANATOMY", 100, 105], ["macrophages", "ANATOMY", 114, 125], ["embryonic", "ANATOMY", 133, 142], ["spleen", "ORGAN", 89, 95], ["liver", "ORGAN", 100, 105], ["macrophages", "CELL", 114, 125], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 133, 142], ["spleen-and liver-sourced macrophages", "CELL_TYPE", 89, 125], ["the antigenic uptake", "PROBLEM", 47, 67], ["spleen", "TEST", 89, 95], ["spleen", "ANATOMY", 89, 95], ["liver", "ANATOMY", 100, 105], ["macrophages", "OBSERVATION", 114, 125]]], ["Working with Sephadexelicited macrophages, we have shown that turkey poults are fully capable of responding to an inflammatory challenge received at day of hatch with the recruitment of blood monocytes into the challenged tissue.", [["macrophages", "ANATOMY", 30, 41], ["blood monocytes", "ANATOMY", 186, 201], ["tissue", "ANATOMY", 222, 228], ["Sephadexelicited macrophages", "CELL", 13, 41], ["turkey poults", "ORGANISM", 62, 75], ["blood monocytes", "ORGANISM_SUBSTANCE", 186, 201], ["tissue", "TISSUE", 222, 228], ["Sephadexelicited macrophages", "CELL_TYPE", 13, 41], ["blood monocytes", "CELL_TYPE", 186, 201], ["turkey", "SPECIES", 62, 68], ["poults", "SPECIES", 69, 75], ["turkey", "SPECIES", 62, 68], ["an inflammatory challenge", "TREATMENT", 111, 136], ["the recruitment of blood monocytes", "TREATMENT", 167, 201], ["inflammatory", "OBSERVATION", 114, 126], ["challenged tissue", "OBSERVATION", 211, 228]]], ["Sephadexelicited abdominal exudate macrophages collected at 3, 5, or 7 d of age are quite efficient in phagocytizing antibodycoated or uncoated antigen targets .MACROPHAGE ACTIVATION AND SOURCEMacrophages obtained after Sephadex elicitation show very typical macrophage morphology.", [["abdominal exudate macrophages", "ANATOMY", 17, 46], ["macrophage", "ANATOMY", 259, 269], ["abdominal exudate macrophages", "CELL", 17, 46], ["antibodycoated", "SIMPLE_CHEMICAL", 117, 131], ["macrophage", "CELL", 259, 269], ["Sephadexelicited abdominal exudate macrophages", "CELL_TYPE", 0, 46], ["Sephadexelicited abdominal exudate macrophages", "PROBLEM", 0, 46], ["MACROPHAGE ACTIVATION", "TEST", 161, 182], ["SOURCEMacrophages", "TEST", 187, 204], ["Sephadex elicitation", "TEST", 220, 240], ["abdominal", "ANATOMY", 17, 26], ["exudate macrophages", "OBSERVATION", 27, 46], ["very", "OBSERVATION_MODIFIER", 246, 250], ["typical", "OBSERVATION_MODIFIER", 251, 258], ["macrophage morphology", "OBSERVATION", 259, 280]]], ["They are quite spread out with several visible vacuoles in the cytoplasm.", [["vacuoles", "ANATOMY", 47, 55], ["cytoplasm", "ANATOMY", 63, 72], ["vacuoles", "CELLULAR_COMPONENT", 47, 55], ["cytoplasm", "ORGANISM_SUBSTANCE", 63, 72], ["cytoplasm", "ANATOMY", 63, 72]]], ["Depending on the time after a single Sephadex injection at which the AEC are harvested, one can also see quite a few heterophils being recruited into the abdominal cavity along with the other AEC ( Figure 1D ).", [["AEC", "ANATOMY", 69, 72], ["heterophils", "ANATOMY", 117, 128], ["abdominal cavity", "ANATOMY", 154, 170], ["AEC", "CANCER", 69, 72], ["heterophils", "CELL", 117, 128], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 154, 170], ["AEC", "CELL_TYPE", 69, 72], ["heterophils", "CELL_TYPE", 117, 128], ["AEC", "PROTEIN", 192, 195], ["a single Sephadex injection", "TREATMENT", 28, 55], ["a few heterophils", "PROBLEM", 111, 128], ["harvested", "OBSERVATION", 77, 86], ["few", "OBSERVATION_MODIFIER", 113, 116], ["heterophils", "OBSERVATION", 117, 128], ["abdominal cavity", "ANATOMY", 154, 170]]], ["In our experience, AEC collected between 30 to 40 h after a single injection of a 3% Sephadex suspension given as 1 cc/100 g BW, yields greater than 90% macrophages in the AEC ( Figure 2A ).", [["macrophages", "ANATOMY", 153, 164], ["AEC", "CANCER", 19, 22], ["macrophages", "CELL", 153, 164], ["macrophages", "CELL_TYPE", 153, 164], ["AEC", "CELL_TYPE", 172, 175], ["AEC", "TEST", 19, 22], ["a 3% Sephadex suspension", "TREATMENT", 80, 104], ["AEC", "ANATOMY", 172, 175]]], ["In addition to the development of a method for the isolation of macrophages from live chickens, our laboratory has established a transformed macrophage chicken cell line (MQ-NCSU), which serves as a unique tool to examine various aspects of chicken macrophage biology and function in many laboratories throughout the world .MACROPHAGE FUNCTIONSSome of the classical macrophage functions include chemotaxis, phagocytosis, the killing of bacteria and tu- mor cells, and cytokine production.", [["macrophages", "ANATOMY", 64, 75], ["macrophage chicken cell line", "ANATOMY", 141, 169], ["MQ-NCSU", "ANATOMY", 171, 178], ["macrophage", "ANATOMY", 249, 259], ["macrophage", "ANATOMY", 366, 376], ["tu- mor cells", "ANATOMY", 449, 462], ["macrophages", "CELL", 64, 75], ["chickens", "ORGANISM", 86, 94], ["macrophage chicken cell line", "CELL", 141, 169], ["MQ-NCSU", "CELL", 171, 178], ["chicken", "ORGANISM", 241, 248], ["macrophage", "CELL", 249, 259], ["macrophage", "CELL", 366, 376], ["tu- mor cells", "CELL", 449, 462], ["macrophages", "CELL_TYPE", 64, 75], ["transformed macrophage chicken cell line", "CELL_LINE", 129, 169], ["MQ", "CELL_LINE", 171, 173], ["NCSU", "CELL_LINE", 174, 178], ["mor cells", "CELL_TYPE", 453, 462], ["cytokine", "PROTEIN", 468, 476], ["chickens", "SPECIES", 86, 94], ["chicken", "SPECIES", 152, 159], ["chicken", "SPECIES", 241, 248], ["chickens", "SPECIES", 86, 94], ["chicken", "SPECIES", 152, 159], ["chicken", "SPECIES", 241, 248], ["a method", "TREATMENT", 34, 42], ["macrophages", "PROBLEM", 64, 75], ["a transformed macrophage chicken cell line", "TREATMENT", 127, 169], ["chemotaxis", "PROBLEM", 395, 405], ["phagocytosis", "PROBLEM", 407, 419], ["bacteria", "PROBLEM", 436, 444], ["tu- mor cells", "PROBLEM", 449, 462], ["cytokine production", "PROBLEM", 468, 487], ["macrophages", "OBSERVATION", 64, 75], ["mor cells", "OBSERVATION", 453, 462], ["cytokine production", "OBSERVATION", 468, 487]]], ["In addition, nutrition, genetics, and numerous environmental factors have been demonstrated to modulate some macrophage functions.MACROPHAGE FUNCTIONSChemotaxis is a function of both monocytes and macrophages, which involves migration toward an inflammatory gradient.", [["macrophage", "ANATOMY", 109, 119], ["monocytes", "ANATOMY", 183, 192], ["macrophages", "ANATOMY", 197, 208], ["macrophage", "CELL", 109, 119], ["monocytes", "CELL", 183, 192], ["macrophages", "CELL", 197, 208], ["monocytes", "CELL_TYPE", 183, 192], ["macrophages", "CELL_TYPE", 197, 208], ["MACROPHAGE FUNCTIONSChemotaxis", "TEST", 130, 160], ["an inflammatory gradient", "PROBLEM", 242, 266], ["both monocytes", "OBSERVATION", 178, 192], ["macrophages", "OBSERVATION", 197, 208], ["migration", "OBSERVATION_MODIFIER", 225, 234], ["inflammatory", "OBSERVATION_MODIFIER", 245, 257], ["gradient", "OBSERVATION_MODIFIER", 258, 266]]], ["Chemotactic signals can be derived from bacterial products, by certain synthetic peptides such as f-met-leu-phe, by certain products of the immune reaction such as complement, or by certain factors released by the damaged cells and extracellular matrix.", [["cells", "ANATOMY", 222, 227], ["extracellular matrix", "ANATOMY", 232, 252], ["f-met-leu-phe", "GENE_OR_GENE_PRODUCT", 98, 111], ["cells", "CELL", 222, 227], ["extracellular matrix", "CELLULAR_COMPONENT", 232, 252], ["damaged cells", "CELL_TYPE", 214, 227], ["Chemotactic signals", "TEST", 0, 19], ["bacterial products", "PROBLEM", 40, 58], ["certain synthetic peptides", "PROBLEM", 63, 89], ["the immune reaction", "PROBLEM", 136, 155], ["extracellular matrix", "OBSERVATION", 232, 252]]], ["For example, neutrophils, upon dying, release elastase or collagenase, which are chemotactic in nature.", [["neutrophils", "ANATOMY", 13, 24], ["neutrophils", "CELL", 13, 24], ["elastase", "GENE_OR_GENE_PRODUCT", 46, 54], ["collagenase", "GENE_OR_GENE_PRODUCT", 58, 69], ["neutrophils", "CELL_TYPE", 13, 24], ["elastase", "PROTEIN", 46, 54], ["collagenase", "PROTEIN", 58, 69], ["neutrophils", "PROBLEM", 13, 24], ["collagenase", "PROBLEM", 58, 69], ["neutrophils", "OBSERVATION", 13, 24], ["chemotactic", "OBSERVATION_MODIFIER", 81, 92]]], ["Furthermore, collagen, elastin, and fibrinogen are also chemotactic in nature.", [["collagen", "GENE_OR_GENE_PRODUCT", 13, 21], ["elastin", "GENE_OR_GENE_PRODUCT", 23, 30], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 36, 46], ["collagen", "PROTEIN", 13, 21], ["elastin", "PROTEIN", 23, 30], ["fibrinogen", "PROTEIN", 36, 46], ["fibrinogen", "TREATMENT", 36, 46], ["chemotactic", "OBSERVATION_MODIFIER", 56, 67]]], ["The chemotactic potential can easily be demonstrated by using chicken blood monocytes and incubating them in the presence of a synthetic bacterial signal peptide such as f-met-leu-phe, or with the supernatants from bacterial cultures.", [["blood monocytes", "ANATOMY", 70, 85], ["supernatants", "ANATOMY", 197, 209], ["cultures", "ANATOMY", 225, 233], ["chicken", "ORGANISM", 62, 69], ["blood monocytes", "CELL", 70, 85], ["f-met-leu-phe", "GENE_OR_GENE_PRODUCT", 170, 183], ["chicken blood monocytes", "CELL_TYPE", 62, 85], ["f-met", "PROTEIN", 170, 175], ["bacterial cultures", "CELL_LINE", 215, 233], ["chicken", "SPECIES", 62, 69], ["chicken", "SPECIES", 62, 69], ["chicken blood monocytes", "TREATMENT", 62, 85], ["a synthetic bacterial signal peptide", "PROBLEM", 125, 161], ["the supernatants", "PROBLEM", 193, 209], ["bacterial cultures", "TEST", 215, 233]]], ["Using a chemotactic assay ( Figure 2C ), we have demonstrated that chicken blood monocytes are very active in responding to chemotactic signals, and that there are differences in the chemotactic potential of blood monocytes depending upon their genetic origin (Qureshi et al., 1988) .MACROPHAGE FUNCTIONSPhagocytosis is perhaps the most evolutionary conserved function of the macrophage.", [["blood monocytes", "ANATOMY", 75, 90], ["blood monocytes", "ANATOMY", 208, 223], ["macrophage", "ANATOMY", 376, 386], ["chicken", "ORGANISM", 67, 74], ["blood monocytes", "CELL", 75, 90], ["blood monocytes", "CELL", 208, 223], ["macrophage", "CELL", 376, 386], ["chicken blood monocytes", "CELL_TYPE", 67, 90], ["blood monocytes", "CELL_TYPE", 208, 223], ["macrophage", "CELL_TYPE", 376, 386], ["chicken", "SPECIES", 67, 74], ["chicken", "SPECIES", 67, 74], ["a chemotactic assay", "TEST", 6, 25], ["chicken blood monocytes", "PROBLEM", 67, 90], ["chemotactic signals", "TEST", 124, 143], ["blood monocytes", "PROBLEM", 208, 223], ["MACROPHAGE FUNCTIONSPhagocytosis", "PROBLEM", 284, 316], ["active", "OBSERVATION_MODIFIER", 100, 106], ["macrophage", "OBSERVATION_MODIFIER", 376, 386]]], ["Macrophages perform phagocytic functions via several different mechanisms.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "TREATMENT", 0, 11], ["phagocytic functions", "TEST", 20, 40], ["phagocytic functions", "OBSERVATION", 20, 40]]], ["Most of the phagocytic functions for particulate antigens are mediated via specific receptors present on the surfaces of macrophage cells.", [["phagocytic", "ANATOMY", 12, 22], ["macrophage cells", "ANATOMY", 121, 137], ["particulate antigens", "GENE_OR_GENE_PRODUCT", 37, 57], ["macrophage cells", "CELL", 121, 137], ["particulate antigens", "PROTEIN", 37, 57], ["macrophage cells", "CELL_TYPE", 121, 137], ["particulate antigens", "PROBLEM", 37, 57], ["macrophage cells", "OBSERVATION", 121, 137]]], ["These receptors are capable of binding specific targets for phagocytosis.", [["phagocytosis", "PROBLEM", 60, 72]]], ["For example, certain pattern recognition molecules present as receptors on the macrophage surface enhance the binding of bacteria with mannose and fructose by their correct spacing.", [["macrophage surface", "ANATOMY", 79, 97], ["mannose", "CHEMICAL", 135, 142], ["fructose", "CHEMICAL", 147, 155], ["mannose", "CHEMICAL", 135, 142], ["fructose", "CHEMICAL", 147, 155], ["macrophage surface", "CELLULAR_COMPONENT", 79, 97], ["mannose", "SIMPLE_CHEMICAL", 135, 142], ["fructose", "SIMPLE_CHEMICAL", 147, 155], ["pattern recognition molecules", "PROTEIN", 21, 50], ["mannose", "TREATMENT", 135, 142], ["bacteria", "OBSERVATION_MODIFIER", 121, 129]]], ["Macrophages also have specific receptors for mannose, and because of this, certain bacterial or viral agents having mannose expressed on their outer surfaces will preferentially bind to the macrophage via those mannose receptors.", [["Macrophages", "ANATOMY", 0, 11], ["outer surfaces", "ANATOMY", 143, 157], ["macrophage", "ANATOMY", 190, 200], ["mannose", "CHEMICAL", 116, 123], ["mannose", "CHEMICAL", 45, 52], ["mannose", "CHEMICAL", 116, 123], ["mannose", "CHEMICAL", 211, 218], ["Macrophages", "CELL", 0, 11], ["mannose", "SIMPLE_CHEMICAL", 45, 52], ["mannose", "SIMPLE_CHEMICAL", 116, 123], ["macrophage", "CELL", 190, 200], ["mannose receptors", "GENE_OR_GENE_PRODUCT", 211, 228], ["Macrophages", "CELL_TYPE", 0, 11], ["macrophage", "CELL_TYPE", 190, 200], ["mannose receptors", "PROTEIN", 211, 228], ["mannose", "TREATMENT", 45, 52], ["mannose", "TREATMENT", 116, 123], ["those mannose receptors", "TREATMENT", 205, 228]]], ["Macrophages also have scavenger receptors.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["scavenger receptors", "PROTEIN", 22, 41], ["scavenger receptors", "TREATMENT", 22, 41], ["scavenger receptors", "OBSERVATION", 22, 41]]], ["Scavenger receptors are utilized to internalize pathogens as well as old and dying red blood cells.", [["red blood cells", "ANATOMY", 83, 98], ["Scavenger receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["red blood cells", "CELL", 83, 98], ["Scavenger receptors", "PROTEIN", 0, 19], ["dying red blood cells", "CELL_TYPE", 77, 98], ["Scavenger receptors", "TREATMENT", 0, 19], ["internalize pathogens", "PROBLEM", 36, 57], ["red blood cells", "TEST", 83, 98], ["pathogens", "OBSERVATION", 48, 57], ["blood cells", "OBSERVATION", 87, 98]]], ["There are other specialized receptors such as the Fc-receptor that are present on the surface of the macrophage that specifically target antigens that are coated with their antibody ( Figure 2D ).", [["surface", "ANATOMY", 86, 93], ["macrophage", "ANATOMY", 101, 111], ["Fc-receptor", "GENE_OR_GENE_PRODUCT", 50, 61], ["surface", "CELLULAR_COMPONENT", 86, 93], ["macrophage", "CELL", 101, 111], ["Fc-receptor", "PROTEIN", 50, 61], ["macrophage", "CELL_TYPE", 101, 111], ["antigens", "PROTEIN", 137, 145], ["antibody", "PROTEIN", 173, 181], ["macrophage", "OBSERVATION", 101, 111]]], ["Also, an antigenic target that is coated with complement can be preferentially bound to the surface of the macrophage via the complement receptor.", [["surface", "ANATOMY", 92, 99], ["macrophage", "ANATOMY", 107, 117], ["surface", "CELLULAR_COMPONENT", 92, 99], ["macrophage", "CELL", 107, 117], ["complement receptor", "GENE_OR_GENE_PRODUCT", 126, 145], ["macrophage", "CELL_TYPE", 107, 117], ["complement receptor", "PROTEIN", 126, 145], ["antigenic target", "OBSERVATION", 9, 25], ["macrophage", "OBSERVATION", 107, 117]]], ["Additionally, there are receptors present on the surface of the macrophage that may not necessarily be directly involved in phagocytosis but which can mediate an activation signal for the LPS-binding receptors.", [["surface", "ANATOMY", 49, 56], ["macrophage", "ANATOMY", 64, 74], ["LPS", "CHEMICAL", 188, 191], ["surface", "CELLULAR_COMPONENT", 49, 56], ["macrophage", "CELL", 64, 74], ["LPS-binding receptors", "GENE_OR_GENE_PRODUCT", 188, 209], ["macrophage", "CELL_TYPE", 64, 74], ["LPS-binding receptors", "PROTEIN", 188, 209], ["phagocytosis", "PROBLEM", 124, 136], ["receptors", "OBSERVATION", 24, 33], ["macrophage", "OBSERVATION", 64, 74], ["may not necessarily be", "UNCERTAINTY", 80, 102]]], ["The percentage of macrophages that are phagocytic is dependent upon the type of target being phagocytized.", [["macrophages", "ANATOMY", 18, 29], ["macrophages", "CELL", 18, 29], ["macrophages", "CELL_TYPE", 18, 29], ["macrophages", "PROBLEM", 18, 29], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["macrophages", "OBSERVATION", 18, 29], ["phagocytic", "OBSERVATION_MODIFIER", 39, 49]]], ["For example, in a typical phagocytosis assay, utilizing nonantibody coated SRBC, one would see approximately 20 to 40% of the adherent macrophage population capable of internalizing two to three sheep red blood cells per phagocytic macrophage.", [["macrophage", "ANATOMY", 135, 145], ["red blood cells", "ANATOMY", 201, 216], ["phagocytic macrophage", "ANATOMY", 221, 242], ["SRBC", "CELL", 75, 79], ["macrophage population", "CELL", 135, 156], ["sheep", "ORGANISM", 195, 200], ["red blood cells", "CELL", 201, 216], ["phagocytic macrophage", "CELL", 221, 242], ["nonantibody coated SRBC", "CELL_LINE", 56, 79], ["adherent macrophage population", "CELL_TYPE", 126, 156], ["sheep red blood cells", "CELL_TYPE", 195, 216], ["phagocytic macrophage", "CELL_TYPE", 221, 242], ["sheep", "SPECIES", 195, 200], ["sheep", "SPECIES", 195, 200], ["a typical phagocytosis assay", "TEST", 16, 44], ["nonantibody coated SRBC", "TREATMENT", 56, 79], ["red blood cells", "TEST", 201, 216], ["adherent", "OBSERVATION_MODIFIER", 126, 134], ["macrophage", "OBSERVATION", 135, 145], ["phagocytic macrophage", "OBSERVATION", 221, 242]]], ["On the contrary, the percentage of phagocytic macrophages increases significantly to 70 to 95%, if the SRBC are coated with a specific antibody ( Figure 2B ).", [["phagocytic macrophages", "ANATOMY", 35, 57], ["SRBC", "ANATOMY", 103, 107], ["phagocytic macrophages", "CELL", 35, 57], ["SRBC", "CELL", 103, 107], ["phagocytic macrophages", "CELL_TYPE", 35, 57], ["SRBC", "CELL_TYPE", 103, 107], ["specific antibody", "PROTEIN", 126, 143], ["Figure 2B", "PROTEIN", 146, 155], ["phagocytic macrophages", "PROBLEM", 35, 57], ["the SRBC", "TEST", 99, 107], ["a specific antibody", "TEST", 124, 143], ["percentage", "OBSERVATION_MODIFIER", 21, 31], ["phagocytic macrophages", "OBSERVATION", 35, 57]]], ["Furthermore, by utilizing opsonized SRBC, the presence of Fcreceptors can be demonstrated on the surface of chicken macrophages where antibody-coated SRBC are bound to the external surface of the macrophage in a typical rosette formation.MACROPHAGE FUNCTIONSBacterial killing or antigen degradation is a logical next step following the process of phagocytosis.", [["surface", "ANATOMY", 97, 104], ["macrophages", "ANATOMY", 116, 127], ["external surface", "ANATOMY", 172, 188], ["macrophage", "ANATOMY", 196, 206], ["rosette", "ANATOMY", 220, 227], ["SRBC", "CELL", 36, 40], ["Fcreceptors", "GENE_OR_GENE_PRODUCT", 58, 69], ["surface", "CELLULAR_COMPONENT", 97, 104], ["chicken", "ORGANISM", 108, 115], ["macrophages", "CELL", 116, 127], ["SRBC", "CELL", 150, 154], ["external surface", "CELLULAR_COMPONENT", 172, 188], ["macrophage", "CELL", 196, 206], ["rosette", "TISSUE", 220, 227], ["opsonized SRBC", "CELL_TYPE", 26, 40], ["Fcreceptors", "PROTEIN", 58, 69], ["chicken macrophages", "CELL_TYPE", 108, 127], ["antibody-coated SRBC", "PROTEIN", 134, 154], ["macrophage", "CELL_TYPE", 196, 206], ["chicken", "SPECIES", 108, 115], ["chicken", "SPECIES", 108, 115], ["opsonized SRBC", "TEST", 26, 40], ["chicken macrophages", "TREATMENT", 108, 127], ["antibody-coated SRBC", "TREATMENT", 134, 154], ["the macrophage", "PROBLEM", 192, 206], ["a typical rosette formation", "PROBLEM", 210, 237], ["MACROPHAGE FUNCTIONSBacterial killing", "TEST", 238, 275], ["antigen degradation", "PROBLEM", 279, 298], ["phagocytosis", "PROBLEM", 347, 359], ["external surface", "ANATOMY_MODIFIER", 172, 188], ["macrophage", "OBSERVATION", 196, 206], ["typical", "OBSERVATION_MODIFIER", 212, 219], ["rosette formation", "OBSERVATION", 220, 237]]], ["For bactericidal function, macrophages can very efficiently bind bacteria to their outer surfaces and bring them into their cytoplasm in the form of a phagosome ( Figure 3A ).", [["macrophages", "ANATOMY", 27, 38], ["outer surfaces", "ANATOMY", 83, 97], ["cytoplasm", "ANATOMY", 124, 133], ["phagosome", "ANATOMY", 151, 160], ["macrophages", "CELL", 27, 38], ["outer surfaces", "CELLULAR_COMPONENT", 83, 97], ["cytoplasm", "ORGANISM_SUBSTANCE", 124, 133], ["phagosome", "CELLULAR_COMPONENT", 151, 160], ["macrophages", "CELL_TYPE", 27, 38], ["bactericidal function", "PROBLEM", 4, 25], ["macrophages", "PROBLEM", 27, 38]]], ["Usually one macrophage is capable of internalizing several bacteria ( Figure 3B ), and some of our studies have shown that nearly 90% of internalized bacteria are killed by Sephadex-elicited macrophages in the first 15 min of internalization (Qureshi et al., 1986) .", [["macrophage", "ANATOMY", 12, 22], ["macrophages", "ANATOMY", 191, 202], ["macrophage", "CELL", 12, 22], ["macrophages", "CELL", 191, 202], ["macrophage", "CELL_TYPE", 12, 22], ["macrophages", "CELL_TYPE", 191, 202], ["internalizing several bacteria", "PROBLEM", 37, 67], ["our studies", "TEST", 95, 106], ["internalized bacteria", "PROBLEM", 137, 158], ["Sephadex", "TEST", 173, 181], ["macrophages", "PROBLEM", 191, 202], ["macrophage", "OBSERVATION", 12, 22], ["bacteria", "OBSERVATION", 59, 67], ["macrophages", "OBSERVATION", 191, 202]]], ["After the bacteria are brought into a phagosome, the fusion of the phagosome with a lysosome must occur so that the enzyme(s) present in the lysosome can degrade the internalized bacteria (Qureshi and Dietert, 1995) .", [["phagosome", "ANATOMY", 38, 47], ["phagosome", "ANATOMY", 67, 76], ["lysosome", "ANATOMY", 84, 92], ["lysosome", "ANATOMY", 141, 149], ["phagosome", "CELLULAR_COMPONENT", 38, 47], ["phagosome", "CELLULAR_COMPONENT", 67, 76], ["lysosome", "CELLULAR_COMPONENT", 84, 92], ["lysosome", "CELLULAR_COMPONENT", 141, 149], ["the bacteria", "PROBLEM", 6, 18], ["a lysosome", "PROBLEM", 82, 92], ["the enzyme", "TEST", 112, 122], ["the internalized bacteria", "PROBLEM", 162, 187], ["bacteria", "OBSERVATION", 10, 18]]], ["After degradation, macrophages are fully capable of presenting bacterial peptides or antigenic determinants to immune cells such as the Band T-lymphocytes in the context of either class I or class II major histocompatibility complex (MHC, B-complex) molecules.MACROPHAGE FUNCTIONSTumoricidal ability of macrophages is a specialized function requiring macrophage activation.", [["macrophages", "ANATOMY", 19, 30], ["immune cells", "ANATOMY", 111, 123], ["Band T-lymphocytes", "ANATOMY", 136, 154], ["macrophages", "ANATOMY", 303, 314], ["macrophage", "ANATOMY", 351, 361], ["macrophages", "CELL", 19, 30], ["immune cells", "CELL", 111, 123], ["Band T-lymphocytes", "CELL", 136, 154], ["class II major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 191, 232], ["B-complex", "GENE_OR_GENE_PRODUCT", 239, 248], ["macrophages", "CELL", 303, 314], ["macrophage", "CELL", 351, 361], ["macrophages", "CELL_TYPE", 19, 30], ["immune cells", "CELL_TYPE", 111, 123], ["Band T-lymphocytes", "CELL_TYPE", 136, 154], ["class I or class II major histocompatibility complex (MHC, B-complex) molecules", "PROTEIN", 180, 259], ["macrophages", "CELL_TYPE", 303, 314], ["macrophages", "PROBLEM", 19, 30], ["presenting bacterial peptides", "PROBLEM", 52, 81], ["immune cells", "PROBLEM", 111, 123], ["the Band T-lymphocytes", "PROBLEM", 132, 154], ["macrophage activation", "TREATMENT", 351, 372], ["macrophages", "OBSERVATION", 19, 30], ["macrophages", "OBSERVATION", 303, 314], ["macrophage activation", "OBSERVATION", 351, 372]]], ["Upon coculture, macrophages bind tumor cell targets very efficiently, as tumor targets are much bigger than bacteria ( Figure 3B ).", [["macrophages", "ANATOMY", 16, 27], ["tumor cell", "ANATOMY", 33, 43], ["tumor", "ANATOMY", 73, 78], ["tumor", "DISEASE", 33, 38], ["tumor", "DISEASE", 73, 78], ["macrophages", "CELL", 16, 27], ["tumor cell", "CELL", 33, 43], ["tumor", "CANCER", 73, 78], ["macrophages", "CELL_TYPE", 16, 27], ["macrophages bind tumor cell targets", "PROBLEM", 16, 51], ["tumor targets", "TEST", 73, 86], ["tumor cell", "OBSERVATION", 33, 43]]], ["Macrophages cannot phagocytize tumor cells.", [["Macrophages", "ANATOMY", 0, 11], ["tumor cells", "ANATOMY", 31, 42], ["tumor", "DISEASE", 31, 36], ["Macrophages", "CELL", 0, 11], ["tumor cells", "CELL", 31, 42], ["Macrophages", "CELL_TYPE", 0, 11], ["phagocytize tumor cells", "CELL_TYPE", 19, 42], ["phagocytize tumor cells", "PROBLEM", 19, 42], ["not", "UNCERTAINTY", 15, 18], ["phagocytize tumor cells", "OBSERVATION", 19, 42]]], ["However, once tumors are bound to the surface of a macrophage, the macrophage can secrete substances such as tumor necrosis factor (Qureshi and Miller, 1991a) or several biologically active metabolites such as nitric oxide (NO) which can mediate either bacterial or tumor cell killing.", [["tumors", "ANATOMY", 14, 20], ["surface", "ANATOMY", 38, 45], ["macrophage", "ANATOMY", 51, 61], ["macrophage", "ANATOMY", 67, 77], ["tumor cell", "ANATOMY", 266, 276], ["tumors", "DISEASE", 14, 20], ["tumor necrosis", "DISEASE", 109, 123], ["nitric oxide", "CHEMICAL", 210, 222], ["NO", "CHEMICAL", 224, 226], ["tumor", "DISEASE", 266, 271], ["nitric oxide", "CHEMICAL", 210, 222], ["NO", "CHEMICAL", 224, 226], ["tumors", "CANCER", 14, 20], ["surface", "CELLULAR_COMPONENT", 38, 45], ["macrophage", "CELL", 51, 61], ["macrophage", "CELL", 67, 77], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 109, 130], ["Qureshi", "GENE_OR_GENE_PRODUCT", 132, 139], ["nitric oxide", "SIMPLE_CHEMICAL", 210, 222], ["NO", "SIMPLE_CHEMICAL", 224, 226], ["tumor cell", "CELL", 266, 276], ["macrophage", "CELL_TYPE", 51, 61], ["macrophage", "CELL_TYPE", 67, 77], ["tumor necrosis factor", "PROTEIN", 109, 130], ["tumors", "PROBLEM", 14, 20], ["tumor necrosis factor", "PROBLEM", 109, 130], ["nitric oxide", "TREATMENT", 210, 222], ["bacterial or tumor cell killing", "PROBLEM", 253, 284], ["tumors", "OBSERVATION", 14, 20], ["macrophage", "ANATOMY", 51, 61], ["macrophage", "ANATOMY", 67, 77], ["tumor", "OBSERVATION", 109, 114], ["bacterial", "OBSERVATION_MODIFIER", 253, 262], ["tumor cell killing", "OBSERVATION", 266, 284]]], ["A detailed account of NO production by chicken macrophages is presented in a later section.MACROPHAGE FUNCTIONSIn addition to macrophages being phagocytic as well as bacteriostatic, bactericidal, tumoristatic, or tumoricidal cells, chicken macrophages are fully capable of producing several types of cytokines.", [["macrophages", "ANATOMY", 47, 58], ["macrophages", "ANATOMY", 126, 137], ["tumoricidal cells", "ANATOMY", 213, 230], ["macrophages", "ANATOMY", 240, 251], ["NO", "CHEMICAL", 22, 24], ["NO", "CHEMICAL", 22, 24], ["NO", "SIMPLE_CHEMICAL", 22, 24], ["chicken", "ORGANISM", 39, 46], ["macrophages", "CELL", 47, 58], ["macrophages", "CELL", 126, 137], ["tumoricidal cells", "CELL", 213, 230], ["chicken", "ORGANISM", 232, 239], ["macrophages", "CELL", 240, 251], ["chicken macrophages", "CELL_TYPE", 39, 58], ["macrophages", "CELL_TYPE", 126, 137], ["tumoricidal cells", "CELL_TYPE", 213, 230], ["chicken macrophages", "CELL_TYPE", 232, 251], ["cytokines", "PROTEIN", 300, 309], ["chicken", "SPECIES", 39, 46], ["chicken", "SPECIES", 232, 239], ["chicken", "SPECIES", 39, 46], ["chicken", "SPECIES", 232, 239], ["macrophages", "PROBLEM", 126, 137], ["phagocytic", "TREATMENT", 144, 154], ["bacteriostatic", "PROBLEM", 166, 180], ["bactericidal", "PROBLEM", 182, 194], ["tumoristatic", "PROBLEM", 196, 208], ["tumoricidal cells", "PROBLEM", 213, 230], ["chicken macrophages", "PROBLEM", 232, 251], ["cytokines", "PROBLEM", 300, 309], ["macrophages", "OBSERVATION", 47, 58], ["macrophages", "OBSERVATION", 126, 137], ["tumoricidal cells", "OBSERVATION", 213, 230], ["chicken macrophages", "OBSERVATION", 232, 251], ["cytokines", "OBSERVATION", 300, 309]]], ["For example, chicken macrophages following activation with a biological signal, or after phagocytosis of an antigen, secrete Interleukin-1.MACROPHAGE FUNCTIONSWe have shown that chicken macrophages from different sources differ in their ability to produce Interlukin-1 when stimulated with either E. coli LPS or Streptococcus antigens.", [["macrophages", "ANATOMY", 21, 32], ["macrophages", "ANATOMY", 186, 197], ["LPS", "CHEMICAL", 305, 308], ["chicken", "ORGANISM", 13, 20], ["macrophages", "CELL", 21, 32], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 125, 138], ["chicken", "ORGANISM", 178, 185], ["macrophages", "CELL", 186, 197], ["Interlukin-1", "GENE_OR_GENE_PRODUCT", 256, 268], ["E. coli", "ORGANISM", 297, 304], ["LPS", "ORGANISM", 305, 308], ["Streptococcus antigens", "ORGANISM", 312, 334], ["chicken macrophages", "CELL_TYPE", 13, 32], ["Interleukin-1", "PROTEIN", 125, 138], ["chicken macrophages", "CELL_TYPE", 178, 197], ["Interlukin-1", "PROTEIN", 256, 268], ["Streptococcus antigens", "PROTEIN", 312, 334], ["chicken", "SPECIES", 13, 20], ["chicken", "SPECIES", 178, 185], ["E. coli", "SPECIES", 297, 304], ["chicken", "SPECIES", 13, 20], ["chicken", "SPECIES", 178, 185], ["E. coli", "SPECIES", 297, 304], ["chicken macrophages", "PROBLEM", 13, 32], ["a biological signal", "TEST", 59, 78], ["phagocytosis", "TEST", 89, 101], ["an antigen", "TEST", 105, 115], ["chicken macrophages", "PROBLEM", 178, 197], ["E. coli LPS", "PROBLEM", 297, 308], ["Streptococcus antigens", "PROBLEM", 312, 334], ["macrophages", "OBSERVATION", 21, 32], ["macrophages", "OBSERVATION", 186, 197]]], ["For example, abdominal exudate macrophages produced lower levels of Interlukin-1 than those from two transformed chicken macrophage cell lines, the HD11 and MQ-NCSU (Qureshi et al., 1994) .NUTRITIONAL INFLUENCES ON MACROPHAGE FUNCTIONSChicken macrophage functions have been shown to be very responsive to several dietary immune modulators.", [["abdominal exudate macrophages", "ANATOMY", 13, 42], ["macrophage cell lines", "ANATOMY", 121, 142], ["FUNCTIONSChicken macrophage", "ANATOMY", 226, 253], ["abdominal exudate macrophages", "CELL", 13, 42], ["Interlukin-1", "GENE_OR_GENE_PRODUCT", 68, 80], ["chicken", "ORGANISM", 113, 120], ["macrophage cell lines", "CELL", 121, 142], ["HD11", "CELL", 148, 152], ["MQ-NCSU", "CELL", 157, 164], ["FUNCTIONSChicken macrophage", "CELL", 226, 253], ["abdominal exudate macrophages", "CELL_TYPE", 13, 42], ["Interlukin-1", "PROTEIN", 68, 80], ["transformed chicken macrophage cell lines", "CELL_LINE", 101, 142], ["chicken", "SPECIES", 113, 120], ["chicken", "SPECIES", 113, 120], ["abdominal exudate macrophages", "PROBLEM", 13, 42], ["lower levels of Interlukin-1", "PROBLEM", 52, 80], ["chicken macrophage cell lines", "TREATMENT", 113, 142], ["the HD11", "TREATMENT", 144, 152], ["macrophage functions", "TEST", 243, 263], ["several dietary immune modulators", "TREATMENT", 305, 338], ["abdominal", "ANATOMY", 13, 22], ["exudate macrophages", "OBSERVATION", 23, 42], ["lower levels", "OBSERVATION_MODIFIER", 52, 64], ["macrophage cell lines", "OBSERVATION", 121, 142]]], ["Some of these macrophage function modulators include \u03b21-3, 1-6, glucan, \u03b2hydroxy \u03b2-methylbutyrate, vitamins A, D, E, and B-complex, vanadium, arginine, spirulina, zinc-methionine, electrolytes, etc. Our studies have shown that avian macrophage functions are improved by the dietary use of all of these compounds (see review Qureshi et al., 2000) .", [["macrophage", "ANATOMY", 14, 24], ["macrophage", "ANATOMY", 233, 243], ["\u03b21-3, 1-6, glucan", "CHEMICAL", 53, 70], ["\u03b2hydroxy \u03b2-methylbutyrate", "CHEMICAL", 72, 97], ["vitamins A, D, E", "CHEMICAL", 99, 115], ["vanadium", "CHEMICAL", 132, 140], ["arginine", "CHEMICAL", 142, 150], ["spirulina", "CHEMICAL", 152, 161], ["zinc-methionine", "CHEMICAL", 163, 178], ["\u03b2hydroxy \u03b2-methylbutyrate", "CHEMICAL", 72, 97], ["vitamins A, D, E, and B", "CHEMICAL", 99, 122], ["vanadium", "CHEMICAL", 132, 140], ["arginine", "CHEMICAL", 142, 150], ["spirulina", "CHEMICAL", 152, 161], ["zinc", "CHEMICAL", 163, 167], ["methionine", "CHEMICAL", 168, 178], ["macrophage", "CELL", 14, 24], ["\u03b21-3", "GENE_OR_GENE_PRODUCT", 53, 57], ["1-6,", "SIMPLE_CHEMICAL", 59, 63], ["glucan", "SIMPLE_CHEMICAL", 64, 70], ["\u03b2hydroxy \u03b2-methylbutyrate", "SIMPLE_CHEMICAL", 72, 97], ["vitamins A", "SIMPLE_CHEMICAL", 99, 109], ["D, E", "SIMPLE_CHEMICAL", 111, 115], ["B-complex", "SIMPLE_CHEMICAL", 121, 130], ["vanadium", "SIMPLE_CHEMICAL", 132, 140], ["arginine", "SIMPLE_CHEMICAL", 142, 150], ["spirulina", "SIMPLE_CHEMICAL", 152, 161], ["zinc-methionine", "SIMPLE_CHEMICAL", 163, 178], ["electrolytes", "SIMPLE_CHEMICAL", 180, 192], ["avian", "ORGANISM", 227, 232], ["macrophage", "CELL", 233, 243], ["these macrophage function modulators", "TEST", 8, 44], ["\u03b2", "TEST", 53, 54], ["glucan", "TEST", 64, 70], ["vitamins", "TREATMENT", 99, 107], ["vanadium", "TREATMENT", 132, 140], ["arginine", "TREATMENT", 142, 150], ["spirulina", "TREATMENT", 152, 161], ["zinc", "TREATMENT", 163, 167], ["methionine", "TREATMENT", 168, 178], ["electrolytes", "TREATMENT", 180, 192], ["Our studies", "TEST", 199, 210], ["avian macrophage functions", "PROBLEM", 227, 253], ["macrophage function", "OBSERVATION", 14, 33], ["avian macrophage", "OBSERVATION", 227, 243], ["improved", "OBSERVATION_MODIFIER", 258, 266]]], ["Using \u03b2 1-3, 1-6 glucan as an example, our studies have shown that macrophage phagocytic function is significantly enhanced if chickens are fed a diet containing 20 or 40 mg/kg of \u03b2 1-3, 1-6 glucan as compared with chickens fed a basal diet.", [["macrophage", "ANATOMY", 67, 77], ["\u03b2 1-3, 1-6 glucan", "CHEMICAL", 6, 23], ["\u03b2 1-3, 1-6 glucan", "CHEMICAL", 180, 197], ["\u03b2 1-3", "GENE_OR_GENE_PRODUCT", 6, 11], ["1-6 glucan", "SIMPLE_CHEMICAL", 13, 23], ["macrophage", "CELL", 67, 77], ["chickens", "ORGANISM", 127, 135], ["\u03b2 1-3", "GENE_OR_GENE_PRODUCT", 180, 185], ["1-6 glucan", "SIMPLE_CHEMICAL", 187, 197], ["chickens", "ORGANISM", 215, 223], ["chickens", "SPECIES", 127, 135], ["chickens", "SPECIES", 215, 223], ["chickens", "SPECIES", 127, 135], ["chickens", "SPECIES", 215, 223], ["our studies", "TEST", 39, 50], ["macrophage phagocytic function", "TEST", 67, 97], ["macrophage phagocytic", "OBSERVATION", 67, 88]]], ["In vitro exposure of macrophages to \u03b21-3, 1-6 glucan induces proliferation greater than seen in sham-exposed macrophages.", [["macrophages", "ANATOMY", 21, 32], ["macrophages", "ANATOMY", 109, 120], ["\u03b21-3, 1-6 glucan", "CHEMICAL", 36, 52], ["macrophages", "CELL", 21, 32], ["\u03b21-3", "GENE_OR_GENE_PRODUCT", 36, 40], ["1-6 glucan", "GENE_OR_GENE_PRODUCT", 42, 52], ["macrophages", "CELL", 109, 120], ["macrophages", "CELL_TYPE", 21, 32], ["sham-exposed macrophages", "CELL_LINE", 96, 120], ["macrophages", "TEST", 21, 32], ["proliferation", "PROBLEM", 61, 74], ["macrophages", "OBSERVATION", 21, 32], ["proliferation", "OBSERVATION_MODIFIER", 61, 74], ["greater", "OBSERVATION_MODIFIER", 75, 82], ["macrophages", "OBSERVATION", 109, 120]]], ["Furthermore, macrophages exposed in vitro to \u03b2 1-3,1-6 glucan also secrete higher levels of nitrite in their culture supernate, which is an indication of macrophage activation by \u03b2 1-3, 1-6 glucan (Guo et al., 2003) .", [["macrophages", "ANATOMY", 13, 24], ["macrophage", "ANATOMY", 154, 164], ["\u03b2 1-3,1-6 glucan", "CHEMICAL", 45, 61], ["nitrite", "CHEMICAL", 92, 99], ["\u03b2 1-3, 1-6 glucan", "CHEMICAL", 179, 196], ["nitrite", "CHEMICAL", 92, 99], ["macrophages", "CELL", 13, 24], ["\u03b2 1-3,1-6 glucan", "GENE_OR_GENE_PRODUCT", 45, 61], ["nitrite", "SIMPLE_CHEMICAL", 92, 99], ["macrophage", "CELL", 154, 164], ["\u03b2 1-3", "GENE_OR_GENE_PRODUCT", 179, 184], ["1-6 glucan", "SIMPLE_CHEMICAL", 186, 196], ["macrophages", "CELL_TYPE", 13, 24], ["macrophages", "PROBLEM", 13, 24], ["secrete higher levels of nitrite", "PROBLEM", 67, 99], ["their culture supernate", "TEST", 103, 126], ["macrophage activation", "TEST", 154, 175], ["macrophages", "OBSERVATION", 13, 24], ["indication of", "UNCERTAINTY", 140, 153], ["macrophage activation", "OBSERVATION", 154, 175]]], ["We have also shown that vitamin E exposure can help up-regulate macrophage phagocytic function.", [["macrophage", "ANATOMY", 64, 74], ["vitamin E", "CHEMICAL", 24, 33], ["vitamin E", "CHEMICAL", 24, 33], ["vitamin E", "SIMPLE_CHEMICAL", 24, 33], ["macrophage", "CELL", 64, 74], ["vitamin E exposure", "TREATMENT", 24, 42], ["macrophage phagocytic function", "OBSERVATION", 64, 94]]], ["For example, in ovo vitamin E administration improved the phagocytic potential and nitrite production by macrophages isolated at 4 wk of age (Gore and Qureshi, 1997) .ARGININE AND NITRIC OXIDE SYNTHASEAnother important nutrient, which has received considerable attention in the field of immunology, especially when as it relates to macrophage activation and function, is arginine.", [["macrophages", "ANATOMY", 105, 116], ["macrophage", "ANATOMY", 332, 342], ["vitamin E", "CHEMICAL", 20, 29], ["nitrite", "CHEMICAL", 83, 90], ["arginine", "CHEMICAL", 371, 379], ["vitamin E", "CHEMICAL", 20, 29], ["nitrite", "CHEMICAL", 83, 90], ["arginine", "CHEMICAL", 371, 379], ["vitamin E", "SIMPLE_CHEMICAL", 20, 29], ["nitrite", "SIMPLE_CHEMICAL", 83, 90], ["macrophages", "CELL", 105, 116], ["macrophage", "CELL", 332, 342], ["arginine", "SIMPLE_CHEMICAL", 371, 379], ["macrophages", "CELL_TYPE", 105, 116], ["ovo vitamin E administration", "TREATMENT", 16, 44], ["ARGININE AND NITRIC OXIDE SYNTHASEAnother", "TREATMENT", 167, 208], ["phagocytic potential", "OBSERVATION", 58, 78], ["nitrite production", "OBSERVATION", 83, 101], ["macrophage", "OBSERVATION", 332, 342]]], ["Arginine is utilized as a substrate by the enzyme nitric oxide synthase (NOS) which catalyzes the biosynthesis of free radical nitric oxide (NO) as a byproduct of an oxidative reaction using the guanidino nitrogen group of L-arginine to make L-citruline.", [["Arginine", "CHEMICAL", 0, 8], ["nitric oxide", "CHEMICAL", 50, 62], ["nitric oxide", "CHEMICAL", 127, 139], ["NO", "CHEMICAL", 141, 143], ["guanidino nitrogen", "CHEMICAL", 195, 213], ["L-arginine", "CHEMICAL", 223, 233], ["L-citruline", "CHEMICAL", 242, 253], ["Arginine", "CHEMICAL", 0, 8], ["nitric oxide", "CHEMICAL", 50, 62], ["nitric oxide", "CHEMICAL", 127, 139], ["NO", "CHEMICAL", 141, 143], ["guanidino nitrogen", "CHEMICAL", 195, 213], ["L-arginine", "CHEMICAL", 223, 233], ["L-citruline", "CHEMICAL", 242, 253], ["Arginine", "SIMPLE_CHEMICAL", 0, 8], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 50, 71], ["NOS", "GENE_OR_GENE_PRODUCT", 73, 76], ["free radical nitric oxide", "SIMPLE_CHEMICAL", 114, 139], ["NO", "SIMPLE_CHEMICAL", 141, 143], ["L-arginine", "SIMPLE_CHEMICAL", 223, 233], ["L-citruline", "SIMPLE_CHEMICAL", 242, 253], ["enzyme nitric oxide synthase", "PROTEIN", 43, 71], ["NOS", "PROTEIN", 73, 76], ["Arginine", "TREATMENT", 0, 8], ["the enzyme nitric oxide synthase", "TREATMENT", 39, 71], ["free radical nitric oxide", "TREATMENT", 114, 139], ["an oxidative reaction", "PROBLEM", 163, 184], ["the guanidino nitrogen group of L-arginine", "TREATMENT", 191, 233], ["L-citruline", "TREATMENT", 242, 253]]], ["Nitric oxide is a highly reactive, low molecular weight, shortlived cytotoxic entity and is converted to nitrite and nitrate that are more stable products.", [["Nitric oxide", "CHEMICAL", 0, 12], ["nitrite", "CHEMICAL", 105, 112], ["nitrate", "CHEMICAL", 117, 124], ["Nitric oxide", "CHEMICAL", 0, 12], ["nitrite", "CHEMICAL", 105, 112], ["nitrate", "CHEMICAL", 117, 124], ["Nitric oxide", "SIMPLE_CHEMICAL", 0, 12], ["nitrite", "SIMPLE_CHEMICAL", 105, 112], ["nitrate", "SIMPLE_CHEMICAL", 117, 124], ["Nitric oxide", "TREATMENT", 0, 12], ["low molecular weight", "PROBLEM", 35, 55], ["nitrite", "TREATMENT", 105, 112], ["nitrate", "TREATMENT", 117, 124], ["highly", "OBSERVATION_MODIFIER", 18, 24], ["reactive", "OBSERVATION_MODIFIER", 25, 33], ["stable", "OBSERVATION_MODIFIER", 139, 145]]], ["We have shown that chicken macrophages express a 4.5-kb NOS in its inducible isoform (iNOS) when macrophages are exposed to bacterial LPS.", [["macrophages", "ANATOMY", 27, 38], ["macrophages", "ANATOMY", 97, 108], ["LPS", "CHEMICAL", 134, 137], ["chicken", "ORGANISM", 19, 26], ["macrophages", "CELL", 27, 38], ["NOS", "GENE_OR_GENE_PRODUCT", 56, 59], ["iNOS", "GENE_OR_GENE_PRODUCT", 86, 90], ["macrophages", "CELL", 97, 108], ["LPS", "SIMPLE_CHEMICAL", 134, 137], ["chicken macrophages", "CELL_TYPE", 19, 38], ["4.5-kb NOS", "PROTEIN", 49, 59], ["inducible isoform", "PROTEIN", 67, 84], ["iNOS", "PROTEIN", 86, 90], ["macrophages", "CELL_TYPE", 97, 108], ["chicken", "SPECIES", 19, 26], ["chicken", "SPECIES", 19, 26], ["a 4.5-kb NOS", "TREATMENT", 47, 59], ["macrophages", "PROBLEM", 97, 108], ["bacterial LPS", "PROBLEM", 124, 137], ["bacterial LPS", "OBSERVATION", 124, 137]]], ["Furthermore, iNOS is fully functional in utilizing arginine as quantitated by the presence of nitrite in macrophage culture supernatants as well as when iNOS activity was quantitated in macrophage cell-lysates Qureshi, 1997, 1998) .NITRIC OXIDE SYNTHASE AND CHICKEN GENOTYPESOur studies have shown that the expression of iNOS in macrophages is variable among chickens of several genotypes.", [["supernatants", "ANATOMY", 124, 136], ["macrophage cell", "ANATOMY", 186, 201], ["lysates", "ANATOMY", 202, 209], ["macrophages", "ANATOMY", 329, 340], ["arginine", "CHEMICAL", 51, 59], ["nitrite", "CHEMICAL", 94, 101], ["arginine", "CHEMICAL", 51, 59], ["nitrite", "CHEMICAL", 94, 101], ["iNOS", "GENE_OR_GENE_PRODUCT", 13, 17], ["arginine", "SIMPLE_CHEMICAL", 51, 59], ["nitrite", "SIMPLE_CHEMICAL", 94, 101], ["macrophage", "CELL", 105, 115], ["iNOS", "GENE_OR_GENE_PRODUCT", 153, 157], ["macrophage cell", "CELL", 186, 201], ["iNOS", "GENE_OR_GENE_PRODUCT", 321, 325], ["macrophages", "CELL", 329, 340], ["chickens", "ORGANISM", 359, 367], ["iNOS", "PROTEIN", 13, 17], ["iNOS", "PROTEIN", 153, 157], ["macrophage cell", "CELL_TYPE", 186, 201], ["iNOS", "PROTEIN", 321, 325], ["macrophages", "CELL_TYPE", 329, 340], ["chickens", "SPECIES", 359, 367], ["chickens", "SPECIES", 359, 367], ["nitrite in macrophage culture supernatants", "TREATMENT", 94, 136], ["iNOS activity", "TEST", 153, 166], ["NITRIC OXIDE SYNTHASE", "TREATMENT", 232, 253], ["CHICKEN GENOTYPESOur studies", "TEST", 258, 286], ["iNOS in macrophages", "PROBLEM", 321, 340], ["iNOS", "OBSERVATION", 321, 325], ["macrophages", "OBSERVATION", 329, 340]]], ["These differences in gene expression are not due to a differential post-transcriptional regulatory mechanism(s), but rather due to enhanced transcriptional activity in iNOS hyper-responder genotypes (Hussain and Qureshi, 1998) .", [["iNOS", "GENE_OR_GENE_PRODUCT", 168, 172], ["iNOS", "PROTEIN", 168, 172], ["enhanced transcriptional activity", "PROBLEM", 131, 164], ["iNOS hyper-responder genotypes", "PROBLEM", 168, 198], ["not due to", "UNCERTAINTY", 41, 51], ["transcriptional activity", "OBSERVATION", 140, 164]]], ["Based on LPS-induced iNOS expression, lines of chicken have been identified as either hyper-or hypo-responders for iNOS Qureshi, 1997, 1998) .", [["LPS", "CHEMICAL", 9, 12], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["iNOS", "GENE_OR_GENE_PRODUCT", 21, 25], ["chicken", "ORGANISM", 47, 54], ["iNOS", "GENE_OR_GENE_PRODUCT", 115, 119], ["iNOS", "PROTEIN", 21, 25], ["iNOS", "PROTEIN", 115, 119], ["chicken", "SPECIES", 47, 54], ["chicken", "SPECIES", 47, 54], ["LPS", "TEST", 9, 12], ["iNOS expression", "PROBLEM", 21, 36], ["lines of chicken", "TREATMENT", 38, 54], ["hyper", "PROBLEM", 86, 91]]], ["It was clear that these differences are genetically intrinsic and are not specific to the commonly used E. coli LPS, since iNOS hyper-and hypo-responsiveness of these strains was maintained regardless of the source of bacterial LPS used (Dil and Qureshi, 2002a) .", [["LPS", "CHEMICAL", 112, 115], ["LPS", "CHEMICAL", 228, 231], ["E. coli", "ORGANISM", 104, 111], ["LPS", "ORGANISM", 112, 115], ["iNOS", "GENE_OR_GENE_PRODUCT", 123, 127], ["LPS", "SIMPLE_CHEMICAL", 228, 231], ["iNOS", "PROTEIN", 123, 127], ["E. coli", "SPECIES", 104, 111], ["E. coli", "SPECIES", 104, 111], ["E. coli LPS", "PROBLEM", 104, 115], ["iNOS hyper", "PROBLEM", 123, 133], ["hypo-responsiveness", "PROBLEM", 138, 157], ["these strains", "PROBLEM", 161, 174], ["bacterial LPS", "PROBLEM", 218, 231], ["coli LPS", "OBSERVATION", 107, 115], ["bacterial LPS", "OBSERVATION", 218, 231]]], ["Because LPS represents a pathogen-associated molecular pattern (PAMP) for which there are unique recognition factors called Toll-like receptors (TLR), we hypothesized that the differential expression of iNOS in macrophages from various chicken genotypes may be due to the differential expression of the LPS-binding molecule CD14 or their signaling molecules, the TLRs.", [["macrophages", "ANATOMY", 211, 222], ["LPS", "CHEMICAL", 8, 11], ["LPS", "CHEMICAL", 303, 306], ["LPS", "SIMPLE_CHEMICAL", 8, 11], ["PAMP", "GENE_OR_GENE_PRODUCT", 64, 68], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 124, 143], ["TLR", "GENE_OR_GENE_PRODUCT", 145, 148], ["iNOS", "GENE_OR_GENE_PRODUCT", 203, 207], ["macrophages", "CELL", 211, 222], ["chicken", "ORGANISM", 236, 243], ["LPS-binding molecule CD14", "GENE_OR_GENE_PRODUCT", 303, 328], ["TLRs", "GENE_OR_GENE_PRODUCT", 363, 367], ["PAMP", "PROTEIN", 64, 68], ["Toll-like receptors", "PROTEIN", 124, 143], ["TLR", "PROTEIN", 145, 148], ["iNOS", "PROTEIN", 203, 207], ["macrophages", "CELL_TYPE", 211, 222], ["LPS-binding molecule", "PROTEIN", 303, 323], ["CD14", "PROTEIN", 324, 328], ["signaling molecules", "PROTEIN", 338, 357], ["TLRs", "PROTEIN", 363, 367], ["chicken", "SPECIES", 236, 243], ["chicken", "SPECIES", 236, 243], ["LPS", "PROBLEM", 8, 11], ["a pathogen", "PROBLEM", 23, 33], ["iNOS in macrophages", "PROBLEM", 203, 222], ["various chicken genotypes", "PROBLEM", 228, 253], ["the LPS", "TEST", 299, 306], ["binding molecule CD14", "TEST", 307, 328], ["pathogen", "OBSERVATION", 25, 33], ["iNOS", "OBSERVATION", 203, 207]]], ["This hypothesis was proven from the findings that macrophages from iNOS hyper-responder genotypes express significantly higher inducible CD14 as well as TLR4 as compared with the hypo-responder genotypes (Dil and Qureshi, 2002a) .", [["macrophages", "ANATOMY", 50, 61], ["macrophages", "CELL", 50, 61], ["iNOS", "GENE_OR_GENE_PRODUCT", 67, 71], ["CD14", "GENE_OR_GENE_PRODUCT", 137, 141], ["TLR4", "GENE_OR_GENE_PRODUCT", 153, 157], ["macrophages", "CELL_TYPE", 50, 61], ["iNOS", "PROTEIN", 67, 71], ["CD14", "PROTEIN", 137, 141], ["TLR4", "PROTEIN", 153, 157], ["iNOS hyper-responder genotypes", "PROBLEM", 67, 97], ["significantly higher inducible CD14", "PROBLEM", 106, 141]]], ["The fact that the CD14 and TLR4 are critical in LPS-induced iNOS expression by macrophages was proven in a subsequent study in which CD14 and TLR4 were blocked with appropriate antibodies which resulted in a significant reduction in iNOS expression and activity (Dil and Qureshi, 2002b) .", [["macrophages", "ANATOMY", 79, 90], ["LPS", "CHEMICAL", 48, 51], ["CD14", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["iNOS", "GENE_OR_GENE_PRODUCT", 60, 64], ["macrophages", "CELL", 79, 90], ["CD14", "GENE_OR_GENE_PRODUCT", 133, 137], ["TLR4", "GENE_OR_GENE_PRODUCT", 142, 146], ["iNOS", "GENE_OR_GENE_PRODUCT", 233, 237], ["CD14", "PROTEIN", 18, 22], ["TLR4", "PROTEIN", 27, 31], ["iNOS", "PROTEIN", 60, 64], ["macrophages", "CELL_TYPE", 79, 90], ["CD14", "PROTEIN", 133, 137], ["TLR4", "PROTEIN", 142, 146], ["antibodies", "PROTEIN", 177, 187], ["iNOS", "PROTEIN", 233, 237], ["the CD14", "TEST", 14, 22], ["a subsequent study", "TEST", 105, 123], ["CD14", "TEST", 133, 137], ["TLR4", "TEST", 142, 146], ["a significant reduction in iNOS expression", "PROBLEM", 206, 248], ["iNOS expression", "OBSERVATION", 60, 75], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["reduction", "OBSERVATION_MODIFIER", 220, 229], ["iNOS expression", "OBSERVATION", 233, 248]]], ["The involvement of nuclear factor (B (NF(B) was also shown to be relevant in hyper-iNOS expression because the hyper-responder genotypes contained greater levels of DNA-bound NF\u03baB than the low-responder genotypes (Dil and Qureshi, 2002b) .", [["B", "GENE_OR_GENE_PRODUCT", 35, 36], ["NF(B)", "GENE_OR_GENE_PRODUCT", 38, 43], ["hyper-iNOS", "GENE_OR_GENE_PRODUCT", 77, 87], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 175, 179], ["nuclear factor", "PROTEIN", 19, 33], ["NF(B)", "PROTEIN", 38, 43], ["iNOS", "PROTEIN", 83, 87], ["NF\u03baB", "PROTEIN", 175, 179], ["nuclear factor", "PROBLEM", 19, 33], ["hyper-iNOS expression", "PROBLEM", 77, 98], ["the hyper-responder genotypes", "PROBLEM", 107, 136], ["DNA", "TEST", 165, 168]]], ["Interestingly, interleukin-1 \u03b2 did not contribute to genetic-based differences in iNOS expression and activity in chicken macrophages (Dil and Qureshi, 2003) .MACROPHAGE FUNCTIONS AND GENETIC FACTORSSeveral macrophage functions are modulated by the genetic makeup of the chickens, especially with regard to the genetic alleles present in the major histocompatibility complex (called B-complex in chickens).", [["macrophages", "ANATOMY", 122, 133], ["macrophage", "ANATOMY", 207, 217], ["interleukin-1 \u03b2", "GENE_OR_GENE_PRODUCT", 15, 30], ["iNOS", "GENE_OR_GENE_PRODUCT", 82, 86], ["chicken", "ORGANISM", 114, 121], ["macrophages", "CELL", 122, 133], ["GENETIC FACTORSSeveral macrophage", "CELL", 184, 217], ["chickens", "ORGANISM", 271, 279], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 342, 374], ["B-complex", "GENE_OR_GENE_PRODUCT", 383, 392], ["chickens", "ORGANISM", 396, 404], ["interleukin-1 \u03b2", "PROTEIN", 15, 30], ["iNOS", "PROTEIN", 82, 86], ["chicken macrophages", "CELL_TYPE", 114, 133], ["major histocompatibility complex", "PROTEIN", 342, 374], ["B-complex", "PROTEIN", 383, 392], ["chicken", "SPECIES", 114, 121], ["chickens", "SPECIES", 271, 279], ["chickens", "SPECIES", 396, 404], ["chicken", "SPECIES", 114, 121], ["chickens", "SPECIES", 271, 279], ["chickens", "SPECIES", 396, 404], ["genetic-based differences in iNOS expression", "PROBLEM", 53, 97], ["iNOS expression", "OBSERVATION", 82, 97], ["FACTORSSeveral macrophage", "OBSERVATION", 192, 217]]], ["For example, our studies have shown that macrophages from chicken lines congenic for their B-complex alleles vary in their chemotactic (Qureshi et al., 1988) , phagocytic, and bactericidal response (Qureshi et al., 1986) .", [["macrophages", "ANATOMY", 41, 52], ["macrophages", "CELL", 41, 52], ["chicken", "ORGANISM", 58, 65], ["B-complex", "GENE_OR_GENE_PRODUCT", 91, 100], ["macrophages", "CELL_TYPE", 41, 52], ["chicken lines", "CELL_LINE", 58, 71], ["B-complex alleles", "DNA", 91, 108], ["chicken", "SPECIES", 58, 65], ["chicken", "SPECIES", 58, 65], ["our studies", "TEST", 13, 24], ["macrophages", "PROBLEM", 41, 52], ["chicken lines congenic", "PROBLEM", 58, 80], ["macrophages", "OBSERVATION", 41, 52], ["chicken lines", "OBSERVATION", 58, 71], ["bactericidal response", "OBSERVATION", 176, 197]]], ["Furthermore, macrophage activation for specialized effector functions, such as tumor necrosis factor production, is also influenced by genotype (Qureshi and Taylor, 1993) .", [["macrophage", "ANATOMY", 13, 23], ["tumor", "ANATOMY", 79, 84], ["tumor", "DISEASE", 79, 84], ["necrosis", "DISEASE", 85, 93], ["macrophage", "CELL", 13, 23], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 79, 100], ["tumor necrosis factor", "PROTEIN", 79, 100], ["specialized effector functions", "PROBLEM", 39, 69], ["tumor necrosis factor production", "PROBLEM", 79, 111], ["macrophage activation", "OBSERVATION", 13, 34]]], ["Differences also exist among various commercial broiler lines in macrophage effector function, such as phagocytosis and bacterial and tumor cell killing (Qureshi and Miller, 1991b) , suggesting an opportunity to exploit macrophage-based immunocompetence in commercial breeding and selection programs.MACROPHAGE FUNCTIONS AND ENVIRONMENTAL/ TOXICOLOGICAL FACTORSChicken macrophages are susceptible to both environmental and toxicological insult.", [["macrophage", "ANATOMY", 65, 75], ["tumor cell", "ANATOMY", 134, 144], ["macrophage", "ANATOMY", 220, 230], ["macrophages", "ANATOMY", 369, 380], ["tumor", "DISEASE", 134, 139], ["broiler lines", "CELL", 48, 61], ["macrophage", "CELL", 65, 75], ["tumor cell", "CELL", 134, 144], ["macrophage", "CELL", 220, 230], ["TOXICOLOGICAL FACTORSChicken macrophages", "CELL", 340, 380], ["commercial broiler lines", "CELL_LINE", 37, 61], ["macrophages", "CELL_TYPE", 369, 380], ["various commercial broiler lines", "TREATMENT", 29, 61], ["phagocytosis", "PROBLEM", 103, 115], ["bacterial and tumor cell killing", "PROBLEM", 120, 152], ["selection programs", "TREATMENT", 281, 299], ["toxicological insult", "PROBLEM", 423, 443], ["broiler lines", "OBSERVATION", 48, 61], ["macrophage effector function", "OBSERVATION", 65, 93], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["tumor cell killing", "OBSERVATION", 134, 152], ["FACTORSChicken macrophages", "OBSERVATION", 354, 380]]], ["For example, macrophage viability and functions are adversely affected by mycotoxins such as aflatoxins (Figure 4 ) (Neldon-Ortiz and Qureshi, 1991), Fumonisin-B1 (Qureshi and Hagler, Jr., 1992) , trichothecenes (Kidd et al., 1995) , T-2 toxin (Kidd et al., 1997) , and others.", [["macrophage", "ANATOMY", 13, 23], ["aflatoxins", "CHEMICAL", 93, 103], ["Fumonisin-B1", "CHEMICAL", 150, 162], ["trichothecenes", "CHEMICAL", 197, 211], ["aflatoxins", "CHEMICAL", 93, 103], ["Fumonisin-B1", "CHEMICAL", 150, 162], ["trichothecenes", "CHEMICAL", 197, 211], ["macrophage", "CELL", 13, 23], ["aflatoxins", "SIMPLE_CHEMICAL", 93, 103], ["Fumonisin-B1", "SIMPLE_CHEMICAL", 150, 162], ["T-2", "GENE_OR_GENE_PRODUCT", 234, 237], ["macrophage viability", "PROBLEM", 13, 33], ["macrophage viability", "OBSERVATION", 13, 33]]], ["Embryonic exposure of chicks to aflatoxin-B1 either through in ovo injection (Neldon-Ortiz and or maternal transfer of toxin metabolites to progeny chicks down regulates macrophage phagocytic function post-hatch.", [["macrophage", "ANATOMY", 170, 180], ["aflatoxin-B1", "CHEMICAL", 32, 44], ["Neldon-Ortiz", "CHEMICAL", 78, 90], ["aflatoxin-B1", "CHEMICAL", 32, 44], ["chicks", "ORGANISM", 22, 28], ["aflatoxin-B1", "SIMPLE_CHEMICAL", 32, 44], ["macrophage", "CELL", 170, 180], ["chicks", "SPECIES", 22, 28], ["aflatoxin", "TREATMENT", 32, 41], ["toxin metabolites", "PROBLEM", 119, 136]]], ["Examples of environmental stressors affecting macrophage functions include heat stress (Miller and Qureshi, 1992a,b,c) and exposure to microbes.", [["macrophage", "ANATOMY", 46, 56], ["macrophage", "CELL", 46, 56], ["heat stress", "PROBLEM", 75, 86]]], ["While existing microbes change to escape the immune system, new mi-crobes evolve continuously.", [["immune system", "ANATOMY", 45, 58], ["escape the immune system", "PROBLEM", 34, 58], ["microbes", "OBSERVATION", 15, 23]]], ["Recent isolation of new variants of E. coli from turkeys (Edens et al., 1997a,b) is a good example of microbial antigenic modulation.", [["E. coli", "ORGANISM", 36, 43], ["turkeys", "ORGANISM", 49, 56], ["E. coli", "SPECIES", 36, 43], ["turkeys", "SPECIES", 49, 56], ["E. coli", "SPECIES", 36, 43], ["E. coli", "PROBLEM", 36, 43], ["microbial antigenic modulation", "TREATMENT", 102, 132], ["new", "OBSERVATION_MODIFIER", 20, 23], ["E. coli", "OBSERVATION_MODIFIER", 36, 43], ["antigenic modulation", "OBSERVATION", 112, 132]]], ["Macrophages do recognize such antigenic change by differential phagocytosis of variant strains of E. coli .", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["E. coli", "ORGANISM", 98, 105], ["Macrophages", "CELL_TYPE", 0, 11], ["E. coli", "SPECIES", 98, 105], ["E. coli", "SPECIES", 98, 105], ["such antigenic change", "PROBLEM", 25, 46], ["E. coli", "PROBLEM", 98, 105], ["E. coli", "OBSERVATION", 98, 105]]], ["The same is true for viruses, examples of which include new variants of astrovirus (Yu et al., 2000) and reovirus ARV-CU98 (Heggen-Peay et al., 2002a) isolated from cases of poult enteritis and mortality syndrome in turkeys.", [["astrovirus", "DISEASE", 72, 82], ["poult enteritis", "DISEASE", 174, 189], ["mortality syndrome", "DISEASE", 194, 212], ["astrovirus", "ORGANISM", 72, 82], ["reovirus ARV-CU98", "ORGANISM", 105, 122], ["turkeys", "ORGANISM", 216, 223], ["turkeys", "SPECIES", 216, 223], ["turkeys", "SPECIES", 216, 223], ["viruses", "PROBLEM", 21, 28], ["astrovirus", "PROBLEM", 72, 82], ["reovirus ARV", "TEST", 105, 117], ["Heggen", "TEST", 124, 130], ["poult enteritis", "PROBLEM", 174, 189], ["mortality syndrome", "PROBLEM", 194, 212], ["viruses", "OBSERVATION", 21, 28], ["poult", "ANATOMY", 174, 179], ["enteritis", "OBSERVATION", 180, 189], ["mortality syndrome", "OBSERVATION", 194, 212]]], ["While macrophages may not allow infection or virus replication, the ARV-CU98 reovirus has been shown to induce functional alterations in the macrophage, such as the up-regulation of interleukin-1 mRNA, even without any signs of viral replication (Heggen-Peay et al., 2002b) .", [["macrophages", "ANATOMY", 6, 17], ["macrophage", "ANATOMY", 141, 151], ["infection", "DISEASE", 32, 41], ["macrophages", "CELL", 6, 17], ["ARV-CU98 reovirus", "ORGANISM", 68, 85], ["macrophage", "CELL", 141, 151], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 182, 195], ["macrophages", "CELL_TYPE", 6, 17], ["macrophage", "CELL_TYPE", 141, 151], ["interleukin-1 mRNA", "RNA", 182, 200], ["ARV-CU98 reovirus", "SPECIES", 68, 85], ["infection", "PROBLEM", 32, 41], ["virus replication", "TREATMENT", 45, 62], ["the ARV", "TEST", 64, 71], ["CU98 reovirus", "PROBLEM", 72, 85], ["functional alterations in the macrophage", "PROBLEM", 111, 151], ["interleukin", "TEST", 182, 193], ["viral replication", "PROBLEM", 228, 245], ["may not allow", "UNCERTAINTY", 18, 31], ["infection", "OBSERVATION", 32, 41], ["macrophage", "OBSERVATION_MODIFIER", 141, 151], ["viral replication", "OBSERVATION", 228, 245]]], ["In fact, in situations where multifactorial infections overwhelm the immune system, such as in poult enteritis and mortality syndrome, macrophage-mediated cytokine-induced immune dysfunction may be a cause of some of the observed clinical pathophysiological signs in the affected poults .CONCLUDING REMARKSMacrophages are crucial cell types in innate immunity and they are potent microbicidal and tumoricidal cells.", [["immune system", "ANATOMY", 69, 82], ["macrophage", "ANATOMY", 135, 145], ["cell", "ANATOMY", 330, 334], ["tumoricidal cells", "ANATOMY", 397, 414], ["infections", "DISEASE", 44, 54], ["poult enteritis", "DISEASE", 95, 110], ["immune dysfunction", "DISEASE", 172, 190], ["macrophage", "CELL", 135, 145], ["poults", "ORGANISM", 280, 286], ["REMARKSMacrophages", "SIMPLE_CHEMICAL", 299, 317], ["cell", "CELL", 330, 334], ["tumoricidal cells", "CELL", 397, 414], ["cytokine", "PROTEIN", 155, 163], ["REMARKSMacrophages", "PROTEIN", 299, 317], ["microbicidal and tumoricidal cells", "CELL_TYPE", 380, 414], ["poults", "SPECIES", 280, 286], ["multifactorial infections", "PROBLEM", 29, 54], ["the immune system", "PROBLEM", 65, 82], ["poult enteritis", "PROBLEM", 95, 110], ["mortality syndrome", "PROBLEM", 115, 133], ["macrophage-mediated cytokine", "PROBLEM", 135, 163], ["immune dysfunction", "PROBLEM", 172, 190], ["the observed clinical pathophysiological signs in the affected poults", "PROBLEM", 217, 286], ["REMARKSMacrophages", "PROBLEM", 299, 317], ["potent microbicidal and tumoricidal cells", "PROBLEM", 373, 414], ["multifactorial", "OBSERVATION_MODIFIER", 29, 43], ["infections", "OBSERVATION", 44, 54], ["immune system", "OBSERVATION", 69, 82], ["enteritis", "OBSERVATION", 101, 110], ["crucial cell types", "OBSERVATION", 322, 340], ["innate immunity", "OBSERVATION_MODIFIER", 344, 359], ["potent", "OBSERVATION_MODIFIER", 373, 379], ["microbicidal", "OBSERVATION_MODIFIER", 380, 392], ["tumoricidal cells", "OBSERVATION", 397, 414]]], ["Macrophages are pivotal in acquired immunity as antigen presenting cells.", [["Macrophages", "ANATOMY", 0, 11], ["cells", "ANATOMY", 67, 72], ["Macrophages", "CELL", 0, 11], ["cells", "CELL", 67, 72], ["Macrophages", "CELL_TYPE", 0, 11], ["antigen presenting cells", "CELL_TYPE", 48, 72], ["Macrophages", "PROBLEM", 0, 11]]], ["Macrophages can greatly influence the local and systemic immune response through the production of cytokines.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["cytokines", "PROTEIN", 99, 108], ["Macrophages", "PROBLEM", 0, 11], ["cytokines", "PROBLEM", 99, 108], ["systemic immune", "OBSERVATION", 48, 63]]], ["Enhanced functional capacity of the animal's macrophages has the potential of being achieved by using classical breeding techniques such as MHCbased selection, dietary manipulations (via selected compounds with known immunomodulatory potential, adequate feeding), and new vaccine strategies (e.g., the use of novel adjuvants) geared towards maximizing the antigenpresentation capacity of macrophages.ACKNOWLEDGMENTSI thank all my wonderful graduate students and collaborators who have over the years contributed toward the understanding of chicken macrophage biology and functions.", [["macrophages", "ANATOMY", 45, 56], ["macrophages", "ANATOMY", 388, 399], ["macrophage", "ANATOMY", 548, 558], ["macrophages", "CELL", 45, 56], ["macrophages", "CELL", 388, 399], ["chicken", "ORGANISM", 540, 547], ["macrophage", "CELL", 548, 558], ["macrophages", "CELL_TYPE", 45, 56], ["macrophages", "CELL_TYPE", 388, 399], ["chicken", "SPECIES", 540, 547], ["chicken", "SPECIES", 540, 547], ["Enhanced functional capacity", "PROBLEM", 0, 28], ["classical breeding techniques", "TREATMENT", 102, 131], ["MHCbased selection", "TREATMENT", 140, 158], ["dietary manipulations", "TREATMENT", 160, 181], ["new vaccine strategies", "TREATMENT", 268, 290], ["novel adjuvants", "TREATMENT", 309, 324], ["functional", "OBSERVATION_MODIFIER", 9, 19], ["capacity", "OBSERVATION_MODIFIER", 20, 28], ["macrophages", "OBSERVATION", 388, 399]]]]}